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 ABSTRACT 
 
INTRODUCTION AND HYPOTHESIS:  The project aims to identify potential 
candidates for chloride (Cl-) ion channels in granulocytes, and granulocytic cell 
lines.  It is hypothesised that Cl- ion channels, in particular hBest1, are 
implicated in the role of granulocytes in response to inflammation.  
METHODOLOGY:  Two main methodologies were used; laboratory techniques 
and systematic review.  Laboratory techniques included RT-PCR, flow cytometry 
and western blot analysis to characterise the expression of hANO1, hBest1 and 
hCLCA1 as potential chloride ion channels in granulocytes and granulocytic cell 
lines.  Systematic review was performed to identify whether chloride ion 
channels are up-regulated in COPD and asthma.  
RESULTS:  RT-PCR demonstrated hCLCA1 expression in granulocytes and 
eosinophils but not HL60.  hBest1 and hBest3 was expressed in all 3 cell types.  
In granulocytes, flow cytometry demonstrated greater hCLCA1 protein 
expression intracellularly, compared to hBest1 protein, and greater hBest1 
plasma membrane expression compared to hCLCA1 (P<0.05).  There was a 
negative correlation between hBest1, and hCLCA1 but also a weak negative 
correlation between hBest1 and hANO1 (P<0.05).  Granulocytes stimulated with 
IL-13 over 24 hours, had a greater protein expression both intracellularly and at 
the plasma membrane.  There was increased migration of HL60s when 
transfected with hBest1, in response to fMLP (P<0.05).  Systematic review did 
not support the project due to limitations. 
CONCLUSIONS:  There is a complex relationship between hBest1, hCLCA1 and 
hANO1 which may contribute to the function of granulocytes.  HBest1 protein 
expression peaked 24 hours after continuous stimulation with IL-13.  This 
correlates with peak symptom expression in diseases such as COPD and asthma.  
It is suggested that hBest1 has a role in migration and activation of 
granulocytes, through regulation of cell shape and volume.  It is concluded that 
hBest1 is a novel therapeutic target in the control of symptoms in chronic 
inflammatory lung diseases. 
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CHAPTER 1:  INTRODUCTION 
22 
 1.1  Inflammatory airway diseases and the role of potential 
chloride ion channel candidates in granulocyte function within 
inflammatory airways. 
  
  Asthma and chronic obstructive pulmonary disease (COPD) have one of 
the highest morbidity and mortality rates in western society (Barnes, 
2008; Sturton et al., 2008; Knight et al., 2012). 
 
  Asthma and COPD are both considered inflammatory airway diseases 
and have similar clinical manifestations, overlapping pathophysiology, and 
similar treatment strategies.  Currently, asthma and COPD are treated 
predominantly with inhaled corticosteroids and inhaled bronchodilators 
(Polosa & Blackburn, 2009; Knight et al., 2012).  Exaccerbations of COPD 
can also be treated with non-invasive positive pressure ventilation.   In 
addition, both diseases are associated with increased incidences of 
hospitalisation, decreasing quality of life associated with symptoms, high 
morbidity and physical disability (Knight et al., 2012).  There are, 
however, different aetiologies for asthma and COPD (Gonem et al., 2012).  
It is widely acknowledged that tobacco smoking is the main risk factor in 
COPD whereas asthma can be considered either an atopic disease with 
acute exaccerbations triggered by allergens, viral infections or air 
pollution, such as tobacco smoke (Polosa & Blackburn, 2009; Gonem et 
al., 2012; Knight et al., 2012), or non-atopic.  Non-atopic asthma is also 
considered intrinsic where there are no external triggers to symptom 
exacerbation, and often as a result of hypersensitivity.  General clinical 
manifestations for asthma are respiratory wheezing, variable airway 
obstruction, dyspnoea and cough, whereas COPD has differences (Polosa 
& Blackburn, 2009).  In COPD, mucous clearance is limited, there is 
greater association with respiratory failure and cardiac failure (cor 
23 
pulmonale) and less variation in obstruction to airflow (Polosa & 
Blackburn, 2009).  In addition, asthma symptoms are responsive to 
glucocorticoid therapies whereas the response in COPD is limited.  Gonem 
et al (2012) have highlighted five domains that can be used to phenotype 
asthma and COPD according to clinical manifestation (Table 1.1 
summarises domains). 
24 
  
Domain Descriptor Clinical manifestation 
A Airway hyper-
responsiveness (AHR) 
Narrowing of the airways related 
to sensitivity and reactivity of 
smooth muscle.  Airflow 
obstruction and dyspnoea.  
Considered a symptom that is 
variable  
B Bronchitis Airway inflammation.  Asthma is 
considered eosinophilic and COPD 
neutrophilic 
C Cough reflex 
hypersensitivity 
Dry cough associated with asthma.  
COPD often presents with a 
productive cough that has poor 
clearance.  Variable symptom. 
D Damage to airways and 
lung parenchyma 
Thickening of the bronchial wall, 
airway remodelling with fibrosis, 
hypertrophy of smooth muscle in 
airways, emphysema and 
bronchiectasis, airway collapse and 
angiogenesis 
E Extra-pulmonary factors These are factors that may impact 
upon presentation of disease and 
examples include obesity and 
rhinosinusitis 
  
 
 
 
Table 1.1:  Five domains to phenotype asthma and COPD:  Five 
domains have been highlighted by Gonem et al. (2012) to assist in phenotyping 
respiratory disease, particularly asthma and COPD.  Domains are labelled A-E 
and the associated clinical manifestations are supported by Polosa and 
Blackburn (2009) and Knight et al. (2012) 
25 
  
  Within the five domains there are variations according to identified 
disease.  Airway hyper-responsiveness (refer to domain A in table 1.1 for 
definition) is common to COPD and asthma however, in asthma, this is 
typically reversed by the use of bronchodilators with resultant variable 
airflow obstruction (Gonem et al., 2012; Knight et al., 2012).  COPD is 
considered to have a fixed obstruction to airflow and prolonged AHR 
which is associated with airway remodelling and fibrosis of the lung 
tissue.  The cough that presents in asthma is often non-productive in 
response to inhaled glucocorticoid therapies, however in COPD, there is 
increased mucous production, with difficulty in clearance (Polosa & 
Blackburn, 2009; Gonem et al., 2012).  Another marked difference 
between the pathophysiological abnormalities of COPD and asthma is the 
damage to airways.  In asthma, there is hypertrophy of smooth muscle, 
however COPD has greater destruction of alveoli (Gonem et al., 2012).    
Figure 1.1 outlines the differences observed in the pathophysiologies of 
COPD and asthma, with related aetiology. 
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  The presence of leukocytes in inflammatory and allergic airway diseases, 
such as asthma, cystic fibrosis (CF) and COPD, has been well documented 
(Martínez-Antón et al., 2006; Holgate & Polosa, 2008; Vercelli, 2008).  
The function of granulocytes within this process remains contentious 
(Walsh et al., 2007; Matsumoto et al., 2008).  Granulocytes (also termed 
polymorphonuclear cells (PMN)) are so named because of the presence of 
granules in the cytoplasm and the varying nuclear shapes.  The term 
“granulocytes” will be used in the general discussion as this is the 
predominant term used within the cited studies and literature.  Within the 
discussion of experimental methods and results in this thesis, the term 
PMN will be predominantly used for granuocytes as cell type was 
determined by nuclear shape.  Often, the term PMN refers to neutrophils 
as these are the most abundant cell type in granulocytes, with neutrophils 
constituting 60-70% of all leukocytes (Bauman, 2006).  Comparably, 2-
4% of leukocytes are eosinophils and less than 1%  are basophils  (Gibbs, 
2005; Bauman, 2006).  For the purpose of this thesis, PMN will refer to a 
mixed population of granulocytes, which includes neutrophils, eosinophils 
and basophils in their relative abundance.  
 
  Asthma and COPD were, historically, considered to be the same disease 
process with differing clinical manifestations (Barnes, 2008; Gonem et al., 
2012).  Sturton et al (2008) however, has suggested that they are 
different diseases, marked clearly by distinctive inflammatory mediators.  
Furthermore, Barnes (2008) proposed that different sub-types of PMNs 
were involved within these processes, and that the resulting clinical 
symptoms, were characteristic to each lung pathology.  Gonem et al. 
(2012) identified the symptoms of asthma and stated that these are 
mediated by eosinphils, mast cells and CD4+ cells.  It has been suggested 
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 that eosinophils are specifically implicated in airway hyper-responsiveness 
and fibrosis as a source of fibrogenic factors (Barnes, 2008; Raap & 
Wardlaw, 2008).  This is associated with the atopic nature of the disease 
and variable symptom expression.  COPD however is mediated by 
macrophages and neutrophils which are associated with the relative fixed 
airflow obstruction and that symptoms tend to be persistent with minimal 
variation (Gonem et al., 2012).  Specifically, neutrophils have a functional 
role in the over-production of sputum (Barnes, 2008).  However, people 
with severe (refractory) asthma, that is insensitive to corticosteroid 
therapy, have been found to have a higher percentage of sputum 
neutrophils, compared to eosinophils (Choi et al., 2012).  This has been 
linked to a role in persistent airway obstruction.  There are overlapping 
symptoms of asthma and COPD.  There are some differences in disease 
manifestation enabling diagnosis, however often patients do not fit the 
expected pattern.  These individuals should be phenotyped according to 
the domains highlighted in Table 1.1 and treatment should be focussed 
upon the manifestations rather than a pre-defined strategy based upon 
diagnosis (Gonem et al., 2012).   
 
  Current treatment strategies appear to focus upon smooth muscle and 
reduction of inflammation and the management of mucus hypersecretion.  
As summarised in figure 1.1, mucus hypersecretion is predominantly 
characteristic of COPD, whereas asthma is associated with a dry cough.  
Clearance of mucus is limited in COPD which may cause bacterial 
infection, and exaccaerbation of clinical symptoms (Gonem et al., 2012).  
Therefore, treatment of symptoms in COPD include airway hydration to 
assist in mucociliary clearance (Graeber et al., 2013).  Chloride (Cl-) 
channels, however, may prove a novel target for pharmacological 
intervention to assist in the hydration of airway epithelia, and clearance of 
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mucus, through fluid flux associated with chloride movement.  For the 
purpose of this project, the term chronic inflammatory lung disease will be 
used in relation to results, to encompass the overlapping symptoms of 
diseases that chloride ion channels and granulocyte function may impact 
upon.  
  Chloride channels may also be implicated in the function of granulocytes 
as they mediate the clinical symptoms of chronic inflammatory lung 
diseases.  Chloride ion channels allow the passage of chloride ions via 
passive diffusion.  This is through pores in either the plasma membrane 
or membrane of intracellular organelles (Altenberg, 2005).  Chloride ion 
channels perform a variety of functions in a number of cellular processes 
including; regulation of cell volume, pH control of lysosomes and 
stabilisation of membrane potential (Eggermont, 2004; Cheng et al., 
2008; Linley et al., 2009).  When the gene encoding a chloride channel 
mutates, channelopathies and dysfunction occur.  This can result in 
diseases such as osteoporosis, renal calculi, cystic fibrosis, epilepsy and 
myotonia (Planells-Cases & Jentsch, 2009).  The presenting disease is 
dependent upon the position, type and functional properties of the 
chloride channel that is affected by the gene mutation.  The function of 
these channels may have a further role in other physiological processes, 
particularly within inflammation and allergic responses.  For example, 
Cheng et al (2008) have suggested that chloride ion channels have a role 
in migration and activation of immune cells in inflammatory and allergic 
lung responses.  In this instance, chloride ion channels would be 
implicated in airway inflammation and granulocyte recruitment as 
highlighted previously in Figure 1.1 and Table 1.1.  
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   Chloride (Cl-) flux governs the movement of fluid, secondary to Cl- 
channel stimulation.  Cl- channels are passive in that Cl- efflux or influx is 
dependent upon the difference between intracellular and extracellular 
concentrations (Jentsch et al., 2005).  This has been highlighted by 
Suzuki et al (2006) who implicate this in both cell volume regulation, and 
transport of water and salts across membranes.  In this case, Cl- 
movement is coupled with Na+ and therefore fluid by creation of an 
osmotic gradient (Jentsch et al., 2002; Suzuki et al., 2006).  There 
appears a clear role for this process in inflamed airway epithelia (Duta et 
al., 2006).  The transport of fluid into inflammatory airways governs the 
clearance of mucus by directly affecting the composition.  This is well 
documented in the pathology of CF which clearly underlines the role of Cl- 
channels in fluid transport. 
 
  This project aims to further discussion, by examining the expression of 
and function of Cl- channels in granulocyte function, with specific 
reference to inflammatory airway diseases.  In order to achieve this aim, 
it is first necessary to present an argument elucidating the role of 
granulocytes in airway diseases.  Following this, there will be discussion 
as to the role that Cl- channels have, clarifying how the sub-types may 
impact on their function within PMNs.  Finally, the molecular candidates 
for Cl- channels will be identified and the evidence surrounding their 
structure and function presented.  This will be linked to overall 
granulocyte function in inflammatory airway diseases.  
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1.1.1 The role of granulocytes in inflammatory airway diseases 
1.1.1.1  Neutrophils 
  Neutrophils have been identified as the main pro-inflammatory mediator 
in COPD (KanKaanranta et al., 2010; Gonem et al., 2012) and cystic 
fibrosis (CF) (Illek et al., 2008; Jacquot et al., 2008).  The presence of 
neutrophils is evident in CF lung even in the absence of bacterial 
infections indicating a role for them within the disease process (Freedman 
et al., 2002; Ulrich et al., 2010).  Barnes (2008) states that while COPD 
can be considered neutrophilic, other inflammatory pathologies such as 
asthma, are considered eosinophilic (Figure 1.2 shows morphological 
differences in nucleus of neutrophils and eosinophils using DAPI staining 
and microscopy).  This is due to differences within the chemotactic factors 
that are released during the inflammatory phases of these diseases.  This 
is supported by Martínez-Antón et al (2006), and Tintinger et al (2005) 
who also highlights the role of neutrophils in CF and acute respiratory 
distress syndrome.  Importantly, neutrophils have been indicated in the 
inflammatory processes of non-eosinophilic asthma (Tintinger et al., 
2005).  The role of neutrophils within asthma is indicated by Barnes 
(2008) who states that while the neutrophil count remains within normal 
limits in mild asthma, there is a marked increase during severe asthmatic 
exacerbations.   
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  A role of neutrophils within inflammation is to phagocytose microbes and 
pathogens (Lollike et al., 2002).  Within inflammatory airway diseases 
chemotaxins attract neutrophils into tissues as a result of inflammation 
(Tintinger et al., 2005).  An integral part of the inflammatory process is 
respiratory burst of neutrophils (Menegazzi et al., 1999).  Respiratory 
Figure 1.2:  Nucleus of neutrophils and eosinophils under microscopy:  
Figure showing images of a neutrophil and eosinophil stained with DAPI for 
nucleus visualisation, at 60x magnification. A) DAPI stained neutrophil with clear 
multi-lobed nucleus and B) distinct bi-lobed nucleus of an eosinophil.   
                                                      
 
                                      
 
 
 
A 
B 
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 burst, also referred to as oxidative burst, is a process by which immune 
cells, such as neutrophils, rapidly release chemicals known as reactive 
oxygen species.  These chemicals are essential for the degradation of 
bacteria and debris that are internalised by neutrophils during 
phagocytosis (Page & Pitchford, 2013). 
 
  It has been shown that neutrophils are stimulated by Tumour Necrosis 
Factor-α (TNF-α) only when they are fixed by fibronectin and 
immobilized, as in inflammatory lung disease (Menegazzi et al., 1999).  In 
the Menegazzi et al (1999) study it was demonstrated that β2 integrin was 
required to cross-link neutrophils with fibronectin in inflamed tissues.  By 
using inhibitors of chloride efflux, they showed that β2 integrin cross-
linking triggers Cl- ion efflux which is responsible for respiratory burst.  
However, the Cl- transport inhibitors that were used were the family of 2-
aminomethyl-4-(1,1-dimethylethyl)-6-iodophenol hydrochloride (MK-447) 
which have been suggested in an earlier study by Parnham et al (1979) to 
effect the mononuclear cell count (Harada et al., 1983).  There may, 
therefore, be an impact upon neutrophils within the study.   In the 
process of respiratory burst, superoxide anions are produced by activation 
of nicotinamide adenine dinucleotide phosphate-oxidase (NADPH oxidase) 
released from lysosomes (Tintinger & Anderson, 2004; Femling et al., 
2006).  This relationship was supported by another study where 
lysosomal fusion and stimulation was not affected by the alternative Cl- 
channel blocker DIDS (4,4’-diisothiocyanostilbene-2,2’-disulphonic acid) 
(Korchak et al., 1980).  In this study lysosomes did not release their 
contents however stimulation of lysosome-lysosome fusion remained 
evident.  This supports the hypothesis that chloride flux is involved in the 
process of respiratory burst in neutrophils. 
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   In COPD inhaled irritants, such as tobacco smoke, may initiate the 
release of chemotaxins (Barnes, 2008).  CXC-chemokinase ligand 1 
(CXCL1) and CXC-chemokinase ligand 8 (CXCL8) have been identified as 
the main candidates for chemotaxis, which are induced by the closely 
related interleukin-17 (IL-17) and IL-17F (Laan et al., 2001).  While 
neutrophil infiltration during inflammation has a therapeutic effect, 
prolonged periods of inflammation can lead to tissue damage.  This is due 
to neutrophil mediated phagocytotic enzymes affecting surrounding tissue 
(Tintinger et al., 2005).  Alveolar damage, which presents as emphysema 
in COPD, is a direct result of neutrophil activation (Taraseviciene-Stewart 
et al., 2006).  In particular, the release of neutrophil elastase from the 
cytosol contributes to this pathology.  This may also explain the presence 
of neutrophils in severe asthmatic exacerbations, as suggested by Holgate 
and Polosa (2008).  They identified IL-17A as being over expressed in 
asthmatic airways, due to T-cell mediation which would initiate 
chemotaxin release.  While poorly understood, neutrophil attraction and 
activation in asthma occurs when the onset is secondary to viral 
infections, or tobacco smoke inhalation and has been supported by mouse 
model studies using a neutrophil elastase antibody (Lee et al., 2007).   
 
  A common symptom of inflammatory airway diseases is the 
overproduction of mucus within the airways (Martínez-Antón et al., 2006).  
It has been suggested that mucus production occurs due to hyper 
secretion by, or hyperplasia of, goblet cells (Rogers, 2003; Martínez-Antón 
et al., 2006; Barnes, 2008).  In turn, neutrophils have been indicated in 
the up-regulation of MUC5AC genes in COPD and asthma, resulting in 
both hyper secretion and hyperplasia of goblet cells (Rogers, 2003; 
Caramori et al., 2004; Barnes, 2008).     Martínez-Antón et al (2006) 
argue that the increase in mucus production and the relationship to 
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 inflammatory processes still remains unclear.  In this study, they suggest 
hyper secretion is due primarily, to eosinophils.  In contrast to Barnes 
(2008) and Rogers (2003), however, Martínez-Antón et al (2006) suggest 
that instead of MUC5A, it is MUC1, MUC4 and MUC8 that are indicated in 
hyper secretion.  It should be noted that in this study, the sample size of 
bilateral nasal polyps was 38, of which 22 were from asthmatic airways.  
No samples were taken using COPD samples to compare the potential 
differences in primary inflammatory cells.  In addition, the relationship 
between nasal epithelia and epithelia from the lower respiratory tract, as 
affected in COPD, remains an area for clarification when considering the 
up-regulation of mucus producing genes.   
 
  It has been suggested that goblet cell hyperplasia, and therefore mucus 
production, is due to up-regulation of calcium activated chloride ion 
channels, such as CLCA (Rogers, 2003).  This will be discussed in section 
1.1.3.3, however it has been shown that CLCA may not be a chloride ion 
channel itself, but rather a regulator of endogenous chloride ion channels 
(Gruber & Pauli, 1999b; Gibson et al., 2005; Hamann et al., 2009).  
Tintinger et al (2005) states that prior to recruitment of neutrophils and 
activation of pro-inflammatory processes, there is a marked increase in 
cytosolic calcium.  This potential relationship will be discussed in further 
detail in section 1.1.3.3. 
 
1.1.1.2  Eosinophils 
 
  In contrast to neutrophils, eosinophils are strongly implicated within the 
pathophysiology of asthma (Cheng et al., 2008; Raap & Wardlaw, 2008; 
Kim et al., 2010; Spencer & Weller, 2010).  In addition, there has been a 
direct link between the termination of inflammatory processes in asthma 
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 and apoptosis in human eosinophils (KanKaanranta et al., 2010).  Barnes 
(2008) reports that the infiltration of eosinophils is evident in the 
bronchial biopsies of asthmatics.  Indeed, Kyoh et al (2008) suggest a 
direct correlation between the number of activated eosinophils in airways, 
and the severity of symptoms displayed in asthma.  Eosinophils have been 
specifically implicated in late responses of asthma, with eosinophil count 
at its peak after 24 hours following exposure to an allergen (O'Byrne et 
al., 2004; Holgate & Polosa, 2008).  O’Byrne, et al (2004) also 
acknowledge that eosinophils cannot be held solely accountable for all 
symptoms during exacerbation of asthma.  They claim that approximately 
half of patients exhibit high levels of eosinophils within their blood stream.  
This may be due to other factors, such as inhaled toxins (such as 
atmospheric pollutants), or viruses, which trigger an onset of symptoms in 
the asthmatic patient.  Matsumoto, Tamari et al (2008) also poses the 
question as to whether eosinophilia can be considered a cause of 
symptom exacerbation, or whether it is purely a marker of disease.  
Despite whether a marker or cause, the presence of eosinophils in 
sputum, tissues or blood may be dependent on the mode of stimulation, 
and attraction of eosinophils to the site of inflammation.   
 
  Simon and Simon (2007) claim that eosinophilic disorders are either 
extrinsic or intrinsic in nature.  Extrinsic eosinophilia is attributable to 
allergen stimulation, mediated by immunoglobulin-E (IgE) whereas 
intrinsic is non IgE mediated.  Asthma may involve eosinophilia as a result 
of exposure to allergens (Holgate & Polosa, 2008), therefore being IgE 
mediated.  Hegab, et al (2004) suggests that some individuals, however, 
have a genetic susceptibility due to markers on chromosome 5q31-q33.  
These markers contain genes which code for IL-4 and IL-13.  In the event 
of allergen exposure, eosinophils are released from bone marrow in 
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 response to T-cell mediated cytokine release (Kim et al., 2010; Walsh & 
August, 2010).  Rosenberg, Phipps et al (2007) states that T-cells produce 
T-helper 2 (TH2) cells which in turn secrete the cytokines IL-4, IL-5 and 
IL-13 (Willis-Karp, 2004; Simon & Simon, 2007; Spencer & Weller, 2010).  
The evidence appears to suggest that these cytokines form a positive 
feedback cycle where IL-4 and IL-13 indirectly further increase 
eosinophilia.  In contrast to previous suggestions (Holgate & Polosa, 
2008) that eosinophils are activated in late phase asthmatic response, it 
has been argued that eosinophils act in early responses to TH2 inducing 
agents, such as in asthma.  This in turn activates TH2 immune responses 
(Spencer & Weller, 2010).  This suggests a dynamic interaction between 
eosinophils and T cells which contribute to the initiation and effects of 
innate immunity. 
 
  It has been suggested that as part of the positive feedback mechanism, 
mature eosinophils produce IL-4 (Raap & Wardlaw, 2008) and IL-13 
which induce polarisation of TH2 cells (Spencer & Weller, 2010; Walsh & 
August, 2010).  The unique nature of eosinophils as a leukocyte means 
that these cytokines are pre-formed and stored in granules within cells 
ready for secretion in response to specific stimuli.  Rosenberg et al (2007) 
identifies the role of IL-4 in eosinophilia.   The secretion of IL-4 further 
increases TH2 cell development, and cause airway epithelia to release 
cytokines (such as IL-4, IL-5 and IL-13) which attract eosinophils to the 
site of inflammation (O'Byrne et al., 2004).  IL-13 has been suggested to 
regulate the synthesis of IgE (Willis-Karp, 2004).  Kariyawasam and 
Robinson (2007) also state that IL-13 induces differentiation of fibroblasts 
into myofibroblasts, and is therefore implicated in the production of 
collagen.  Eosinophilia may be as a result of these two pro-inflammatory 
cytokines working together (Willis-Karp, 2004).  It has been shown, 
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however, that the response to IL-13 in asthma phenotypes varies 
according to the distinct cell type upon which it is acting (Lee et al., 
2001).  Human epithelial cells, bronchial smooth muscle and human 
fibroblasts were stimulated with IL-13.  RNA was extracted and protein 
expression analysed using Western blot analysis (Lee et al., 2001).  This 
showed that gene expression varied among cells which results in differing 
asthma phenotypes.  This highlighted that IL-13 activated a common 
transcription factor (STAT6) however the resultant gene expression 
varied.  That IL-13 stimulates differing gene expression is a result of the 
receptor sub-unit that may be present or activated in a given cell type.  
Lee et al. (2001) stated that IL-13 will bind to one of 3 receptors; 
common IL-4 receptor and one of 2 subunits of the IL-13 receptor 
(alpha1 and alpha2).  The resultant gene expression is dependent upon 
the pathway and receptor that IL-13 binds to.    Therefore, the symptoms 
of asthma may not be due to eosinophilia alone but a response to direct 
IL-13 stimulation of airway cells, and the receptor that IL-13 binds to 
(common IL-4 receptor, or IL-13 receptor subunit alpha1 or alpha2).  It 
has been demonstrated in murine models that STAT6 can be suppressed 
by using an IL-13 receptor antagonist (Lee et al., 2001), and as a result, 
the symptoms of asthma were prevented.   This was supported in a later 
study whereby STAT6 was suppressed and so IL-13 mediated asthma 
phenotypes were controlled (Nakano et al., 2006).  This study however 
appears to link IL-13 and chloride channels as STAT6 was suppressed 
using niflumic acid, a specific calcium activated chloride channel blocker.  
They also showed that IL-13 directly up-regulated mCLCA3 (human 
homologue hCLCA1). 
  In contrast, there appears clear evidence suggesting that IL-5 is 
essential in the process of eosinophilia in airway inflammation (Kim et al., 
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 2010; Spencer & Weller, 2010).  This cytokine is required for the terminal 
differentiation of eosinophils into their mature form (O'Byrne et al., 2004; 
Kariyawasam & Robinson, 2007; Spencer & Weller, 2010).  IL-5 is 
subsequently implicated in the recruitment and activation of these 
eosinophils at the site of inflammation (Berlin et al., 2004; Matsumoto et 
al., 2008).  Simon and Simon (2007) also stated that IL-5 has an 
important role in the survival of eosinophils.  This was supported by 
Rosenberg, Phipps et al (2007) who claim that in the absence of IL-5, 
eosinophils undergo spontaneous apoptosis in vitro.  This has been 
supported by a recent study whereby apoptosis was enhanced by histone 
deacetylase in the absence of IL-5, considered to prolong the survival of 
polymorphonuclear cells (KanKaanranta et al., 2010).  They suggested 
that this was only evident in terminally differentiated PMNs.  In addition 
to these functions, IL-5 has been suggested to contribute to the positive 
feedback mechanisms by stimulating eosinophil production of IL-13 
(Willis-Karp, 2004).   
 
  Further contribution to the inflammatory process is the attraction of 
activated TH2 cells which release of IL-4, IL-5 and IL-13.  TH2 cells are 
attracted to the site of airway inflammation as a result of chemokine 
ligand 17 (CCL17) and chemokine ligand 22 (CCL22) interacting with CC-
chemokine receptor 4 (CCR4) (Liu, 2006).  Differentiated eosinophils are 
also attracted to the site of inflammation by chemokines (such as CC-
chemokine 5 and CC-chemokine 11) released from airway epithelial cells 
(Holgate & Polosa, 2008; Vercelli, 2008).  In addition, airway epithelial 
cells are responsible for recruiting mucosal mast cells to the epithelial 
surface through release of stem cell factor (Barnes, 2008).  Activated 
mast cells contribute to inflammation by release of histamine from 
granules but in addition also release cytokines IL-4, IL-5 and IL-13 (Galli 
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 et al., 2005; Barnes, 2008).  Berlin, Lincoln et al (2004) suggests that 
mast cell stem cell factor (SCF) also has an important role in eosinophil 
recruitment acting via IL-5 directly in the epithelial cells of airways.  They 
suggest that when SCF is inhibited, there is a reduction in the cytokine IL-
5.  As a result of IL-4, IL-5 and IL-13, eosinophils are then differentiated 
and recruited to the area of inflammation as outlined previously, resulting 
in eosinophil influx (Holgate & Polosa, 2008).  Xanthou et al (2003) also 
suggest that airway epithelial cells release chemokine ligand-11 (CCL11), 
further recruiting eosinophils by acting upon CCR3.  At the site of 
inflammation, activated eosinophils release pro-inflammatory and 
cytotoxic proteins, such as eosinophil peroxidise and major basic protein 
which contribute to the severity of disease symptoms (Raap & Wardlaw, 
2008; Kim et al., 2010).  (Figure 1.3 is a diagrammatic summary of 
chemokine and cytokine interactions) 
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Figure 1.3:  Summary of cytokine and chemokine reactions in eosinophils:   Diagram 
(personal) to summarise the complex and positive feedback cytokine and chemokine reactions.  
Information extracted from previous discussion.  Allergen exposure results in T-helper 2 cell 
responses namely IL-4, IL-5 and IL-13 release.  Airway epithelia recruit mucosal mast cells to 
epithelial surface, through mast stem cell factor, and release cytokines to attract eosinophils to 
the site of inflammation.  Additional response is chemokine receptor 4 (CCR4) binding 
chemokine ligand 17 and 22 (CCL17 and CCL22 respectively) which forms the positive feedback 
and further activation of the TH2 cells.  IL-5 is thought to be involved in the terminal 
differentiation of eosinophils, survival of mature cells and the stimulation of eosinophils to 
produce IL-13.  Together with IL-13, eosinophil release of IL-4 from granules polarises TH2 
cells so forming a positive feedback response 
42 
  
 
  Another protein in both eosinophil and basophil granules is the Charcot-
Leyden crystal protein (Char-LCP) which has been directly associated with 
asthmatic inflammation (Leonidas et al., 1995).  It has been shown that 
there are distinct differences between major basic protein (MBP) and 
Char-LCP.  Therefore, when eosinophils degranulate, Char-LCP may have 
distinct functional properties in inflammation (Gleich et al., 1976).  This is 
supported in a study whereby the human myeloid leukaemia cell line 
(AML14) was stimulated with the pro-inflammatory cytokine IL-13 and IL-
5 (Paul et al., 1994).  In this instance mRNA encoding Char-LCP was 
produced and the expressed protein examined using Western Blot 
analysis.  This demonstrated up-regulation of Char-LCP in response to 
these cytokines.  Char-LCP was considered to have lysophospholipase 
(LPL) activity which may account for a role in inflammation (Leonidas et 
al., 1995).  More recently however, it has been shown that Char-LCP is 
not an LPL itself but may interact with this enzyme group in eosinophils 
(Ackerman et al., 2002).  Char-LCPs are now considered to be a member 
of the galectin family (Leonidas et al., 1995; Dyer & Rosenberg, 1996).  
One role of galectins includes inhibition of inflammation and allergic 
responses.  Therefore, there are clear implications for inhibition of allergic 
responses and chronic inflammation for Char-LCP in eosinophils and 
basophils. 
 
  While the recruitment and activation of eosinophils appears well 
documented, the role of these remains a contentious issue (Berlin et al., 
2004; Kariyawasam & Robinson, 2007; Barnes, 2008).  Walsh et al (2007) 
has suggested that the lack of clarity regarding the role of eosinophils is 
due to inadequate cell models.  Indeed, many authors quote studies that 
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have been performed using mice however Rosenberg et al (2007) 
highlight the inadequacies in these results by outlining the fundamental 
differences between human eosinophils and those found in mice.  While 
both cells stain in a similar fashion, it has been noted that the granules 
are very different in nature.  For example, human eosinophils express 
large numbers of IgE receptors whereas mouse eosinophils don’t, the 
mouse eosinophil also has limited degranulation (Rosenberg et al., 2007). 
It has been suggested that release of toxins from secondary granules 
have a direct impact upon the function of eosinophils (Jacobsen et al., 
2007).  Therefore, this may have a large impact on the functional role of 
eosinophils in the mouse and human models.  This difference is also of 
particular relevance when considering the role that IgE plays in the 
recruitment of eosinophils in inflammatory responses. 
  Despite the concerns involved in applying findings from mouse studies to 
human eosinophils, the mouse model remains the most prevalent.  It has 
been heavily suggested that a role of eosinophils is to stimulate airway 
hyper-responsiveness (AHR) (O'Byrne et al., 2004; Willis-Karp, 2004; 
Kariyawasam & Robinson, 2007; Venge, 2010).  Berlin, Lincoln et al 
(2004) however, claims that AHR may not be directly associated with the 
presence of eosinophils, but due to activation of such by direct release of 
mast cell stem cell factor within the lung.  As a result of activation, 
eosinophils are stimulated to release cytokines causing AHR, as 
demonstrated in the laboratory of Berlin et al (2004).  In these 
experiments, anti-stem cell factor was administered to mice.  Airway 
hyper-responsiveness was measured along with enzyme-linked 
immunosorbent (ELISA) assays for chemokines and cytokines.  These 
were animal studies and as such, should be applied to human eosinophils 
with caution.  More recently, Kyoh et al (2008) implicates cysteinyl-
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 leukotrienes (cys-LTs), derived from eosinophil membrane, in the process 
of bronchoconstriction (Jame et al., 2007).  This may contribute to the 
symptomatic AHR demonstrated in the asthmatic lung.  In contrast, 
mouse studies have demonstrated that T cell expression of IL-5 is a key 
candidate in the stimulation of AHR by initiating spontaneous 
degranulation of eosinophils (Kariyawasam & Robinson, 2007; Walsh & 
August, 2010).  Controversially, it has been demonstrated in human 
studies that IL-5, while increasing the number of eosinophils, does not 
impact on AHR.  In these studies, humanised anti-IL-5 monoclonal 
antibodies were given to human, mildly allergic subjects (Leckie et al., 
2000). As a result, there was a decrease in eosinophil numbers in blood 
and sputum, but with no reduction in AHR.  Simon and Simon (2007) 
claims that this may be as a result of continued activation of T-cells 
further releasing IL-5 but that continued AHR may be due to minimal 
reduction of eosinophils in sputum.  This is supported by Rosenberg et al 
(2007) who show that anti IL-5 antibodies result in a significant decrease 
in peripheral eosinophils, while there remains a presence of these cells in 
lung tissue (Kariyawasam & Robinson, 2007).  These controversies within 
eosinophils and their role in AHR however further confirm the difficulties 
in transferring mouse studies to the human lung. 
 
  It has been suggested (Barnes, 2008) that while AHR is unaffected by 
anti-IL-5 antibody mediated reduction in eosinophils, there is an impact 
on fibrosis within sub-epithelial cells in airways.  As a result, eosinophils 
have been implicated in the incidence of fibrosis in asthmatic airways.  
Prolonged activation of eosinophils, and therefore inflammation, results in 
increased fibrosis due to degranulation and release of cytotoxins which 
damage epithelial cells.  Kariyawasam and Robinson (2007) identify the 
key toxins as major basic protein (Cheng et al., 2008), eosinophilic 
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 cationic protein, eosinophil derived neurotoxin and eosinophil derived 
peroxidase (Holgate & Polosa, 2008), which in turn produces reactive 
oxygen molecules.  In addition to the direct fibrinolytic damage caused by 
these chemicals, further damage may also be stimulated due to triggering 
local tissue activity (Kariyawasam & Robinson, 2007).  These processes 
contribute to the maintenance and progression of tissue injury and repair 
(Holgate & Polosa, 2008).  As stated previously, IL-5 is essential in the 
activation, and therefore degranulation of eosinophils and tissue re-
modelling (fibrosis), however Willis-Karp (2004) suggest that IL-13 is 
responsible for fibrosis.  While in asthmatic airways, this has been 
demonstrated in murine studies, it is also implicated in fibrosis of other 
inflammatory lung diseases, including COPD.  The exact mechanism for 
this remains unclear.  One possible process is that IL-13 up-regulates 
arginase I, an enzyme which results ultimately in the synthesis of collagen 
through hydrolysis of L-arginine (Willis-Karp, 2004).  Whilst not relating 
IL-13 to fibrosis, a recent study (Siddiqui et al., 2009) used flow 
cytometry to demonstrate that in human asthmatic subjects, IL-13 was 
up-regulated in comparison to healthy humans.  The up-regulation of IL-
13 was predominantly in peripheral T cells with some suggestion of an 
increased expression in eosinophils, however this was non-significant.  
This supports the hypothesis that there is involvement of the peripheral 
blood inflammatory cells in asthma and that the responses seen may not 
be localised entirely in airway epithelium.  Kariyawasam and Robinson 
(2007) support the role of IL-13 in fibrosis, and suggest that eosinophils 
are a source of the chemotactic factor for fibroblasts, transforming growth 
factor-β1 (TGF- β1).   
 
  In addition to the role eosinophils play in AHR, airway remodelling (Raap 
& Wardlaw, 2008; Allakhverdi et al., 2009), and fibrosis, there is evidence 
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 to suggest that they have an important role in increased mucus 
production in asthma (Walsh & August, 2010).  Eosinophil influx in 
inflammatory asthmatic airways up-regulates the genes MUC1, MUC4 and 
MUC5B which causes mucus hyper secretion (Martínez-Antón et al., 
2006).  In this study using bilateral nasal polyp cells, it was shown that a 
reduction in eosinophils directly decreases the expression of MUC8 in 
patients receiving steroid treatments.  This may indicate a treatment 
pathway for mucus hyper secretion in inflammation and therefore, 
asthma.  It should be noted however that the experiment contained no 
samples from patients with COPD and further experiments may be 
necessary to clarify the relationship between eosinophils and mucus 
secretion in other inflammatory airway disorders. While Kariyawasam and 
Robinson (2007) and Jame et al (2007) acknowledge the potential role for 
eosinophils in increased mucus secretion, they link this to the presence of 
cys-LTs derived from cell membranes (Kyoh et al., 2008).  The process for 
this remains relatively undefined.  
 
1.1.1.3  Basophils 
 
  Historically, the role of basophils was not considered important in 
inflammatory airway diseases (Nouri-Aria & Durham, 2004; Gibbs, 2005).  
In contrast however, Marone et al (2005) claims that they have a pivotal 
role in antigen stimulated allergic asthmatic responses (Heinemann et al., 
2005).  Basophils have been found in the sputum and biopsies of 
asthmatic individuals, particularly after an acute episode of 
bronchoconstriction (Nouri-Aria & Durham, 2004).  The decreased 
basophil count, comparable with other essential inflammatory cells may 
indicate either selective recruitment (Heinemann et al., 2005), or is a 
result of lower differential numbers.  In which case, this may inform 
47 
 findings relating to potency of their actions once stimulated.  While there 
appears little evidence supporting the role of basophils in other 
inflammatory airway disorders, there are emerging research papers 
implicating their role in non IgE mediated response.  This includes those 
stimulated by parasites and viruses (Gibbs, 2005).  This may have some 
impact on inflammation in the airways during COPD and CF, perhaps in 
the presence of viral inflammation.   
 
  The mechanism of recruitment and activation of basophils in allergic 
airways remains unclear (Nouri-Aria & Durham, 2004; Heinemann et al., 
2005).  As basophils constitute less than 1% of leukocytes, Gibbs (2005) 
suggests that this may be a contributory factor in the limited evidence 
supporting their recruitment.  With such small numbers, purification of 
such cells becomes problematic.  In addition, Nouri-Aria and Durham 
(2004) suggested that securing an appropriate antibody for fluorescent 
labelling had previously been unsuccessful until recently, resulting in 
either unstable antibodies, or those that are not specific enough to 
accurately evaluate the data.  It appears that there are currently two 
main antibodies for use (BB-1 and 2D7) in labelling basophils that have 
contributed to the current evidence supporting their role (Gibbs, 2005).  
Using these antibodies, they have been identified in late phase responses 
(Holgate & Polosa, 2008). 
 
  Basophil count increases by 7 hours following antigen stimulation 
(O'Byrne et al., 2004).  The relatively late onset may be because they are 
not present in healthy tissue (Marone et al., 2005).  When stimulated, 
basophils differentiate in bone marrow and emerge into vasculature as 
mature cells, for migration to sites of tissue inflammation (Gibbs, 2005).  
Nouri-Aria and Durham (2004) have shown that during allergic asthmatic 
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 exacerbation, the numbers of basophils in peripheral blood increases 
slightly, possibly two-fold.  In contrast, the numbers in the inflamed tissue 
can be increased markedly, as much as one hundred-fold.  These were 
demonstrated in nasal brushings and so may not be truly representative 
of those found in bronchial cells.  The late responses of basophils may 
also be due to an agonistic relationship with eosinophils.  Both PMN 
subtypes differentiate from a shared common stem cell precursor; CD34 
stem cell in bone marrow (Nouri-Aria & Durham, 2004; Allakhverdi et al., 
2009).  The basophil count appears to peak before the eosinophil count 
and is reduced by approximately 24 hours following antigen stimulation 
(O'Byrne et al., 2004).  At this point, as stated in section 1.1.1.2, 
eosinophilia begins to become evident.  This relationship may indicate the 
role of basophils in eosinophilia and there is evidence demonstrating that 
basophils release the cytokines IL-4 (Khodoun et al, 2004) and IL-13 
(Willis-Karp, 2004).   
 
  Heinemann et al (2005) have shown that stem cell factor (SCF) plays an 
essential role in the recruitment and survival of basophils.  Initially, SCF 
induces CD11b up-regulation of basophils.  In fact, their studies have 
suggested that SCF is responsible for the selective recruitment of 
basophils.  In their experiment, basophils were demonstrated to be 
selectively recruited, preferentially to either eosinophils or neutrophils.  
This was in response to chemotaxis only in the presence of SCF.  When 
SCF was applied alone, there was no basophil migration evident.  A 
secondary finding within this experiment was that survival of basophils 
was enhanced by the increase in IL-3 anti-apoptotic effects in the 
presence of SCF.  These results appear interesting and offer some insight 
into the potential mechanisms of basophil migration. 
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  It has been suggested that basophils are recruited to tissues primarily 
due to the TH2 cytokine, IL-13, for which basophils have membrane 
receptors (Nouri-Aria & Durham, 2004; Willis-Karp, 2004).  Marone et al 
(2005) have highlighted that basophils themselves produce IL-13, peaking 
at approximately 8 hours following antigen stimulation (Nouri-Aria & 
Durham, 2004).  IL-13 is a pro-inflammatory cytokine in itself which may 
indicate that basophils are responsible both for the onset, and 
maintenance of allergic inflammation in asthmatic airways (Plath et al., 
2001; Gibbs, 2005).   
  While there appears a clear need for IL-13 in the recruitment of 
basophils to inflammatory tissues, IL-3 is also essential for the maturation 
of basophils within bone marrow before release into the circulation 
(Gibbs, 2005; Holgate & Polosa, 2008; Allakhverdi et al., 2009).  
Additionally, IL-3 is required for movement of these mobilised basophils 
from vasculature and across airway endothelium (Gibbs, 2005).  It has 
been acknowledged however that the role of IL-3 is not singularly 
important in these processes and that other chemokines, such as eotaxin, 
are required for this, as are mast cells (Gibbs, 2005).  Marone et al (2005) 
propose that basophils and mast cells serve a complementary relationship 
to one another.  In their paper, they highlight that, at the site of tissue 
inflammation, mast cells are responsible for the production of IL-3 and IL-
5. This, in turn, increases the secretion of histamine and production of
IL-4 by basophils (Khodoun et al., 2004).  Basophils are believed to 
express CD40 ligand which causes IL-4, and IL-13 release, but in addition, 
proliferation of B-cells, and therefore, increased IgE synthesis (Gibbs, 
2005).  As a result of IL-4 production, there is a reciprocal increase in the 
production of cytokines by mast cells.  Nouri-Aria and Durham (2004) 
suggest that the release of IL-4 peaks at 6 hours following exposure to 
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 antigens and in their study have demonstrated that the presence of IL-4 
increases in bronchial biopsies, and is directly correlated to the number of 
basophils.  Part of this positive feedback mechanism is the resultant 
increase in IgE synthesis, mediated by IL-4 (Jacobsen et al., 2007; 
Vercelli, 2008; Allakhverdi et al., 2009).  This may also be responsible for 
the continued activation of mast cells, resident within inflamed tissues 
(Nouri-Aria & Durham, 2004).  The presence of IL-4 may encourage TH2 
responses (Gibbs, 2005).  This includes the release of cytokines IL-4 and 
IL-13, and pro-inflammatory mediators which may enable continuation of 
late phase allergic inflammation, and further increased migration of 
basophils.  It has more recently been shown that basophils are antigen-
presenting cells which directly impact upon Th2 responses in allergy and 
inflammation (Sokol et al., 2009; Ito et al., 2011).   
 
  Histamine release from basophils is widely considered an integral role in 
the inflammatory process in allergic inflammatory airways (Nouri-Aria & 
Durham, 2004).  Histamine also has a critical role in the 
bronchoconstriction that is characteristic in asthma (Barnes, 2008).  This 
is acknowledged by Marone et al (2005) who also indicate that histamine 
plays a large part in the long term clinical symptoms of allergic asthma.  
Histamine release occurs following antigen stimulation.  In turn, this 
causes cross linking and activation of the IgE surface receptor, FCεRI  in 
basophils (Nouri-Aria & Durham, 2004; Gibbs, 2005; Marone et al., 2005; 
Vercelli, 2008).  The result of histamine release is to regulate the function 
of immune cells (Marone et al., 2005).  Through this process, basophils 
may induce chemotaxis of mast cells, and increase lysosomal enzyme 
release.  Histamine may also serve to regulate basophil recruitment by 
binding to receptors, whereby the release of other cytokines from 
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 basophils appear to form a positive feedback mechanism (Marone et al., 
2005).  
 
  It has been suggested that in addition to histamine release, cross linking 
of FCεRI receptors can also induce LTC4, a member of the cysteinyl 
leukotriene (cysLT) family (Nouri-Aria & Durham, 2004; Gauvreau et al., 
2005). This may be relevant in the clinical symptoms of allergic asthma as 
the increase in cysLTs in turn causes bronchoconstriction (Gauvreau et 
al., 2005).  In addition, there is an increase in mucus secretion, and on a 
cellular level, there is enhancement of eosinophil survival and basophil 
accumulation.  This appears in accordance with the findings of Nouri-Aria 
and Durham (2004) who reported a correlation between the number of 
peripheral basophils, and airway responsiveness.  While Heinemann et al 
(2005) support the notion of basophil involvement in increased AHR, they 
relate it to the increased presence of SCF.  AHR may be a result of 
basophil degranulation, as basophils share common granules with 
eosinophils.  These include major basic protein and eosinophil peroxidise 
(Jacobsen et al., 2007) which has been reported in section 1.1.1.2 as 
involved in local tissue activity.  The conflicting reports may be due to lack 
of suitable cell line models to fully examine the receptors and activities of 
activated basophils.  While receptors for cysLTs have been determined on 
progenitor cells (for basophils and eosinophils) they have yet to be 
evaluated on mature basophils (Gauvreau et al., 2005).  In one study, a 
weak receptor for cysLT1 was identified (Gauvreau et al., 2005).  It 
should be noted however, as acknowledged by the authors, their sample 
came from humans whose allergic status was unknown and so results in 
allergic asthmatic patients should be applied with caution.   
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   Airway remodelling is associated with structural changes in asthma and 
linked to declining lung function (Kariyawasam & Robinson, 2007).  There 
is also a link between airway remodelling and poor regulation of FCεRI 
cells (Marone et al., 2005).  This is not clearly quantified however, clear 
evidence in the role of basophils in angiogenesis of asthmatic airways has 
been presented.  Basophils have been shown to  release angiogenic 
factors from the granules (Marone et al., 2005).  This may directly 
contribute to airway remodelling. 
 
  There appears little clarity, and much controversy as to both the 
mechanism for recruitment and activation, and the role of basophils in 
allergic asthmatic airways.  This may be due to small numbers of cells 
within total leucocyte population, poor cell models, or inadequate 
antibodies.  It has also been shown that basophils are antigen presenting 
cells which may directly impact upon responses to allergens.  Advances 
continue and so this remains an area clearly in need of further 
investigation. 
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1.1.2 Chloride ion channels 
  Chloride (Cl-) channels have been extensively studied for several years.  
While many of them conduct several different anions, chloride remains 
the most prevalent, and so they are named chloride ion channels (Jentsch 
et al., 2002).  Non-specific Cl- channels may also form due to the 
clustering of several peptides in the plasma membrane (Suzuki et al., 
2006).  One of the problems in studying Cl- ion channels is the lack of 
specific agents that can block these channels, as many commercial Cl- 
channel blockers also affect other ion channels (Leblanc et al., 2005; 
Greenwood & Leblanc, 2007).  These issues have historically made 
experimentation, and clear identification of the roles of Cl- channels, 
problematic (Coelho et al., 2004).   
  With advances in the field, several Cl- channels have now been identified 
and cloned.  However, the method of classification of Cl- ion channels 
varies.  Cl- channels may be classified according to their functions or the 
method of regulation of the conductance (Jentsch et al., 2002; Suzuki et 
al., 2006).  Cl- channels may also be classified according to their position 
within the cell, either on the membrane or within the intracellular 
organelles.  This is discussed by Jentsch et al (2002) who highlight that 
none of these methods of classification are without issue.  This is due to 
the lack of clear boundaries between the classes, for example, there is 
often more than one method of regulation for a single channel.  In their 
review they suggest that a more appropriate definition of Cl- ion channel 
would be based upon molecular candidates, or identified gene families.     
Cl- channels can be classified according to their size of single 
conductance, and there have been three classes suggested (Suzuki et al., 
2006). 
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 Those with an in vivo conductance of less than 10 picosiemens (pS) are 
considered “small” and include the ClC family, cystic fibrosis 
transmembrane conductance regulator (CFTR) and Bestrophin.  CLCA1 
and GABAA genes are “middle” sized channels having a conductance of 
10-100 pS whereas the tweety homolog 3 (TTYH3) gene has a “large” 
conductance of over 100 pS.  While this appears a relatively simple 
method of classification, it defines little about either the structure or 
function of such Cl- channels.  It has been stated (Suzuki et al., 2006) 
that the conductance size of channels can merge across the sub-classes 
depending on their state of opening.  Using classes of conductance, it is 
difficult to identify the structure of these families as the transmembrane 
domains (TMDs) are variable and do not appear to relate to the 
conductance.  For example, TTYH3 has been identified as possessing 
between five and six TMDs, bestrophin has four, and CFTR and ClCs have 
between ten and twelve (Jentsch et al., 2002; Suzuki et al., 2006) (Figure 
1.4 presents some predicted models of transmembrane spanning 
regions).  While these molecular candidates will be considered in more 
depth later, they are presented at this point to highlight the difficulties 
with Cl- channel classification based upon conductance.  In addition, there 
appears no clear relationship between regulation of Cl- channels and their 
conductance.  As such, regulation has been used as an independent 
method of classification (Leblanc et al., 2005; Suzuki et al., 2006; 
Greenwood & Leblanc, 2007). 
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Figure 1.4:  Potential chloride ion channel structure (full title on following 
page) 
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  Five categories of Cl- channel have been identified (Greenwood & 
Leblanc, 2007) based on their mechanism of activation; 1.  cAMP/PKA 
activated, 2.  membrane voltage gated, 3.  ligand gated, 4.  cell volume 
activated (also known as swell activated) and 5.  calcium activated 
(CaCC), (Jentsch et al., 2002; Suzuki et al., 2006), (Figure 1.5).  Leblanc 
et al (2005) suggest, however that CaCC channels are ligand gated in 
their nature.  Therefore, the distinction appears to be that ligand gated 
channels are regulated by extracellular ligands and are widely 
documented to be primarily associated with GABAA receptors (inhibitory 
neurotransmitters) (Jentsch et al., 2002; Greenwood & Leblanc, 2007).  
In contrast, CaCC channels are controlled by intracellular ion ligands 
(Suzuki et al., 2006).  For the purpose of this thesis, ligand gated 
Figure 1.4:  Potential chloride ion channel structure:  Diagrams A-D are 
adapted from (Winpenny et al., 2009).  Diagram E adapted from (Ahmen et al., 
2000) and F adapted from (Robinson et al., 2004) A.  Topological model of hCLCA 
showing 1 transmembrane domain (discussion in 1.1.3.3 regarding numbers of 
transmembrane domains) with von Willebrand factor domain A (VWA) located near 
to the remaining C-terminal and demonstrating the cleavage of N-terminal.  B. 
Human bestrophin 1 with 5 transmembrane domains.  C. Represents human CFTR 
as having 12 transmembrane domains which are separated along the phospholipid 
bilayer by a regulator domain and two nucleotide binding domains as ATP binding 
sites. D. Shows the 8 transmembrane spanning regions of human TMEM16A, also 
referred to as ANO1.  E. and F. portray the different topology models for ClC-2 and 
ClC-3.  Whilst in the same family, the number of membrane spanning domains 
differs and segmented portions of the channel 
57 
channels will not be discussed due to their relationship to 
neurotransmitters and not granulocytes or inflammatory airway diseases. 
Figure 1.5:  Five proposed chloride ion channel categories:  
Diagrammatic representation of five propsed chloride ion channel categories 
(Jentsch et al., 2002; Suzuki et al., 2006).  A.  cAMP dependent chloride ion 
channel such as CFTR which is a cAMP-activated ATP-gated anion channel.  B. 
Represents a voltage gated chloride ion channel whereby the change in 
membrane potential causes the channel to open and allow chloride passage 
through the membrane via a selectivity filter.  The response is either 
inhibitory or excitatory depending on the electrochemical potential for chloride 
in a given cell.  C.  Ligand gated ion channel which refers to an extracellular 
ligand required to activate the channel.  D.  Diagrammatic representation of a 
volume regulated chloride ion channel.  The channel opens in response to 
tension within the membrane allowing chloride and potassium to exit the cell, 
which in turn allows passage of intracellular fluid and therefore reduce cellular 
volume.  E.  A Ca2+ activated chloride ion channel which acts in a similar way 
to C with the exception that the ion ligand is intracellular such as an increase 
in intracellular Ca2+ 
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  For overall cell volume regulation the movement Cl- governs the 
movement of fluid, secondary to volume gated Cl- channel stimulation.  Cl- 
channels are passive in that Cl- efflux or influx is dependent upon the 
difference between intracellular and extracellular concentrations (Jentsch 
et al., 2005).  This has been highlighted by Suzuki et al (2006) who 
implicates this in both cell volume regulation, and transport of water and 
salts across membranes.  In this case, Cl- movement is coupled with Na+ 
and therefore fluid by creation of an osmotic gradient (Jentsch et al., 
2002; Suzuki et al., 2006).  There appears a clear role for this process in 
inflamed airway epithelia (Duta et al., 2006).  The transport of fluid into 
inflammatory airways governs the clearance of mucus by directly affecting 
the composition.  This is well documented in the pathology of CF which 
clearly underlines the role of Cl- channels in fluid transport.   
  This highlights the difficulty in both classification of Cl- channels, and the 
definition of their function within granulocytes.  It has become clear 
however, that in order to establish this, there needs to be further clarity 
as to the molecular candidates for these channels, particularly within 
granulocytes.  For the purpose of this project this will include ClCs, CFTR, 
CLCA and Bestrophin.  Tables 1.2-1.9 present some key references used 
in the discussion of molecular candidates. 
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Table 1.2: Key references human CLCA1-4 (hCLCA1-4):  Table summarising some 
of the key references used to formulate the discussion for human CLCA1-4 (hCLCA1-4), 
with tissue expression and postulated function identified within the literature 
Protein 
Identity 
Tissue expression 
of gene 
Key role References 
hCLCA1 Airway epithelia Mucus production 
via cell signalling 
Ion channel 
regulator 
(Zhou et al., 2001; Hoshino et 
al., 2002; Gibson et al., 2005; 
Hauber et al., 2007; Hegab et 
al., 2007; Hauber et al., 2008; 
Hamann et al., 2009) 
Intestinal epithelia Mucus production (Gruber et al., 1998) 
Uterus, stomach, 
testis, kidney, foetal 
spleen 
Ion channel 
regulator 
(Agnel et al., 1999) 
Brain Cell signalling (Zhang et al., 2007) 
hCLCA2 Optic nerve Cell signalling (Piirsoo et al., 2009) 
Kidney Cell signalling/ion 
channel regulator 
(Elble et al., 2006) 
Lung, trachea and 
mammary gland 
Cell signalling/ion 
channel regulator 
(Agnel et al., 1999; Gruber et 
al., 1999) 
Cornea, skin, 
vagina, larynx 
Cell signalling/ion 
channel regulator 
(Itoh et al., 2000; Connon et 
al., 2004; Connon et al., 2005) 
hCLCA3 Spleen, trachea, 
breast, thymus and 
lung 
Cell signalling (Gruber & Pauli, 1999b) 
hCLCA4 Colon, bladder, 
brain, uterus, 
trachea, prostate, 
stomach and 
mammary gland 
Cell signalling (Agnel et al., 1999) 
Nasal epithelium Cell signalling (Mall et al., 2003) 
Optic nerve Cell signalling (Piirsoo et al., 2009) 
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Protein Identity Tissue expression of 
gene 
Key role References 
mCLCA1 Smooth muscle of portal 
vein 
Ion channel 
regulation 
(Britton et al., 
2002) 
Intestine, spleen, bone 
marrow, trachea, aorta, 
brain 
Secretion (Leverkoehne et 
al., 2002; 
Leverkoehne et al., 
2006; Roussa et 
al., 2010) 
Dorsal root ganglia, 
intestine, cecum, brain 
Secretion (Al-Jumaily et al., 
2007) 
Breast  (Gruber & Pauli, 
1999c) 
mCLCA2 Intestine Secretion (Leverkoehne et 
al., 2006; Al-
Jumaily et al., 
2007; Roussa et 
al., 2010) 
Breast  (Gruber & Pauli, 
1999c; 
Leverkoehne et al., 
2002) 
Intestine, trachea, colon, 
thymus, bladder, 
epididymus, skin 
Secretion (Leverkoehne et 
al., 2002) 
Dorsal root ganglia, cecum Secretion (Al-Jumaily et al., 
2007) 
mCLCA3 Airway epithelial mucus 
cells 
Secretion/ion 
channel 
regulation 
(Zhou et al., 2001; 
Leverkoehne & 
Gruber, 2002; 
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Brouillard et al., 
2005; Gibson et 
al., 2005) 
Stomach, uterus, colon Secretion (Komiya et al., 
1999) 
Intestine Secretion (Komiya et al., 
1999; Leverkoehne 
et al., 2006) 
mCLCA4 Smooth muscle ; bladder, 
intestine, stomach, uterus, 
aorta and lung 
Cell signalling (Elble et al., 2002; 
Leverkoehne et al., 
2006) 
Epithelial cells Cellular 
processing and 
regulation 
(Huan et al., 2008) 
mCLCA5 Squamous epithelium 
(keratinocytes) 
Maturation (Braun et al., 
2010) 
Eye, intestine and spleen Cancer cell 
adhesion 
(Evans et al., 
2004) 
Dorsal root ganglion (Al-Jumaily et al., 
2007) 
mCLCA6 Intestines Secretion (Bothe et al., 2008) 
Stomach Secretion (Evans et al., 
2004) 
Table 1.3:  Key references mouse CLCA1-6 (mCLCA1-6):  Table to 
summarise some of the key references used to formulate the discussion for 
mouse CLCA1-6 (mCLCA1-6), with tissue expression and postulated function 
identified within the literature 
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Protein 
Identity 
Tissue 
expression of 
gene 
Key role References 
bCLCA1 Trachea Secretion (Cunningham et al., 
1995) 
bCLCA2 Lung 
endothelium 
(Cunningham et al., 
1995; Elble et al., 2006) 
eCLCA1 Small airways Cell signalling (Anton et al., 2005; 
Ryhner et al., 2008; 
Gerber et al., 2009) 
eCLCA2 Olfactory 
neurons 
Cell signalling (KanehisaLaboratories, 
2009) 
pCLCA1 Colon and 
retinal epithelia 
Secretion/channel 
regulator 
(Gaspar et al., 2000; 
Loewen et al., 2002a; 
Loewen et al., 2002b; 
Loewen et al., 2003; 
Loewen et al., 2004; 
Plog et al., 2009) 
rCLCA1 Salivary cells, 
ileum, lung 
Secretion (Yamazaki et al., 2005; 
Ishibashi et al., 2006) 
rCLCA2 Cerebellum, 
cerebrum, 
kidney, 
stomach, spinal 
cord, lung small 
intestine 
Cell signalling? (Yoon et al., 2006) 
rCLCA4 Uterus, lung and 
heart 
Cell signalling (Song et al., 2009) 
Table 1.4:  Key references mixed species CLCA:  Table to summarise some of the key 
references used to formulate the discussion for bovine (b), equine (e), porcine (p) and rat 
(r) CLCAs, with tissue expression and postulated function identified within the literature 
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Protein 
Identity 
Tissue 
expression of 
gene 
Key role References 
hBest 1 Retinal pigment 
epithelium 
Volume 
regulation 
(Marmorstein et al., 
2002; Tsunenari et 
al., 2003; 
Fischmeister & 
Hartzell, 2005; Hagen 
et al., 2005; Yu et al., 
2006; Milenkovic et 
al., 2007; Mullins et 
al., 2007; Yu et al., 
2007; Burgess et al., 
2008; Eksandh et al., 
2008; Milenkovic et 
al., 2008; Qu & 
Hartzell, 2008; Xiao et 
al., 2008; Boon et al., 
2009; Davidson et al., 
2009; Milenkovic et 
al., 2009; Qu et al., 
2009; Xiao et al., 
2009) 
Retinal pigment 
epithelium 
Ion channel 
regulation 
(Yu et al., 2008) 
Colon 
epithelium 
Cell proliferation (Spitzner et al., 2008) 
Pancreatic duct Secretion (Marsey & Winpenny, 
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epithelial cells 2009) 
Airway/intestinal 
epithelium 
Secretion (Duta et al., 2004; 
Kunzelmann et al., 
2007; Kunzelmann et 
al., 2009) 
hBest2 Kidney, 
bronchial 
epithelium 
Secretion, 
membrane 
conductance 
(Tsunenari et al., 
2003; Qu & Hartzell, 
2008; Milenkovic et 
al., 2009) 
Non-pigmented 
ciliary 
epithelium 
Secretion/fluid 
regulation 
(Zhang et al., 2010) 
hBest3 Skeletal muscle Cell Signalling ? (Stöhr et al., 2002) 
Testis and 
retina 
(Tsunenari et al., 
2003) 
hBest4 Airway 
epithelium 
Membrane 
conductance 
(Milenkovic et al., 
2009) 
Testis and brain (Tsunenari et al., 
2003) 
Kidney and 
ovary 
membrane (cell 
lines) 
(Tsunenari et al., 
2006) 
Table 1.5:  Key references human bestrophin 1-4 (hBest1-4):  Table to 
summarise some of the key references used to formulate the discussion for human 
bestrophin 1-4 (hBest1-4), with tissue expression and postulated function identified 
within the literature 
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Protein 
Identity 
Tissue 
expression of 
gene 
Key role References 
mBest1 Retinal pigment 
epithelium 
Volume 
regulation 
(Bakall et al., 
2003; 
Marmorstein et 
al., 2006; 
Neussert et al., 
2010) 
Trachea Secretion (Barro-Soria et 
al., 2008; Barro-
Soria et al., 
2009) 
Renal collecting 
duct 
Ion channel 
regulation, cell 
proliferation 
(Aldehni et al., 
2009; Barro-
Soria et al., 
2009; O'Driscoll 
et al., 2009) 
Dorsal root 
ganglia, brain 
Ion channel 
regulation 
(Boudes et al., 
2009; Park et al., 
2009) 
mBest2 Trachea Secretion (Barro-Soria et 
al., 2008) 
Nasal, eye, colon 
epithelia, 
trachea, brain, 
lung and kidney 
Secretion (Bakall et al., 
2008; Zhang et 
al., 2009) 
Olfactory 
sensory neurons 
? (Pifferi et al., 
2006; Pifferi et 
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al., 2009b) 
Colon Secretion (Yu et al., 2010) 
Salivary glands Secretion (Srivastava et 
al., 2008) 
mBest3 Heart Ion conductance (O'Driscoll et al., 
2008; Srivastava 
et al., 2008) 
Parotid gland ? (Srivastava et 
al., 2008) 
Vascular smooth 
muscle 
Conductance (Qu et al., 2010) 
Table 1.6:  Key references mouse bestrophin 1-3 (mBest1-3):  Table to 
summarise some of the key references used to formulate the discussion for 
mouse bestrophin 1-3 (mBest1-3), with tissue expression and postulated 
function identified within the literature 
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Protein 
Identity 
Tissue expression 
of gene 
Key role References 
Drosophila 
Best1 
? derived from cell 
line drosophila S2 
Ion transport (Chien et al., 2006; 
Chien & Hartzell, 
2007) 
Drosophila 
Best2 
Ion transport (Chien et al., 2006) 
Drosophila 
Best3 
Ion transport (Chien et al., 2006) 
Drosophila 
Best4 
Ion transport (Chien et al., 2006) 
Canine Best1 Retinal pigment 
epithelium 
Volume 
regulation 
(Guziewicz et al., 
2007) 
Rat Best1 Retinal pigment 
epithelium 
Volume 
regulation 
(Rosenthal et al., 
2005) 
Rat Best2 Olfactory epithelial Cell 
differentiation 
and proliferation 
(Klimmeck et al., 
2009) 
Rat Best3 Vascular smooth 
muscle 
Ion transport (Matchkov et al., 
2008) 
Xenopus Best1 Embryo Embryogenesis (Qu et al., 2003; 
Onuma et al., 2009) 
Xenopus Best2 Embryo Embryogenesis (Qu et al., 2003; 
Onuma et al., 2009) 
Porcine Best1 Eye Ion regulation (Stanton et al., 
2006) 
Table 1.7:  Key references multi-species Bestrophins:  Table to summarise some of 
the key references used to formulate the discussion for drosophila, canine, rat, xenopus and 
porcine bestrophins, with tissue expression and postulated function identified within the 
literature 
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Protein 
Identity 
Tissue 
expression of 
gene 
Key role References 
ClC-0 Ubiquitous Chloride ion 
regulation, 
regulation of 
membrane potential 
(Pusch et al., 1995; 
Middleton et al., 1996; 
Ludewig et al., 1997; 
Bykova et al., 2006; 
Engh et al., 2007) 
ClC-1 Skeletal muscle Voltage stabilization (Steinmeyer et al., 
1991; Steinmeyer et 
al., 1994; Fahlke et al., 
1996; Fahlke et al., 
1997a; Fahlke et al., 
1997b; Fahlke et al., 
1998; Rychkov et al., 
1998) 
ClC-2 Ubiquitous Volume regulation (Jentsch et al., 1995) 
T cells, B cells, 
neutrophils and 
myeloid cells 
Activation, cell 
volume and shape 
regulation 
(Jiang et al., 2002) 
ClC-3 Brain, kidney, 
skeletal muscle, 
retina, lung 
Ion regulator (Duan et al., 1997) 
Neutrophils Activation (Moreland et al., 2006; 
Moreland et al., 2007; 
Davis-Volk et al., 2008) 
T cells, B cells, 
neutrophils and 
myeloid cells 
Activation, cell 
volume and shape 
regulation 
(Jiang et al., 2002) 
ClC-4 Brain, heart, Ion (Picollo & Pusch, 2005) 
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skeletal muscle regulation/antiporter 
B cells, 
neutrophils 
Activation, cell 
volume and shape 
regulation 
(Jiang et al., 2002) 
ClC-5 Kidney, myeloid 
cells 
Chloride ion 
regulation, cell cycle 
progression 
(Jiang et al., 2004; 
Picollo & Pusch, 2005) 
T cells, B cells, Activation, cell 
volume and shape 
regulation 
(Jiang et al., 2002) 
ClC-6 Ubiquitous Volume regulation, 
stabilization of 
membrane potential 
(Eggermont et al., 
1997; Neagoe et al., 
2010) 
ClC-7 Kidney, testis, 
skeletal muscle, 
brain, bone 
Ion 
regulation/antiporter 
(Kornak et al., 2001; 
Wartosch et al., 2009) 
ClC-Ka Kidney Fluid regulation in 
urine, chloride ion 
regulation 
(Markovic & Dutzler, 
2007; Picollo et al., 
2007; Zifarelli et al., 
2010) 
ClC-Kb Ubiquitous Volume regulation (Jeck et al., 2000; 
Picollo et al., 2007) 
Table 1.8:  Key references human ClC family:  Table to summarise some of the 
key references used to formulate the discussion for human ClC-0-7, ClC-Ka and ClC-
Kb, with tissue expression and postulated function identified within the literature 
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Protein 
Identity 
Tissue expression of 
gene 
Key role References 
mANO1 Oesophagus, bladder, 
breast 
Epithelial 
secretion 
(Rock et al., 2007) 
Epithelial cells; eye, 
inner ear, blood vessel 
walls, olfactory nerves, 
lung 
Secretion, action 
potential 
generation, 
smooth muscle 
contraction, 
chloride 
conductance, 
apoptosis, cell 
proliferation 
(Schroeder et al., 
2008; Yang et al., 
2008; Almaça et al., 
2009; Gritli-Linde et 
al., 2009; Schreiber et 
al., 2010) 
Trachea smooth muscle 
and epithelia 
Embryonic 
development of 
trachea 
(Rock et al., 2008; 
Huang et al., 2009) 
mANO2 Epithelial cells Chloride 
conductance 
(Schroeder et al., 
2008; Pifferi et al., 
2009a) 
Neuronal and muscle 
tissue 
Chloride 
conductance 
(Schreiber et al., 
2010) 
mANO3 Neuronal and muscle 
tissue, eye, cartilage 
and bone 
? (Gritli-Linde et al., 
2009; Schreiber et al., 
2010) 
mANO4 Neuronal and muscle 
tissue 
? (Schreiber et al., 
2010) 
mANO5 Neuronal and muscle 
tissue 
? (Schreiber et al., 
2010) 
mANO6 Epithelial tissue Chloride 
conductance and 
secretion 
(Schreiber et al., 
2010) 
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Neuronal, eye, 
olfactory neurons, 
mouth, cartilage, bone, 
skin, teeth 
Chloride 
conductance and 
secretion 
(Gritli-Linde et al., 
2009) 
mANO7 Epithelial tissues Chloride 
conductance 
(Schreiber et al., 
2010) 
mANO8 Epithelial tissues ? (Schreiber et al., 
2010) 
Neuronal tissues, eye, 
ear, olfactory and nasal 
epithelia, mouth, 
cartilage, bone, skin, 
teeth 
? (Gritli-Linde et al., 
2009) 
mANO9 Epithelial tissues ? (Schreiber et al., 
2010) 
Neuronal tissues, eye, 
ear, olfactory and nasal 
epithelia, mouth, 
cartilage, bone, skin, 
teeth 
? (Gritli-Linde et al., 
2009) 
mANO10 Epithelial tissue ? (Schreiber et al., 
2010) 
Table 1.9:  Key references mouse anoctamin 1-10 (mANO 1-10) 
(also known as TMEM16) family:  Table to summarise some of the key 
references used to formulate the discussion for mouse ANO1-10, with tissue 
expression and postulated function identified within the literature 
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1.1.3 Potential molecular candidates for chloride ion channels 
in granulocytes 
1.1.3.1  ClC 
  This small conductance gene family currently consists of ten members; 
ClC-0, ClC-1-7, ClC-Ka and ClC-Kb (Jentsch et al., 2002; Suzuki et al., 
2006; Cheng et al., 2008; Jentsch, 2008).  The structure of these proteins 
has been reported to be similar across the members, having between 10-
12 TMDs, a transmembrane transport domain and a soluble regulatory 
domain (Dutzler, 2006).  Despite the structural similarities, these proteins 
have a variety of functions which appear dependent upon three main 
variables.  These being the primary function, either as a Cl- channel or a 
Cl-/H+ antiporter (Dutzler, 2006; Matulef & Maduke, 2007), their cellular 
position (either intravesicular or within the cell membrane) or the tissue 
location (Jentsch, 2008).  There also appears to be some differences 
across the family members with regard to their regulation.  ClCs can be 
either voltage or volume gated (Jentsch et al., 2002; Suzuki et al., 2006)  
and fast gated acting on an individual pore, or slow gated also known as 
common gating (Jentsch et al., 2002; Bykova et al., 2006).  All of these 
factors impact upon the perceived function of each member. 
  The ClC family have classically been considered as voltage gated Cl- 
channels (Jentsch et al., 2002; Moreland et al., 2006; Suzuki et al., 2006) 
however, ClC-2 and ClC-3 have been identified as volume gated Cl- 
channels (Duta et al., 2006; Suzuki et al., 2006).  Jentsch et al (2002) 
have suggested that members ClC-0, ClC-1, ClC-2, ClC-Ka and –Kb are 
membrane bound whereas all other members are located within 
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intracellular organelles, namely lysosomal vesicles (Jentsch et al., 2005; 
Mummery et al., 2005; Cheng et al., 2008).  It has been suggested that 
those within intracellular vesicles have a clear role in regulating pH within 
lysosomes, and are in fact not classical Cl- channels but Cl-/H+ antiporters 
(Jentsch et al., 2005; Picollo & Pusch, 2005).  This is supported by Iyer et 
al (2002), however their focus was on bacteria.  This must be considered 
cautiously in relation to human tissues due to the differences in molecular 
structure between vertebrates and bacteria (Chen, 2005). 
1.1.3.2  CFTR 
  The cystic fibrosis transmembrane conductance regulator (CFTR) has 
been implicated in the pathology of cystic fibrosis (CF) (Boucher, 2007; 
Bangel et al., 2008; Moran & Zegarra-Moran, 2008).  CFTR is considered 
a cAMP activated channel as activation of the channel can only occur 
when protein kinase A is stimulated.  This causes an increase in 
intracellular cAMP (Jentsch et al., 2002; Boucher, 2007).  While they are 
considered a member of the ATP-Binding Cassette (ABC) family, they 
have also been discovered to be a Cl- channel in their own right 
(Schwiebert et al., 1999; Sheppard & Welsh, 1999; Suzuki et al., 2006; 
Moran & Zegarra-Moran, 2008).  The location of these channels has been 
identified as primarily the apical lung epithelia (Yoshimura et al., 1991), 
pancreatic ducts (Bubien, 2001; Sanz et al., 2010), colon (Ntimbane et 
al., 2009), and cardiac muscle (Horowitz et al., 1993).  There has also 
been evidence to suggest CFTR in lymphocytes (Krauss et al., 1992; 
Lepple-Wienhues et al., 2001) and more specifically, neutrophils (Painter 
et al., 2006; Painter et al., 2010).   
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  Dysfunction of the CFTR channel in inflammatory airways causes a 
decrease in Cl- secretion into the airway lumen.  As a result, there is 
decreased fluid movement resulting in classical clinical symptoms of CF.  
Primarily the increased viscosity of mucus within airways and increased 
infection (Jentsch et al., 2002; Mummery et al., 2005; Suzuki et al., 2006; 
Boucher, 2007; Döring & Gulbins, 2009).  It has also been suggested that 
CFTR dysfunction can regulate other ion channels such as outwardly 
rectifying Cl- channels (Jentsch et al., 2002) and epithelial Na+ channels 
(ENaC).   
  It has been hypothesised that CFTR inhibits Na+ absorption through 
ENaC which in CF is compromised by depletion of the CFTR gene.  In this 
instance, there is hyper-absoprtion of Na+ through ENaC and reduction in 
Cl- secretion via CFTR which alters the balance of fluid movement across 
the apical membrane of airway cells.  Hyper-abosorption of Na+ further 
increases airway dehydration (Jentsch et al., 2005; Suzuki et al., 2006; 
Boucher, 2007).  Boucher (2007) supports this citing a study using CF 
mice whereby increased Na+ absorption due to absence of CFTR 
increased pro-inflammatory cytokine release from airway epithelia 
(Terheggen-Lagro et al., 2005).  This in turn may lead to increased 
migration of neutrophils and the neutrophilia observed in CF lungs.  
Freedman et al (2002) however has shown in CFTR knockout mice that 
neutrophil levels were not different from wild type mice suggesting that 
CFTR mediated cytokine release may not impact upon migration.  Murine 
models of CFTR should be considered with caution when applying to 
human cells as there is markedly less CFTR in healthy murine tissue and 
some differences in phenotypes (Bangel et al., 2008).  The suggestions 
here however are tentatively supported by clinical trials in humans. 
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  Human studies examining bronchoalveolar lavage have demonstrated 
increased IL-8 in CF airways compared to non-CF airways (Khan et al., 
1995; Bonfield et al., 1999).  It has been suggested that this is a direct 
result of CFTR dysfunction and directly correlates with neutrophil 
migration (Chmiel et al., 2002).  The migration of neutrophils is increased 
due to cytokine secretion from airway epithelial cells, as a result of 
imbalanced ion transport.  
1.1.3.3  CLCA 
  The CLCA gene family was first discovered in 1995 (Cunningham et al., 
1995) and since then, has been the focus of many articles trying to 
elucidate the structure and function of the family members (Britton et al., 
2002; Leblanc et al., 2005; Patel et al., 2009; Winpenny et al., 2009).  
There are several isoforms of CLCA including; 4 human (hCLCA1-4), 6 
murine (mCLCA1-6), 5 rat (Piirsoo et al., 2009), 2 porcine (pCLCA1-2) and 
2 bovine (bCLCA1-2) (Elble et al., 1997; Loewen & Forsyth, 2005).  In 
addition, Anton et al (2005) reported the first equine CLCA (eCLCA1) 
which has a similar homolog to hCLCA1 and mCLCA3.  And more recently, 
the Kanehisa Laboratories (2009) have examined eCLCA2.   
    The human CLCA homologues have a distinct and differential pattern 
of tissue expression (Loewen & Forsyth, 2005; Patel et al., 2009). This 
may be related to the genomic organization.  hCLCA1-4 genes have cDNA 
sequence identities from 52% to 92% and are found in chromosome 1 
(1p31-22) and run consecutively (Gruber & Pauli, 1999a; Pauli et al., 
2000; Loewen & Forsyth, 2005).  These are ordered with hCLCA2 being 
the most 5’, hCLCA1, hCLCA4 and hCLCA3 as most 3’ in the gene cluster 
loci (Patel et al., 2009; Piirsoo et al., 2009).  One mechanism of temporal 
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gene expression control is thought to be by such gene clustering.  It has 
been argued however that the clustering of the CLCA genes has no 
regulatory significance (Gruber & Pauli, 1999a).   
  The protein level of CLCA expression remains unclear however each 
isoform has a different structure and function (Loewen & Forsyth, 2005). 
With the exception of hCLCA3, the human CLCA homologues have a 
precursor translation protein product of approximately 125 kDa.  This is 
product is then thought to cleave, via a proteolytic cleavage site, to 
subunits of approximately 90 kDa of N-terminal product and 35kDa of C-
terminal product (Gruber & Pauli, 1999b; Pauli et al., 2000; Patel et al., 
2009).  In contrast, hCLCA3 has a premature stop codon and a shorter 
protein product (approximately 37kDa) (Gruber & Pauli, 1999b).  A 
common feature of all the human CLCA homologues is that they have a 
protein-protein interaction domain known as the von Willebrand factor 
type A (VWA).  This is found directly adjacent to the N-terminal however 
the structure of this differes in each isoform (Abdel-Ghany et al., 2001; 
Patel et al., 2009).  hCLCA2 VWA contains a β4-integrin binding site 
whereas the other isoforms bind proteins using a highly conserved set of 
five residues (metal ion-dependent adhesion site) (Loewen & Forsyth, 
2005; Patel et al., 2009). 
  In addition to differences in tissue gene expression, protein size, and 
VWA domains, there are differences in the structure of the four human 
homologues and how they cleave.  Both N-terminal and C-terminal 
products of hCLCA1, along with full length protein, have been found 
secreted into media when expressed in human cell lines (Gibson et al., 
2005; Mundhenk et al., 2006).  In contrast, hCLCA2 C-terminal protein 
products remain membrane bound, secreting the N-terminal product 
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(Elble et al., 2006; Pawlowski et al., 2006).  hCLCA3 has been considered 
to be completely secreted whilst hCLCA4, similar to hCLCA2, maintains a 
membrane bound C-terminus (Patel et al., 2009; Plog et al., 2012).  
  The prediction of transmembrane domain (TMD) number for each 
human CLCA isoform differs.  hCLCA1 has several potential models.  One 
suggests that there are four TMDs however and alternative suggestion is 
that there is only one (Pauli et al., 2000; Loewen & Forsyth, 2005).  
hCLCA1 was also considered to possess 5 TMDs (Suzuki et al., 2006).  
This was in contrast previous studies suggesting that hydropathy analysis 
of hCLCA1 discovered 4 TMDs (Gruber et al., 1998).  Hamann et al (2009) 
have alternatively stated that there are no transmembrane domains 
evident at all for CLCA proteins (Gibson et al., 2005).  hCLCA2 however, is 
considered to have five TMDs.  In contrast, the hCLCA3 contains two 
internal stop codons which create open reading frames coding for two 
sequences.  One stop codon in hCLCA3 terminates the polypeptide 
sequence before any potential TMDs, therefore producing a secreted 
hCLCA3 product.  The second open reading frame codes a second 
polypeptide which lacks a signal peptide (Gruber & Pauli, 1999b; Loewen 
& Forsyth, 2005; Patel et al., 2009).  To date, there is limited evidence on 
the structure of hCLCA4.  Experimental data using porcine and murine 
orthologs (pCLCA4a and mCLCA6 respectively) suggest that hCLCA4 also 
secretes the N-terminal and that the C-terminal product is bound to the 
cell membrane by at least one TMD (Plog et al., 2012). 
  Whilst there are similarities in the structure of each CLCA isoform, the 
differences between them may impact upon potential functions.  As their 
name suggests, these proteins were originally considered to be Ca2+ 
activated Cl- channels (Gruber & Pauli, 1999b; Britton et al., 2002).  
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Greenwood and Leblanc (2007) however state that the evidence for this is 
weak as there is disparity between properties of Ca2+ activated Cl- 
channels and CLCAs.   
  As discussed, some CLCA isoforms have been considered secretory 
proteins which exit a cell and re-binds externally (hCLCA1 and hCLCA3), 
whereas others cleave the N-terminal portion and maintain a cell 
membrane bound product with TMDs (Gruber & Pauli, 1999b; Jentsch et 
al., 2002).    In one study, Gibson et al (2005) used bioinformatics 
analysis which differs from previous studies using hydrophobicity analysis. 
They found that the N-terminal cleavage products of hCLCA1 were found 
in the broncho-alveolar lavage fluid of patients with asthma where 
hCLCA1 is strongly up-regulated in airway epithelia and goblet cells 
(Rogers, 2003; Tyner et al., 2006).  This further supports the hypothesis 
that it is a secreted protein.   However, all isoforms have been shown to 
possess protein-protein binding sites (VWA) (Loewen & Forsyth, 2005; 
Patel et al., 2009).  These would bind to alternative chloride ion channels. 
CLCA proteins have therefore been considered regulators of functional 
aspects of some ion channels, and the expression of endogenous Cl- 
channels within cell membranes (Loewen et al., 2002a; Gibson et al., 
2005; Leblanc et al., 2005; Suzuki et al., 2006; Greenwood & Leblanc, 
2007). 
  CLCAs have been implicated in cell-cell adhesion in carcinoma and as a 
tumor suppressor (Pauli et al., 2000; Piirsoo et al., 2009).  That CLCAs 
have a role in Cl- channel conductance also appears well established in 
that an increase in CLCA expression leads to an increase in Cl- 
conductance and efflux (Britton et al., 2002; Loewen et al., 2002a; Gibson 
et al., 2005; Loewen & Forsyth, 2005; Hamann et al., 2009).  It should be 
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noted however that the evidence appears to come from a variety of CLCA 
members and so application across the group should be considered with 
caution. 
  The role of CLCA in chloride conductance remains unclear and appears 
reliant upon whether it is secreted or cleaved leaving a membrane bound 
portion (Loewen & Forsyth, 2005; Pawlowski et al., 2006; Piirsoo et al., 
2009).  It has been shown that on addition of a Ca2+ ionophore 
(ionomycin) CLCA proteins were activated.  This produced an outwardly 
rectifying current, as examined under patch clamping, which was inhibited 
by a chloride conductance inhibitor (DIDS) (Cunningham et al., 1995; 
Gruber et al., 1998).  This was supported with a later murine study of 
mCLCA5 (homologue of hCLCA2) and mCLCA6 (homologue hCLCA4) 
which showed that ionomycin stimulated a current in HEK293 transfected 
cells, that had a reversal potential that was correlated to the equilibrium 
potential for chloride.  This was not found in cells that weren’t transfected 
with mCLCA5 or mCLCA6, or mock transfected (Evans et al., 2004).   
Whilst this contributes evidence that they are involved in Ca2+ activated 
chloride conductance, the method remains unclear.  Secreted proteins 
hCLCA1 and hCLCA3 may modulate this by activation of an alternative 
Ca2+ activated chloride channel.  For CLCAs with membrane bound 
portions, the protein-protein binding site may bind to alternative channels. 
It has been suggested that this is due to the metal ion-dependent 
adhesion site in the VWA binding calcium in CLCA proteins, which in turn 
alter the conductivity of other chloride ion channels (Loewen & Forsyth, 
2005).  It has been argued however that hCLCA3 may not have any 
biological function (Loewen & Forsyth, 2005).   
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  There remains difficulty in clearly defining the structure of CLCAs, and 
mapping channel activity to sequences for CLCAs. Therefore, functional 
role of CLCAs remains contentious (Pawlowski et al., 2006).  There is 
mounting evidence to suggest a role for the CLCA family of proteins in 
Ca2+ chloride conductance but not as a channel directly transporting 
chloride in itself.  CLCA proteins may indirectly be involved in chloride 
conductance, therefore, by interacting with alternative calcium activated 
chloride channels in a potential signalling capacity (Loewen & Forsyth, 
2005; Pawlowski et al., 2006; Patel et al., 2009). 
  The CLCA1 gene has been considered to be asthma specific in airway 
epithelial cells (Lloyd & Saglani, 2010).  This was demonstrated in both 
murine and human models whereby mCLCA3 and hCLCA1 respectively 
were up-regulated in response to Th2 cytokines simulating asthma (Zhou 
et al., 2001).  More recently, IL-13 has been shown to up-regulate 
mCLCA3 which supports this (Nakano et al., 2006).  It appears that the 
role of hCLCA1 in asthma and inflammatory airway diseases is mucus 
production (Izuhara et al., 2009).  Overexpression of hCLCA1 leads to 
hyperplasia of airway goblet cells and mucus hyper secretion (Rogers, 
2003) via increased Cl- efflux, and therefore fluid movement following 
osmotic gradients (Gruber & Pauli, 1999b; Gibson et al., 2005).  This was 
supported by a study using rats whereby niflumic acid directly affected 
mucous production by blocking CLCA1 (Hegab et al., 2007).  
  Anton et al (2005) also suggest that blocking hCLCA1 can decrease 
airway inflammation in these pathophysiologies and use equine CLCA 
clones as a model.  It appears unclear however, as to whether there are 
local effects on epithelial cells, a decrease in migration of granulocytes, or 
whether there are actions of granulocytes themselves.  Equine studies are 
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also not considered a strong model for use in human asthma or COPD 
due to the environmental effects of stabling, such as dust irritation.  
There appears no published evidence supporting the expression of CLCA 
proteins in granulocytes. However, Anton et al (2005) suggest that 
mCLCA3 (which is of a similar isoform to hCLCA1) acidifies mucin granule 
content of goblet cells (Gibson et al., 2005).  If a similar relationship were 
apparent in granulocytes, there may be both intracellular and extracellular 
responses.  Theses responses include release of inflammatory cytokines 
and granule content, resulting in respiratory burst and airway 
inflammation (Gibson et al., 2005). 
  hCLCA1 may also be implicated in cell maturation, which could be 
applicable to granulocytes.  The findings of Loewen and Forsyth (2005) 
support this claiming that mCLCA3 increases Cl- conductance to balance 
H+-ATPase processes.  This restores electrical neutrality following granule 
acidification in cell maturation processes.  Again it should be noted that 
this is speculative as no published evidence supports expression of CLCA 
in granulocytes.  There are clear indications that further studies are 
needed, particularly structural and functional studies to elucidate the role 
of CLCAs in granulocyte function. 
1.1.3.4  Bestrophin 
  Bestrophin is a protein that was discovered in 2002 (Sun et al., 2002).  
There are four homologues in humans; hBest1-4.  It has also been 
described in animals, including mice, Gram negative bacteria and some 
fungi (Hagen et al., 2005).  Bestrophin proteins are considered Ca2+ 
activated Cl- channels regardless of their locality (Suzuki et al., 2006; 
Greenwood & Leblanc, 2007; Kunzelmann et al., 2007; Barro-Soria et al., 
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2010).  That they are Cl- channels is supported by Leblanc et al (2005) 
who suggest that they are sensitive to the specific Cl- channel blocker 
DIDS (4,4’-diisothiocyanatostilbene-2,2’-disulphonic acid) (Barro-Soria et 
al., 2010).  Unlike CLCA proteins, there also appears consensus that they 
are membrane bound, having 4-6TMDs (Leblanc et al., 2005; Greenwood 
& Leblanc, 2007). 
  These proteins appear to be self-regulating.  Qu et al (2006) found in 
their study that bestrophins have a C-terminus that regulates their activity 
(Hagen et al., 2005; Qiang et al., 2007).  While this seems to support an 
independent role for bestrophin, Kunzelmann et al (2007) have suggested 
that a Cl- selective filter has been found only on the second TMD.  They 
postulated that bestrophins may therefore work in a complementary 
relationship with another protein.  It has been suggested that CLCA and 
bestrophin may be complementary partners in Ca2+ activated Cl- channels 
and resultant Cl- movement (Loewen & Forsyth, 2005).  In a recent study 
(Barro-Soria et al., 2010), it was demonstrated however, that human 
bestrophin1 did not appear on the membrane of epithelial cells, but 
presented evidence that it localises to the endoplasmic reticulum 
(Kunzelmann et al., 2009).  In these cells, bestrophin1 assists intracellular 
calcium signalling and was linked to activation of TMEM16A (anoctamin1), 
an alternate Ca2+ activated Cl- channel. 
  Bestrophins have been linked to the pathology of Best’s disease, macular 
dystrophy of the retina.  This is due to dysfunction of the bestrophin Cl-
channel and fluid shifts following osmotic gradients (Duta et al., 2004; Qu 
et al., 2004; Chien et al., 2006). It has also been shown that hBest1 is 
permeable to HCO3- which directly causes fluid shift in disease processes 
(Qu & Hartzell, 2008). While this is linked to the retina, the movement of 
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fluid may have functional implications for granulocytes.  Fluid movement 
particularly impacts cell volume regulation implicated in migration to areas 
of inflammation, and suggests that bestrophins are dual activated by both 
Ca2+ and cell volume (Chien & Hartzell, 2007).  The evidence presented 
for bestrophin1 in retinal pigment epithelium cells has been questioned as 
electro-physical properties of such are not altered by mutations of 
bestrophin 1 and in knock-out mice, ocular pathology is not evident 
(Kunzelmann et al., 2009).  If the hypothesis of bestrophin1 implication in 
retinal fluid movement can be proven, it may also be suggested to play an 
important role in the production of mucus in inflammatory airways (Duta 
et al., 2004; Barro-Soria et al., 2010).  Unfortunately however, there 
appears no published evidence supporting the presence of bestrophin in 
granulocytes. 
  There appears a need, therefore, for further examination into the 
expression of bestrophin, potentially coupled with other proteins such as 
CLCA, in granulocytes, and discussion as to their function in humans.   
1.1.3.5  TMEM16A and tweety (hTTYH3) as potential candidates 
  While the above outline the major candidates for Cl- channels in 
granulocytes, it must be acknowledged that there are some putative Cl-
channels which may be considered in the future.  Due to the apparent 
lack of evidence either for Cl- channels in granulocytes, or hTTYH3 and 
TMEM16A, it remains difficult to relate these to either eosinophils, 
neutrophils or basophils.  They may however be potential candidates for 
Cl- channels in need of further investigation. 
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  Tweety was originally discovered as the flightless gene in flies (Suzuki et 
al., 2006) but has however been identified as having human homologs 
(Suzuki, 2006).  One of these is the human tweety, hTTYH3, which is a 
large conductance Ca2+ -activated Cl- channel, and also a cell volume 
regulated channel.  Suzuki (2006) suggests that by investigating this 
particular protein, we may gain more information about other channels, 
particularly those involved in the maintenance of body fluid volumes.  In 
addition, it seems an appropriate candidate to explore for granulocyte 
roles, such as cell shape and size regulation during inflammatory 
migration. 
  Another potential target for investigation is TMEM16A, also referred to 
as Anoctamin1 (ANO1).  TMEM16A was identified by three groups 
(Caputo et al., 2008; Schroeder et al., 2008; Yang et al., 2008).  This has 
been identified as one of 10 homologues in a family of proteins 
(Kunzelmann et al., 2009; Schreiber et al., 2010).  Schroeder et al (2008) 
highlight this family of proteins, stating that they are found within the cell 
membrane of Xenopus oocytes, however that function is currently 
unknown.  They hypothesise from their studies that they are Ca2+
activated Cl- channels responsible for stabilising membrane potentials.  
They may also be present on the membranes of intracellular organelles 
(Rock et al., 2008), which if present in granulocytes, may impact upon the 
inflammatory response and respiratory burst, particularly in chronic airway 
diseases.  It has been argued recently that whilst ANO1 itself acts as a Cl- 
channel, the structure and properties of the homologous group will vary 
according to tissue and cell site.  Indeed, the structure for ANO1-8 has 
been predicted and suggests that these homologues may function as 
chloride ion channels.  ANO9 and 10 structure and function remains 
unpredicted (Kunzelmann et al., 2009).  There is clear evidence 
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(Schreiber et al., 2010) for ANO1 in airway epithelial cells in mice, and 
mice lacking in ANO1 display a general defect in epithelial electrolyte 
transport.  Electrolyte transport has a direct impact upon the movement 
of fluid across epithelial cells.  This influences the consistency of mucus in 
airway cells particularly, and mice lacking ANO1 will mimic the pathology 
of cystic fibrosis in that mucus becomes thick and clearance is reduced 
(Rock et al., 2008; Kunzelmann et al., 2009; Schreiber et al., 2010).  It 
has been shown in laboratory experiments that ANO1 null mice have a 
decrease in mucocilliary clearance (Kunzelmann et al., 2009). 
  Anoctamins 1, 6-10 have been found predominantly in epithelial cells 
however ANO2-ANO5 have been found in neuronal and muscle tissues 
(Schreiber et al., 2010).  This may further impact upon the symptoms of 
chronic inflammatory lung disease, due to failure of smooth muscle 
contraction (Kunzelmann et al., 2009). 
  This supports the role of ANO1 in chloride conductance and particularly 
the implications for mucus clearance in inflammatory lung diseases.  As 
yet, the presence of this protein has not been described in human 
granulocytes. 
1.1.3.6  CLIC 
  The first chloride intracellular channel (CLIC) was characterised in 
bovine kidney cortex (Redhead et al., 1992; Landry et al., 1993) and 
named p64.  The human homologue, NCC27, was later cloned in a 
myelomonocytic cell line and localised to the cell nucleus (Valenzuela et 
al., 1997).  This was named CLIC1.  Conversely, it was later shown using 
immunofluorescent microscopy that CLIC1 is present throughout the 
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cytoplasm of cells (Berryman & Bretscher, 2000), and is also an integral 
membrane protein (Tonini et al., 2000).  Therefore, CLIC1 can be one of 
two structures; soluble globular protein or integral membrane protein 
(Littler et al., 2010).  CLIC1, with the other members of the CLIC family, 
have been described as a “metamorphic proteins” (Murzin, 2008; Littler et 
al., 2010).  This is due to their ability to form more than one stable 
structure.  CLIC1 can be either a soluble monomer or an oxidised dimeric 
state.  The transition between monomer and channel involves membrane 
docking and insertion of the N-terminal through the phospholipids bilayer 
(Littler et al., 2010).  This reversible reaction makes function difficult to 
establish.  Early electrophysiological studies have shown that several 
membrane insertions of the CLIC1 protein through the phospholipid 
membrane acts as a chloride ion channel (Valenzuela et al., 1997; Tonini 
et al., 2000).  In support it has been shown that when CLIC1 is added to 
a buffer, it will insert into synthetic phospholipid bilayers (Tulk et al., 
2002).  The function for CLIC1 is predominantly chloride transport 
(Berryman & Bretscher, 2000).   
  CLIC2 was first identified as a protein of 243 amino acids (Heiss & 
Poustka, 1997).  It has been shown in similar electrophysiological studies 
that this also integrates phospholipid membranes and is therefore 
considered a chloride ion channel structure which creates a loop in the C-
terminal allowing possible recognition of neighbouring proteins (Cromer et 
al., 2007).  The postulated function of CLIC2 is linked directly to this 
structural feature.  It has been suggested that CLIC2 may have a role in 
the suppression of Ca2+ release intracellularly (Board et al., 2004; Littler 
et al., 2010). 
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  As CLIC1, the later identified CLIC3 has also been primarily localised in 
the nucleus of cells (Qian et al., 1999).  Qian et al (1999) suggest that the 
CLIC family of proteins are not themselves chloride channels as they lack 
the ability to span the membrane.  However, they may modulate chloride 
channel activity.  It was shown that the COOH-terminal tail of CLIC3 
reacts with mitogen-activated protein (MAP) kinases and so may be 
involved in cell growth regulation (Qian et al., 1999). 
  It has been shown that CLIC4 acts as an ion channel (Chuang et al., 
1999).  It has been considered that the transmembrane domain at the N-
terminus may assist in the insertion of CLIC4 into the phospholipid 
membrane (Singh & Ashley, 2007).  The selectivity of this channel, 
however, is poor and there has been suggestion that is may not be an 
exclusive anion channel but may also transport cations such as potassium 
(Singh & Ashley, 2007; Singh et al., 2007; Littler et al., 2010).  Like 
CLIC1, CLIC4 appeared to be diffuse throughout the cytoplasm of human 
placenta (Berryman & Bretscher, 2000).  However, in human kidney cells, 
CLIC4 has been found predominantly in the apical membrane and 
endoplasmic reticulum (Edwards, 1999; Littler et al., 2010).  The variance 
in locality may have implications for the functions of CLIC4.  It has been 
implicated in the biogenesis of some neuropeptides, secondary to changes 
in Cl- permeability either directly as a channel, or as a channel regulator 
(Chuang et al., 1999).  They may also have an important role in the 
formation of collateral arterial circulation through angiogenesis (Littler et 
al., 2010). 
  CLIC5 was identified in 2000 using placental microvilli (Berryman & 
Bretscher, 2000).  It has been shown that CLIC5, like CLIC1 and CLIC4 
will integrate phospholipid membranes and act as a non-selective ion 
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channel (Singh & Ashley, 2007; Singh et al., 2007).  There is strong 
evidence to suggest that CLIC5 may have an important function within 
muscle cells.  Berryman and Bretscher (2000) demonstrated through 
expressional analysis that CLIC5 was expressed at higher levels in skeletal 
muscle and heart tissue.  They used biochemical fractionation and 
immuno-labelling to show that sub-cellular distribution of CLIC5 was at 
the apical membrane of polarised epithelial cells.  Within muscle cells, 
CLIC5 may have an important functional role as it interacts directly with 
the actin cytoskeleton and so may be acting as a scaffolding protein 
(Littler et al., 2010). 
  The human homologue CLIC6 was first cloned in 2003 (Friedli et al., 
2003).  This followed from the rabbit orthologue, Parchorin, which was 
expressed in the cytosol primarily but also identified in the apical 
membrane of gastric glands (Nishizawa et al., 2000).  In contrast to the 
other members of the CLIC family, human CLIC6 possesses a long N-
terminal end, and is the largest member with 704 amino acid residues 
(Friedli et al., 2003).  As yet, whether CLIC6 functions as a chloride 
channel is yet to be confirmed (Friedli et al., 2003; Griffon et al., 2003).  
It was shown that it localises to the plasma membrane however Griffon et 
al did not demonstrate any changes to chloride conductance in HEK293 
transfected cells (Griffon et al., 2003). 
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1.1.4 Evidence for Cl- channel candidates in granulocytes 
1.1.4.1  Volume gated Cl- channels 
  Volume gated Cl- channels are activated when there is an increase in the 
tension of cellular plasma membrane (Suzuki et al., 2006).  This process 
allows the regulation of both Cl- and K+, and therefore the transport of 
fluid across the cell membrane.  The dysfunction of these channels have 
been implicated in mice with degraded retina, and the presence of large 
conductance volume regulated Cl- channel has been well documented in 
renal cells (Suzuki et al., 2006).  It has been suggested in a recent review 
(Salmon & Ahluwalia, 2009) that neutrophils may contain a swell 
activated chloride ion channel.  This channel may be stimulated in 
activated neutrophils in order to counteract the phagocyte, NADPH 
oxidase, generated depolarisation.  This may provide a link between 
neutrophils, inflammatory responses in airways and chloride ion channels 
in humans.  However, the evidence to support the role of swell activated 
chloride ion channels in either granulocytes or in inflammatory airway 
diseases remains limited.  The reason may be a lack of clarity surrounding 
the molecular candidates for such channels, or that they have currently 
not been clearly identified in many cell types, making research into 
structure and function problematic (Jentsch et al., 2002; Suzuki et al., 
2006).  Despite this, it has been suggested that volume gated anion 
channels, through control over cell volume, have a role to play in cellular 
differentiation and apoptosis (Zholos et al., 2005).  While this may have a 
direct impact upon granulocytes, this is not clarified.   
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  Ducharme et al (2007) supports the role of volume gated channels in 
the control of cell volume and continues to suggest that ClC-2, ClC-3 and 
Bestrophin 1-4 have been identified as protein candidates.  These were 
identified, however, in the neurological immune cells, microglia.  In this 
instance, volume gated channels were implicated in cellular migration, as 
a response to chemotactic stimuli.  This was, however, in murine samples. 
The question remains, therefore, can this be applied to either humans, or 
granulocytes?   
  The molecular candidates implicated in granulocytes, particularly 
eosinophils are shown in the earlier findings of Schwingshackl et al 
(2000).  In this study, CFTR, ClC-2, ClC-3, ClC-4, ClC-5 and ClC-6 were 
identified using reverse transcriptase polymerase chain reaction (RT-PCR). 
It was demonstrated that the only proteins studied that were expressed in 
eosinophils were ClC-3.  An advantage of this study was that they used 
asthmatic patients and so would account for any up-regulation of genes 
during inflammatory processes in the airways.  Their conclusions, 
however, support the role of Cl- channels in eosinophils, with respect to 
regulation of cellular volume.  This is implicated in the process of cellular 
migration, as eosinophils need to decrease their volume for extravasation 
and infiltration into inflamed tissues (Schwingshackl et al., 2000; Agrawal 
et al., 2008).   
  It has been suggested that Cl- ion channels involved in volume 
regulation have an essential role in phagocytotic functions and cellular 
migration (Cheng et al., 2008).  This is because they govern cell shape 
changes (Moreland et al., 2006).  These Cl- channels must, in which case, 
be membrane bound to facilitate transmembrane transport of water and 
salts (Moreland et al., 2006; Jentsch, 2008). 
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  Controversially, it has been shown that ClC-3 was directly linked to 
phagocytosis and respiratory burst activity (Moreland et al., 2006).  The 
release of superoxides and perpetuation of inflammatory tissue damage is 
a further result of this process.  Moreland et al (2006) have shown that 
ClC-3 is located in secretory vesicles.  In this study, they showed that ClC-
3 knockout mice demonstrated a decrease in NADPH oxidase function.  
Therefore, a decrease in neutrophil respiratory burst.  It may be 
suggested that in addition to a role in pH regulation of such vesicles, 
stimulation of these may trigger membrane bound channels that are 
involved in fluid transport, and therefore cell shape changing.  They also 
demonstrated that by decreasing anion activity, migration of neutrophils 
decreased.    It should be noted that experiments were on mice and 
therefore application to humans should be considered cautiously.  To 
further strengthen their argument, however, supporting the role of ClC-3 
in neutrophil action, they found that the mice used in their experiment 
died of sepsis when ClC-3 was inhibited, in contrast to the control mice 
who did not.  They suggested that this was due to the blocked anion 
channel decreasing NADPH oxidase activity.  It has been shown, however, 
that tamoxifen, a swell activated chloride channel inhibitor, decreased 
respiratory burst but that in neutrophils, it did not inhibit swell activated 
chloride conductance (Ahluwalia, 2008).  This suggests that there may be 
alternative modulation of chloride channels.  For example, extracellular pH 
may have an important role in regulation of ClC-3 rather than swell 
activation.  
  Other members of the ClC gene family are not clearly linked to 
granulocytes however this appears to be due to a lack of performed 
experiments, rather than suggesting there is no function in these cells. 
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The observed role of this family is to regulate electrical excitability, 
maintain transepithelial water and salt transport and maintenance of 
intracellular organelle pH (Dutzler et al., 2002; Bykova et al., 2006; Cheng 
et al., 2008).  Differing ClC members have been found in specific target 
organs.  For example, those involved in the renal disease processes 
Bartter syndrome and Dent’s disease are suggested to be ClC-Ka and ClC-
5 respectively and can be found in kidney cells (Dutzler et al., 2002; 
Suzuki et al., 2006; Jentsch, 2008).  A role for ClC-K in the defence 
against inflammatory airway diseases has also been suggested (Mummery 
et al., 2005).  Using the human model for sub-mucosal gland cells, Calu-
3, Mummery et al (2005) demonstrated that ClC-K compensated for 
dysfunction of the CFTR Cl- channel by increasing Cl- conductance.  This 
may indicate that as yet, functions for members of the ClC family are not 
entirely known and suggests the need for further experimentation, with 
particular reference to granulocytes and their function.   
1.1.4.2 Voltage gated Cl- channels 
  Greenwood and Leblanc (2007), Jentsch et al (2002) and Suzuki et al 
(2006) have suggested that voltage gated Cl- channels are encoded by 
the ClC gene family, specifically ClC-1.  This is of specific relevance in 
skeletal muscle as these membrane bound Cl- channels are responsible 
for the regulation of cellular electrical excitability (Jentsch et al., 2002).  
In this process, resting membrane potential is stabilised by an influx of Cl- 
to counteract the influx of Na+ or Ca2+.   
  Secondly, Cl- ion channels can lead to an excitatory response in 
alternative cells, such as smooth muscle where the electrochemical 
potential for chloride is higher than the resting potential.  In this instance 
93 
the opening of Cl- drives chloride outward and the membrane to an 
excitatory depolarisation voltage of -20mV (Suzuki et al., 2006).  In this 
instance, open Cl- channels cause an increase of intracellular Ca2+, as a 
response to a second messenger system which may drive depolarisation.   
The result is an increase in vascular tone (Jentsch et al., 2002).  This 
raises the question as to how these channels may impact upon 
granulocyte function; are they excitatory or a stabilizing agent?  If voltage 
gated Cl- channels are excitatory in granulocytes, this may result in some 
of the inflammatory processes outlined above. 
  Simchowitz et al (1993) have suggested that, in neutrophils, Cl- channels 
are opened in response to chemotaxis, and as a result the membrane 
depolarizes which may support the hypothesis of excitation in 
granulocytes.  In contrast, Krause and Welsh (1990) argue that while 
membrane depolarization is an excitable response in many cells (i.e. 
skeletal), in neutrophils, this is an inhibitory effect.  They suggest that a 
negative feedback mechanism occurs where there is a reduction in 
production of oxygen radicals, and a decrease in the release of granules.  
While this examines whether membrane depolarization is excitatory or 
inhibitory, it does not clarify the role of voltage regulated channels in this 
process.  In one early study,  three ion channels were identified in 
neutrophils; voltage gated K+ channels, and Ca2+ activated K+ and Cl- 
channels (Krause & Welsh, 1990).  This study, however, used blood 
samples from healthy donors only and so may not account for up-
regulation of proteins during inflammation, such as in asthma, COPD or 
CF.  In contrast, Schwingshackl et al (2000), suggested that in response 
to Cl- channel stimulation, eosinophils are activated.  As a result of 
eosinophil activation, there is a release of superoxides, respiratory burst, 
and a release of toxins (Femling et al., 2006).  In their experiment, they 
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demonstrated that Cl- flux was blocked by the application of anti-
asthmatic drugs.  Schwingshackl et al (2000) also implicate ClC-3 as the 
Cl- channel responsible for respiratory burst in eosinophils.  Their samples 
were taken from asthmatic subjects which allows clearer application to Cl- 
channels in granulocyte function, focused upon airway inflammatory 
diseases.  In a similar study using human T lymphocytes, application of 
4,4’-diisothiocyanatostilbene-2,2’-disulphonic acid (DIDS)  and 5-nitro-2-
(3-phenylpropylamino) benzoic acid (NPPB) inhibited cell signalling and 
activation (Phipps et al., 1996).  This was also demonstrated in an earlier 
study using B lymphocytes (McCann et al., 1990).  This study used the 
mouse model to block chloride ion channels and measure single channel 
conductance.  This supports the role of chloride ion channels in the 
activation of lymphocytes and so may support a similar role in 
granulocytes.   
  In contrast however, Agrawal et al (2008) showed that activation of Cl- 
channels decreased eosinophil activation in their research using human 
asthmatic subjects.  This suggests that depolarisation has an inhibitory 
effect.  In this study, an anti-asthmatic drug currently used in Japan 
(suplatast tonsilate) was applied and the effects upon chemotaxis, 
migration and respiratory burst recorded.  This was done with and 
without the presence of Cl- channel blockers, including; DIDS, 
anthracene-9-carboxylic acid (9AC), gadolinium chloride, R(+)-[(6,7-
dichloro-2-cyclopentyl-2,3-dihydro-2-methyl-1-oxo-1H-inden-5yl)-oxy] 
acetic acid 94 (IAA94), and NPPB.  This was in order to establish the 
relationship between eosinophil action and Cl- channels.  These 
contrasting studies add further confusion, however studies of eosinophil 
Cl- channel function remain problematic as molecular candidates remain 
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largely unknown (Agrawal et al., 2008).  To elucidate these, may provide 
a target for treatment in asthma.   
  In contrast, it has been shown that volume sensitive chloride channels in 
the plasma membrane are responsible for whole cell conductance of 
chloride (Ross et al., 1994; Lepple-Wienhues et al., 1998).  Alternatively 
lymphocytes may have a cAMP dependent Cl- ion channel.  It has been 
shown using peripheral blood samples from CF patients that this chloride 
channel may be similar to that found in the epithelial airway cells and 
dysfunction may lead to some of the symptoms in this disease (Chen et 
al., 1989; Bubien et al., 1990).  In a replicate study this was not 
supported (Hagiwara et al., 1989) however this may be due to density of 
the chloride channel or phase of cell cycle.  This may account for the 
difficulties in obtaining data from granulocytes.  Wang et al (2006) further 
examined lymphocytes and chloride channels.  In this study they found 
that, by blocking chloride channels with DIDS in conjunction with the 
inhibitor of calcium entry SK&F 96365, there was a significant reduction in 
ClC-3 mRNA.  This was in comparison with either blocking agents being 
applied alone.  This suggests that the lymphocyte chloride channels may 
be calcium activated.  Further elucidation of structure and function of 
chloride ion channels is required to postulate a role in granulocytes.  
1.1.4.3 Calcium-activated Cl- channels 
  Despite having identified gene families for CaCC channels, Suzuki et al 
(2006) claims that the structure and function of these channels remains 
unclear. Therefore, the role of these channels is difficult to assess in 
relation to granulocytes.  There appears to be a role for these such as in 
cellular migration, or maturation, particularly in neutrophils, (Krause & 
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Welsh, 1990).  Tintinger et al (2005) also suggest that prior to onset of 
inflammatory processes in neutrophils (superoxide production, 
degranulation, adhesion and synthesis of IL-8), there is an increase in 
cytosolic Ca2+.  The relationship between this and Cl- channel stimulation 
is not discussed however it supports the hypothesis that Cl- channels may 
have a role within neutrophil function.  
1.1.4.4 cAMP-activated channels 
  CFTR has been identified in lymphocytes and neutrophils (Painter et al., 
2006; Painter et al., 2010).  In neutrophils, is has been shown that in CF 
defective cells, the transport of chloride is decreased, and therefore the 
bactericidal properties of neutrophils is reduced (Painter et al., 2006).  
This was shown using immunofluorescence staining, reverse transcriptase 
polymerase chain reaction and immunoblotting.  Painter et al (2010) 
claims that chloride is essential in phagosomal function, activation of 
neutrophils and infection defence (Jacquot et al., 2008).  Activation of 
neutrophils in CF lung is known to cause inflammatory responses.  This is 
due to production of proteases and reactive oxygen species resulting in a 
reduction of mucociliary bacterial clearance (Jacquot et al., 2008).   
  Figure 1.6 presents a diagrammatical summary of postulated chloride 
channel functions. 
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Figure 1.6:  Diagrammatical summary of postulated chloride channel functions. The functions of chloride 
channels within cells may be dependent upon cell type and localisation within the cell.  This figure presents a 
summary of overall postulated functions of chloride ion channels, adapted from Cheng et al (2008) 
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1.1.5 Summarising remarks; Cl- channels and granulocyte 
function 
  The evidence presented appears to implicate granulocytes in 
inflammatory processes, which can be applied to airway pathologies such 
as asthma and COPD.  However, the recruitment and roles of each 
granulocyte subtype is not often presented with absolute clarity or 
application to human airway diseases.  By examining the role of chloride 
channels within granulocyte function the function of granulocytes may 
become more evident.   
  The role of Cl- channels has been discussed, in order to firstly; elucidate 
the role of granulocytes in chronic inflammatory lung diseases, and 
secondly; to identify potential molecular candidates for such channels. 
  What remains consistent is the need for further research in all of these 
areas, particularly linking to human granulocytes.  If the molecular 
proteins for Cl- channels on granulocytes could be clearly identified, an in-
depth analysis of their structure and function within specific cells could 
ensue.  This in turn would add evidence supporting the role of Cl-
channels within granulocytes, and ultimately, clarify how these cells may 
first be stimulated, attracted, and act in response to inflammatory airway 
diseases. 
  In summary, there is a clearly identified need to discover which Cl-
channel protein and gene families are present in granulocytes. 
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1.2  Hypothesis and rationale 
  The evidence is clear that granulocytes have a role to play in chronic 
inflammatory lung diseases, such as COPD and asthma.  The lung 
pathology of these diseases differs with differing clinical manifestations.  
This may be due to differing cells involved in the inflammatory process, 
such as agranulocytes, or granulocytes.  That white blood cells migrate to 
inflammatory tissues is clearly documented however there appears to be 
little evidence to identify which chloride ion channels are up-regulated, if 
at all, in granulocytes.  If up-regulation of a specific chloride ion channel 
is evident, then there needs to be further clarity as to the potential role of 
this in granulocytes in chronic inflammatory lung diseases. 
  The aim of this project is to elucidate potential candidates for chloride 
ion channels in granulocytes.  A second aim is to provisionally explore the 
potential role of human bestrophin 1 in granulocyte function. 
  Human bestrophin 1 has been selected as a focus for experimental work 
as one of the potential candidates for chloride ion channels.  The 
discussion presented within the introduction has identified that chloride 
ion channels are implicated in the function of granulocytes particularly 
through cell volume regulation, activation and proliferation of cells, cell 
signalling through cytokine release and regulation of alternative ion 
channels (see figure 1.6) (Agrawal et al., 2008; Cheng et al., 2008).   It 
has also been shown that prior to the recruitment and activation of pro-
inflammatory processes in specifically neutrophils, there is a significant 
increase in cytosolic calcium (Tintinger et al., 2005).  This suggests that 
chloride ion channels in granulocytes may be calcium activated, of which 
human bestrophin 1 is a prime candidate (Kunzelmann et al., 2007; 
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Barro-Soria et al., 2010).  Anoctamin 1 is also considered a calcium 
activated chloride ion channel (Schroeder et al., 2008) however it has 
been shown that hBest1 may modulate its activity (Barro-Soria et al., 
2010).  This further suggests that hBest1 requires focus.  As stated, there 
are a number of chloride ion channels which may prove candidates for 
chloride ion channels in granulocytes.  hBest1, however, also appears to 
be commonly implicated with  the key functions associated with chloride 
ion channels in granulocytes (Cheng et al., 2008) (figure 1.6).      
 Experimental aims will be drawn together and applied to inflammatory 
lung diseases following a systematic review of the evidence for up-
regulation of chloride ion channels in inflammatory lung diseases.   
  It is hypothesized that chloride ion channels, specifically focussed upon 
human Bestrophin 1, are up-regulated in granulocytes during 
inflammatory lung disease processes.  It is suggested that up-regulation 
impacts upon the functional role of granulocytes and are a novel 
therapeutic target in the management of symptoms in these disease 
processes.  hBest1 may modulate activity and regulation of alternative 
channels such as hANO1.  Additionally, hBest1 may have a role in 
granulocyte volume regulation through fluid shifts.  It is hypothesised that 
changes in cell volume and shape will directly impact upon cellular 
migration and activation.  hBest1 up-regulation may have therapeutic 
inflammatory effects such as allowing phagocytosis through cell shape 
modulation.  Alternatively however, up-regulation of hBest1 in 
granulocytes over a prolonged period of time may cause tissue damage.  
In this instance, hBest1 may be implicated in respiratory burst, airway 
fibrosis and airway hyper-responsiveness.  The evidence suggests a 
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positive correlation between granulocyte accumulation in COPD and 
asthma, and exacerbation of symptoms. 
  It is hypothesised therefore, that hBest1 is implicated in the role of 
granulocytes in chronic inflammatory lung dieases.  It is hypothesised that 
hBest1 is a novel therapeutic target for pharmacological interventions in 
chronic inflammatory lung diseases, for the control and management of 
symptoms.  It is acknowledged, however, that there are a number of 
targets which require investigation, and that hBest1 is among them.    
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CHAPTER 2:  MATERIALS AND METHODS 
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2.1  Cell and tissue culture 
2.1.1  Commercial cell lines 
2.1.1.1  EoL-1 cell line 
  The commercial human eosinophilic leukaemia cell line (EoL-1) was 
supplied by the Health Protection Agency Culture Collections (HPACC), 
United Kingdom.  The country of origin being Japan.  Cells are non-
adherent and were suspended in RPMI 1640 with 4mM L-glutamine 
(Invitrogen, UK) supplemented with 10% foetal bovine serum (BioSera, 
East Sussex, UK), 100 IU/ml penicillin and 100 mg/ml streptomycin, and 
cultured in a T75 flask.  Cultures were incubated at 37oC in humidified 5% 
CO2.  Concentration of cells was maintained between 5 x 105 cells/ml and 
1 x 106 cells/ml according to HPACC recommendations, and at 
approximately 60-80% confluence.  Concentration was established by 
using trypan blue solution (Sigma-Aldrich, UK) (section 2.1.1.5).  EoL-1 
cells were re-suspended according to concentration and confluence by 
centrifuging at 150 relative centrifugal force (RCF) for 8 minutes at 4 oC 
to pellet cells and re-suspending in media as outlined above. 
2.1.1.2  dEoL-1 
  EoL-1 cells in media (as in 2.1.1.1) were split into T25 flasks and re-
suspended to 5 x 105 cells/ml.  N6, 2’-0-dibutyryladenosine 3’:5’-cyclic 
monophosphate sodium (dbcAMP, Sigma, UK), was diluted with deionised 
water (dH2O) to 100mg/ml, alliquoted and stored at -20 oC according to 
manufacturer instructions.  250 μl (25mg) of dibutyryl cAMP was added to 
each flask.  Cells were cultured for 9 days with re-stimulation with 
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dbcAMP and readjustment of cell numbers to 5 x 105 cells/ml every 3 
days.  After day 9, cells were examined under microscopy to establish 
differentiation and therefore dEoL-1 cells.  
2.1.1.3  HL60 cells 
  HL60 cells were obtained from Dr Dietmar Steverding (Norwich Medical 
School, UEA). HL60 cells are a commercial human promyelocytic 
leukaemia cell used as a model for human polymorphonuclear cells 
(PMNs).  HL60 cells are also non-adherent and suspended in media.  They 
were cultured using the same method as the EoL1 cells. Cells were 
seeded into a T75 flask in RPMI 1640 with 4mM L-glutamine (Invitrogen, 
UK) supplemented with 20% foetal bovine serum (FBS) (BioSera, East 
Sussex, UK), 100 IU/ml penicillin and 100 µg/ml streptomycin.  FBS was 
increased to 20% to improve culture growth.  Cultures were incubated at 
37oC in humidified 5% CO2.  The concentration of cells was maintained 
between 5 x 105 cells/ml and 1 x 106 cells/ml according to HPACC 
recommendations for culture, and at approximately 60-80% confluence.  
2.1.1.4  Epithelial cells 
  A variety of commercially available cells have been used including A549 
(derived from human alveolar basal epithelial tumours), SAEC (primary 
non-cancerous small airway epithelial cells), NAEC (nasal epithelial cell 
line), Calu-3 (human sub-mucosal cell line), CHO (Chinese hamster 
ovary), Vero-SG (kidney from the African green monkey), HEK293 (human 
embryonic kidney) and CFPAC (cystic fibrosis pancreatic duct 
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adenocarcinoma cell).  These have been used in order to act as a control 
for PMN data and also for transfection of purified bestrophin cDNA. 
  Each of the epithelial cell lines were cultured in either T25 or T75 flasks 
with the appropriate media (Table 2.1).  Media for each cell line was 
supplemented with 10% foetal calf serum, 100 IU/ml penicillin and 100 
µg/ml streptomycin.  All media changed 3 times per week (supplied by 
Invitrogen, UK).  Cells were incubated at 37OC in 5% CO2 and grown to 
1x105 cells/cm2. 
Cell 
line 
Media 
A549 Dulbeccos Modified Eagles Media (DMEM) with 4mM L-
glutamine (Invitrogen, UK)  
SAEC Bronchial Epithelial Basal Media (Lonza Walkersville, 
Switzerland)  
NAEC Bronchial Epithelial Basal Media (Lonza Walkersville, 
Switzerland)  
Calu-3 DMEM with 4mM L-glutamine (Invitrogen, UK) 
CHO Minimum Essential Medium Eagle with 4mM L-glutamine 
(Invitrogen, UK) 
Vero-SG DMEM glutamax (Invitrogen, UK) 
HEK293 DMEM with 4mM L-glutamine (Invitrogen, UK) 
CFPAC DMEM with 4mM L-glutamine (Invitrogen, UK) 
 
Table 2.1:  Culture media used for each epithelial cell line:   
Epithelial cell lines used and the recommended culture media for growth. 
Information for growth media from cell providers and HPACC 
recommendations 
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2.1.1.5  Trypan and kimura staining 
  To establish cell viability, and to calculate cellular concentration, cells 
were stained with trypan blue (Sigma Aldrich, UK).  Cells were stained at 
a dilution factor of 2.  This was 10μl trypan with 10μl cell solution.  
Stained cells were applied to the plate of a haemocytometer and 
visualised under 40x magnification.   
  Stained cells were visualised and any blebbing of the cell, or excess blue 
staining was noted and these cells were not considered viable.  Viable 
cells were visualised as bright, clear cells which were consistently uniform 
in shape.  The viable cells were counted in four large squares of the 
haemocytometer field and an average number of cells per large 
haemocytometer square calculated (N).  To convert the observed cell 
count into a calculation of cells/ml the following calculation was used 
Cells/ml = N x 104 x dilution factor 
This concentration was used to resuspend cells as appropriate for 
experimentation or tissue culture. 
  Kimura staining was used to differentiate PMNs.  This was used at a 
concentration of 1:10 where 10µl cell suspension was added to 90µl 
kimura stain.  Eosinophils cytoplasm stained green, whereas monocytes 
and neutrophils did not. 
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2.1.2  Primary cells 
2.1.2.1  Peripheral blood and PMN purification 
  Peripheral blood was harvested by trained phlebotomists from healthy 
human donors following informed consent.  Ethics approval for the study 
had been obtained from the Faculty of Health Ethics Committee (Appendix 
1 for letter of approval).  Polymorphonuclear cells were purified using 
dextran sedimentation and percol density gradient separation, with lysis 
steps to remove remaining red blood cells.  Protocol outlined in figure 2.1  
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Figure 2.1:  Protocol for preparation of peripheral blood:  Protocol for 
purification of PMNs from whole blood using dextran sedimentation techniques. 
Dextran is added to whole blood to sediment red blood cells and supernatant 
removed for further processing.  Sample centrifuged and pellet resuspended in 
phosphate buffered saline (PBS).  Percol added and further centrifuge to pellet 
PMNs.    PBS and Hepes supplied by Invitrogen, UK  
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  40ml of harvested peripheral blood was added to 4ml of sodium citrate 
tribasic as an anticoagulant.  This was centrifuged, without brake, at 350 
RCF, 21 oC, for 20 minutes.  Serum was aspirated from the top of the 
sample and discarded.  Remaining cells were re-suspended to 40ml in PBS 
with gentle agitation of cell pellet.  10ml of 6% dextran was added to the 
40ml sample, mixed and allowed to sediment for removal of red blood 
cells.  The sample was incubated for 30 minutes at room temperature.  
Following this, the supernatant (upper layer) was removed and kept, red 
blood cells isolated with dextran sedimentation discarded.  Supernatant 
contained nucleated cells and some contaminating red blood cells.  These 
cells were centrifuged to form a pellet (350 RCF for 6 min at 21 oC) and 
washed with PBS.  Supernatant was removed to leave 5-10ml and the 
pellet which was then re-suspended in the remaining supernatant.  10ml 
of 69% percoll was added to falcon tubes and equal volumes of the 
suspension layered on top of this.  The sample was centrifuged at 700 
RCF for 20 minutes at 21 oC to force the PMNs through the percoll to the 
bottom of the tube, leaving an upper monocyte layer which was removed 
and discarded.  The percoll supernatant was then removed and the PMN 
pellet washed with PBS as per previously described wash step.  In order 
to lyse contaminating red blood cells, a hypotonic shock solution (9.7ml 
deionised water with 300μl of 1M Hepes buffer solution) was prepared 
and 9ml added to the cell pellet and incubated at room temperature for 
30 seconds.  1ml of 10 times concentrated PBS was added to make the 
solution isotonic and avoid lysis of PMNs. 
  In order to purify the PMN population, negative selection of eosinophils 
from neutrophils was used.  This technique was used throughout all blood 
preparation as the isolated neutrophils had minimal eosinophil 
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contamination.   Contamination of eosinophils was considered by RT-PCR 
(section 2.3).  The signal for mixed PMNs was much brighter than those 
for purified eosinophils for any commonly detected band (ie hBest1 and 
hBest3).  It was deduced therefore that the weaker signal for any 
eosinophils would not create a false positive where there may not have 
been mRNA in PMNs.  In this instance, mixed PMNs were considered over 
90% neutrophils and any contamination minimal.  This was not 
considered significant to impact upon the results for mixed PMNs.  Human 
CD16 purified antibody (Invitrogen, UK) was applied to the cells and the 
sample added to a membrane column using a magnetic field to filter 
neutrophils which were labelled with beaded CD16.  CD16 is more 
prevalent in neutrophils however there is some present in eosinophils.  To 
ensure maximal purification, cells were distinguished morphologically 
under light microscopy at 60x magnification (see figure 1.1 for DAPI 
stained images) using DAPI, and 40x magnification using kimura staining.  
No monocyte contamination was observed on differential counts.  The 
sample was cell counted using trypan staining and haemocytometer 
techniques as described above.   
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2.1.3  Microscopy for cellular morphology 
  Cells were trypan stained using the method outlined in 2.1.1.5 and 
visualized under a light microscope at 40 x magnification to establish cell 
viability.  Morphological changes, such as blebbing, indicated that cells 
were not viable.  Cell suspensions were cytospun onto Superfrost 
microscope slides by readjusting cell concentration to 1 x 106 cells/ml and 
adding 50-100μl of cell suspension to each chamber in the Shandon 
Double Cytofunnel (Thermo Electron Corp, Cheshire, UK).  Each chamber 
was clamped to the glass slide and cytospun at 500 RCF for 5 minutes.  
Cells were either fixed prior to, or following, cytospinning using 4% 
paraformaldehyde (PFA) for 15 minutes, protected from light, at 4 oC.  To 
establish nuclear morphology, DAPI dihydrochloride nucleic acid stain was 
used.  DAPI (Invitrogen, UK) 10mg vial of dry powder was reconstituted 
with 2ml dH2O to yield a 5mg/ml stock solution.  This was alloquoted to 
50μl and stored at -20 oC until required.  For use, stock DAPI solution was 
diluted to 1:2000 with PBS and 10-20μl applied to the surface of the slide 
over the area of cells.  Slides were incubated for 15 minutes at room 
temperature, protected from light.  Following incubation, DAPI was 
removed and the surface of the slide rinsed with non-sterile PBS three 
times.  The cell area was then covered with Fluoromount-G 
(SouthernBiotech, Birmingham, UK) for fluorescence and 22mm2 cover 
slips were applied.  Slides were left to set at 4 oC, protected from light, for 
30 minutes and the cover slips were fixed.  Prepared slides stored at 4 oC 
until required. 
  Cells that were immunolabelled were cytospun directly onto glass slides 
and fixed and mounted as per above. 
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  Immunolabelled and DAPI stained slides were examined using 
fluorescent microscopy on AxioCam©.  The microscope was prepared as 
per manufacturer instructions.  Microscope slides were oil submerged and 
visualized under 60x magnification using appropriate filters for staining; 
Blue for DAPI stained, GFP for immunolabelled with either Alexafluor 488 
or FITC (see table 2.3).  For PMNs or EoL-1 and dEoL-1 cells, images 
captured using multidimensional acquisition and “z-stacking” appropriate 
to measured cell sizes. 
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2.1.4  Cytokine stimulation 
  Granulocytes (PMNs) and purified eosinophils were washed and 
resuspended in fresh media at a concentration of 1x106 cells/ml.  1 ml 
aliquots were placed in 24 well plates.  Cytokines (IL-4, IL-5 and IL-13) 
were added to the appropriate wells at a final concentration of 10ng/ml 
for each cytokine.  Plates were incubated at 370C, 5% CO2 humidified air 
for either 24 or 48 hours according to the defined time course.  Following 
incubation, cells were washed in PBS and resuspended in lysis buffer for 
RT-PCR analysis or in staining buffers for flow cytometry (Sections 2.2.1 
and 2.3.1).  All cytokine stimulations were performed under sterile 
conditions. 
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2.2  RNA expression and DNA sub-cloning 
2.2.1  Reverse transcriptase polymerase chain reactions 
2.2.1.1  Preparation of mRNA 
mRNA was prepared using two methods; TRIzol® preparation and cell 
lysate preparation for smaller cell yields. 
2.2.1.1.1  TRIzol® preparation of mRNA 
Cells were centrifuged at 200 RCF, room temperature, for 2.5 minutes 
and washed using PBS (as described previously).  800µl TRIzol® 
(Invitrogen, UK) was added to the cell pellet and vortex used to re-
suspend.  200µl chloroform was added and repeat vortex to mix.  This 
was incubated for 3 minutes at room temperature.  To separate RNA from 
the organic phase, the samples were centrifuged at 13000 RCF, 4°C for 
15 minutes and the upper clear RNA removed and transferred into a 
sterile eppendorf.  The equivalent volume of isopropanol was added and 
repeat vortex to mix.  The sample was then incubated for 10 minutes at 
room temperature.  A repeat 15 minute centrifuge at 4°C, 13000 RCF to 
pellet RNA was performed and supernatant removed and discarded.  1ml 
70% ethanol (made with nuclease free water) was added to the RNA 
pellet and gently mixed.  The sample was centrifuged as described above 
and the ethanol supernatant removed and discarded allowing the RNA 
pellet to air dry.  Finally, RNA was re-suspended in nuclease free water 
and stored at -20°C until required for use. 
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2.2.1.1.2  Cell lysate preparation 
For smaller cell numbers, such as purified eosinophils, cell lysis buffer 
supplied by Signosis (Signosis Inc, California) was used according to the 
manufacturer’s protocol.  All preparations were performed on ice.  Cell 
numbers from 1x104 to 1x105 were centrifuged at 200RCF at 4°C for 2.5 
minutes and washed with ice cold PBS.  Cells were snap frozen at -80°C 
after being re-suspended in 100µl ice-cold cell lysis buffer.  Samples were 
incubated on ice for 20 minutes and then centrifuged at 4°C, 10000 RCF 
for 2 minutes.  Supernatant was heated for 15 minutes at 75°C and 
stored at -20°C until required for use.  
2.2.1.1.3  Analysis of concentration and purity of RNA 
Samples were all analysed for purity and concentration using NanoDrop™ 
2000 (Thermo Scientific).  1µl of sample was analysed by applying it 
directly to the pedestal of the NanoDrop™.  Measurement was taken of 
the sample to acquire concentration in ng/µl and final concentration of 
sample used at 1µg per reaction. 
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2.2.1.2  RT-PCR reaction 
Reverse transcription polymerase chain reactions were all performed 
using a one-step kit (One-step RT-PCR kit, Qiagen, UK).  Master mix was 
prepared in accordance with manufacturer’s handbook as per the 
following Table 2.2.  For all RT-PCR reactions, β actin was used as a 
positive control.  Negative controls were performed for each sample which 
were preparations of the master mix (Table 2.2) without addition of 
template RNA. 
REAGENT CONCENTRATION VOLUME PER 
REACTION (µl) 
Buffer (5x) 1x 5 
dNTP mix 400µM of each dNTP 1 
“Q” solution (5x) 1x 5 
Enzyme mix - 1 
RNAse inhibitor* 5 units/reaction 2 
Primer A 0.6µM 1.5 
Primer B 0.6µM 1.5 
RNAse free water - Variable 
Template RNA 1µg/reaction Variable 
TOTAL VOLUME 25µl 
Table 2.2: Master mix for one-step RT-PCR:  Table showing 
concentration and volumes of components of the Qiagen one-step RT-
PCR kit used for reactions.  * RNAse inhibitor optional but used due to 
nature of cells (ie PMNs).  RNAse inhibitor supplied by Qiagen, UK.   
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  Primers were designed using Invitrogen OligoPerfectTM primer designer 
tool (Invitrogen, UK).  The nucleotide sequence for each, and expected 
size of band in base pairs is presented in Table 2.3.  Each primer pair was 
analysed using the primer design tool, Primer-BLAST (available via 
www.ncbi.nlm.nih.gov/tools/primer-blast see figure 2.2 for an example 
analysis using hCLCA1 KW (mid) primers).  This utilises the Primer3 
interface to check existing primers and to ensure that each pair of primers 
spanned an intron, or that at least one of the primers was located at an 
exon-exon junction as recommended.  The purpose of this in primer 
design is to ensure that only cDNA is amplified during the PCR process 
and not genomic DNA (Ye et al., 2012).  All primer pairs listed in Table 
2.3 spanned an intron with the exception of hBest1 (5 mid).  Primer pair 
hBest1 (5 mid) also did not have either the sense, or antisense primer 
that was located at an exon-exon junction.  This primer was not used for 
any RT-PCR.  Of the other primer pairs (Table 2.3), several also had one 
primer located at an exon-exon junction; hCLCA1 KW (mid), hCLCA2 (b), 
hANO4, hANO5 and hANO6.  Several primers were tested to amplify 
hCLCA1, hCLCA2, hCLCA3 and hBest1.  These were kindly donated by 
Laura Marsey (Winpenny Lab, UEA, 2004); using primers identified by 
previous papers (Gruber et al., 1998) or designed using OligoPerfect™ 
primer designer tool.  Primers used for RT-PCR have all been analysed 
using Primer-BLAST (Figure 2.2 for example), and been successfully 
sequenced (see section 2.2.1.3.2).  For all hCLCA1 reactions, primer pair 
hCLCA1 KW (mid) was used, for hCLCA2, primer pair hCLCA2 (b), and for 
hBest1, primer pair hBest1 (mid) was used.   
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PRIMER ACCESSION 
NUMBER 
BAND 
SIZE 
(bp) 
SENSE ANTISENSE 
hCLCA1 JW NM_001285.3 572 5’-gatacagtgtaaaagtgcggg-3’ 5’-gtgcaatgttggatatttctg-3’ 
hCLCA1 KW 
(mid)* 
322 5’-tgtccaaaatgacaggaggt-3’ 5’-gatttggaggtaggccattt-3’ 
hCLCA1 
(Gruber et al., 
1998) 
510 5’-gaaatggagctgtctctcag-3’ 5’-ctgctccattatccagtagttc-3’ 
hCLCA1 (3) 454 5’-gaaggggccctgagtaattc-3’ 5’-cgtcaaatactccccatcgt-3’ 
hCLCA1 (8) 502 5’-aagcacatgggaagtgatcc-3’ 5’-gatggcaccacttgtttga-3’ 
hCLCA2 NM_006536.5 529 5’-ctagtctttggattccaggaac-3’ 5’-ctttcgctcctcctcatttc-3’ 
hCLCA2 (a) 370 5’-acctgccacatggaaagct-3’ 5’-ctttttccaggaacggggg-3’ 
hCLCA2 (b)* 518 5’-gaaaggatttgaggtggttgaa-3’ 5’-gctgttcctggaatccaaagac-3’ 
hCLCA2 (c) 424 5’-ttgacctggaagctgtaaaagt-3’ 5’-acccattgctgttaaaactcct-3’ 
hCLCA3 NM_004921 517 5’-ctcctaatggtaatcattctc-3’ 5’-gttacaatatgtatgaaccatttg-
3’ 
hCLCA3 (a)* 508 5’-gaaaaaacacagctaggcta -3’ 5’-attggcttcatggatggctt-3’ 
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hCLCA4 (3) NM_012128.3 481 5’-cttccatctgctctggaattaaata-
3’ 
5’-gaaattttccattattgttccactg-
3’ 
hBest1 (3) NM_004183.3 407 5’-ggacatgtactggaataagccc-3’ 5’-gtctgtggggcactgtagta-3’ 
hBest1 (5) 488 5’-gtattgcgacagctacatccag-3’ 5’-atccagtcgtaggcatacaggt-3’ 
hBest1 (mid)* 460 5’-acctgtatgcctacgactggat-3’ 5’-ctggaactccatctcctctttg-3’ 
hBest1 (5 mid) 312 5’-ctgtatcagaggccaggcta-3’ 5’-ggttggtgattgttccaaag-3’ 
hBest2 NM_017682.2 420 5’-agtttgaaaacctgaactcatccta-
3’ 
5’-
agaaagttggtctcaaagtcatcat-3’ 
hBest3 NM_032735.2 515 5’-acaagtgacagctccatgttcttac-
3’ 
5’-
ttttagaaaggtatcaccagggtct-3’ 
hBest4 NM_153274.2 609 5’-tttgagacaaatcagctcatagacc-
3’ 
5’-atccctgtcttgaactttctcttct-3’ 
hANO1 NM_018043.5 275 5’-tgatcttcaaggctttcctg-3’ 5’-gctgcttcagcttcaggtag-3’ 
hANO2 NM_020373.2 208 5’-ctccggagtacatggaaatg-3’ 5’-cttgccaattccagagagaa-3’ 
hANO3 NM_031418.2 153 5’-tgatagacctctgcctccag-3’ 5’-ttttcccactgaggtatgga-3’ 
hANO4 NM_178826.3 202 5’-tgaatgccagcttgtctgta-3’ 5’-aaaacacgaggtgctcaaag-3’ 
hANO5 NM_213599.2 
(Transcript  
variant 1) 
337 5’-tgggtcaccttatttttgga-3’ 5’-ttgacctgctttaaggatgc-3’ 
120 
hANO6 NM_001025356.2 
(Transcript 
variant 1) 
200 5’-gttttggaaccctggtcttt-3’ 5’-gaatgcgttcttcttcctga-3’ 
hANO7 NM_001001891.3 
(Transcript 
variant NGEP-L) 
220 5’-ttcaccctcaaggtgttcat-3’ 5’-acctcctgcatgttgttgat-3’ 
hANO8 NM_020959.2 261 5’-gtgcctcgtctgtgtcttct-3’ 5’-gaggctcaggtacgagttga-3’ 
hANO9 NM_001012302.2 174 5’-gacgggcctcttagtctttc-3’ 5’-attgtcaaagaggtgggtga-3’ 
hANO10 NM_018075.3 221 5’-gacagtgaagccctgaagaa-3’ 5’-cgaggcaaagatcacgtact-3’ 
Βeta Actin NM_001101.3 456 5’-gcatcctcaccctgaagtac-3’ 5’-cacgcactgtaattcctctt-3’ 
ClC3 NM_173872.2 259 5’-accagctacaatggctttcct-3’ 5’-tccaccacgatctccattggg-3’ 
Table 2.3:  Primers used for reverse transcription polymerase chain reactions:  Table presents 
nucleotide sequence for primers used in RT-PCR including accession numbers (National Centre for 
Biotechnology Information, US, National Library of Medicine) and expected size of band in base pairs.  Primers 
all designed using OligoPerfectTM primer designer supplied by Invitrogen, UK.  Primers hCLCA1 KW (mid), 
hCLCA2 (b), hCLCA3 (a) and hBest1 (mid) marked with * to indicate that these primers were used for 
experimental RT-PCR and have undergone Primer-BLAST analysis and successful sequencing (see section 
2.2.1.3.2) to ensure cDNA amplification and specificity of primers.
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  All solutions, primers and template RNA was defrosted on ice and master 
mix prepared as per Table 2.2.  All RNA samples were analysed using 
NanoDrop™ (section 2.2.1.1.3) to establish concentration and purity of 
samples before adding to the master mix.  Eppendorfs were placed into 
the PTC-100 Programmable Thermal Controller (MJ Research Inc.) for 
thermal cycling in accordance with the handbook for Qiagen One-Step RT-
PCR kit, depicted in Table 2.4. 
THERMAL STEP TIME TEMPERATURE 
1. Reverse transcription 30 minutes 50 °C 
2. Initial PCR activation step 15 minutes 95 °C 
3-step cycling (steps 3-5 repeated total of 40 times) 
3. Denaturing 1 minute 94 °C 
4. Annealing 1 minute 52 °C 
5. Extension 1.5 minutes 72 °C 
6. Final extension 10 minutes 72 °C 
7. Maintenance and storage Variable 4 °C 
Table 2.4:  Thermal cycling for RT-PCR:  All thermal cycling steps for 
RT-PCR as per Qiagen One-Step RT-PCR handbook (Qiagen, UK) 
  On completion of thermal cycling, samples were prepared by adding 
loading buffer (Bioline, UK) at 1:5 concentration.  Samples were then 
analysed by electrophoresis on an agarose gel, using a quantifiable 
molecular marker (Hyperladder TM I, Bioline, UK).   
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2.2.1.3  Analysis  
2.2.1.3.1  Electrophoresis 
Electrophoresis was performed using agarose gel and tris-borate-EDTA 
(TBE) buffer for a running media to separate DNA.  A 1.5% agarose gel 
was prepared using the following protocol; 
1. 50 ml TBE + 0.75 g agarose into conical flask and heat used to
dissolve agarose
2. Solution cooled
3. 2µl ethidium bromide (EtBr) (Sigma, UK) added and solution
poured into gel case with appropriate size comb for number of
samples inserted
4. Gel allowed to set for 15 minutes
The 1.5% agarose gel was placed into an electrophoresis bath containing 
TBE as a running buffer.  The first and last lanes contained HyperladderTM 
I and 10-15µl (variable dependent on size of comb used for well-size) of 
prepared samples were loaded into remaining wells.  Controls were 
loaded as per section 2.2.1.2.  Electrophoresis was set to run at 100V for 
40-60 minutes. 
  On completion, the gel was removed from the TBE buffer and placed 
into an ultraviolet light box to visualise RT-PCR bands.  The size of 
banding was established by comparison to the ladders loaded and 
considered likely to represent the anticipated DNA if comparable to 
expected band size (see table 2.3). 
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  To confirm visual results, bands of DNA were excised from the agarose 
gel using a scalpel, and sent for sequence confirmation at the Genome 
Enterprise Centre (section 2.2.1.3.2).    
2.2.1.3.2  Sequence confirmation 
  Once excised, the slice of agarose gel was prepared to purify the DNA 
using the QIAquick® gel extraction kit (Qiagen, UK).  Figure 2.3 
demonstrates the overall protocol used for this as outlined in the 
QIAquick® handbook.  Once prepared, samples along with primers, were 
sent to the Genome Enterprise Centre for nucleotide sequence 
confirmation.  These were then aligned with the nucleotide sequences 
available on NCBI for each gene of interest, using BioEdit software 
(Section 3.4, Figure 3.8 for an example of sequence alignment images 
produced). 
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2.2.1.3.3  Semi-quantification of results 
Bands visualised on RT-PCR were analysed using densitometry techniques 
to semi-quantify results.  Statistical analysis was performed as outlined in 
section 2.6.  Ethidium bromide gels were placed under an ultraviolet lamp 
to visualise bands.  Images were captured onto floppy disk and then 
converted to bitmap images.  Images were opened in ImageJ software 
(developed by the National Institute for Health, available via 
http://rsb.info.nih.gov/ij/).  Using ImageJ, bands were selected and the 
optical density of each was recorded (as a product of the area of band in 
Figure 2.3:  Process for DNA extraction from agarose gel slice:  QIAquick 
gel extraction kit was used to purify DNA from an agarose gel slice.  Agarose gel 
slice with band of interest was solubilised and applied to a spin column .  DNA was 
eluted from the membrane.  Samples were sent to the Genome Enterprise Centre 
for sequence confirmation 
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pixels, and mean grey area as an average of the grey of all pixels in a 
band).  Samples were normalised against the optical density for β actin; 
Optical density of sample selected band / optical density of β actin 
The results were statistically analysed (section 2.6) to establish potential 
correlations between genes expressed.   
It is important to note that this process is semi-quantification and not 
exact quantification.   
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2.2.2  Sub-cloning 
2.2.2.1  Transformations of plasmids into bacteria 
  Commercially prepared sub-clone competent cells, DH5 α E. Coli, were 
used for transformations.  All competent cells and plasmids were 
defrosted on ice and 100ng of each plasmid containing DNA of interest 
was added to 50µl of cells and further incubated on ice for 30 minutes 
with gentle mixing. 
  Following incubation, cells were exposed to heat shock for 40 seconds at 
42⁰C and further incubated on ice for 2 minutes.  Each sample was added 
to 500µl of LB broth and incubated for 1 hour at 37⁰C.  Samples were 
diluted to 1:10 and 100µl spread onto agar plates and incubated at 37⁰C 
overnight until single colonies could be visualised.  An individual colony 
was harvested and added to 250ml LB broth and incubated overnight at 
37⁰C.  To make LB broth; 10g Tryptone, 5g yeast extract, 5g NaCl and 1g 
D-glucose were mixed and made up to 1000ml with dH2O.  To make agar 
plates, 5g agar was added to 250ml LB broth and autoclaved to dissolve.  
Specific antibiotics were added according to which the vector was 
resistant to, at a final concentration of 100µg/ml.  Table 2.5 presents all 
vectors used and the antibiotic resistance for each. 
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Gene of 
interest 
Vector Plasmid name Antibiotic 
resistance 
hBest1 pRK5 pRK5-hBest1-IRES-
eGFP 
Ampicillin 
hBest2 pRK5 pRK5-hBest2 Ampicillin 
mBest2 pRK5 pRK5-mBest2 Ampicillin 
hBest3 pBS pBS-hBest3 Ampicillin 
hBest4 pRK5 pRK5-hBest4-c-
termRIMtag 
Ampicillin 
Table 2.5:  Vectors used for transformations:  Table presenting all 
vectors and plasmids used for transformation into DH5 α E. Coli 
competent cells with antibiotic resistance for selection 
2.2.2.2  Purification of cDNA 
Glycerol stocks of transformed bacteria were prepared by adding 800µl of 
LB broth containing cells, to 200µl glycerol and stored at -80⁰C for future 
use.  Transformed cells were then processed using a Qiagen (UK) Midi-
Prep kit for purification of cDNA following manufacturer 
recommendations; 
1. LB broth solution decanted into cornings tubes and centrifuged at
8000RCF for 15 minutes at 4⁰C to pellet bacteria 
2. 4ml of buffer P1 was added and the tube vortexed to mix
3. 4ml of buffer P2 was added and the tube vortexed to mix turning
the solution blue.  This was incubated at room temperature for 5
minutes
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4. 4ml of chilled buffer P3 was added turning the solution white and
incubated on ice for 15 minutes
5. The sample was centrifuged for 30 minutes at 20000RCF, 4⁰C and
supernatant pipette off and applied to equilibrated (using buffer
QBT) Qiagen Filter 100 columns
6. The filter was washed with 10ml buffer QC and a repeat wash with
a further 10ml allowing the run through to drain to waste
7. Filter units were placed into clean corning tubes to elute DNA by
applying 5ml buffer QF
8. 3.5ml isopropanol was added to flow through to precipitate the
DNA and immediately centrifuged at 15000RCF for 30 minutes at
4⁰C
9. The supernatant was discarded and the DNA pellet was washed
with 2ml of room temperature 70% ethanol (made with nuclease
free water).  The sample was re-centrifuged at 15000RCF for 10
minutes
10. The supernatant was discarded and the pellet allowed to air dry for
10 minutes
11. Cell pellet was re-suspended in 10mM Tris-Cl, pH 8.5 and stored in
-80⁰C
2.2.2.3  Restriction digestion 
  Each sub-cloned plasmid was validated by using restriction digest 
techniques to extract the DNA of interest, and analysis using 
electrophoresis on an agarose gel as outlined previously (Section 2.2.1.3) 
for 1.5 hours at 100V.  The band identified at the correct size for 
bestrophin 1-4 was excised and sent for sequence analysis as outlined in 
130 
Section 2.2.1.3.2.  All bands were confirmed by 100% sequence analysis.  
Vector maps were obtained from BD PharMingen technical data and used 
to establish the enzymes required to digest out the multiple cloning site 
(MCS) for each of the vectors used for bestrophin 1-4 transformations and 
sub-cloning of cDNA.  20ng of DNA was used in an eppendorf, and 1µl of 
the appropriate enzyme buffer (supplied with enzyme) was added.  6.5µl 
of H2O was added and finally 0.5µl of each enzyme (Table 2.6).  All 
enzymes and buffers supplied by Roche, UK.  Samples were incubated for 
1 hour at 37 °C in a water-bath and analysed on an agarose gel.  Each 
sample was analysed against a control for the entire plasmid (no enzyme 
therefore uncut), linearized plasmid (one enzyme only added) and with 
cDNA cut out (both enzymes used). 
Sample Vector Enzyme A 
(start of MCS) 
Enzyme B (end of MCS) 
pRK5-hBest1-
IRES-eGFP 
pRKS Cla1 KpnI (100µg/ml BSA 
added as per 
manufacturer 
instruction) 
pRK5-hBest2 pRKS Cla1 KpnI (100µg/ml BSA 
added as per 
manufacturer 
instruction) 
pBS-hBest3 pBS Kpn1 SaCl 
pRK5-hBest4-c-
termRIMtag 
pRKS Cla1 KpnI (100µg/ml BSA 
added as per 
manufacturer 
instruction) 
 
 
Table 2.6: Enzymes used for restriction digest of plasmids:  Table 
presenting the plasmid names and identified vectors.  Vector maps were 
used to establish the multiple cloning site that each DNA of interest was 
inserted into during transformations.  Enzymes used to cut plasmid at MCS 
to either linearise or completely cut out the cDNA of interest. 
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2.2.2.4  Transfection of cDNA  
 
    Purified cDNA was transfected into cell lines using JetPRIME™ 
transfection reagent (Polyplus Transfection,  France).  Protocol according 
to the manufacturers recommendations.  CHO cells were used to transfect 
hBest1 and analyse with Western blot and RT-PCR to establish antibody 
specificity.  CHO were used as they were previously screened using RT-
PCR techniques and no evidence of bestrophin 1-4 mRNA was found.  
HL60 cells were transfected with hBest1 for functional analysis.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Cells seeded into 6 well plates at least 24 hours prior to 
transfection;  1.5-2.5 x 106 cells per well in 2ml media 
Transfection medium prepared; 
• 2µg DNA (section 2.5.2) diluted into 200µl JetPRIME™ buffer and 
vortex to mix 
• 4-6µl of JetPRIME™ reagent added and incubated at room 
temperature for 10 minutes 
Added to 6-well plate; 
• 200µl added per well 
• Rocked to distribute an even spread of transfection medium 
Incubated for 4 hours at 37 oC at 5%CO2.  After 4 hours, 
transfection media replaced with growth media and incubated 
as per previous.  Analysis was performed after at least 24hours. 
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2.3  Protein expression 
2.3.1  Flow cytometry 
2.3.1.1  Method for immunolabell ing w ith primary and secondary 
antibodies 
  All cells were cultured as outlined in section 2.1.  For immunolabelling, 
cells were re-suspended to 1 x 106 cells/ml.  Table 2.7 outlines the stock 
solutions for immunocytochemistry preparation. 
Requirement for immunolabelling Contents of solution 
Surface staining buffer PBS + 1% bovine serum albumin 
(BSA) 
Surface wash buffer PBS 
Intracellular staining buffer PBS + 1% BSA + 0.5% Triton* 
Intracellular wash buffer PBS + 0.5% Triton 
Table 2.7:  Stock solutions for immunolabelling:  Solutions prepared 
for surface staining and intracellular staining of cells for flow cytometry.  
Phosphate buffered saline (PBS) was used with additives of bovine serum 
albumin (BSA) and triton as appropriate.  BSA was used as a block for 
non-specific binding sites.   *Triton (Sigma, UK) used for intracellular 
staining to permeabilise cell membranes 
  Cells were readjusted for cellular concentration and removed from the 
stock culture. The removed sample was centrifuged at 200 RCF for 5 
minutes at room temperature.  Supernatant was removed and discarded 
and the pellet re-suspended in 4% PFA for 10 minutes at 4 oC to fix.  
Fixation prior to immunolabelling was required as PBS has been found to 
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cleave hCLCA1 from cell surfaces and therefore potentially cause a false 
negative result (Gibson et al., 2005).  The suspension was re-centrifuged 
at 200 RCF and the supernatant removed and discarded whilst the cell 
pellet was re-suspended in the appropriate wash buffer according to 
whether cells were surface stained or intracellularly stained (Table 2.7).  
This was repeated three times to wash the cells.  Cells were centrifuged 
at 200 RCF and the pellet re-suspended in 100μl of staining buffer 
appropriate to either surface or intracellular protocol, and incubated for 
15 minutes at 4 oC to prevent non-specific binding by allowing BSA 
blocking.  A comparative experiment for blocking non-specific binding 
sites was performed.  Samples were incubated for 5 mins, 10 mins, 20 
mins and 40 mins in goat serum prior to primary antibody staining.  There 
was no discernible difference in results, or isotype control results, 
therefore all subsequent staining was performed with BSA blocking.  
Primary antibodies were added to a final concentration of 10μg/ml in 
100μl of cell suspension (Table 2.8 lists primary and secondary antibodies 
used in flow cytometry) and incubated at 4 oC for 30 minutes, protected 
from light to prevent photo-bleaching.  Cells were centrifuged at 200 RCF 
to pellet, and were washed in the appropriate wash buffer three times as 
outlined above (Table 2.7). 
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PRIMARY ANTIBODY CONCENTRATION 
OF PRIMARY 
ANTIBODY 
DETAILS (number and 
supplier) PRIMARY 
SECONDARY ANTIBODY 
(all added at a 
concentration of 1:200) 
SUPPLIER OF 
SECONDARY 
ANTIBODY  
Mouse IgG1 (purified) for 
isotype control 
10µg/ml in 100µl MG100; Invitrogen, UK Goat anti-mouse with FITC 
(green) or phycoerythrin 
(PE)(red) conjugate 
Goat anti-mouse Alexa Fluor 
® 488  
Beckham 
Coulter 
Invitrogen 
Rabbit IgG1 (purified) 1µg in 100µl AbD Serotec, UK Donkey anti-rabbit Alexa 
Fluor ® 488 
Invitrogen 
Mouse anti-human CD44 
monoclonal 
10µg/ml in 100µl MCA2726T; AbD Serotec, UK, 
clone 156-3C11 
Goat anti-mouse with FITC 
conjugate 
Goat anti-mouse Alexa Fluor 
® 488 
Beckham 
Coulter 
Invitrogen 
Mouse anti-siglec 8 
monoclonal for surface 
stain of eosinophil markers 
1µg in 100µl Clone 3H1; Sigma-Aldrich Goat anti-mouse with FITC 
or PE conjugate 
Goat anti-mouse Alexa Fluor 
® 488 
Beckham 
Coulter 
Invitrogen 
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Annexin V fluorescein 
conjugate (FITC) 
2µl in 100µl of Ca2+ 
buffered PBS 
Invitrogen NA NA 
Propidium iodide nucleic 
acid stain 
5µl in 200µl Sigma-Aldrich NA NA 
Mouse anti-human major 
basic protein for 
intracellular marking of 
eosinophils  
1µg in 100µl 4180-2008; AbD Serotec, UK Bodipy ® FL dye Invitrogen 
Mouse anti-human CLCA1 
monoclonal  
1µg in 100µl H00001179-M03; Abnova, 
clone 2C10 
Goat anti-mouse with FITC 
conjugate 
Goat anti-mouse Alexa Fluor 
® 488 
Bodipy ® FL dye 
Beckham 
Coulter 
Invitrogen 
Invitrogen 
Mouse anti-human CLCA2 
monoclonal 
1µg in 100µl H00009635-M01; Abnova, 
clone 1B9 raised against a 
partial recombinant 
Goat anti-mouse with FITC 
conjugate 
Bodipy ® FL dye 
Beckham 
Coulter 
Invitrogen 
Mouse anti-human Best1 
monoclonal 
1µg in 100µl Novus Biologicals (E6-6) and 
AbCam (ab2182 clone E6-6) 
Goat anti-mouse with FITC 
conjugate 
Beckham 
Coulter 
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Rabbit anti-human Best1 
polyclonal 
Fabgennix (Bst-121AP) 
Goat anti-mouse Alexa Fluor 
® 488 
Bodipy ® FL dye 
Mouse anti-rabbit with FITC 
conjugate 
Invitrogen 
Invitrogen 
Invitrogen 
Rabbit anti-human ANO1 
monocolonal 
1µg in 100µl Abnova (clone SP31) Donkey anti-rabbit Alexa 
Fluor ® 488 
Invitrogen 
Table 2.8:  Antibodies used for immunolabelling in flow cytometry:  Primary antibodies were all alloquoted to 
avoid freeze-thaw cycles and stored at -20 oC on receipt from the supplier.  Secondary antibodies and IgG1 stored at 4 
oC, protected from light.  Primary antibodies were used to label the protein of interest either on the cell surface or 
intracellularly.  Secondary antibodies used as specified above for intracellular and surface staining and were anti- 
primary antibody host.  Alexafluor 488 used if cells were to by cytospun due to the increased photo stability in 
comparison to FITC.  Bodipy was used for intracellular staining as it is non-polar and therefore will not non-specifically 
bind to intracellular granules. 
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  Secondary antibodies were prepared by diluting to 1:200 with the 
appropriate staining buffer and re-suspending the cell pellet in 100μl 
of secondary antibody solution.  Samples were incubated at 4 oC for 
30 minutes, protected from light.  As outlined above, the cell pellet 
was then washed three times in the appropriate wash buffer and 
finally re-suspended in 200μl of PBS for flow cytometry. 
   Secondary antibodies were Fab2 fragments targeted against the 
host species of the primary antibodies used. Secondary antibodies 
were conjugated to FITC [Ex 488nm; Em 533/30nm], PE [Ex 488nm; 
Em 585/42nm], Bodipy® FL dye (green) [Ex 488nm; Em 533/30nm] 
or Alexa Fluor 488 [Ex 488nm; Em 533/30nm]. Relative expression 
data from flow cytometry analysis was limited to fluorophore-specific 
comparisons.  For intracellular staining the non-polar Bodipy ® FL 
dye (green) was used to limit non-specific staining of the cytoplasm. 
For fluorescence microscopy Alexa Fluor 488 was used due to its 
increased resistence to photobleaching relative to FITC. Specific use 
of fluorosphores use is detailed appropriately in all sections of this 
thesis.  Alexa Fluor 488 was not used for flow cytometry and 
therefore there was no pooling of data between the two secondary 
antibodies.   
    Each cell type for flow cytometric phenotyping included a tube 
with: 
1. nil control: no antibodies added as an assessment of
autofluorescent background,
2. negative isotype control: to check whether there was non-
specific or Fc recptor-mediated binding to the host species by
primary antibodies,
3. secondary control: only the secondary antibody was added to
determine non-specific binding by secondary to target cells
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4. positive control: to ascertain the effectiveness of cell labelling
and flow cytometric analysis.  CD44 was used as a positive
control for surface labelling of all cells. Siglec-8 and major
basic protein (MBP) were used, respectively, as positive
surface and intracellular markers, for eosinophils.
5. Annexin V and propidium iodide (PI) used as indicators of
apoptosis and necrosis (Section 2.3.1.2).
2.3.1.2  Apoptosis assay 
To examine possible apoptosis and cellular necrosis, cells were 
prepared without fixation and re-suspended to 1 x 105 cells/ml.  Cell 
suspensions were centrifuged at 200 RCF for 5 minutes and the 
supernatant removed and discarded.  The cell pellet was then re-
suspended in calcium buffered PBS (5mM CaCl).  Calcium was 
required to enable annexin V to bind.  2μl of human recombinant 
annexin V conjugated with FITC (supplied by Invitrogen, UK) was 
added and incubated for 15 minutes, protected from light, at room 
temperature.  Cells were centrifuged and washed as above with 5mM 
CaCl and re-suspended in 5mM CaCl.  5μl propridium iodide (PI) 
(Invitrogen, UK) was added and the cells immediately analysed using 
flow cytometry.  A time course for annexin V and PI was performed 
by incubating cells and analysing with flow cytometry at time=5 
minutes, 15 minutes and 30 minutes.  Annexin V and PI were used 
according to manufacturers recommendations.  A brief time course 
was performed, however, to establish whether the process of 
staining with Annexin V or PI caused apoptosis or necrosis in itself 
and to validate methodology.  Optimal time for annexin V was 15 
minute incubation, and PI staining required immediate analysis as it 
appeared to stimulate cellular necrosis.  The assay was also 
performed before and after PFA fixing, which showed no difference 
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in fluorescence.  Experimental conditions included group 1, annexin 
V only, group 2, PI only for specified time points, and group 3, 
annexin V incubated for time points and PI added immediately prior 
to analysis.  
2.3.1.3  Analysis using flow  cytometry 
2.3.1.3.1  Beckman Coulter Epics flow  cytometer 
  Samples were collected and prepared as in section 2.3.1.1.  
Analysis early in the project time course was performed using a 
Beckman Coulter Epics (XL IXL-MCL) flow cytometer following 
manufacturer recommendations for quality control measures and 
operation of equipment.  All scatter plots were standardized to a 
continuous voltage and gain.  Fluorescence was examined using a 
logarithmic scale and histogram comparisons by overlaying each 
experimental results, and exporting the produced image into 
Microsoft Paint application.  In order to minimize non-specific 
fluorescence or multi-cellular interactions, the scatter plots were 
gated according to expected forward scatter for overall cellular size, 
and side scatter for an indication of granularity.  Events recorded in 
the lowest range for both were excluded as considered to be cellular 
debris.  X-mean (median of the fluorescence intensity) for each 
population was compared however statistical testing not completed 
at this stage.  Laser light used was at 488nm in all machines as this 
was the wavelength that was able to excite all fluorpohres used.  
The emission for each was measured on a standardised axis; FL1 for 
blue/green emission and FL3 for red emissions.  FITC is excited at a 
wavelength of 495nm whereas Alexa Fluor ® 488 is excited at 
500nm.  The results are comparable as both emit fluorescence at 
520nm which was measured on the FL1 detector, set for blue/green 
emission measurement.  Phycoerythrin (PE) is excited at 565nm, 
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however laser light can be set to 488nm.  The emission wavelength 
is in the yellow/orange spectrum at 575nm and was measured on 
FL3 detectors across all machines.  Results were examined using fold 
difference in median fluorescence intensity, from the isotype control, 
for each protein of interest.   
2.3.1.3.2  Accuri, C6 flow  cytometer 
  Over the course of the project, the original flow cytometer was 
replaced with an Accuri, C6 flow cytometer in September 2009.  
Initial data collected using the Beckman Coulter Epics flow cytometer 
was used as an indicator for further experimentation only.  From this 
point, all flow cytometric acquisition and analysis was performed 
using the alternative equipment.  Results were not pooled for any 
statistical analysis.  
  Preparation of samples was as outlined in 2.3.1.1 and equipment 
used as per manufacturers recommendations.  Event collection was 
set to a minimum of 10000 events however this began after the 
gating for cellular specificity had been set to minimize contamination 
of results.  Apoptosis using annexin V was analysed by plotting FL1 
(green) on the x-axis and necrosis with PI measured by FL3 (red) on 
the y-axis onto a singular scatter plot and establishing cell 
percentages in all 4 quadrants.  Cells in the upper 2 quadrants were 
fluorescing red and considered necrosing.  Cells in the right 2 
quadrants were fluorescing green and may possibly have been 
apoptotic.  
  Scales for mean fluorescence were standardized to allow 
comparison of pairwise means between samples and different 
populations.  Mean fluorescence intensity was measured to 2 decimal 
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places (2dp) ± standard deviation (SD) to 2dp.  These were 
compared using a two-tailed students t-test.  Statistical significance 
was established at p<0.05.   
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2.3.2  Western blot analysis 
2.3.2.1  Samples and sample preparation 
2.3.2.1.1  Preparation of protein lysates 
  All samples were cultured as described in section 2.1.  Preparation 
of protein initially used a process of sonication whereby cells were 
centrifuged at 200 RCF for 5 minutes at room temperature to pellet 
and washed with sterile PBS.  The supernatant was removed and the 
cell pellet lysed with 50-100µl hot sodium dodecyl sulphate (SDS) 
lysis buffer.  This was from a 10ml stock made up of 8.8ml dH2O, 
200µl of 0.5M Tris (pH 6.8) and 1ml of 10%SDS.  The final 
concentration was 1% SDS and 10mM Tris.  The cell lysate was 
sonicated and re-centrifuged for 5 minutes at 13000 RCF to pellet 
cell debris.  Supernatant removed and kept as protein lysate.  The 
alternative protocol was using RIPA buffer.  RIPA buffer was 
prepared using the following Millipore (UK) protocol: 
1. 790mg Tris base was made to 75 ml dH2O and 900mg NaCl
added
2. pH adjusted to 7.4 using HCl
3. 10ml Triton x100 and 2.5ml 10% sodium deoxycholate added
4. 1ml of 100mM EDTA added and volume adjusted to 100ml
5. 1 tablet of PhosSTOP (Roche, UK) in 10ml of solution was
added for phosphatase inhibition
6. 1 tablet of Complete, EDTA-free cocktail (Roche, UK) was
added for protease inhibition
Protein lysate was then prepared by applying 200µl RIPA buffer to 
the cell pellet on ice.  Eppendorfs were inverted for gentle mixing 
and then centrifuged at 13000 RCF, at 4 ⁰C for 15 minutes to pellet 
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the cellular debris.  The protein of interest was removed as 
supernatant and stored at -20 ⁰C until required. 
2.3.2.1.2  Analysis of protein concentration 
All protein samples were analysed for protein concentration to allow 
appropriate loading for western blot analysis.   This was performed 
using a BCA assay kit supplied by Qiagen (UK).  Stock solutions of 
proteins were made according to Table 2.9, using bovine serum 
albumin (BSA) (2.0mg/ml) diluted into dH2O. 
VIAL DILUTENT (µl) dH2O VOLUME OF BSA 
(µl) 
FINAL CONC 
BSA (µg/ml) 
A 0 300 of stock 2000 
B 125 375 of stock 1500 
C 325 325 of stock 1000 
D 175 175 of vial B 750 
E 325 325 of vial C 500 
F 325 325 of vial E 250 
G 325 325 of vial F 125 
H 400 100 of vial G 25 
I 400 0 0 
Table 2.9: Stock solutions of bovine serum albumin (BSA) for 
protein concentration assay:  Table with protein standards 
prepared with BSA and dH2O.  Absorbance of protein standards were 
measured using spectrometry and a linear graph plotted.  Samples 
also measured and plotted against the line of best fit with an 
equation generated for the linear line.  This was used to calculate the 
concentration of samples. 
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  BCA working reagent A was mixed with working reagent B to a ratio 
of 50:1.  25µl of stock solutions and samples were added to 
individual wells of a 96 well plate.  200µl of mixed working reagent 
was added to each well and the plate was shaken to mix.  Samples 
were incubated for 30 minutes at 37⁰C and then cooled to room 
temperature.  Samples were analysed using spectrometry at 550nm 
to measure absorbance and a standard curve plotted to calculate 
concentration of the unknown samples.   
  Figure 2.4 shows an example of a linear graph plotted for a set of 
protein standards.  In the same experiment, samples were loaded 
into the same plate to measure light absorbance using spectrometry. 
The measurement of absorbance was substituted for ‘y’ and 
concentration calculated as ‘x’.  In the above example, the equation 
is y=0.0006x + 0.0417.  This was rearranged for each of the 
following samples (Table 2.10).  The measured absorbance for 
samples was adjusted for the nil control (Sample I) by 
 Ab.1-(Sample I Ab.1)=Ab.2 
Sample absorbance (Ab.2) then substituted into ‘y’ for example, for 
the CFPAC cells (Table 2.10) the calculation for concentration (x) 
was; 
Absorbancy (Ab.2=y) → 2.921 – 0.076 = 2.845 
Equation → y= 0.0006x + 0.0417 
→  y-0.0417 = 0.0006x 
→ (y-0.0417)/0.0006 = x 
Where y =2.845 →(2.845 – 0.0417)/0.0006=4672.2 µg/ml 
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Figure 2.4:  Protein standards used to measure absorbance for 
calculation of unknown concentration of protein samples:  Protein 
samples were used to plot a linear graph and generate an equation for the 
line of best fit.  This was used to calculate the concentration of protein 
samples of unknown concentration 
y = 0.0006x + 0.0417 
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Sample  Ab.1 Conc.(ug/ml) Ab.2 
A 1.290 2000 1.214 
B 1.022 1500 0.946 
C 0.787 1000 0.711 
D 0.622 750 0.546 
E 0.459 500 0.383 
F 0.269 250 0.193 
G 0.183 125 0.107 
H  0.102 25 0.026 
I 0.076 0 0.000 
Samples CFPAC 2.921 4672.2 2.845 
A549 0.537 698.8 0.461 
A549 (CLCA1 
KD) 0.448 550.5 0.372 
PMNs 0.212 157.2 0.136 
NAEC 0.616 830.5 0.540 
Table 2.10:  Measures of absorbance using spectrometry for 
protein standards and samples:  The measures of absorbance at 
550nm for protein standards (samples A-I) were used to calculate a linear 
equation (Figure 2.4).  The absorbance measured for each sample was 
substituted as ‘y’ in the equation to calculate the unknown protein 
concentration (x) in µg/ml. Ab.1=Measured absorbance which is adjusted 
for the nil (Ab.1-Sample I Ab.1)=Ab.2.  Conc. = Of protein samples this is 
known and in the sample group, calculated from the equation. 
2.3.2.1.3  Sample preparation for loading onto Western gel 
  Lysates of protein were prepared on ice.  20µg of sample was 
diluted with nuclease free water to a volume of 17µl.  In the instance 
where samples were too dilute to allow volumes of less than 17µl 
they were applied to Amicon® Ultra-0.5 centrifugal filter devices in 
accordance with manufacturer protocols (Millipore, UK) to 
concentrate.  Lysates were then added to sample preparation buffer 
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(10ml 1.5M Tris at pH 6.8, 6ml 20% SDS, 30ml glycerol, 15ml β-
mercaptoethanol and 1.8mg bromphenol blue adjusted to 100ml with 
dH2O).  The final ratio of buffer to sample was 1:5 respectively with 
a final volume of 20µl.  Prepared samples were heated to 95⁰C for 3 
minutes to denature proteins and pulse centrifuged at high speed. 
2.3.2.1.4  Loading of samples and electrophoresis 
  12% acrylamide gels were prepared as in Figure 2.5.  Gels were 
poured into Bio-Rad glass plates and levelled using isopropanol. 
Figure 2.5:  Acrylamide gel for western blot analysis:  
Ingredients and volumes of solutions for preparation of 12% 
acrylamide gel for western blot analysis.  Resolving gel is set into 
glass plates and left to set.  Stacking gel is layered onto the resolving 
gel and a comb inserted for well formation. 
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  Ladder (4µl) was added to the first and last well in each gel and 
samples loaded in remaining wells.  The gels were placed into an 
electrophoresis tank containing running buffer pH 8.3 (1L dH2O, 
30.3g Tris base, 144.0g glycine and 10g SDS final solution diluted to 
1:10) at 100V for 1.5 hours.  Time course for electrophoresis was 
performed, at 1 hour, samples were clustered which made analysis 
problematic.  At 2 hours, the samples had run to the bottom of the 
gel, and in some cases, out of the bottom of the gel.   
2.3.2.2  Process of western blotting 
2.3.2.2.1 Transfer of proteins onto membrane and antibody 
labelling 
  Following electrophoresis, the gel was removed from the tank and 
proteins transferred from the acrylamide gel onto a membrane.  This 
was labelled with antibodies specific for the protein of interest.  
Figure 2.6 presents a summary of the process. 
  Proteins were transferred from the gel onto Immobilon-FL 
membrane (Millipore, UK) using a semi-dry transfer method.  To 
permeabilise membrane, it was first soaked in ethanol for 15 
minutes.  This involved layering blotting paper, membrane, gel and 
blotting paper.  Blotting paper and membrane were soaked in 
transfer buffer (10 times concentration of stock at pH9.2 of 390mM 
glycine, 480mM Tris and 0.3% SDS diluted to single strength 
concentration with 100ml transfer buffer, 200ml methanol and 700ml 
dH2O).  This was then electrophoresed for 30 minutes at 25V for two 
gels using Bio-Rad (UK) semi dry transfer unit. 
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Figure 2.6:  Summary of process for western blot analysis:  
Summary of the overall process and order of steps for western blot 
analysis as in section 2.3.2 
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  When electrophoresis was complete, membranes were removed 
and placed into 5% marvel (milk) made with Tris buffered saline 
0.5% tween (TBST) to block non-specific binding.  This was put onto 
a fast rocker (100rpm) for 1 hour.  Primary antibodies were mixed 
following an initial concentration assay using primary antibodies at 
1:250, 1:500, 1:750, 1:1000 and 1:1500.   Primary antibodies were 
finally made at a concentration of 1:500 with anti-actin at 1:1000 in 
5% marvel/TBST which prevented excess background on analysis 
but allowed clear visualisation of banding.  This was made to a final 
volume of 10ml and applied to the membrane and incubated for 12 
hours at 4⁰C.  Secondary antibodies were also examined for optimal 
concentration.  These were; 1:500, 1:1000, 1:2000, 1:5000 and 
1:10000.  Final concentration was 1:2000 as an optimal 
concentration for clear visualisation of bands.  All primary antibodies 
used for western blot analysis are presented in Table 2.11.  All 
secondary antibodies were IgG conjugated with IRDye® 
recommended for use with Odyssey, supplied by LI-COR Biosciences. 
Secondary labelling of primary antibodies that were mouse anti-
human used a goat anti-mouse IgG antibody.  For primaries that 
were rabbit anti-human, goat anti-rabbit IgG were used.  All 
secondary antibodies were available conjugated with either 
IRDye®800 (green banding) or IRDye®680 (red banding).  Each 
blot was standardised so that the protein of interest (for example 
hBest1, hCLCA1) was labelled with IRDye®800 and the band 
visualised was green for each experiment.  All controls (β-actin) were 
labelled with IRDye®680 to give a red band on analysis. 
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PROTEIN OF 
INTEREST 
CONC. ANTIBODY DETAILS (number and supplier) EXPECTED 
MOLECULAR WEIGHT 
(kDa) 
Rabbit anti-actin 1:1000 Rabbit anti-actin Invitrogen, UK 42-48 
Mouse anti-actin 1:1000 Mouse anti-actin monoclonal Millipore clone C4 43 
CLCA1 1:500 Mouse anti human CLCA1 monoclonal H00001179-M03; Abnova, clone 2C10 37.11 
CLCA2 1:500 Mouse anti human CLCA2 monoclonal H00009635-M01; Abnova, clone 1B9 raised 
against a partial recombinant 
79.9 
Bestrophin 1 1:500 Mouse anti human Best1 monoclonal Novus Biologicals (E6-6) and alternative from 
AbCam (ab2182 clone E6-6) 
68 
Rabbit anti-human Best1 polyclonal Fabgennix (Bst-121AP) 
Bestrophin 2 1:500 Rabbit anti human Best2 polyclonal AbCam (ab32830) 65 
Bestrophin 3 1:500 Rabbit anti-human Bestrophin 3 polyclonal AbCam (ab94904) 51 (alternative bands at 
74 and 120) 
Bestrophin 4 1:500 Rabbit anti-human Bestrophin 4 polyclonal AbCam (ab66632) 60 
ANO1 1:500 Rabbit anti human ANO1 monocolonal Abnova (clone SP31).  Not used previously 
for Western blot analysis and not successful 
for this 
74 
Rabbit anti human ANO1 polyclonal AbCam (ab53212) 
Table 2.11:  Antibodies used for western blot analysis:  All antibodies used for western blot analysis however those highlighted in 
grey were non-specific.  Antibodies for hBest2-4 were unable to detect a band.  Blots were repeated at least 3 times.  Due to constraints 
of resources, and the focus of the thesis, these were not repeated with different antibodies 
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  Membranes were washed with TBST for 15 minutes, and repeated 
4 times before the secondary antibody was applied.  This was either 
red or green fluorescence, as stated, made to a concentration of 
1:2000 in TBST.  A further wash cycle of 15 minutes, repeated 4 
times in TBST was completed before analysis using the Odyssey V3.0 
scanner.   
 
2.3.2.2.2  Western blot membrane re-probe 
 
  Membranes that contained proteins, and had been probed with 
antibodies were stripped using Re-Blot Plus Strong Solution (2504) 
10x concentration (Millipore, UK).  The process was intended to 
remove the antibodies that had bound to the proteins in order to 
allow re-probing with alternative antibodies for the same sample.  
Re-Blot solution was diluted to 1:10 with dH2O and 10ml of solution 
applied to the membrane.  Membranes were incubated at room 
temperature, agitated for 10 minutes.  The Re-Blot solution was 
washed with TBST and membranes were either sotred at 4OC for 
future use or immediately re-probed with antibodies using the same 
process as outlined previously.  On examination, the process of 
stripping the membrane of antibodies appeared to also strip the 
protein of interest.  The process was repeated and increasing 
concentrations of antibodies used however bands were either poorly 
visible or not present.  On using new samples and completing full 
western blotting, bands had been visualised.  The samples had been 
taken from the same stock.  This indicated that it was the membrane 
stripping process that had affected results. 
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2.3.2.3  Analysis of results 
  Antibody stained membranes were placed onto a scanner plate and 
analysed using the Odyssey V3.0 software.  As standard, the 
membrane was scanned at an intensity of 5 for each wavelength 
however this was adjusted to visualise bands as required.  β-actin 
protein was labelled with red antibodies, as a housekeeping process, 
and visualised at wavelengths between 680 and 700 nanometers.  All 
proteins of interest were labelled with green antibodies and 
measured at a wavelength of 800 nanometers.   
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2.4 Transmigration assay 
  Transmigration of the HL60 cell line was established.  Cells were 
cultured as per section 2.1 and divided into 3 experimental groups;  
HL60 (nil) as a control, HL60 treated with transfection reagent only 
(no DNA added) as a control, and HL60 transfected with hBest1 
(section 2.5.4) (n=3 for each experimental group)  Cells were 
counted using trypan staining and haemocytometer technique.  A 
total of 135 000 cells for each group were re-suspended as 250µl of 
sample in culture media (as per Section 2.1).   
  400µl of growth media (RPMI-1640 with FCS and 
penicillin/streptomycin additions) was added to each well of a 24 well 
plate.  3 experimental conditions were prepared by adding IL-13, or 
formyl-methionyl-leucyl-phenylalanine (fMLP) and nil to the plates.  
IL-13 was added to a final concentration of 10µg/ml and fMLP added 
to 1µM.  MilliCell culture plate inserts (Millipore, UK) with a 3µm pore 
size were put into each well and each sample applied to the plate 
insert (Figure 2.7).   
  With a known number of cells added to the insert, cells were 
incubated at 37OC, 5% CO2 for 1 hour to allow migration across the 
membrane.  A sample of cells was taken from each well and cell 
counted using trypan staining and haemocytometer technique, and 
the total number of cells in 400µl calculated.  This was converted to 
a percentage of the total cells added to the membrane as a 
percentage of cell migration across 3 experimental conditions, for 
three groups (n=3).   
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Figure 2.7: Transmigration assay equipment set 
up:  Millicell plate insert with 3µm pore inserted into 
each well of a 24 well plate.  Wells contained media and 
additives.  Sample was added to the Millicell plate 
insert. 
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2.5 Chloride and calcium flux assay 
  HL60 cells were transfected with hBest1 as per section 2.2.2.  As 
with the transmigration assay, there were 3 experimental groups; 
HL60 nil, HL60 that were treated with transfection reagents only (no 
DNA) and HL60 transfected with hBest1.  There were three samples 
for each group (n=3).  Chloride and calcium flux was measured in 
response to inhibitory or stimulatory cytokines.   In order to assess 
intracellular chloride movement, cells were re-suspended to 1x106 
cells/ml and washed 3 times with Krebs ringer buffer (KRB) to mimic 
physiological conditions.  Cells were treated with 5mM N-
[ethoxycarbonylmethyl]-6-methoxy-quinolinium bromide (MQAE) and 
incubated at 37OC by placing in a water bath, protected from light.  
Samples were washed five times with KRB.  For calcium flux, cells 
were re-suspended to 4x106 per ml and washed in KRB.  1µl of 
calcium sensor dye was added to 1ml cells (5µM) and incubated for 
30 min at 37OC in a water bath, protected from light.  Cells were 
washed 5 times with KRB. 
  Each sample underwent 4 experimental treatments; nil (no 
additions), addition of ionomycin at 10µM, uridine 5'-triphosphate 
(UTP) at 100µM, and niflumic acid (100µM) followed by UTP.  
Samples were analysed using flow cytomtery.  The chloride flux 
assay was performed using the BD FACS Aria II flow cytometer, 
whereas the calcium flux was performed on the BD Accuri C6 
cytometer.  All samples were run for baseline and the appropriate 
concentration of ionomycin, UTP or niflumic acid added accordingly.  
The sample run was then continued to establish the response to the 
inhibitors/stimulants.  The final experimental group was run following 
the addition of niflumic acid and then stopped to add UTP and run 
further and changes in fluorescence measured.   
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2.6   Statistical analysis 
  Experimental replicates are represented as ‘n’ and all values and 
error bars are expressed as means ± standard error of the mean.    
Expressional data using RT-PCR (including cytokine stimulation 
assays), flow cytometry and transmigration assay were analysed 
using two-factor ANOVA (with replication) within Excel (as part of 
Microsoft Office Professional Plus 2010).  Add-in “Analysis ToolPak” 
for Excel was downloaded and used for all statistical analysis.  Two-
factor ANOVA was used as data was classified along two dimensions.  
The null hypothesis (H0) was that the gene or translated protein 
expression across cell samples, and for hCLCA1, hBest1 and hANO1 
was taken from the same population, in that there was no difference 
across cells, or for each gene or protein.  Using ANOVA, f values 
were calculated to establish whether populations were taken from 
different distributions.  When the critical F value was shown to be 
less than the f value, the null hypothesis was rejected.  P<0.05 was 
considered statistically significant, and P<0.01 and P<0.001 as highly 
significant, and therefore the alternate hypothesis was assumed.   
  Correlation coefficients were calculated for EoL-1 cells stained with 
hCLCA1 and propidium iodide/annexin V.  A students paired t-test 
was used to establish any significant difference in flow cytometry 
between annexin V/PI staining before and after fixing EoL-1 cells, 
and with and without IL-5 stimulation.  Levels of significance were 
established as P<0.05, P<0.01 and P<0.001.   
  To establish whether there was a correlation between genes 
expressed, scatter plots of hBest1 and hCLCA1 expression were used 
for linear regression and correlation coefficients were calculated.  
The statistical significance of any correlation was evaluated using a 
paired t-test and P<0.05 was considered statistically significant. 
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  To compare HL60s with PMNs and eosinophils for hBest1 protein 
and gene expression, an unpaired 2 tailed students t-test was used 
to establish whether population means were statistically significant. 
Statistical significance was established as P<0.05. 
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2.7 Systematic review 
A systematic review was performed in order to establish the 
expression of chloride ion channels in chronic inflammatory lung 
diseases.  Methodology can be found in Chapter 6, Section 6.3.  
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2.8 Experimental summary 
  Throughout the project, there were numerous experiments to test 
methodological processes.  This included western analysis following 
transfection to test specificity of antibodies, cell lines as models of 
primary cells, and preparation of RNA and proteins for analysis.  
Following this, experiments were focussed within 3 domains.  Firstly 
examining the expression of molecular candidates for chloride ion 
channels.   This was established by RT-PCR for mRNA encoding the 
candidates and  translation into protein expression.  Functional 
analysis explored the responses of cells transfected with hBest1 to 
cytokines and stimulation or inhibition of chloride and calcium flux.  
Finally, the project contextualised the expressional and functional 
experiments in chronic inflammatory lung disease through the 
completion of a systematic review (Chapter 6). 
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CHAPTER 3:  CHARACTERISATION OF ANTIBODIES, 
SPECIFICITY OF RT-PCR PRIMERS AND METHODOLOGY 
OPTIMIZATION 
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3.1 Flow cytometry equipment 
Flow cytometry was performed using two different machines, as 
resources became available, however, results between the two were 
comparable.  Figure 3.1 presents the forward and side scatter plots 
between the two machines for EoL1 cells.  Gate A in the EPICS XL 
(Beckman Coulter) used October 2008 corresponds to gate P5 in the 
Accuri C6.  This was gated as these were considered the viable cells, 
as demonstrated in apoptosis assay (Section 3.1.2).  The orientation 
for the data collected for forward scatter and side scatter using the 
Accuri C6 is on the opposite axis.  Whilst this can be reversed on the 
Accuri C6, default settings were maintained as much as allowable to 
decrease the risk of computational error.  In addition the settings for 
EPICS XL data collection allowed detectors to be set to automatically 
gate out smaller particles, which were considered to be cell debris.  
The Accuri C6 data allows this to be done during analysis.  All data, 
and statistical analysis, was collected and performed using the Accuri 
C6.  Data collected using the Beckman Coulter Epics flow cytometer 
was used as an indicator for further experimentation only and results 
were not pooled with the Accuri C6 data.  
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Figure 3.1: Forward scatter and side scatter for flow 
cytometers:  Please see following page 
FACS (used Oct 08-Dec 08): 
CFlow Accuri C6 (used Sept 09-Dec 09): 
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Figure 3.1: Forward scatter and side scatter for flow 
cytometers:  Early experiments were on the EPICS XL, Beckman 
Coulter, later experiments used the Accuri C6.  Representative 
forward scatter and side scatter plots for EoL-1 cells, on both flow 
cytometry machines showing the comparable information between 
the two resources taking into consideration the opposite 
orientations. 
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3.2 Cell lines selected as an effective model of human cells 
  EoL1 and dEoL1 cells were initially examined to establish whether 
they could be used as a model for primary human cells.  EoL-1 cells 
are considered eosinophilic however when stimulated with dbcAMP 
they are driven towards terminal differentiation and become more 
eosinophilic.  Both EoL-1 and dEoL-1 cells were stained with both 
Annexin V and propidium iodide (PI) (see Section 2.3.1.2) as an 
indicator of cellular apoptosis and necrosis respectively.  When PI 
(FL3; 670LP; Ex 488nm) was plotted against annexin V (FL1; 
533/30nm; Ex 488nm) a scatter plot was produced and divided into 
quadrants (see Figure 3.2 for an example).  Cells in the lower left 
quadrant (LL) were negative for both annexin V and PI and, 
therefore, not considered either necrotic or apoptotic.  Cells in the 
upper right (UR) were positive for both PI and annexin V.  Those in 
the upper left (UL were positive for PI only and the lower right (LR) 
were positive for annexin V only.  Annexin V is a protein, which binds 
to phosphatidylserine as it moves to the outer leaflet of the plasma 
membrane as an early indicator of apoptosis.  PI stains both DNA 
and RNA and when applied to whole cells is an indicator of cellular 
viability, and therefore necrosis.  
 When the cell population was sorted however, and annexin V/PI 
stained, the cells that were positive for hCLCA1 were also positive for 
apoptosis (n=6, see Figure 3.3).  On analysis, there was a positive 
correlation between annexin and hCLCA1, and also between PI 
fluorescence and hCLCA1 (correlation coefficient 0.76 and 0.89, 
respectively).  This was a significant relationship (P<0.05) (Table 
3.1, Figure 3.3).   
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Figure 3.2:  Apoptosis assay for EoL-1 and dEoL-1:  
Apoptosis assay of EoL1 cells demonstrating positive annexin and 
propidium iodide.  Results were similar for differentiated cells 
(dEoL-1).  Apotosis assay as detailed in section 2.3.1.2.  PI (FL3; 
670LP; Ex 488nm) was plotted against annexin V (FL1; 
533/30nm; Ex 488nm).  A: EoL1 in gate P5 (Figure 3.1) were 
negative for PI and annexin V (A1) but also negative for hCLCA1 
(A2).  B:  EoL1 in gate P6 (Figure 3.1) were positive for hCLCA1 
(B2), however, they were also positive for PI and annexin V (B1) 
indicating necrosis and apoptosis (n=6). 
 
B1 
A1 
Isotype 
(black) 
hCLCA1 
(red)
hCLCA1 
(red)
Isotype 
(black) 
A2 
B2 
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Median fluorescence 
Sample Isotype control hCLCA1 
PI fresh 
cells 
Annexin V 
fresh cells 
PI fixed 
cells 
Annexin V 
fixed cells 
EoL1 535 217 729 169 740 426 
EoL1 823 18839 26067 16101 24197 13546 
EoL1 993 365 663 1040 532 732 
EoL1 887 553 459 220 
EoL1 1056 57512 36948 15355 
EoL1 1138 14785 24208 13117 
Mean 905 15379 14846 7667 8490 4901 
SD 195 20259 14773 7251 11107 6114 
Table 3.1:  Median fluorescence of propidium iodide (PI) and 
annexin V in relation to hCLCA1 in EoL-1 cells:  Median 
fluorescence of isotype control, hCLCA1, PI and annexin V in EoL-1 
(n=6 for fresh EoL-1 cells, n=3 for fixed EoL-1 cells).  There is a 
positive correlation between hCLCA1 and PI (coefficient 0.89) and 
hCLCA1 and annexin V (coefficient 0.76) which was significant 
(P<0.05) (Figure 3.4).  There was no statistically significant 
difference between fixed or fresh EoL-1 cells.  PI positive cells were 
in either upper left or right quadrant (UL and UR), annexin V positive 
cells were in either the lower or upper right quadrants (LR or UR). 
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 In order to ascertain whether the process of annexin V or PI staining 
would induce apoptosis or necrosis, or whether it was an internal 
response of EoL-1 cells, a time course was performed (n=2) (Table 
3.2, Figure 3.4).  Whilst n=2 and, therefore, statistical analysis was 
not performed, this indicated that the process of annexin V surface 
staining was unlikely to cause spontaneous apoptosis.  PI staining 
compared to nil controls, did increase fluorescence over time 
however is it known that propidium iodide is cytotoxic and therefore 
should only be applied immediately prior to analysis (manufacturers 
recommendations).   
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Figure 3.3:  Correlation between hCLCA1 and PI/annexin V 
in EoL-1 cells: Median fluorescence of hCLCA1, PI and annexin V in 
EoL-1 cells (n=6).  Error bars are standard error.  There is a positive 
correlation between hCLCA1 and PI (coefficient 0.89) and hCLCA1 
and annexin V (coefficient 0.76) which was significant (P<0.05)   
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Time Nil 
Annexin 
V 
PI (no 
annexin) 
PI (plus annexin 
V) 
0 mins 
1 2451 2798 19365 23751 
2 4837 4360 5755 
5 mins 
1 2506 2822 31949 33590 
2 4920 5424 7259 
10 mins 
1 2423 2845 57458 43091 
2 4562 6039 9844 
15 mins 
1 2404 2766  -  - 
2 4269  -  - 
30 mins 
1 2407 2764  -  - 
2 4578  -  - 
60 mins 
1 2321 2744  -  - 
2 4661  -  - 
Table 3.2:  Time course of fluorescence for annexin V and 
PI staining of EoL-1 cells:  EoL-1 cells (n=2) were stained 
with annexin V for time 0, 5, 10, 15,30 and 60 minutes and 
median fluorescence (logarithmic scale to base 10) measured on 
FL1 (FL1; 533/30nm; Ex 488nm).  PI was measured on FL3 (FL3; 
670LP; Ex 488nm) after 0, 5 and minutes of staining.  N=2 
therefore no statistical analysis could be performed however 
results indicate that there may be no effect of annexin V staining 
over time on intensity of fluorescence.  PI (a known cytotoxin) 
caused increase fluorescence the longer it was applied to the 
sample (Figure 3.4).  As a known cytotoxin, the time course was 
not continued for PI staining after 10 minutes as it is known to 
cause necrosis after prolonged application to cells. 
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  Further analysis was performed on the EoL-1 cells to establish 
whether the process of permeabilising cells for intracellular staining 
caused interference in the staining technique and its specificity.  This 
was examined to establish whether samples could be fixed and 
maintain annexin V staining.  EoL-1 cells (n=3) were stained with 
annexin V and PI with and without Triton treatment (Table 3.3).  
Two way ANOVA was performed and there was no statistically 
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Figure 3.4:  The effect of PI ± annexin V exposure, over time, on 
EoL-1 cell viability: Graph depicting median fluorescence following annexin 
V and PI staining over a time course (Table 3.2).   EoL-1 cells (n=2) were 
stained with annexin V for time 0, 5, 10, 15, 30 and 60 minutes.  PI was 
stained for 0, 5 and 10 minutes after staining.  N=2 therefore no statistical 
analysis could be performed however results suggest that there may be no 
effect of annexin V staining over time on the intensity of fluorescence for 
EoL-1 cells measured on FL1 (FL1; 533/30nm; Ex 488nm).  PI (a known 
cytotoxin) caused increase fluorescence, as measured on FL3 (FL3; 670LP; Ex 
488nm) the longer it was applied to the sample.  (2) in legend above denotes 
second sample. 
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 significant difference between nil controls (no annexin V/PI staining) 
and surface or intracellular staining.  There was also no statistically 
significant difference between surface and intracellular staining for 
annexin V and PI (P>0.7).
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Sample Nil surface Annexin V surface 
Fold 
change 
Annexin 
V surf 
(2dp) 
PI surface 
Fold 
change  
PI surf 
(2dp) 
Nil 
intracellular 
Annexin V 
intracellular 
Fold 
change 
Annexin 
V int 
(2dp) 
PI 
intracellular 
Fold change PI 
int.(2dp) 
1 314 1150 3.66 880 2.80 174 259 1.49 923 5.30 
2 219 554 2.53 194 0.89 157 1269 8.08 1147 7.31 
3 3482 6265 1.80 3976 1.14 1915 5821 3.04 11407 5.96 
Mean 1338 2656 2.66 1683 1.61 749 2450 4.20 4492 6.19 
Standard 
deviation 2829 2563 0.77 1645 0.85 825 2419 2.82 4890 0.83 
Table 3.3:  The effect of Triton treatment on cellular viability of EoL-1 cells:  EoL-1 cells (n=3) were treated with Triton 
(intracellular) and stained with annexin V and PI to establish whether permeabilisation causes apoptosis or necrosis in samples.  
This was measured as fluorescence intensity.  PI was measured on FL3 (670LP; Ex 488nm) and annexin V measured on FL1 
(533/30nm; Ex 488nm).  These were compared to cells that had not been treated with Triton (surface).  Sample 3 skewed data 
causing large standard deviations of fluorescence.  Therefore data was normalised by calculating fold change for fluorescence 
intensity of PI and Annexin V from nil controls for both surface and intracellular staining.  Two-way ANOVA was performed and any 
differences noted were not statistically significant (P>0.7) either from the nil, or between surface or intracellular staining.  The null 
hypothesis (that there is no difference between populations) could not be rejected.      
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  Under light microscopy, EoL-1 and dEoL-1 cultures that were 
annexin V and PI positive did not appear to be contaminated with 
either infection or cross culture contamination.  To establish whether 
apoptosis or necrosis could be prevented, PI and annexin V assays 
were performed before and after fixing EoL-1 cells with 
paraformaldehyde (n=3, Table 3.1) and after stimulation with IL-5 at 
10ng/ml final concentration and incubated for 24 hours (n=3, Table 
3.4).  There was no statistically significant difference in annexin V/PI 
staining between fixed or fresh cells, or stimulating with IL-5 
compared to non-stimulated EoL-1s (P>0.7).  There was no 
statistically significant difference in annexin V/PI staining between 
cells that had been fixed, compared to those that hadn’t, prior to 
staining (P>0.9). 
Median fluorescence Median fluorescence 
Sample PI Annexin V Sample PI Annexin V 
EoL-1 (IL-
5) 23023 13421 EoL-1 42350 32459 
EoL-1 (IL-
5) 34329 26720 EoL-1 33251 15132 
EoL-1 (IL-
5) 35345 25200 EoL-1 24208 13117 
Mean 30899 21780 Mean 33270 20236 
SD 5585 5943 SD 7406 8682 
Table 3.4:  The effect of IL-5 on EoL-1 cell viability using 
measurements of median fluorescence for PI/annexin V: 
EoL-1 cells were stained with PI and annexin V after 24h 
stimulation with IL-5, compared to nil which were not stimulated 
(n=3).  PI measured on FL3 (670LP; Ex 488nm) and annexin V 
measured on FL1 (533/30nm; Ex 488nm).  There was no 
statistically significant difference in apoptosis/necrosis assays 
between the two groups (P>0.7). 
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  EoL-1 cells are an eosinophilic leaukaemic cell line which has the 
phenotypical features of myeloblasts.  Under microscopy myeloblasts 
are non-granular and consist of a large nucleus.  When stimulated 
with N6, 2’-0-dibutyryladenosine 3’:5’-cyclic monophosphate sodium 
(dbcAMP) (Section 2.1.1.2) EoL-1 cells differentiate into eosinophils.  
These cells are distinctive with development of cytoplasmic granules 
and a bi-lobed nucleus (Figure 1.2 shows images of primary 
neutrophils and eosinophils captured under microscopy).  Both EoL-1 
and dEoL-1 cells were stained with annexin V to identify whether 
cells were undergoing programmed cell death which compromises 
the viability of cells.  Prior to differentiation, EoL-1 cells were 
susceptible to spontaneous apoptosis, or alternatively, the process of 
differentiation itself may have caused degranulation, and apoptosis.  
Cells can trigger apoptosis either intracellularly due to stressors, 
infection or hypoxia, or due to extracellular triggers such as toxins.  
Both EoL-1, and dEoL-1 cells were vulnerable to apoptosis which 
would compromised the reliability of the results.  
  EoL-1 and dEoL-1 cells, when stained with hCLCA1, may have been 
fluorescing because hCLCA1 is present intracellularly and in 
apoptosis/necrosis the membrane is compromised allowing the 
antibody access to intracellular contents, and therefore intracellular 
hCLCA1.  Conversely however, there may have been non-specific 
binding.  This would be due to the compromised cell membrane and 
release of intracellular contents, which may non-specifically bind the 
anti-hCLCA1 antibody.  Further analysis of EoL-1 and dEoL-1 cells is 
indicated to confirm their use as a model for human eosinophils.  
Mycoplasmic infections could not be discounted.  Although cultures 
were examined under microscopy, mycoplasma is not easily detected 
without the use of alternative methods such as ELISA or PCR.  
Additionally, further examination as to any possible correlation 
between apoptosis and necrosis and differentiation would be 
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beneficial.  This could be performed by using siglec 8 and major 
basic protein as markers of differentiation.  As indicated, the sample 
number for annexin V and PI staining was 2 (due to contraints of 
resources) and therefore statistical analysis was not performed.  RT-
PCR analysis was performed and no bands were visualised for 
hCLCA1 in either dEoL-1 or EoL-1 cells (Figure 3.5).  This could not, 
therefore, clarify the characterisation of hCLCA1 in this cell line to 
support the initial flow cytometry phenotyping. Whilst EoL-1 and 
dEoL-1 cells cannot be discounted for use as a model for eosinophils, 
further experimentation is required to establish the cause of positive 
annexin V and PI staining, and the correlation with hCLCA1 staining.  
Due to the contraints of resources, and that PMNs were readily 
available, EoL-1 and dEoL-1s were no longer used in the project.  
HL60s, an alternative commercial cell line, was phenotyped to 
establish use as a model for eosinophils, or PMNs. 
EoL-1 dEoL-1 
600bp 600bp 
400bp 400bp 
Figure 3.5:  hCLCA1 expression in EoL-1 and dEoL-1 cells: EoL-1 and 
dEoL-1 cells analysed using RT-PCR for hCLCA1.  Beta actin at the expected 
band size (456 bp).  No band in nil control.  No band visualised for hCLCA1 
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  HL60s have been used previously as an alternative for human pro-
myelocytic cells as they have a neutrophilic phenotype (Fischkoff et 
al., 1984; Varnai et al., 1993; Schrenzel et al., 1995).  This was 
confirmed by RT-PCR of HL60 cells as they demonstrated the same 
RNA expression pattern of bestrophin1-4, in that bands were 
detected for both hBest1 and hBest3, and not hBest2 or hBest4, as 
in PMNs and eosinophils (see Figure 3.6).   Primers used were as 
identified in section 2.2.1.2 and gave bands at the predicted sizes 
(Table 2.3). HL60s were not positive for annexin or PI and so were 
considered an appropriate model for human PMNs in this project as 
the focus was hBest1.  To examine functional properties of 
bestrophin, HL60s were cultured and used to transfect DNA and 
over-express protein.   
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Figure 3.6:  hBest1-4 expression in eosinophils, PMNs and HL60: 
Representative image of RT-PCR for eosinophils, PMNs (granulocytes) and 
HL60s for all bestrophins (n=3).  Primers used as identified in section 2.2.1.2, 
and all bands at the predicted sizes as outlined in Table 2.3.  HL60s were used 
as a model for PMNs in examination of hBest1-4.  RT-PCR demonstrated a 
similar pattern of hBest1-4 in HL60s to both mixed PMNs and purified 
eosinophils as shown above with bands detected for hBest1 and hBest3, but 
not hBest2 or hBest4 in all three cell types.  Nil control showed no bands 
when primers only (no RNA) were added RT-PCR master mix 
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 3.3  Preparation of mRNA and proteins 
 
  Cells were prepared for RT-PCR and western blotting following a 
series of experiments to optimize mRNA and protein yield 
respectively.  All prepared samples for RT-PCR were quantified  using 
a NanoDrop spectrophotometer (Thermo Fisher Scientific) to 
establish concentration of mRNA yield as described in 2.3.1.3.  Two 
preparations were compared to identify the optimum methodology 
for maximum yield.  These are outlined in Section 2.3.1.1 and 
2.3.1.2.  Signosis buffer was used to prepare cell lysates and 
compared to the signal produced in RT-PCR using TRIzol® 
preparation.  The amount of mRNA loaded was standardized as 
described in Section 2.3.1.3.  Signosis buffer is recommended by the 
manufacturer for use when sample size is small as the resultant 
yield, and signal amplification, is greater.  In this case, however, the 
preparation of mRNA was more effective using TRIzol®.  There was a 
more distinct and brighter band for hBest1 using TRIzol® in 
comparison to Signosis lysate buffer.  hBest3 was not detected at all 
using Signosis buffer.  This was evident when compared to beta-
actin positive control which was similar in each sample preparation 
(n=3) (Figure 3.7).  It was concluded, therefore that in this project, 
TRIzol® preparation was more effective for extraction of mRNA from 
PMNs.     
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Figure 3.7:  TRIzol® preparation compared to Signosis 
lysate buffer:  Representative image of RT-PCR comparing 
TRIzol to Signosis buffer preparation (n=3). The two methods 
of mRNA preparation for RT-PCR were examined to optimize 
mRNA yield and signal amplification.  There were clear 
differences between the two methods, concluding that for 
PMNs, the optimum preparation is using TRIzol® to examine the 
mRNA encoding hBest1-4.  Negative control was performed at 
the same time as RNA added experiments  
600bp 
400bp 
600bp 
Negative controls (no RNA 
added) 
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 Protein samples were similarly tested for optimal preparation.  
Protein was extracted by either application of hot SDS and sonication 
method or RIPA buffer lysis (Section 2.4.1.1).  On analysis of protein 
yield (Section 2.4.1.2) there was a greater concentration when using 
RIPA buffer to lyse the sample.  For example, hot SDS preparation 
gave a granulocyte sample concentration of 127.3 µg/ml in 
comparison to RIPA buffer preparation from the same sample 
yielding a concentration of 875.9 µg/ml. 
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 3.4  Specificity of primers for RT-PCR 
 
  A number of cell lines were screened using RT-PCR for hBest1-4, 
hCLCA1-4 and hANO1-10 (see Section 3.2.1 for results summary).  
Specific primers used are identified in Section 2.2.1.2, Table 2.3.    
Each positive band at the predicted size (as outlined in Table 2.3), in 
each cell type, was excised, purified and sent for nucleotide 
sequencing (Section 2.3.3.2).  Using BioEdit software, the returned 
nucleotide sequencing was aligned with the appropriate nucleotide 
sequence held in the NCBI BLAST database (Figure 3.7 shows an 
example sequence alignment).  All samples were sent for sequencing 
at least 3 times for confirmation.  Table 3.5 summarizes the 
sequencing and which bands were confirmed, non-specific or 
indicative of a splice variant.   
 
  hBest3 has been found to have a transcript variant known as Best3 
delta 2,3,6 (hBest3Δ2,3,6).  This splice variant lacks exons 2, 3 and 6 
which has functional implications for the protein as a Ca2+ activated 
Cl- channel (Srivastava et al., 2008) (see section 4.1.3.2 for 
discussion).  The primer pair used for hBest3 did not span exons 2, 3 
or 6 therefore were not specific enough to determine which 
transcript variant was being expressed. 
 
  All primers produced bands on RT-PCR, and the bands were 
considered to be the expected amplified product with the exception 
of hANO9 and hCLCA4. 
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 Family Summary of sequence analysis 
hBest1-4 
(figure 3.7 
for an 
example of 
sequence 
alignment) 
Bands were confirmed as 100% matching of sequence 
to hBest1and hBest3 respectively in all samples sent. 
hBest3 has 2 transcript variants however primers 
were not specific to either variant as hBest3Δ2,3,6 
misses exons not spanned by primer pair.  hBest2 
produced a strong upper band at 1kilobase and a 
weaker band at 400bp.  The upper band matched 
approximately 30% of the hBest2 sequence.  hBest4 
was confirmed as 100% matching the BLAST 
sequence in CFPAC cells however in another sample, 
there was a higher band visualized at approximately 
900bp which was non-specific to any part of the 
hBest4 sequence.      
hCLCA1-4 All bands for hCLCA1-3 were confirmed as 100% 
matching the nucleotide sequence on NCBI BLAST 
database.  hCLCA4 was not confirmed.  One sequence 
returned with no clear peaks so was considered to 
have been contaminated.  All other bands sequenced 
were not specific despite different primer sequences.  
Due to the focus of the project, no further sequencing 
was performed due to constraints of resourcing. 
hANO1-10 hANO1-8 and hANO10 were 100% confirmed for 
sequence alignment, however, all bands returned for 
hANO9 were non-specific 
Table 3.5: Summary of sequence alignments for RT-PCR:  
All bands visualized were sent for sequencing and aligned to 
NCBI BLAST database using BioEdit software.  Table gives a 
summary of all sequence alignments for RT-PCR.  All samples 
were sent at least 3 times (n=3). 
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 3.5  Characterization and specificity of antibodies 
 
  The focus of this project was primarily human bestrophin 1 to 
human bestrophin 4.  In order to demonstrate specificity of 
antibodies a number of cells were phenotyped to exclude any cells 
that had endogenous bestrophin 1-4.  A number of cell lines were 
screened using RT-PCR which included Vero-SG, CHO and HEK293.  
CHO cells were the only samples that did not have endogenous 
hBest1-4 (n=3, see Figure 3.9). 
 
  CHO cells were cultured as per Section 2.1.1.4.  Four flasks were 
cultured to a confluence of approximately 80%.  DNA for hBest1-4 
was transfected into separate samples using lentiviral transfection 
and bacterial delivery via E.Coli (Section 2.5) to over-express 
proteins which were then examined using RT-PCR and western blot.  
Each sample was successfully transfected as demonstrated in Figure 
3.10 (n=3).  Each transfected sample only expressed the transfected 
bestrophin with no other bands seen.  CHO transfected with hBest4 
was however very faint.  CHO nil expressed only β actin as a 
negative control and HEK293 expressed hBest1, hBest3 and β actin 
as a positive control, as per previous RT-PCR.  All bands were sent 
for sequencing with 100% alignment to NCBI BLAST database using 
BioEdit alignment software (method as outlines in Section 2.3.3.2). 
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  Antibodies for hBest1-4, used for flow cytometry and western 
blotting, were characterized to ensure specificity.  Each transfected 
sample was lysed with RIPA buffer to prepare for Western Blot 
analysis.  Each was loaded onto a single gel (using methodology as 
outlined in Section 2.4).  Four gels were prepared and loaded with 
the same sample distribution across wells; CHO (nil transfected), 
CHO transfected hBest1, CHO transfected hBest2, CHO transfected 
hBest3, CHO transfected hBest4 and HEK293 as a positive control.  
Each membrane was labelled with either hBest1, hBest2, hBest3 and 
hBest4 respectively (Table 2.9 for antibodies used in western blotting 
with expected molecular weights).  The antibodies used for hBest2, 
hBest3 and hBest4 were not specific and did not label CHO 
transfected with appropriate bestrophin (n=3).  One antibody used 
for hBest1 was a mouse monoclonal anti-bestrophin (E6-6) (Novus 
Biologicals).  On western blotting there was a 68kDa band visualized 
as expected for hBest1, however, there were bands for all samples 
including the nil which on RT-PCR did not express any bestrophins 
(Figure 3.11).  This was considered non-specific, however, 
transfection was confirmed for hBest1 using the GFP tag on the 
plasmid.  A similar result was found using a similar clone (AbCam 
ab2182, clone E6-6).  
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  hBest1 transfected into CHO included a green fluorescent protein 
(GFP) at the C-terminus.  To ensure accurate transfection three 
samples were loaded onto a gel for Western blot; CHO (nil with no 
transfection), CHO transfected with pRK5-hBest1-IRES-eGFP and a 
positive GFP control using MEF feeder cells with a GFP tag.  This 
shows that the hBest1 with GFP tag was successfully transfected by 
using an antibody to label the GFP (Figure 3.12) 
75kDa 
50kDa 
50kDa 
37kDa 
Figure 3.11:  Antibody characterization using anti-bestrophin mouse 
monoclonal antibody:  Image representing hBest1 labelling (expected 
molecular weight of 68kDa) for antibody characterisation.  Repeated n=3 also 
using an alternative antibody with a similar clone.  Bands visualized in all 
samples demonstrating non-specific binding.  A is a greyscale image of anti-
bestrophin label and B is colourized.  Bestrophin visualized as a green band.  C 
is greyscale of β actin as a positive house-keeping control 
A 
B 
C 
189 
  Further CHO samples were transfected and alternative antibodies 
used for hBest1 as the focus of the project.  An antibody specific to 
hBest1 was identified as Bst-121AP, a rabbit polyclonal supplied by 
FabGennix Inc (Texas) (Figure 3.13).  As identified by the 
manufacturer, this was appropriate for western Blot and 
immunohistocytochemistry analysis.   
A 
B 
Figure 3.12:  Western blot of anti-GFP labelling to demonstrate 
successful transfection:  A is a colourised image with green labeling 
for green fluorescent protein and red for anti actin.  Bands evident in 
positive control and CHO transfected with pRK5-hBest1-IRES-eGFP 
(well 2) and positive GFP control  (well 3).  GFP band at the expected 
molecular weight of 37kDa.  B is a grey scale image of anti-actin 
labelling as a control for sample loading (band as expected for β actin 
at 43kDa). N=3 
37kDa 
50kDa 
37kDa 
50kDa 
190 
37kDa 
50kDa 
75kDa 
Bestrophin1 
Figure 3.13:  Antibody characterization for Bst-121AP (FabGennix):  
Clear green band visualized at the expected molecular weight of 68kDa, in 
CHO cells transfected with bestrophin1 and none in other transfected 
samples demonstrating specificity.  HEK293 used as a positive control with a 
feint green band.  Red bands depict β actin as a positive loading control.  
N=3  
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CHAPTER 4:  EXPRESSION OF POTENTIAL CHLORIDE ION 
CHANNELS 
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4.1  Gene expression determination by RT-PCR
  RT-PCR was performed on multiple cell types to amplify mRNA 
signals encoding hCLCA1-4, hBestrophin1-4 (hBest1-4) and the 
anoctamin (hANO1-10) family.  The evidence presented in chapter 1 
identifies that chloride ion channels may be implicated in granulocyte 
function and to date, the molecular candidates have yet to be 
identified.  It has been shown that there is an increase in cytosolic 
calcium prior to recruitment and activation of pro-inflammatory 
processes in neutrophils.  This suggests that chloride ion channels 
may be calcium activated.  hBest1 was the focus for RT-PCR as a 
prime candidate.  hANO1 is also examined as another potential 
calcium activated chloride ion channel.  Chapter 1 also identified that 
there may be a complex relationship between hANO1, hBest1 and 
hCLCA1.  Therefore, the RNA expression for all 3 potential 
candidates was examined by RT-PCR, and potential relationships 
identified. 
4.1.1  Results 
Primers used as in section 2.2.1.2 and Table 2.3.  Each reaction had 
a corresponding nil control where no RNA was added. All bands have 
been confirmed by gel extraction and sequence analysis (JIC, 
Norwich).  Primers for hCLCA4 are yet to provide a clear band for 
any cell line.  hANO9 primers have provided bands, however, on 
sequence verification analysis these are non-specific.  Epithelial cell 
lines were used as controls for RT-PCR technique and primers.  
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4.1.1.1  hCLCA expression  
  Eosinophils and PMNs express the same pattern of mRNA encoding 
hCLCA1-4 (Figure 4.1 of expression pattern for PMNs).  hCLCA1 was 
detected in both PMNs (n=5) and eosinophils (n=6), however a 
weaker signal in PMNs was observed.  HL60s however do not 
express hCLCA1 (n=4).   
  A549 and NAEC express hCLCA1 and 3 (Figure 4.2 & 4.3).  The 
SAEC cells were positive for hCLCA1-3 (Figure 4.4) whereas CFPAC 
only clearly expressed hCLCA1, Calu-3 and HEK293 only expressed 
hCLCA2 (Figure 4.5).  The focus of the current project was 
Figure 4.1:   RT-PCR of PMNs for hCLCA 1-4 mRNA signal: 
Representative RT-PCR image of bands visualised for PMNs using 
primers for hCLCA 1-4.  hCLCA1 at 322bp has been confirmed by 
sequence analysis.  No bands visualised for hCLCA2-4.  Beta actin was 
used as a control for RT-PCR enzymes and sample loading (n=5).  
Negative controls were master mix with primers only added and no RNA. 
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 bestrophin and therefore the implication of this spread was not 
considered.  RT-PCR was performed however to identify positive 
controls and relationships to bestrophin 1.   
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Figure 4.2:  RT-PCR of A549 for hBest1-4 and hCLCA 1-4:  A. 
Representative image of RT-PCR bands visualised for A549 cell line 
using primers for human hBest1-4 and hCLCA1-4.   All bands 
confirmed by gel extraction and sequence analysis.  N=3 for all RT-
PCR reactions.  B.  Negative controls for all hCLCA1-4, hBest1-4 and 
beta actin primers where no RNA is added. 
A 
B 
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A B 
Figure 4.5:  RT-PCR for HEK293, CFPAC and Calu-3 showing 
hCLCA1-4 expression:  A.  HEK293 cells screened for hBest1-4 and 
hCLCA1-4.  Bands at expected sizes as outlined in section 2.3.2.  hBest1, 
hBest3 and hCLCA2 expressed (n=3).  Only positive bands labelled for 
clarity of figure  B.  Beta actin as positive control for HEK293.  C.  CFPAC 
screened for hCLCA1-4.  Positive band at expected size for hCLCA1.  D.  
Beta actin for CFPAC at expected size.  E.  Calu-3 demonstrating a band 
visualised for hCLCA2 at the expected size and F. Beta actin for Calu-3.  All 
Calu-3, HEK293 and CFPAC n=3.  Nil controls (no RNA) as in Figure 4.2. 
600bp 
400bp 
400bp 
600bp 
C 
400bp 
D 
400bp 
600bp 
E 
600bp 
400bp 
F 
600bp 
400bp 
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 4.1.1.2  Bestrophin expression 
 
  Mixed PMNs, purified eosinophil population and HL60s have clear 
expression of mRNA encoding hBest1 and 3 (Section 3.2, Figure 3.3).  
In addition, hBest1 and hBest3 are present in all cells examined, 
regardless of potential biological location.   
 
  Results were less comparable for the epithelial cell lines.  As with 
the PMNs, expression of hBest1 mRNA was demonstrated on all 
epithelial cell lines (Figures 4.2 – 4.4) and for all except Calu-3, 
hBest2 was also confirmed.  hBest3 was confirmed on all cell lines.  
Calu-3 had an mRNA signal for hBest4 however this was not at the 
expected size and on sequence analysis may potentially be a splice 
variant.  CFPAC and SAEC both expressed hBest4.  Figures 4.2, 4.3, 
and 4.4 present images of the agarose gels for A549, SAEC and 
NAEC for hBest1-4 and hCLCA 1-4.  Figure 4.6 presents an image of 
SAEC and CFPAC for hBest1-4 with positive controls.  Sequence 
analysis for hBest2 confirmed that the band at 1Kb matched to the 
last 3rd of the hBest2 sequence therefore this may represent a splice 
variant. 
 
 
 
 
 
 
 
 
 
 
 
 
200 
SAEC CFPAC 
600bp 
400bp 
600bp 
400bp 
Positive controls 
Figure 4.6:  RT-PCR of SAEC and CFPAC for hBest1-4:  A.  
Representative image of RT-PCR bands visualised for SAEC and 
CFPAC cell lines using primers for hBest 1-4.  hBest2 on sequence 
analysis appears to be a splice variant (n=3).  B.  Negative controls 
were no RNA added to the master mix and primers. 
600bp 
400bp 
200bp 
Negative controls (no RNA) 
for hBest1-4 and beta actin 
A 
B 
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4.1.1.3  hANO expression  
 
  For the anoctamin family, there was 100% sequence alignment 
confirmed for all with the exception of hANO9 which when analysed 
was non-specific.   hANO6, hANO8 and hANO10 were expressed in 
all cell lines both commercial and primary.  Of note however, hANO7 
was only visualized in PMNs and eosinophils and none of the other 
samples examined.  This may indicate a unique role of hANO7 in the 
function of PMNs.  That it was not visualized in HL60s may also 
indicate a link between cellular differentiation.  hANO1 was 
expressed in PMNs, eosinophils and SAECs however not in HL60s.  It 
was visualized and confirmed in all other cell lines (Figure 4.7 and 
4.8 shows example RT-PCR gels). 
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 4.1.1.4  RT-PCR summary and densitometry 
 
  RT-PCR was performed on multiple cell types to amplify mRNA 
signals encoding hCLCA1-4, hBestrophin1-4 (hBest1-4) and the 
anoctamin (hANO1-10) family.  Primers used as in section 2.2.1.2 
and Table 2.3.  Table 4.1 summarises all expressional screening 
using RT-PCR where each reaction was repeated a minimum of 3 
times (n=3).  Each reaction had a corresponding nil control where no 
RNA was added. All bands have been confirmed by gel extraction 
and sequence analysis (JIC, Norwich).  Primers for hCLCA4 are yet to 
provide a clear band for any cell line.  hANO9 primers have provided 
bands, however, on sequence verification analysis these are non-
specific.  Epithelial cell lines were used as controls for RT-PCR 
technique and primers.  
 
  Densitometry was performed on bands for hCLCA1, hBest1 and 
hANO1 for eosinophils (n=6), granulocytes (n=5), HL60s (n=4) and 
SAEC (n=3) (Table 4.2 for optical density of bands normalised to β 
actin).  Optical density (normailsed to β actin) was plotted as a bar 
chart, with error bars (Figure 4.9), and scatter plots are presented to 
establish any correlation between expression of genes (Figure 4.10 
and 4.11).  
 
  hCLCA1 was detected in both PMNs (n=5) and eosinophils (n=6), 
however a weaker signal in PMNs was observed.  HL60s however do 
not express hCLCA1 (n=4).  On analysis of variance (ANOVA), this 
difference between cells was statistically significant (P<0.05) (Table 
4.2, * in Figure 4.9).    
 
  It appears that hCLCA1 is up-regulated in the epithelial respiratory 
tissues (A549, NAEC and SAEC) (Figure 4.2, 4.3, and 4.4) relative to 
PMNs, however not eosinophils.   Mean optical density (normalised to 
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 β actin) for SAEC was 0.278, greater than PMNs (0.223) however 
less than eosinophils (0.299).  This observed difference was 
statistically significant (P<0.05). The expression pattern, of hCLCA1, 
hBest1 and hANO1 was significantly different within each sample 
(P<0.0001).  hCLCA1 was plotted against both hBest1, and hANO1 
and correlation coefficients calculated (Figure 4.10 and Figure 4.11).  
There was a negative correlation (coefficient -0.62) between hCLCA1 
and hBest1, in that as the expression of hCLCA1 increases, hBest1 
decreases (P<0.0005).  Whilst a positive correlation (0.84) was 
observed between hCLCA1 and hANO1, this was not statistically 
significant (P>0.1).   
 
  Semi-quantification using densitometry has shown that the 
expression of hBest1 is significantly greater than either hANO1 or 
hCLCA1 in PMNs, eosinophils, HL60s and SAECs (P<0.0001) (Figure 
4.9).  There is a negative correlation between hCLCA1 expression 
and hBest1 (coefficient -0.62, P<0.0005) (Figure 4.10).  Therefore as 
hCLCA1 expression increases, hBest1 decreases.  It has also been 
shown that there is a weak negative correlation between hBest1 
which is statistically significant (coefficient -0.36, P<0.0001) (Figure 
4.11).  The expression of hBest1, as with hCLCA1 is greatest in 
eosinophils and least in PMNs (Figure 4.9).  This difference across 
cell samples is statistically significant (P<0.05, *2 in Figure 4.9).   
 
  HL60s were compared to both eosinophils and PMNs to establish 
whether they were an appropriate model for functional analysis of 
granulocytes.  Using an unpaired 2 tailed students t-test, there was 
no statistically significant difference between gene expression of 
hBest1 in PMNs (n=5) and HL60s (n=4) (P>0.6).  Conversely, the 
difference in gene expression of hBest1 in HL60s and eosinophils 
(n=6) was statistically significant (P<0.05).     
206 
PMNs Eosinop
hils 
HL60 A549 NAEC SAEC CFPAC Calu-3 HEK293 
CLCA1 √ √ weak x √ √ √ √ x x 
CLCA2 x x x x x √ x √ √ 
CLCA3 x x x √ √ √ x x x 
CLCA4 x x x x x x x x x 
Bestrophin
1 
√ √ √ √ √ √ √ √ √ 
Bestrophin
2 
x x x √ √ √ √ x x 
Bestrophin
3 
√ √ √ √ √ √ √ √ √ 
Bestrophin
4 
x x x x X √ √ x x 
ANO1 √ x x √ √ √ √ √ √ 
ANO2 x x x √ √ √ √ x √ 
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 ANO3 x x x x x x √ x √ 
ANO4 x x x √ √ √ x √ √ 
ANO5 √ x √ √ √ √ √ √ √ 
ANO6 √ √ √ √ √ √ √ √ √ 
ANO7 √ √ x x x x x x x 
ANO8 √ √ √ √ √ √ √ √ √ 
ANO9 x x   x √ √ √ x √ √ 
ANO10 √ √ √ √ √ √ √ √ √ 
Table 4.1:  Summary of all results for RT-PCR screening:  Table to summarize all RT-PCR screening (human cells).  CLCA4 and 
ANO9 are not confirmed on sequencing and alignment.  Those ticked are visualized bands which have been confirmed.  PMN, eosinophils and HL60s 
were screened to establish whether HL60s could be used as a reliable model for human PMNs.  Other cell lines were screened to establish any 
patterns in expression of RNA and to identify possible cell lines that could be employed as positive controls.  All RT-PCR was repeated 3 times (n=3) 
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hCLCA1 hBest1 hANO1 β actin 
Cells/Sample 
Optical density 
of band 
Normalised to β 
actin (3dp) 
Optical density 
of band 
Normalised to β 
actin (3dp) 
Optical density 
of band 
Normalised to β 
actin (3dp) 
Optical density 
of band 
PMNs (n=5) 
1 12325 0.051 16943 0.070 10897 0.045 243712 
2 0 0 81889 0.850 6942 0.072 96390 
3 26027 0.190 52513 0.383 12530 0.091 137173 
4 22967 0.461 38811 0.780 - - 49776 
5 26911 0.191 93381 0.664 - - 140675 
Mean 22058 0.223 56707 0.549 10123 0.069 133545 
Standard 
deviation 6705 0.172 31218 0.322 2873 0.023 71761 
Eosinophils (n=6) 
1 17867 0.230 0 0 16031 0.206 77775 
2 49827 0.215 156366 0.674 15637 0.067 232169 
3 21726 0.232 29359 0.314 8786 0.094 93619 
4 6239 0.521 27982 2.336 - - 11979 
5 0 0 45577 0.388 - - 117572 
6 - - 34357 0.332 - - 103428 
Mean 23915 0.299 58728 0.809 13485 0.122 106090 
Standard 
deviation 18486 0.148 55018 0.866 4074 0.074 71901 
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 HL60 (n=4)               
1 0 0 77588 0.580 0 0 133705 
2 0 0 12206 0.279 0 0 43775 
3 0 0 63988 0.895 0 0 71502 
4 0 0 54519 0.833 0 0 65450 
Mean  0 0 52075 0.647 0 0 78608 
Standard 
deviation 0 0 28216 0.281 0 0 38612 
SAEC (n=3)               
1 52581 0.376 70635 0.505 55233 0.395 139825 
2 40732 0.310 69904 0.532 44234 0.337 131325 
3 27302 0.147 131257 0.708 43537 0.235 185487 
Mean  40205 0.278 90599 0.582 47668 0.322 152212 
Standard 
deviation 12648 0.118 35213 0.110 6561 0.081 29128 
Table 4.2:  Densitometry performed on bands visualised in PMNs, eosinophils, HL60s and SAEC for hCLCA1, hBest1 
and hANO1:  Bands were visualised and optical density was calculated as a product of mean grey area and band area in pixels.  
Optical densities for each were normalised to β actin.  ‘0’ indicates samples where no band was visualised.  These were excluded from 
the calculation of mean values.  ANOVA was performed to establish whether there was a difference in the sample means, and that 
they are considered to be taken from different populations.  Where the critical F value was less than the f value the null hypothesis 
was rejected.  Statistical significance was accepted at P<0.05.  The expression of hCLCA1, hBest1 and hANO1 was significantly 
different within each sample (P<0.0001).  The expression of each hCLCA1, hBest1 and hANO1 was statistically different across each 
sample (P<0.05). 
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Figure 4.9: Expression of hCLCA1, hBest1 and hANO1 as optical 
density of bands visualised in PMNs, eosinophils, HL60s and 
SAEC (outlined in table 4.1):  Optical density for hBest1, hCLCA1 and 
hANO1 in PMNs (n=5), eosinophils (n=6), HL60s (n=4) and SAECs (n=3). 
Error bars relate to standard error mean.  Differences observed between 
samples, and within samples for expression of hCLCA1 and hANO1 were 
considered statistically significant as determined using 2-way ANOVA 
(P<0.05, * above, and P<0.0001 respectively).  hBest1 gene expression 
was not significantly different between PMNs and HL60s (P>0.6).  
However, the diference between hBest1 expression in eosinophils and 
HL60s was significant (P<0.05, *2 above)  
*2
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Figure 4.10:  Correlations between gene expression of hCLCA1 and 
hANO1 and hBest1:  Correlation coefficient calculated for hCLCA1 expression 
against hBest1 and hANO1across all samples.  Negative correlation (correlation 
coefficient -0.62) observed between hCLCA1 and hBest1 expression which was 
statistically significant (P<0.0005).  Whilst a positive correltation (coefficient 
0.84) was observed between hCLCA1 and hANO1 this was not statistically 
significant (P>0.1).  
Figure 4.11:  Correlation between gene expression of hANO1 and 
hBest1:  Correlation coeeficient calculated for hANO1 expression against 
hBest1 expression which shows a weak negative correlation (coefficient -
0.36) which is statistically significant (P<0.0001). 
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 4.1.2  Discussion 
 
4.1.2.1  hCLCA expression 
 
  As outlined in section 1.1.3.3, hCLCA1 is no longer considered to be 
a chloride ion channel itself but may have a regulatory role in the cell 
to modulate the activity of other chloride ion channels (Greenwood & 
Leblanc, 2007; Hamann et al., 2009).  The data presented in this 
project, on the lack of expression of hCLCA1 in HL60s may support 
this. 
 
  It has been proposed that hCLCA1 modulates the activity of other 
chloride ion channels.  Coupled with other published evidence (as 
discussed in Chapter 1) and the significant differences between 
hCLCA1, hBest1 and hANO1 expression, and the correlation between 
hBest1 and hCLCA1 presented here, supports this.   These 
observations may occur as the gene signal stops when optimal 
activity and modulation of an alternative channel is achieved. 
Conversely, it may be that the signal of hCLCA1 ceases not as a 
result of optimum modulation of another channel, but that hCLCA1 is 
implicated in the activation of cells which may be supported by the 
observations of differing expression across PMNs and eosinophils.  In 
this instance, the hCLCA1 signal would be optimal as the cell is 
reaching maturity until electrical neutrality is restored (Loewen & 
Forsyth, 2005).  The mature, or differentiated cell, may then have a 
different expression pattern of ion channel families which would be 
reflected in mRNA.  A positive correlation between hCLCA1 and other 
channels (such as hANO1) may mean that an increased expression of 
hCLCA1 would result in modulation of alternative ion channel activity, 
and resultant chloride flux.  This relationship within the current 
project was not statistically significant however but indicates the 
need for further examination.  The relationship between hCLCA1 and 
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 hBest1 however was negative in that as hCLCA1 increases, hBest1 
decreases indicating that the modulation of this channel is inhibitory.  
This supports the work of others (Britton et al., 2002; Loewen & 
Forsyth, 2005) and is further supported by the spread of hCLCA1 in 
the commercial cell lines examined here. 
 
  Expression of hCLCA1 in respiratory epithelia was also found by 
Rogers (2003) and Tyner et al (2006).  The locality of mRNA 
encoding hCLCA1 in respiratory epithelia suggests a role in airway 
processes such as chloride flux and associated mucus production.   
 
  The relationship between hCLCA1, cell differentiation and other 
chloride ion channels may therefore be a complex relationship of 
several factors.  Further research is required to identify whether the 
decrease in hCLCA1 is as a result of terminal differentiation as it is 
required for maturation, or because it is required for optimal activity 
of another chloride ion channel (such as hBest1 and hANO1).  The 
expression of hCLCA1 would therefore be different depending on the 
function of hCLCA1.   
 
4.1.2.2  Bestrophin expression 
 
  As discussed in 1.1.3.4, bestrophins are considered to be calcium 
activated chloride channels and it has been shown that they are 
sensitive to DIDs, a specific Cl- channel blocker (Greenwood & 
Leblanc, 2007; Kunzelmann et al., 2007; Barro-Soria et al., 2010).  It 
has been suggested that hCLCA1 may modulate the activity of 
hBest1 through a selective filter on the second TMD of hBest1 
(Loewen & Forsyth, 2005).  This is supported by the current data in 
that the negative correlation between hCLCA1 and hBest1 expression 
was significant.  However, it appears that as hCLCA1 expression 
increases, hBest1 decreases which suggests that the role of hCLCA1 
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 is inhibitory.  Alternatively, hBest1 and hBest3 are expressed in all 
cells screened and may be self-regulating.   Barro-Soria (2010) 
however, demonstrated that bestrophin1 was localized to the 
endoplasmic reticulum and suggested that activation of hANO1 was 
reliant upon intracellular calcium signalling modulated by hBest1.  
This relationship does not seem supported by the spread of 
expression.  As stated, the observed relationship between hBest1 
and hANO1 is negative in that as hBest1 increases, hANO1 
decreases.  This is not however statistically significant and therefore 
requires further examination.  A complex interaction between 
hBest1, hANO1 and hCLCA1 may be evident.  
 
  hBest3 has two transcript variants, one of which does not have 
exons 2, 3 and 6 (hBest3Δ2,3,6), whilst the other is full length.  The 
differences between the two may have functional implcations for 
bestropin 3 as a Ca2+ activated Cl- channel.  It has been shown in 
mouse studies that Best3Δ2,3,6 proteins lack two TMDs and the N-
terminus which may impact upon the ability of this variant to act as a 
chloride channel (Srivastava et al., 2008).  Within these experiments, 
it has also been shown that there are differences in expression of the 
two variants.  Mouse heart expresses full length Best3 whereas the 
variant Best3Δ2,3,6 has been found in exocrine glands, lung, testis 
and kidney (Srivastava et al., 2008).  To further examine hBest3 in 
human granulocytes or lung, firstly expression of variants should be 
established. Functional implications could be established by utilising 
patch clamp techniques to determine chloride flux and application of 
DIDs to cells transfected with full length hBest3 and hBest3Δ2,3,6.  
This would further clarify the expressional pattern of the Best3 
variants and elucidcate functional implications. 
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 4.1.2.3  hANO1 expression 
 
  hANO1 was expressed in PMNs, eosinophils and SAECs however not 
in HL60s.  It was visualized and confirmed in all other cell lines.  This 
mRNA expression pattern is similar to that of hCLCA1 and therefore 
may support the hypothesis that hCLCA1 is the complementary 
partner of an alternative chloride channel (Britton et al., 2002; 
Loewen & Forsyth, 2005).  It has been shown that there is a positive 
correlation between hANO1 and hCLCA1 however this is not 
statistically significant (coefficient 0.84, P>0.1) (Figure 4.10 and 
Figure 4.11).  There is greater expression in SAECs than either PMNs 
or eosinophils however eosinophils have a greater expression than 
PMNs (P<0.05) (Figure 4.9).  This may also suggest a relationship to 
the differentiation and maturation of cells.   
   
  At the point of this project, the evidence for hANO1 remained 
sparse and further experimentation is indicated to establish the role 
of hANO1 and it’s relationship to other chloride ion channels. 
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 4.2  Protein expression determination by flow cytometry  
  
  Flow cytometry phenotyped both surface, and intracellular, protein 
expression for PMNs, eosinophils and HL60.  Flow cytometry was 
used to examine whether mRNA encoding for hCLCA1, hBest1 and 
hANO1 translated into protein expression in PMNs.  Fresh PMNs 
purified by percoll density gradient centrifugation (see Section 
2.1.2.1) were used for both intracellular and surface staining for 
hCLCA1, hBest1 and hANO1 (Methodology found in Section 2.2).  
Figure 4.12 and 4.13 present example histograms from both 
intracellular and surface staining respectively for both hCLCA1 and 
hBest1.  Figure 4.14 and 4.15 present hANO1 data.  Mean 
fluorescence was measured for PMNs (n=3), eosinophils (n=3) and 
HL60s (n=3) (Table 4.3 for results) 
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Figure 4.12:  Intracellular staining of mixed PMNs and eosinophils:  
Representative histogram overlays demonstrating a rightward shift in 
fluorescence for hCLCA1 and hBest1 intracellular staining (FL1-A [533/30nm] 
Ex 488nm).  A=PMNs and B=eosinophils.  Primary labelled with hCLCA1 (red 
curve) and hBest1 (blue curve) and secondary labelled with bodipy as in 
section 3.4.  Compared against the nil (black curve), and isotype control (green 
curve) as described in section 3.4.  A rightward shift is indicative of increased 
fluorescence, and therefore increased protein labelled with specific antibodies.  
All experiments repeated 3 times (n=3)  
Nil 
hCLCA1 
hBest1 
Isotype control 
A 
B 
hBest1 
hCLCA1 
Nil 
Isotype control 
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Figure 4.13:  Surface staining of mixed PMNs and eosinophils:  
Histogram demonstrating a rightward shift of hCLCA1 and hBest1 staining 
on the cell surface (FL1; 533/30nm; Ex 488nm) (n=3).  A=PMNs and 
B=eosinophils. Primary labelling for hCLCA1 (red curve) and hBest1 (blue 
curve) proteins and secondary labelled with goat anti-mouse FITC or 
alexafluor 488.  Compared against nil (black curve) and isotype control 
(green curve).  AlexaFluor 488 has a longer half-life and so is used when 
samples are cytospun and under microscopy for morphological assessment  
hBest1 
hCLCA1 
Nil 
Isotype control 
B 
A 
hBest1 
Isotype control 
Nil 
hCLCA1 
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Figure 4.14:  Surface hANO1 protein on mixed PMNs:  
Histogram of hANO1 antibody labelling (red curve) compared to nil 
(black curve) and isotype control (green curve) (FL1; 533/30nm; Ex 
488nm).  Secondary antibody was an anti-rabbit-FITC (n=3) 
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Figure 4.15: Intracellular hANO1 on mixed PMNs:  Histogram 
of hANO1 antibody labelling (red curve) compared to nil (black 
curve) and isotype control (green curve) (n=3) (FL1; 533/30nm; Ex 
488nm).  Greater rightward shift indicates a greater expression of 
hANO1 protein intracellularly   
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Sample Nil Int 
Nil 
surface 
Isotyp. 
Int 
Isotype
surface 
CLCA1 
Int 
CLCA1 
surface 
Best1 
int 
Best1 
surface 
CD44 
int 
CD44 
surface 
Eos 1 664.35 353.04 1122.03 464.98 15579.15 5678.25 3557.28 635.82 63144.44 80417.81 
Eos 2 788.87 509.33 793.31 544.74 17295.57 4276.32 2571.42 824.54 51701.09 77833.66 
Eos3 654.36 701.62 1079.76 891.18 20472.47 4646.65 2304.49 1025.74 47950.43 61781.45 
Mean 702.53 521.33 998.37 633.63 17782.40 4867.07 2811.06 828.70 54265.32 73344.31 
SD 61.19 174.60 178.84 226.58 2482.72 726.49 659.88 194.99 7914.92 10096.74 
           
           
 
Sample 
Nil 
Int 
Nil 
surface 
Isotype 
Int 
Isotype 
surface 
CLCA1 
Int 
CLCA1 
surface 
Best1 
int 
Best1 
surface 
CD44 
int 
CD44 
surface 
PMNs (1) 352.45 244.8 303.34 405.05 33150.97 1383.79 19040.3 6161.86 31203.53 37643.76 
PMNs (2) 404.51 264.83 468.9 285 27812.95 1278.82 13206.52 4523.78 26390.4 33249.02 
PMNs (3) 398.87 272.17 313.45 508.14 25808.95 1974.63 18484.66 5511.75 27181.38 42427.78 
Mean 385.28 260.60 361.90 399.40 28924.29 1545.75 16910.49 5399.13 28258.44 37773.52 
SD 23.33 11.57 75.78 91.18 3098.67 306.28 2628.91 673.47 2107.38 3748.34 
 
           
A 
B 
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Sample 
Nil 
Int 
Nil 
surface 
Isotype 
Int 
Isotype 
surface 
Best1 
int 
Best1 
surface 
HL601 865.37 1079.39 769.79 1076.18 1609.17 1353.73 
HL602 683.43 918.23 508.64 874.08 1454.18 1373.39 
HL603 725.3 782.02 682.54 812.49 1629.04 1265.36 
Mean 758.03 926.55 653.66 920.92 1564.13 1330.83 
SD 77.80 121.54 108.55 112.63 78.17 46.98 
Table 4.3:  Surface and intracellular protein expression of Best1 and CLCA1 in PMNs, eosinophils and HL60s:  Samples were 
prepared as per previous section.  Samples were labelled for protein on the cell surface and intracellularly (“int” in above) for hCLCA1 and 
hBest1. hBest1 is the project focus and the antibody (Bst-121AP) used was characterized for specificity (section 3.5). Median fluorescence 
was measured (FL1; 533/30nm; Ex 488nm) and means calculated with standard deviation (SD) all to 2dp. A=PMNs (n=3), B=eosinophils 
(n=3) and C= HL60 (n=3) for bestrophin only.  Using 2 way ANOVA, there was no statistically significant difference between nil and 
isotype controls indicating that there was not any non-specific binding (P>0.1).  Isotype controls were used to establish change in hBest1 
and hCLCA1 expression.  Differences in protein expression observed were between Isotype controls both intracellular and surface staining 
and intracellular and surface staining for hBest1 and hCLCA1 (P<0.0001).  The differences between intracellular and surface staining for 
each hBest1 and hCLCA1 was also significantly different (P<0.0001).  Figure 4.16 for bar chart of results, section 4.2.1 for summary of 
lt   
  
C 
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 4.2.1  Summary of flow cytometry experimental results 
 
  Polymorphonuclear cells and eosinophils were phenotyped for 
hCLCA1 and hBest1 protein expression using both surface and 
intracellular staining.  This was to identify any relationship between 
these proteins (Figure 4.16, Table 4.3) and to gene expression.  The 
bar charts presented (Figure 4.16 and 4.17) have mean fluorescence 
on the vertical axis measured on a logarithmic scale to base 10 
(Log10).  Individual experiments are measured as median 
fluorescence of each histogram.  Collective representation (n=3) is 
calculated as a mean of these.  This was to allow visualization of 
values for nil, isotype and positive controls.  Isotype was used as a 
control to measure the effect of any non-specific binding to the host 
species of antibody used.  There was no statistically significant 
difference between nil and isotype controls for all cell types, and 
both intracellular and surface staining (P>0.1).  Isotype controls 
were therefore used to compare the mean of fluorescence.    
 
  Intracellular isotype mean for PMNs was increased from 362 ± SD 
76 at least 46 fold for intracellular hBest1 (* in figure 4.16) to 16910 
± SD 2629.  There was, however, a much larger increase in mean 
fluorescence for intracellular hCLCA1 at 80 fold (hCLCA1 = 28924± 
SD 3099) (*2 in Figure 4.16).  These changes in protein expression 
from the isotype mean were statistically significant (P<0.005).  The 
difference between fluorescence of intracellular hCLCA1 and hBest1 
was also statistically significant (P<0.0001, indicated by *3 in figure 
4.16).  As antibodies used were from the same animal (with the 
same isotype), and the same secondary antibody was used, it can be 
suggested that intracellularly, hCLCA1 protein expression is greater 
than hBest1. 
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  The comparison between nil and isotype controls was not 
statistically significant (P>0.05) and, therefore, there was not 
considered to be any non-specific binding and isotype was used as a 
control.   
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Figure 4.16:  Intracellular and surface protein expression of CLCA1 and 
Best1 in PMNs and eosinophils:  Bar chart showing the mean of median 
fluorescence of  PMNs (labelled in graph as granulocytes, blue bar) and 
eosinophils (n=3) (red bar), in logarithmic scale to base 10, for hCLCA1 and 
hBest1 proteins both intracellularly and surface compared to negative and 
positive controls.  Error bars are ± standard deviation (SD) to 2dp.  Differences 
between isotype (IgG) controls (both intracellular and surface) and hCLCA1 and 
hBest1 are statistically significant (P<0.005).  Differences between hCLCA1 and 
hBest1 protein expression for both intracellular and surface staining are 
significant.  Intracellular staining shows greater hCLCA1 than hBest1 (P<0.0001, 
*3 above).  Surface staining has a greater protein expression of hBest1 compared
to hCLCA1 (P<0.0001, *4 above).  There is a significant difference between 
surface staining and intracellular staining for each hCLCA1 and hBest1 (*5 above) 
*3
*4
*5 *5
*
*2
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Figure 4.17:  Surface and intracellular protein expression of Best1 in 
HL60s, PMNs and eosinophils:  Graph showing the median fluorescence of 
PMNs (labelled as grans, red bar), in logarithmic scale to base 10, for hBest1 
both intracellularly and surface stained compared to negative controls 
(IgG=isotype).  Error bars are ± standard deviation (SD).  A statistically 
significant (P<0.05) increase in fluorescence intensity for hBest1 both surface 
and intracellularly stained however the difference between the two was not 
significant (P>0.05).  There was a significant difference between HL60s 
(purple)  and PMNs (P<0.01) however the difference between HL60 and 
eosinophils (blue)  was not significant (P>0.07).   
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  When PMN cells (n=3) were surface stained, the relative 
fluorescence increase from isotype control for hCLCA1 was 3 fold; in 
contrast the hBest1 increase from isotype control was 13 fold.  This 
increase in fluorescence from isotype for both intracellular and 
surface staining for hCLCA1 and hBest1 was statistically significant 
(P<0.05).  The difference noted between hCLCA1 and hBest1, in that 
there was a greater increase in surface staining of hBest1, compared 
to hCLCA1 was statistically significant (P<0.0001, *4 in Figure 4.16). 
Whilst both hCLCA1 and hBest1 have greater amounts of protein 
intracellularly than the surface stain (P<0.005, *5 in Figure 4.16), the 
relationship between the two is inverse.  Intracellularly there is a 
greater amount of hCLCA1 compared to hBest1 (*3 in Figure 4.16) 
and on the surface a greater amount of hBest1 compared to hCLCA1 
(*4 in Figure 4.16).   
  
  In eosinophils (n=3), there is a similar intracellular pattern in that 
there is a much greater expression of hCLCA1 intracellularly (17 fold 
increase from isotype control, P<0.005), than either on the surface 
(*5 in Figure 4.16), or compared to intracellular hBest1 (which 
increased by 3 fold from isotype control, P<0.005, *3 in Figure 4.16).  
In comparison to PMNs, however, whilst the expression of surface 
hCLCA1 in eosinophils is less than intracellular (7 fold increase in 
surface staining from control, compared to 17 fold increase in 
intracellular staining), it is greater than that observed for hBest1 (1.5 
fold increase).  The greater expression of hCLCA1 surface staining 
eosinophils, compared to surface hBest1 is statistically significant 
(P<0.0001, *4 in Figure 4.16).   The changes in protein expression 
for hCLCA1 and hBest1 both from the isotype control (P<0.005), and 
surface compared to intracellular were statistically significant 
(P<0.005, *5 in Figure 4.16).  
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   CD44 has been used as a positive control for flow cytometry (Figure 
4.16).  CD44 is a glycoprotein used for cellular migration, and cell-
cell interations.  As such, it is predominantly found on the cell 
surface.  There was, however, no significant difference found 
between surface and intracellular staining in either granulocytes or 
eosinophils (Figure 4.16).  CD44 interacts with lymphocyte-specific 
protein tyrosine kinase (Lck) which is a protein, found intracellularly 
in predominantly lymphocytes.  It has been found, however, that Lck 
is also present in granulocytes (Pulford et al., 1999).  In this 
instance, CD44 may be interacting with Lck when the cell is 
permeabilised and allowing entry of CD44 into the cell.  Alternatively, 
is has been shown that a proportion of CD44 molecules cleave the C-
terminal tail as an intracellular cytoplasmic domain (Mellor et al., 
2013).  There are also non-degraded CD44 molecules that remain 
membrane bound.  In this instance, the permeabilisation of cells 
would allow the antibody to enter the cell and bind to the 
cytoplasmic domain of CD44, or to bind to those that remain non-
degraded as transmembrane proteins. 
 
  When cells are not permeabilised, antibodies have access only to 
surface bound proteins.  Through permeabilisation, there is access to 
both surface and intracellular proteins.  That there is little difference 
between surface and intracellular staining of CD44 is likely due to 
surface bound protein still being stained and fluorescing regardless 
of whether the cell is permeabilised.  The antibody would still be 
exposed to surface proteins in addition to any that are intracellular. 
 
  The hBest1 antibody used was Bst 121-AP (Fabgennix Inc, Texas).  
This antibody recognises an amino acid sequence that is located at 
the C-terminus of bestrophin, which is an extracellular portion of the 
protein (Marmorstein et al., 2000; Marmorstein et al., 2002).  
hCLCA1 was labelled with monoclonal antibody (M03), clone 2C10 
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 (Abnova).  The immunogen sequence provided by the manufacturer 
was analysed using protein BLAST (NCBI) and mapped against the 
full amino acid sequence for hCLCA1.  This antibody labels the amino 
acid sequence from 677 to 776 of the 914 amino acid sequence for 
hCLCA1.  This is extracellular and found after any potential 
transmembrane domains (Gruber et al., 1998).  Both hBest1 and 
hCLCA1 had greater fluorescence when permeabilised for 
intracellular staining.  When surface stained, antibodies would be 
binding only to the extracellular amino acid sequence for hCLCA and 
hBest1.  When permeabilised, the antibody would bind to both the 
surface, extracellular amino acid sequence, and to any protein found 
intracellularly.  This would result in an overall greater fluorescence 
than surface staining alone.  That the fluorescence is greater for 
intracellular staining indicates that there is hCLCA1 and hBest1 
intracellularly.  If both proteins were bound to the cell surface only, 
there would be no difference in the relative fluorescence between 
the intracellular and surface staining.  
 
  In summary, in both PMNs and eosinophils, there is a statistically 
significant increase in both hBest1 and hCLCA1 both intracellularly 
and on surface staining compared to isotype controls.  There is a 
greater amount of fluorescence intracellularly for both hBest1 and 
hCLCA1 compared to surface in both PMNs and eosinophils.  In 
PMNs, there is a greater amount of hBest1 compared to hCLCA1 on 
surface staining.  In eosinophils, there is a greater amount of 
hCLCA1 compared to hBest1 on surface staining, indicating that on 
the surface there is a negative correlation between hCLCA1 and 
hBest1.  The relationship between intracellular and surface staining 
for PMNs and eosinophils is of interest.  To date, this has not been 
examined elsewhere and should be further researched.  The overall 
expression of hCLCA1 and hBest1 protein correlates to the findings 
of gene expression and semi-quantification using densitometry.  As 
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 discussed in section 4.1.2 and 4.1.3 there is a statistically significant 
negative correlation between gene expression of hCLCA1 and 
hBest1. 
 
  To confirm the use of HL60s as an appropriate model for human 
cells, samples (n=3) were phenotyped for intracellular and surface 
expression of hBest1 protein only.  hCLCA1 or hANO1 were not 
screened as the functional assays were refined to hBest1 only.  As 
identified in section 4.1.3, the gene expression of hCLCA1 and 
hANO1 differs between PMNs and eosinophils compared to HL60s.  
This is an area which requires further research.  Figure 4.17 is a bar 
chart showing the results of HL60 screening compared to both 
eosinophils and mixed PMNs.    
 
  HL60 cells did not have a statistically significant difference between 
the nil and isotype controls.  There was a statistically significant 
increase in both intracellular and surface expression of hBest1 
protein from isotype control (P<0.005).  The difference between 
surface and intracellular expression was not statistically significant.  
On comparison of HL60s to PMNs with a student’s t-test, the 
difference was significant (P=0.01, n=3).  On comparison however 
to eosinophils, the difference was not significant (P>0.07).    As 
discussed in section 4.1.3, there was no statistically significant 
difference between gene expression of hBest1 in PMNs (n=5) and 
HL60s (n=4) (P>0.6).  Conversely, the difference in gene expression 
of hBest1 in HL60s and eosinophils (n=6) was statistically significant 
(P<0.05).  From the results presented, it was concluded therefore 
that HL60s are an appropriate model for human eosinophils or 
granulocytes in this instance although this may be reliant upon the 
stage of differentiation and cell cycle. 
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4.2.2  Results in context 
 
  As demonstrated in RT-PCR, and densitometry (section 4.1) there is 
a negative correlation between hCLCA1 gene expression and hBest1 
gene expression in that as one increases, the other decreases.  This 
is supported by and comparable with the findings of flow cytometry 
whereby on surface staining, there is a decreased expression of 
hBest1 when hCLCA1 is greater, and vice versa.  This is 
demonstrated in the protein expression pattern of hBest1 and 
hCLCA1 on surface staining of eosinophils and PMNs. 
 
  In the present study, the results seem to suggest a relationship 
between hCLCA1 and hBest1.  This is supported by the work of 
Loewen and Forsyth (2005).  There is clear evidence using flow 
cytometry that there is expression of hBest1 protein intracellularly, 
indicated by a greater fluorescence when samples were 
permeabilised compared to surface staining alone.   This also 
supports previous studies.  In these, hBest1 was found to localize to 
the endoplasmic reticulum and was thought to activate hANO1 
through calcium signalling (Kunzelmann et al., 2009; Barro-Soria et 
al., 2010).  The results from both gene and protein expression 
analysis using RT-PCR and flow cytometry support the suggestion 
that there is a complex relationship between hCLCA1, hBest1 and 
hANO1.  This, however, requires further research to gain statistical 
power by increasing replicates, but also to establish where the 
proteins are localised within the cells, and what pathways may be 
activated for functionality. 
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 4.3  Western blot analysis 
 
  Western blot analysis is required to further confirm whether the 
genes of interest translate into proteins, whether intracellularly or 
membrane bound.  Results were used to support the findings, and 
discussion, of flow cytometry.  Whilst RT-PCR had shown hBest1 and 
hBest3 in PMNs, eosinophils and HL60s, the antibody for hBest1 
(n=3) only had been characterized (Section 3.5). To date, all 
antibodies used for hBest3 were unsuccessful either as no band 
detected on Western Blotting, or that non-specific bands were 
visualized.   
 
  hCLCA1 has been confirmed on CFPAC, A549, NAEC, SAEC and 
Calu-3 on three experiments at expected weights.  In granulocytes, 
hCLCA1 however was visible as a band at approximately 60kDa 
which was an unexpected weight (n=3).  Whilst it could be 
suggested that this band may be a form of hCLCA1 following 
cleavage of the N-terminus, the band for β actin was faint.  β actin is 
a cytoskeletal protein with an expected band weight of 48kDa and 
was used as a positive control for sample loading.  A faint band may 
indicate inadequate sample loading however the band for hCLCA1 
may be a different form of hCLCA1.  There is evidence to suggest 
that hCLCA1 undergoes modification after translation which is 
different depending on the tissue expression demonstrating two 
subgroups of CLCA proteins (Bothe et al., 2012).  The pattern of 
protein expression shown (Figure 4.18) was seen in all three 
experiments, however, conclusions from this cannot be drawn with 
any confidence as the band was not at the expected weight and 
differed from other positive controls.  In addition the antibody had 
not been characterized for specificity (Figure 4.18).   
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  hBest1 Western blot supports the findings of RT-PCR and suggests 
that the mRNA encoding hBest1 translates into protein with bands 
seen in CFPAC, A549, NAEC and SAEC.  As with hCLCA1 blot, no 
band was seen for PMNs however there was also a weak β actin 
visualised (Figure 4.19).  This was repeated following optimization of 
process and bands were visualized at molecular weight of 68kDa, as 
Figure 4.18: hCLCA1 protein expression in epithelial cell lines 
and PMNs:  Representative greyscale image of a western blot labelled 
for hCLCA1 for epithelial samples and PMNs (granulocytes).   A.  
Samples as listed with pre-cursor for hCLCA1 at 125kDa as expected.  
Protein band expected molecular weight of 37kDa.  Faint band on SAEC 
sample however this was visualised on another earlier experiment.  B.  
Beta actin blot demonstrating loading control of sample and bands as 
expected at molecular weight of 48kDa.  The nil control is a sample 
with no protein added. 
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expected, for PMNs, NAEC, SAEC, A549 and CFPAC (Figure 4.20).  
Western blots were undertaken on both HL60 cells and eosinophils 
however no band could be detected for hBest1 in any of these 
samples (Figure 4.21).  In addition, the beta actin for these was also 
weak.  This may be due to the nature of the cells or the amount of 
bestrophin 1 at a lower concentration making detection problematic.  
Figure 4.19: hBest1 protein expression in epithelial cell lines 
and PMNs:  Representative greyscale image of western blot for 
hBest1.  A.  Samples as listed with bands at a molecular weight of 
68kDa as expected.  No band visualised for PMNs (granulocytes).  B. 
β actin blot with bands as expected at 48kDa.  Very weak band 
visualised for PMNs   
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Figure 4.20:  hBest1 protein expression showing a band for PMNs: 
A; hBest1 bands at expected molecular weight of 68kDa.  Weak band for 
PMNs (granulocytes) however beta-actin was also weak.  Nil was negative 
control with no protein added to the well.  B; Beta actin control at the 
expected weight 
75kDa 
50kDa 
Figure 4.21:  Greyscale western blot of hBest1 for positive 
controls, HL60s and eosinophils:  A: hBest1 bands at expected 
molecular weight of 68kDa.  No band visualised for either HL60s or 
eosinophils.  Nil was negative control with no protein added.  B: Beta actin 
at expected weight 
B 
A 
A 
B 
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  The western blots do, therefore, support the findings of flow 
cytometry.  That bands for hBest1 could not be visualized for 
eosinophils and HL60s correlates with the reduced expression of 
hBest1 in these cells as demonstrated in flow cytometry (Figure 
4.17).  Further experimentation is required to establish whether 
visualised bands of hCLCA1 are cleaved products of hCLCA1.  All 
blots for hANO1 have been unsuccessful (n=5, Figure 4.22) although 
the antibody used is not recognised by the manufacturer for western 
blot analysis and other antibodies that were commercially available 
(AbCam rabbit anti-human polyclonal anti-bodies: AbCam ab53212 
and AbCam ab72984) also did not produce a band on western blot. 
75kDa 
50kDa 
50kDa 
37kDa 
B 
A 
Figure 4.22: Greyscale western blot of hANO1 for positive 
controls and PMNs:  A. hANO1 band expected at 74kDa.  No 
band visualised in any sample.  Western blot repeated n=5.  B.  
Beta actin demonstrating samples loaded with band as expected 
at 48kDa.  Nil was negative control with no protein added to the 
well 
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CHAPTER 5:  FUNCTIONAL ANALYSIS OF hBEST1   
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 5.1  Cytokine stimulation 
 
  Chloride ion channels may be implicated in the function of 
granulocytes as mediators of clinical symptoms in chronic 
inflammatory lung disease (Chapter 1).  The current project focusses 
upon hBest1 as one of the candidates for chloride ion channels in 
granulocytes.  hBest1 may have a role in granulocyte volume 
regulation through fluid shifts.  It is hypothesised that changes in cell 
volume and shape will directly impact upon cellular migration and 
activation.  hBest1 up-regulation may have therapeutic inflammatory 
effects such as allowing phagocytosis through cell shape modulation.  
In order to examine a potential role of hBest1 in granulocyte 
response in inflammation, functional experiments were performed.  
These included RT-PCR and flow cytometry following cytokine 
stimulation, transmigration assays and Cl- and Ca2+ assays.  Cytokine 
stimulation of PMNs, and HL60s was performed to establish whether 
there is upregulation in response to pro-inflammatory mediators.  
Transmigration assays were performed following upregulation of 
hBest (through transfection) to assess whether greater expression of 
hBest1 would impact upon the migration HL60s in response to 
inflammatory cytokines. 
 
5.1.1  Results 
 
  Polymorphonuclear cells were purified from peripheral blood (see 
Chapter 2) and treated with cytokines over 24 and 48 hours.  
Samples were then antibody labelled for hBest1 protein expression 
on flow cytometry and prepared for RT-PCR to establish any changes 
in mRNA.   
 
  The gel images collected from RT-PCR demonstrated that at the 
gene expression level, there appeared a slight change in signal for 
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 hBest1 in a mixed PMN population (Figure 5.1).  Over time, it 
appeared that mRNA peaked in response to IL-13 at 24 hours and 
then decreased below that at time=0h (Figure 5.2, Table 5.1).  Using 
semi-quantifiable densitometry, bands for hBest1 in PMNs that were 
stimulated with IL-13 over 48 hours, compared to PMNs, which were 
not stimulated, were measured.  On ANOVA, the critical F value was 
much greater than the f value therefore the null hypothesis was 
accepted.  Any observed differences were not statistically significant 
(P>0.2).  It was not possible, therefore, to be confident that any 
change in band size was due to IL-13 stimulation, or as a result of 
natural variation.  It was also not possible to be confident that any 
observations were not due to time as there was no significant 
difference either over time, or between the nil and IL-13 stimulated 
group.  Therefore, any observations are not confirmed and further 
experimental analysis would be required.   
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Figure 5.1:  hBest1 gene expression in PMNs in response to IL-13 
stimulation at 0h, 24h and 48h:  A:  Sample of PMNs (grans) with and without 
IL-13 stimulation (n=3).  Intensity of the band visualized appears brighter at 
time=24h.  There appears a weaker signal at time=48h however on densitometry 
and resultant ANOVA, there is no significant difference with over time, or between 
the nil group and the IL-13 stimulated group (P>0.2) (Table 5.1, Figure 5.2).  Nil is 
a negative control with no RNA added to the master mix plus primers for hBest1.  
B: Beta actin controls for each experimental group 
A 
B 
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  hBest1 (Time=0h) β actin hBest1 (Time=24h) β actin hBest1 (Time=48h) β actin 
Cells/Sample Optical density 
Normalised 
to β actin 
Optical 
density 
Optical 
density 
Normalised 
to β actin 
Optical 
density 
Optical 
density 
Normalised 
to β actin 
Optical 
density 
PMNs (nil) 
1 76653 0.79 96991 82093 0.846 97001 64294 0.66 97478 
2 18020 0.535 33677 12223 0.372 32844 26010 0.652 39899 
3 67909 0.835 81325 72665 0.848 85674 59677 0.705 84680 
Mean 54194 0.72 70664 55660 0.689 71840 49994 0.672 74019 
SD  25827 0.132 26925 30955 0.224 27959 17063 0.023 24686 
PMNs (IL-13 stimulated) 
1 75442 0.838 89992 76908 0.843 91257 54247 0.589 92165 
2 20383 0.501 40681 53686 1.516 35406 24599 0.771 31909 
3 68522 0.854 80257 81762 0.932 87771 49870 0.605 82448 
Mean 54782 0.731 70310 70785 1.097 71478 42905 0.655 68841 
SD  24488 0.163 21324 12252 0.298 25546 13067 0.082 26414 
Table 5.1:  Optical density (normalised to β actin) of hBest1 gene expression in PMNs in response to IL-13 
stimulation over 48hrs:  PMNs were stimulated with IL-13 over 48 hours and compared to a nil control (no IL-13) (n=3).  
Samples were analysed at time=0, 24 and 48 hours.  Optical density of RT-PCR bands for hBest1 were normalised to β actin 
to semi-quantify results.  ANOVA was used to establish significance of results.  There was no statistically significant 
difference between the IL-13 stimulated samples and the nil samples (P>0.2).  There was also no statistically significant 
difference over time (P>0.2).   
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  To further analyse the effect of IL-13 on hBest1 protein expression, 
flow cytometry was performed.  In PMNs (nil) (n=3), the median 
fluorescence on flow cytometry for hBest1 did not alter for either 
intracellular or surface staining over the incubation periods 24 and 48 
hours.  Any change noted was not statistically significant.  In 
response to IL-13 stimulation (n=3) (section 2.1.4 for methodology) 
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Figure 5.2:  Changes in hBest1 gene expression in PMNs stimulated 
with IL-13 over 48 hours:  Bar graph of results presented in Table 5.1.  
PMNs were stimulated with IL-13 over 48 hours and compared to a nil control 
(no IL-13) (n=3).  Samples were analysed at time=0, 24 and 48 hours.  
Optical density of RT-PCR bands for hBest1 were normalised to β actin to 
semi-quantify results.  ANOVA was used to establish significance of results.  
There was no statistically significant difference between the IL-13 stimulated 
samples and the nil samples (P>0.2).  There was also no statistically 
significant difference over time (P>0.2).   
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 however, the median fluorescence for hBest1 increased two-fold 
intracellularly and 1.5 fold for surface expression by 24 hours.  As 
cells were incubated for a further 24 hours to reach total 48 hour 
incubation period, median fluorescence decreased both intracellularly 
and surface bound.  The resultant fluorescence remained greater 
than control (Figure 5.3).  This differences in hBest1 expression over 
time was statistically significant (P<0.05) as was the difference 
between both intracellular and surface staining, and the increased 
fluorescence from nil controls (no IL-13) (P<0.05).  Whilst RT-PCR 
results were not statistically significant (Table 5.1, Figure 5.2, and 
Figure 5.4), this suggests responses to IL-13 may be at message 
level and translates into protein expression.  It is acknowledged that 
the outlying result in RT-PCR skews data, and the number of 
replicates weakens the statistical power.  Further replicates are 
required to elucidate the response to IL-13 however the flow 
cytometry data demonstrates that greater protein is produced, which 
could be indicative of either increased mRNA expression, or 
stabilization of synthesized mRNA.  The greatest increase in hBest1 
expression was intracellular and further supports the hypothesis that 
hBest1 may be localized to the endoplasmic reticulum, as discussed 
previously (Kunzelmann et al., 2009; Barro-Soria et al., 2010).  This 
also supports the expressional data (Chapter 4) for both gene and 
protein expression of hBest1 in PMNs. 
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Figure 5.3:  Changes in hBest1 protein expression in response to IL-
13 stimulation of PMNs over 24 and 48 hours:  PMNs (grans) were 
stimulated with IL-13 and incubated for 48 hours.  Samples were taken at 0, 
24 and 48 hours and analyzed using flow cytometry to label hBest1 protein 
intracellularly and surface bound.  (n=3).  Using ANOVA, the differences in 
hBest1 expression observed over time in response to IL-13 were statistically 
significant (P<0.05).  The differences between intracellular and surface 
staining were statistically significant (P<0.05).  The increased expression in 
response to IL-13 was statistically significantly different from nil controls 
(PMNs with no IL-13 stimulation) 
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   RT-PCR and flow cytometric analysis suggests that changes in 
mRNA encoding hBest1 is translated into protein expression (Figure 
5.4).  Polymorphonuclear cells that were stimulated with IL-13 
appeared to have greater expression of hBest1 mRNA which was 
most evident at 24 hours of incubation.  It should be noted that this 
is observational only and any changes are not statistically significant.  
Further replication is indicated.  The band becomes weaker for 
hBest1 after 48 hours however is greater than that seen in PMNs 
with no stimulation as a control.   
 
  The data presented suggests that IL-13 up-regulates both the 
hBest1 gene expression and translation into protein.  There appears 
to be greater expression of hBest1 protein intracellularly which peaks 
at 24 hours when exposed to the pro-inflammatory cytokine IL-13.  
This is a statistically significant up-regulation of protein (P<0.05)   
 
  Figure 5.5 (Table 5.2, eosinophil data) shows that intracellular 
protein expression of hCLCA increases from isotype control 
marginally however, in response to all cytokines, there is a decrease 
in hCLCA1 expression from the nil control in eosinophils.  This is also 
observed on surface staining however the difference in expression is 
less.  Conversely, there is a marked increase in hBest1 expression 
intracellularly in response to cytokine stimulation with a marginal 
increase in surface expression.  After 24 hours, the greatest 
response was observed in intracellular hBest1 expression following 
stimulation with IL-5 and IL-13.  Intracellular hBest1 also had an 
observed increase in response to IL-13 alone.  The peak in hBest1 at 
24 hours after cytokine stimulation may correlate with the 
manifestations of inflammatory responses, however, further research 
is required to examine the relationship between cytokines and 
chloride ion channel expression. 
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Figure 5.5:  Changes in protein expression of intracellular and surface 
CLCA1 and Best1 in response to cytokine stimulation: Graph showing 
mean fluorescence of eosinophils following stimulation with cytokines for 24 
hours.  Experiment performed once (n=1) due to the constraints of resources 
however further repetition would benefit to allow statistical analysis 
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Sample 
 
Isotype 
Int 
Isotype 
surface 
CLCA1 
Int 
CLCA1 
surface 
Best1 
int 
Best1 
surface 
Eos nil 793.31 544.74 17295.57 4276.32 2571.42 824.54 
Eos +IL-5 6738.52 1898.03 8274.37 2640.68 7578.83 2107.77 
Eos +IL-13 6031.5 2164.87 7356.97 1490.86 17510.61 1719.65 
Eos + IL-5 and 
IL-13 5493.26 2087.66 8001.59 1536.89 20465.77 1692.04 
Eos and TNF-a 5543.37 2157.78 8394.59 1674.05 14439.62 1683.94 
 
 
 
 
 
 
 
 
Table 5.2:  Changes in intracellular and surface protein expression of CLCA1 and Best1 in 
response to cytokine stimulation:  Table showing mean fluorescence of eosinophils for hCLCA1 and 
hBest1 intracellularly and surface expression.  Eosinophil samples were in five experimental groups using 
cytokines to stimulate cells and measured after 24 hours incubation.  Experiment performed once (n=1) 
due to the constraints of resources however further repetition would benefit to allow statistical analysis 
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 5.1.2  Discussion 
 
  It has been shown that the symptoms of inflammatory lung 
diseases are linked to migration and activation of granulocytes.  
Particularly, asthma is considered to be primarily an eosinophilic 
disease with symptoms positively correlated to eosinophil migration 
to the site of inflammation (Kyoh et al., 2008; KanKaanranta et al., 
2010).  It has been previously shown that peak in eosinophil 
accumulation occurs 24 hours after exposure to an allergen (O'Byrne 
et al., 2004; Holgate & Polosa, 2008).  The activation of eosinophils 
has been linked to IL-13 as this cytokine is pre-formed and stored in 
granules and released in response to stimuli (Spencer & Weller, 
2010; Walsh & August, 2010).  The positive correlation between IL-
13, eosinophils and exacerbation of chronic inflammatory lung 
disease symptoms is therefore clear and well documented in murine 
models.  The role of chloride ion channels in this, particularly hBest1 
has not been clearly established. 
 
  The data presented has implied that gene expression may increase 
at 24 hours following stimulation with IL-13.  In the current project, 
this has not been shown to be statistically significant.  At protein 
level, there is a statistically significant increase in hBest1 (Figure 5.3) 
in PMNs stimulated with IL-13, both from time 0h and compared to 
nil controls.  There may also be a similar response in eosinophils as 
implied by initial cytokine stimulation and flow cytometry (Figure 5.5, 
Table 5.2) however further repetition is required.  This may be 
mediated by hCLCA1 as Nakano et al (2006) have demonstrated that 
in response to IL-13, there is increased expression of mCLCA3 
(human isoform hCLCA1).  This was not the case in the current 
project which found that in response to IL-13, there was a decrease 
in hCLCA1 in eosinophils.  This is observational only however and 
further replication is required to eludicate the expression of hCLCA1 
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 in response to IL-13.  In RT-PCR gene expression screening (Chapter 
4) however, it has been shown that the relationship between hCLCA1 
and hBest1 is negative.  In this instance, if there were an increase in 
hCLCA1, it would be expected that there would be a decrease in 
hBest1, and vice versa.  This appears to support the observations in 
Figure 5.5.  It may be suggested therefore, that hCLCA1 and hBest1 
may work in a complementary way and that either one may be up-
regulated in response to IL-13.  This is supported by the findings of 
Nakano et al (2006) and the expressional screening presented in 
Chapter 4 and 5.  
 
  The relationship between granulocytes, chronic inflammatory lung 
disease and symptoms seems supported as the data shows a 
response to IL-13 stimulation with a peak in hBest1 intracellularly at 
24 hours, which decreases after 48 hours.  This also supports the 
findings of others who suggest that hBest1 is located primarily 
intracellularly and may be linked to activation of hANO1 (Kunzelmann 
et al., 2009; Barro-Soria et al., 2010).  In this process, inflammation 
may stimulate IL-13 release and therefore an increase in hCLCA1 
(Nakano et al., 2006).  This may be responsible for maturation and 
differentiation of granulocytes, which peaks at 24 hours after 
stimulation (Holgate & Polosa, 2008).  Alternatively, there may be an 
increase in hBest1 expression primarily intracellularly (Kunzelmann et 
al., 2009; Barro-Soria et al., 2010), with exacerbation of symptoms.  
As a result, activation of hANO1 may occur.  As activated 
granulocytes begin apoptosis at 24 hours (KanKaanranta et al., 
2010), this supports the findings and possible process as the 
expression of hBest1 begins to decrease after this point.  Conversely, 
the expression of eosinophils in this study do not fully support this 
hypothesis (Figure 5.5 and Table 5.2).  This was performed once 
(n=1) due to the constraints of resources and therefore conclusions 
cannot be statistically supported. 
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  The peak hBest1 in eosinophils in response to IL-13 and IL-5 
together (Figure 5.5) supports Willis-Karp (2004) who state that in 
the presence of IL-5, eosinophils are further activated to increase IL-
13 release.  This combined action and process would increase the 
expression of hBest1 protein as demonstrated in figure 5.5.  This is 
indicative of the in vivo responses to inflammation as IL-5 and IL-13 
are considered to act in partnership (Kim et al., 2010; Spencer & 
Weller, 2010).  IL-5 alone demonstrates an increase in hBest1 
protein however this is not as great as any of the other experimental 
groups.  This may not be a true reflection of in vivo responses.  IL-5 
response in inflammation has been shown to terminally differentiate 
eosinophils, increase recruitment and attraction of eosinophils to the 
site of inflammation and to delay apoptosis (Kariyawasam & 
Robinson, 2007; Simon & Simon, 2007; Matsumoto et al., 2008).  In 
this study, the true biological response would have been prohibited 
as the number of eosinophils was defined and the action of recruiting 
further eosinophils was not possible.  It would be beneficial to 
examine this in more depth, possibly in combination with 
transmigration techniques so that eosinophil recruitment could be 
established.   
 
   TNF-a also caused a significant increase in hBest1 protein 
intracellularly however this needs replication (n=1).  The role of TNF-
a is considered to be a neutrophilic chemo-attractant.  As discussed 
previously, this process would be inhibited by the in vitro limitations.   
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 5.2  Transmigration assay 
 
5.2.1  Transmigration results 
 
In order to establish a potential function for hBest1 in PMNs the 
transmigration of HL60s with over-expressed (transfected) hBest1 
protein was measured as a response to N-formyl-methionyl-leucyl-
phenylalanine (fMLP) and IL-13 (see section 2.6 for concentration 
and methodology).  The number of cells were counted in one large 
square (1mm2 = 100nl) using a haemocytometer (A in Table 5.3).  
This was converted to cells/ml and then total number of cells in 
400µl by; 
 
 Cell count in 1mm2 x 104 x 2 (dilution factor) = cells/ml 
 
 Cell/ml x 0.4 = Total cells in 400µl  (B in Table 5.3) 
 
The total number of cells in 400µl was used to calculate a 
percentage of total cells migrated across the membrane.  The known 
number of cells added into the well were 13.5 x 104 therefore the 
final percentage (C in Table 5.3) was calculated as; 
 
 (Cells in 400µl / (13.5 x 104) ) x 100 = Percentage migration 
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Well additive = nil Well additive = fMLP Well additive = IL-13 
A B C A B C A B C 
Sample 
1. HL60 (nil) 2 16000 12 2 16000 12 10 80000 59 
2. HL60 (nil) 4 32000 24 4 32000 24 8 64000 47 
3. HL60 (nil) 3 24000 18 2 16000 12 4 32000 24 
Mean HL60 (nil) (n=3) 3 24000 18 3 21333 16 7 58667 43 
Standard Deviation NA 8000 NA NA 9238 NA NA 24440 NA 
1. HL60 +hBest1 3 24000 18 10 80000 59 13 104000 77 
2. HL60 +hBest1 2 16000 12 9 72000 53 14 112000 83 
3. HL60 + hBest1 2 16000 12 7 56000 41 11 88000 65 
Mean HL60 +hBest1 (n=3) 2.33 18667 14 9 69333 51 13 101333 75 
Standard Deviation NA 4619 NA NA 12220 NA NA 12220 NA 
1. HL60 + JetPrime 2 16000 12 3 24000 18 11 88000 65 
2. HL60 + JetPrime 3 24000 18 1 8000 6 9 72000 53 
3. HL60 + JetPrime 3 24000 18 0 0 0 8 64000 47 
Mean HL60 + JetPrime 
(n=3) 2.67 21333 16 1 10667 8 9 74667 55 
Standard Deviation NA 4619 NA NA 12220 NA NA 12220 NA 
Table 5.3:  Effects of transfecting hBest1 into HL60s on transmigration in response to fMLP and IL-13:  HL60 cells were transfected 
with hBest1.  Three experimental groups (nil, hBest1 transfected and JetPrime only treated) were applied to a 3µm pore membrane and the number 
of cells migrated across in response to fMLP and IL-13 measured (section 2.6 for concentration).  A= Cell count using haemocytometer, B= 
Conversion to number of cells in 400µl of cell media, C= Percentage of cells migrated.  N=3 and mean of cell count with ± standard deviation (SD). 
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   The transmigration of nil HL60s, compared to HL60s treated with 
transfection reagent, JetPrime only (n=3), were not statistically 
significant (P>0.05) (see section 2.8 for statistical analysis method).  
Therefore, it was considered that the process of transfection itself, 
did not affect the transmigration of cells either due to cell shape or 
alterations in function.  This was also the case for each experimental 
group (nil, fMLP and IL-13 addition, section 2.6 for concentrations) in 
that the HL60 nil group were not statistically different from the 
HL60s treated with JetPrime only.    Therefore, the HL60 group with 
no treatment were used as a control group.  In the control group, 
the number of cells migrating through the membrane in response to 
IL-13 was double that in the nil, and the fMLP group, with 43% of 
cells migrated.  Using ANOVA, this was a statistically significant 
migration in response to IL-13 for HL60s (nil) (P<0.05, n=3, * in 
figure 5.6).   
 
  However, when HL60s were transfected with hBest1 (n=3), the 
response to fMLP and IL-13 addition in the well was statistically 
significant (P<0.05) (*2 in Figure 5.6).  When examining hBest1 
transfected cells, there was no difference between nil HL60s and 
those transfected with hBest1 when there was no addition to the 
well.  In response to fMLP, there was a statistically significant 4 fold 
increase in the number of cells migrating across the membrane, into 
the well containing fMLP (P<0.01, *2 in Figure 5.6).  Whilst there was 
migration in the HL60 nil group in response to IL-13 (* in Figure 
5.6), there was a greater migration of HL60s transfected with hBest1 
when IL-13 was added to the well.  The migration was over 5 times 
greater than nil which was statistically significant (P<0.01).  This was 
also nearly twice the migration observed in HL60s (nil) in response to 
IL-13.  This was statistically significant and therefore responses in 
migration when IL-13 is added to the well were thought to be hBest1 
specific (P<0.05, *3 in Figure 5.6).  Moreover, the different migration 
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 responses to fMLP and IL-13 were also statistically significant 
(P<0.05).  From this assay, it is reasonable to conclude that hBest1 
has a role in cellular migration.  The role of hBest1 intracellularly 
requires further experimentation however it may be implicated in cell 
signalling, and maturation of cells.  It has also been suggested that 
there is an interaction between hBest1 and hCLCA1 or hANO1.  In 
this instance, there may be a secondary impact upon cell volume 
through activation of alternative chloride ion channels.  This 
relationship requires further clarity. 
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Figure 5.6:  The effect of transfection with hBest1 on the 
transmigration of HL60s in response to fMLP and IL-13: Transmigration 
of HL60 cells transfected with hBest1, compared to nil, and transfection reagent 
treated only.  This was in response to fMLP and IL-13 additive to the well (n=3 
for each experimental group).  Error bars for standard deviation.  There was no 
statistically significant difference between HL60 (nil) and those treated with 
transfection reagent only.   The migration when transfected with hBest1 in 
response to both fMLP and IL-13 was statistically significant (P<0.05, *2 above ) 
with a greater migration in response to IL-13 (* and *3 above) .  This appears to 
suggest a role for hBest1 in cellular migration 
*3
*2
*2
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5.2.2  Implications and discussion 
 
  hBest1 has previously been linked to Best’s disease, in which fluid 
shifts occur as a result of dysfunction of the hBest1 chloride channel 
(Qu et al., 2004; Chien et al., 2006).  Additionally there is evidence 
suggesting that hBest1 is involved in the conductance of airway 
epithelial cells (Duta et al., 2004).   
 
  fMLP is found in vivo following bacterial protein breakdown.  It is 
also present in the inflammatory process as a bi-product of 
mitochondrial protein degradation, which would also be present in 
epithelial tissues of the lungs in chronic inflammatory lung diseases.  
The transmigration assay, therefore, was performed to establish any 
link between inflammation and the potential function of hBest1 in 
granulocytes.   
 
  fMLP is a powerful chemo attractant which has been shown to 
attract neutrophils, specifically during inflammation (Virchow et al., 
1998; Zhu et al., 2005).  It would seem reasonable to expect 
migration of HL60s, as a model of PMNs, in the presence of fMLP 
therefore, regardless of whether hBest1 was transfected.   This was 
not a statistically significant observation in the current assay.    
However, it has been shown that fMLP stimulated neutrophils have a 
role to play in the inflammatory process.  Zhu et al (2005) have 
shown that neutrophils stimulated with fMLP have a role in 
inflammation and cellular permeability.  That neutrophils are 
essential in this response is demonstrated when fMLP was applied 
directly to tissues with no response in permeability.  fMLP has been 
implicated in inflammation as it initially attracts neutrophils to the 
site of inflammation, and  increases granulocyte respiratory burst, 
with an increase in oxygen free radical species (Virchow et al., 1998; 
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 Zhu et al., 2005).  It is the oxygen free radicals that are responsible 
for the observed cellular permeability in inflammation and infection.  
In addition, fMLP stimulates an increase in intracellular Ca2+(Zhu et 
al., 2005) in neutrophils.  This is specifically relevant to the current 
transmigration assay.  As discussed previously, hBest1 is a Ca2+ 
activated chloride channel (Suzuki et al., 2006; Greenwood & 
Leblanc, 2007).  Therefore, if intracellular Ca2+ rises in response to 
fMLP, it may result in increased activity of hBest1 as a chloride ion 
channel, if the transfected HL60s have an over-expression of hBest1.  
Whether this is by direct Cl- movement, or by stimulating another 
channel such as ANO1 (Kunzelmann et al., 2009) is not clear in the 
current study.   
 
  It has been suggested that hBest1 acts to volume regulate the cell 
however this has been established in the retina in Bests disease 
(Duta et al., 2004; Qu et al., 2004; Chien et al., 2006).  The 
increased transmigration of HL60s when transfected with hBest1, 
may be due to increasing Ca2+ stimulating the over-expressed hBest1 
and therefore an increased conductance of Cl- and resultant fluid 
movement.  This is through the interaction between intracellular and 
membrane bound chloride ion channels 
 
  It has been suggested that there is a complex interaction between 
hBest1, hCLCA1 and hANO1 expressed intracellularly, and cell 
membrane bound.  The functions of intracellular and surface chloride 
channels may complement each other in the control of cell volume in 
granulocytes.  Intracellular chloride channels are considered to have 
several roles.  Among these is regulation of intracellular pH through 
electrogenic transport of cations, such as vacuolar proton ATPase.  
In this instance, using energy released from ATP hydrolysis, 
hydrogen ions are pumped across the membranes of intracellular 
organelles (Edwards & Kahl, 2010).   However, it has been 
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 hypothesised that another role intracellular chloride channels, such 
as hBest1, is to increase intracellular calcium.  There is a release of 
calcium ions from the endoplasmic reticulum through counterion 
movement (Pollock et al., 1998; Barro-Soria et al., 2010; Edwards & 
Kahl, 2010).  This control of calcium intracellularly, through hBest1, 
may therefore modulate the activity of membrane bound calcium 
activated chloride channels such as hBest1 or hANO1 (Edwards & 
Kahl, 2010).  In granulocytes, the activation of membrane bound 
chloride channels would impact upon overall cell volume.  Increasing 
chloride conductance across the membrane would increase 
movement of sodium, coupled as salt (NaCl).  By osmosis, there 
would be a greater movement of water across the cell membrane 
(Figure 5.6).  This would decrease cell volume and allow a greater 
migration of HL60s through the defined 3µm pore membrane.  This 
process would be similar in physiological inflammation however there 
would be further exacerbation of epithelial symptoms as 
granulocytes go through respiratory burst, degranulate and release 
oxygen free radicals in response to fMLP (Virchow et al., 1998; Zhu 
et al., 2005).  This in turn would increase permeability of airway 
epithelia, exacerbation of sputum clearance, and airway hyper-
responsiveness.   
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Figure 5.7:  Diagrammatic representation of the hypothesis of cell volume 
control through interactions between intracellular and surface bound chloride 
ion channels:  Intracellular hBest1 may modulate the activity of surface bound chloride 
ion channels by increasing release of calcium from endoplasmic reticulum.  This increase 
in intracellular calcium may activate surface bound calcium activated chloride ion 
channels causing an increase in secretion of chloride, coupled with sodium, across the 
cell membrane.  A resultant movement of fluid, due to osmosis, would regulate overall 
cell volume. 
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   In the current transmigration assay, there was a larger migration of 
HL60s in response to IL-13 additive to the well.  This difference in 
migration in response to IL-13 and fMPL was statistically significant.  
The larger migration supports a possible role of hBest1 with hCLCA1 
and hANO1.  IL-13 addition may cause a positive feedback system as 
during inflammation, IL-13 causes PMNs, particularly eosinophils, to 
migrate to the site of inflammation.  This causes an increase in IL-13 
release from eosinophils which further increases migration.  This may 
account for the differences observed in Figure 5.4 however may 
suggest a further relationship between alternative chloride channels.  
As identified, IL-13 up-regulates mCLCA3 (human ortholog hCLCA1) 
(Nakano et al., 2006).  In the human model, this may increase the 
expression of hCLCA1 in HL60s.  There has also been suggestion of a 
correlation between hCLCA1 expression and up-regulation of hBest1 
((Kunzelmann et al., 2007; Hamann et al., 2009).  In cells 
transfected with hBest1, there is already over-expression and the 
result may be an increase in hBest1 greater than that observed in 
the fMLP experimental condition.  As stated, hBest1 may be localized 
to the endoplasmic reticulum and responsible for mediation and 
activation of hANO1 (Kunzelmann et al., 2009; Barro-Soria et al., 
2010).  This would result in an overall increase in net efflux of Cl-, 
and therefore fluid, decreasing cell volume with greater migration, as 
observed.   
 
  The transmigration assay supports the hypothesis that hBest1 may 
be involved in cellular migration during periods of inflammation, and 
increase in epithelial responses.  Polymorphonuclear cells, 
particularly HL60s in this assay, are responsive to fMLP and IL-13 
release during inflammatory responses.  This may be due to an 
overall net increase in Cl- flux changing cell volume, or an increased 
expression of Ca2+ activated Cl- ion channel mediators.   It would 
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 indicate further analysis as to the relationship between hCLCA1, 
hBest1 and hANO1. 
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 5.3  Cl- and Ca2+ flux assays 
 
  The flux of Cl- would further add evidence to the growing 
discussions regarding hBest1 and the role in either granulocyte 
migration or activation, and the links to exacerbation of clinical 
symptoms in chronic inflammatory lung diseases.   
 
  N-(ethoxycarbonylmethyl-6-methoxyquinolinium bromide (MQAE) 
was used in accordance with manufacturers recommendations 
(Invitrogen) and previous laboratories (Koncz & Daugirdas, 1994).  
The MQAE fluorescent probe has been used in a number of cell types 
(Koncz & Daugirdas, 1994; Marandi et al., 2002) however the level at 
which MQAE is either self-quenching, or quenched by non-chloride 
anions, specifically in HL60s is unclear at this point, therefore 
analysis using this technique is problematic.  Marandi et al (2002) 
highlight the limitations of MQAE and state that quantification of Cl- 
flux is difficult and a limitation of these studies as the dye is non-
ratiometric.  In addition, the leakage of MQAE from different cell 
types is varied, and dependent upon the preparation of samples.  
One extraneous variable is temperature.  This indicates the need for 
extensive methodology modification however, it should be justified 
given that results are difficult to quantify.   
 
  The calcium flux assay used a calcium sensor dye eFluor®514 
(eBioscience).  On initial flow cytometry there appeared to be clear 
changes in fluorescence however when the cells were stained with 
propridium iodide (PI) (Figure 5.8), there appeared to be evidence of 
cellular necrosis.  The increase in calcium flux was correlated with PI 
positive staining (PI binding to DNA material).  As the calcium dye is 
a membrane permeable dye, it may be that this stimulates cellular 
apoptosis, and further necrosis.  This may also be due to preparation 
of the dye as it is constituted in DMSO, as per manufaturers 
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instruction, at the recommended concentration.  This in itself is a 
nucleophilic acid which may cause cellular necrosis.  It seems, 
therefore, that results are inconclusive possibly due to issues in 
methodology which would require extensive optimization.  The 
change in fluorescence cannot be specifically attributed to any 
experimental condition as the dye may be non-specifically binding as 
the cell becomes necrotic.   
Figure 5.8:  Effect of calcium sensor dye staining on HL60 cell 
viability 
HL60 cells (n=3) were treated with calcium sensor dye [2nM final conc.] 
for 30min at 37oC/5% CO2/humidified air.  The cells were then assessed 
for viability by propidium iodide (PI) exclusion immediately before 
analysis on a BD Accuri C6 flow cytometer (Ex 488nm; Em 533/30nm 
(Calcium sensor dye; FL-1A), 670LP (PI; FL-3A). This representative 
histogram overlay reveals that dye labelled cells exhibited dual peaks in 
the PI channel (red line) while undyed cells exhibited a single PI 
negative peak (black line).  
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CHAPTER 6: SYSTEMATIC REVIEW: 
IS THE GENE AND PROTEIN EXPRESSION OF CHLORIDE ION 
CHANNELS UPREGULATED IN THE RESPIRATORY 
EPITHELIA, OR GRANULOCYTES, OF SUBJECTS WITH 
CHRONIC INFLAMMATORY LUNG DISEASE 
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6.1 Rationale for systematic review 
 
  Systematic reviewing is a rigorous research method designed to 
collate all of the evidence on a specific question.  The Cochrane 
Handbook defines a systematic review as; 
 
“A systematic review attempts to collate all empirical evidence that 
fits pre-specified eligibility criteria in order to answer a specific 
research question.  It uses explicit, systematic methods that are 
selected with a view to minimizing bias, thus providing more reliable 
findings from which conclusions can be drawn and decisions made”  
(Higgins & Green, 2008, pg6).   
 
It is acknowledged, however, that systematic reviewing is designed 
predominantly for collating a large number of randomized control 
trials in order to apply findings to healthcare.  In this project, the 
principles of systematic reviewing are applied to laboratory based 
studies.  
 
  It has been established in the literature review (Chapter 1, 
Introduction) that granulocytes are implicated in the process, and 
symptoms, of chronic inflammatory lung disease.  There has also 
been considerable discussion as to the role of chloride ion channels 
in these cells.  Through laboratory experiments, the expression of a 
number of putative chloride ion channels, and some of the functional 
properties of bestrophin 1 in humans (hBest1) has been established 
in granulocytes, and HL60s.  The relationship between chloride ion 
channels and chronic inflammatory lung disease needs to be 
assessed to address the project question.  It may be possible to 
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 identify whether chloride ion channels are up-regulated, or 
implicated in lung disease.  Provisionally experimental plans were 
formulated to address this question and to further explore functional 
properties of hBest1, such as using patch clamping techniques to 
establish calcium and chloride flux.  However, due to changes in 
funding, and therefore available resources, further experimental 
work was prohibited.  In discussion with, and under the guidance of 
an expert in systematic reviewing alternative methods for addressing 
the hypothesis were explored.  It was considered that, whilst the 
preferred research method would be primary laboratory work, 
systematic reviewing of evidence could be utilised.  However, this 
systematic review may be subject to publication bias and must be 
acknowledged.  The studies identified may not be representative of 
all experiments conducted due to the risks of publishing only 
“positive” results.  Limitations of the systematic review will however 
be explored in section 6.5.1. 
 
  A systematic review was undertaken to examine evidence on the 
expression of chloride ion channels in subjects with chronic 
inflammatory lung diseases. 
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 6.2 Objectives of systematic review 
 
The systematic review aims to study whether the gene and protein 
expression of chloride ion channels is different in chronic 
inflammatory lung disease compared to health.  The term 
“granulocytes” will be used in this section as this was the prevalent 
term in the literature found.  With a focus on chronic inflammatory 
lung disease, and a control of those without disease, specific 
objectives are; 
 
• To examine both granulocytes and airway epithelial cells, in 
order to establish whether there is a different expression 
pattern in health and disease.  This relates specifically to the 
different family groups (bestrophins, CLCAs, anoctamins, ClCs, 
CFTR and Tweety) 
 
• To consider both protein and gene expression to establish 
whether there is up-regulation, and increased protein 
expression in the presence of disease 
 
This will complement the experimental data on expressional 
screening and functional analysis in granulocytes. 
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 6.3  Methodology 
6.3.1  Formulation of systematic review question 
 
A protocol was formulated and has been used to develop the 
methodology reported.  The question to be answered through 
systematic review was formulated using a framework of case, control 
and mechanism/factor (Table 6.1). 
 
 
Cases Controls Mechanism/factor 
Subjects with 
chronic 
inflammatory lung 
disease 
Granulocytes 
(eosinophils, 
neutrophils and 
basophils) 
Epithelia (tracheal, 
bronchial and small 
airways) 
Chronic inflammatory 
lung disease (COPD 
and asthma) 
Subjects without 
chronic 
inflammatory lung 
disease 
Chloride ion 
channel expression 
Bestrophins (1-4), 
CLCAs, ANOs, ClCs, 
Tweety 
Protein and gene 
expression 
 
 
 
 
 
 
 
Table 6.1:  Table using case/control/mechanism to formulate 
systematic review question:  Bold font signifies the population within the 
case, control and factor groups.  Detail of inclusions within this population are 
listed beneath.  From this the systematic review question was formulated 
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  From this, the systematic review question was formulated; Is the 
gene and protein expression of chloride ion channels upregulated in 
the respiratory epithelia, or granulocytes, of subjects with chronic 
inflammatory lung disease, as assessed by Bestrophins (1-4), CLCAs, 
ANOs, ClCs, Tweety protein and gene expression, using all available 
cohort, case control and laboratory studies? 
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 6.3.2  Inclusion/exclusion criteria 
 
  The systematic review was performed using guidelines adapted 
from the Cochrane Handbook (Higgins & Green, 2008).  The 
inclusion and exclusion criteria were defined (Table 6.2) and all 
primary research papers identified were considered for inclusion, 
which included both cohort studies and laboratory based 
experimental studies.   
Criteria 
no. 
Inclusion/Exclusion criteria 
1 Is the study laboratory based/cohort study? (Include all primary 
laboratory research.  Exclude all opinion papers, reviews, meta-
analyses, editorials, letters and studies published only in abstract 
form) 
2 Are the samples/subjects mammalian? (Include all studies using 
either human subjects, mammals or mammalian commercial cell 
lines.  Exclude all samples taken from non-mammals such as 
amphibians, reptiles and fish)  
3 Is the focus upon blood cells or airway tissue? (Include all blood 
cell types such as granulocytes and agranulocytes, and all airway 
cells such as tracheal, bronchial etc.  Exclude cells/samples from 
other organs such as pancreas.  Exclude nasal) 
4 Focussed upon chronic inflammatory lung diseases? (Include all 
inflammatory lung diseases.  Exclude non-inflammatory disease of 
the lungs such as cancers, inflammatory disease or symptoms not 
of the airways such as bowel, exclude cystic fibrosis) 
5 Chloride ion channels? (To include all types such as voltage 
gated, volume regulated, calcium activated and ligand gated.  
Include those assumed to be either regulators of chloride flux or 
a channel; CLCA, bestrophins, ClC, tweety etc.  Exclude all other 
ion channels such as potassium and sodium) 
 
 
  
Table 6.2:  Table of inclusion and exclusion criteria for selection of 
evidence for systematic review:  All inclusion and exclusion criteria 
identified by which studies were selected, or rejected for use in the systematic 
review 
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   Comparison groups were control (considered “healthy” tissue) and 
tissues involved in chronic inflammatory lung disease.  Those disease 
processes for inclusion were primarily COPD and asthma.  Cystic 
fibrosis was excluded due to multiple pathological processes.  Other 
diseases excluded were; rhinitis, asbestosis and cancer.  These 
diseases were considered to have physiological processes that would 
not be generalizable to COPD or asthma.   
 
  Outcome measures and factors for inclusion were chloride channels 
and channel families.  This included; CLCA, bestrophins, anoctamins, 
ClCs, CFTR and Tweety.  Other channels, such as potassium or 
sodium, were excluded from the systematic review.  Studies were 
included if they considered protein or gene expression of these 
channels using methodologies such as RT-PCR, Western and 
Northern blot analysis, immunohistocytochemistry and flow 
cytometry.   
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 6.3.3  Identification of studies and search protocol 
 
  To identify appropriate studies Medline and EMBASE databases 
were searched using the OVID platform on 19th May 2012.  Search 
terms for these databases are outlined in Table 6.3.  In addition, the 
Cochrane library was searched to ensure that the review question 
had not already been addressed in another systematic review.  A 
personal collection of studies was hand-searched to identify potential 
papers for inclusion.  Reference lists of all papers were scanned for 
potentially included studies.  Full text of those identified was 
accessed as appropriate.  To ensure that all potential studies were 
considered, letters were written to key laboratories in Europe to ask 
if any unpublished data could be shared for the purpose of the 
systematic review (Appendix 2 presents a copy of the letter).  
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Search terms with Boolean operators and truncation 
1. gene expression regulation/ or gene expression/
2. (western blot adj5 analys*).ti,ab.
3. RT-PCR.ti,ab.
4. (reverse adj3 transcript*).ti,ab.
5. (gene* adj3 upreg*).ti,ab.
6. (protein adj3 express*).ti,ab.
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp lung disease/ or exp respiratory tract disease/ or exp
bronchiolitis/ or exp chronic lung disease/ or exp chronic obstructive 
lung disease/ or exp lung alveolitis/ or exp lung emphysema/ 
9. (chronic adj5 lung adj5 disease).ti,ab.
10. (resp* adj5 lung adj5 disease*).ti,ab.
11. COPD.ti,ab.
12. (chronic adj5 obstructive adj5 pulmonary adj5 disease*).ti,ab.
13. (chronic adj5 obstructive adj5 airway* adj5 disease*).ti,ab.
14. COAD.ti,ab.
15. asthma*.ti,ab.
16. (inflammato* adj5 lung adj5 disease*).ti,ab.
17. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16
18. exp chloride channel/ or exp chloride channelopathy/
19. (chloride adj5 ion adj5 chan*).ti,ab.
20. bestrophin.ti,ab.
21. CLCA.ti,ab.
22. anoctamin.ti,ab.
23. anoc*.ti,ab.
24. ClC.ti,ab.
25. tweety.ti,ab.
26. (volume adj5 regulated).ti,ab.
27. (ligand adj5 gate*).ti,ab.
28. (voltage adj5 act*).ti,ab.
29. calcium act*.ti,ab.
30. 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or
29 
31. 7 and 17 and 30
 
 
Table 6.3:  Search terms with Boolean operators and truncation:  All terms 
used to search Medline and Embase using OVID as a platform 
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  The initial list of identified studies was examined and any duplicates 
across databases identified.  Any duplicates were removed prior to 
assessing inclusion and exclusion criteria.  A standardized 
“inclusion/exclusion” form was used to assess whether studies met 
the inclusion criteria (Appendix 3).  This was performed at two points 
in the literature search process.  The first exclusion point (Point A in 
Figure 6.1, in Section 6.4) used title and abstract to assess eligibility 
for inclusion.  The second point (Point B in Figure 6.1, in section 6.4) 
used the full text articles for each identified study.  At exclusion point 
C, the focus was narrowed to expression of genes or protein in order 
to accurately assess the systematic review question.  
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 6.3.4  Assessing the risk of bias 
    
  To complete the selection process, papers were assessed for the 
risk of bias.  A tool (Appendix 4) was developed from adapting the 
Cochrane Handbook risk of bias tool for randomized controlled trials 
(Higgins & Green, 2008).  This was combined with an adapted tool 
from the National Institute for Clinical Excellence (NICE, 2007).  Final 
selected papers were independently assessed by two reviewers to 
reduce the risk of bias in the systematic review process.    To judge 
the studies for eligibility to be included, the risk of bias was assessed 
in three domains; internal validity, overall assessment and study 
description.  Each domain was rated as low, medium or high risk of 
bias by totaling the number of areas that were either not addressed 
or not reported.  Studies that scored 15% or less were considered to 
have a low risk of bias and the conclusions were very unlikely to 
alter.  Any study that was assessed with medium or high risk of bias 
in any of the three domains was excluded from the systematic 
review.   
  Publication bias has been considered however thorough assessment 
is problematic.  Systematic reviewing, as stated, is intended for 
randomised controlled trials which maybe subject to registration at 
the beginning of the study (Song et al., 2010).  This would allow 
identification of all prospective data sets, regardless of whether they 
are null or not.  Laboratory experiments are not subject to 
registration and therefore identification of all prospective studies is 
unlikely.  Publication bias was addressed during the systematic 
review by writing to key European laboratories requesting all data 
collected relevant to the research question, regardless of whether 
results were considered “positive” or null.  However, non-response 
may be due to results not being processed if considered null.  A 
funnel plot was considered however not performed following final 
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 selection of studies due to the differences in populations examined, 
and the limited number of studies identified.  It has been assumed, 
therefore, that the review presented has a high risk of publication 
bias and therefore application of findings is unlikely.   
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 6.3.5  Data extraction and synthesis of results 
  Data from identified studies, meeting inclusion criteria, was 
intended to be pooled using outcomes measures of protein, and 
gene expression.  Variables to be considered were; with or without 
chronic inflammatory lung disease (as the independent variable), and 
protein and gene expression of each potential chloride ion channel 
(as the dependent variable).  Pooled results were to be tabulated 
with the mean, and standard deviation, calculated for protein and 
gene expression, for each identified chloride ion channel.  The mean 
gene and protein expression in samples with chronic inflammatory 
lung disease was to be compared to samples without disease.  
Statistical significance would have been identified using ANOVA to 
assess whether there was upregulation of chloride ion channels in 
chronic inflammatory lung diseases, compared to those without.  
  Whilst this was the intended method of data extraction and 
synthesis, the limited number of studies identified used differing 
outcome measures and therefore pooling data was not possible.     
   To ensure transparency and full reporting of the systematic review, 
a PRISMA checklist was completed (Appendix 5).   
 
 
 
 
 
 
 
278 
 6.4  Results 
6.4.1  Literature search results 
 
  Database searches, and hand-searching, yielded 560 potential 
papers for inclusion.  There were however 36 duplicates therefore 
524 studies were considered for inclusion by scanning the title and 
abstract.  From the initial search, 438 studies were excluded as they 
did not meet inclusion criteria (Figure 6.1, exclusion point A).  This 
was assessed by accessing the title and abstract only.  Of these 187 
were excluded as they didn’t focus upon inflammatory lung disease.  
These studies primarily considered either cystic fibrosis or cancer.  A 
large number of the 438 excluded were due to the tissue type used.  
117 used tissues other than lung or blood cells, such as intestinal, 
pancreatic, brain.  Other reasons for excluding studies were that they 
were not primary research, or that the focus was on other ion 
channels such as sodium or potassium.  Of the 86 papers initially 
identified, a further 46 were excluded after accessing the full text 
(Figure 6.1, exclusion point B).  At exclusion point C, a further 25 
studies were excluded as the focus was not upon expression of 
genes or proteins.  There were 15 studies selected for possible 
inclusion in the systematic review following assessment of the risk of 
bias.   Figure 6.1 summarizes the results of the literature searching 
process. 
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Medline (402)+Embase (151)= 553 
Plus hand-searched studies=  7 
Plus Cochrane reviews= 0 
Minus duplicates= 36 
____________ 
TOTAL IDENTIFIED= n= 524 
Papers provisionally included for full 
text review (n=86) 
A. Excluded 
following review of 
title and abstract 
(n=438)  
B. Excluded 
following review of 
full text (n=46)  
Papers provisionally included for 
narrowing to focus on expression (n=40) 
Papers selected to assess the risk of 
bias (n=15) 
C. Excluded 
following narrowing 
to expression focus 
(n=25)  
Figure 6.1:  Flow chart of process for literature searching:  524 
papers were initially identified for assessment against the 
inclusion/exclusion criteria.  A standardized form (appendix 2) was used 
at exclusion point A and B.  Final papers were selected at point C by 
narrowing the focus to expressional data only.  15 papers were identified 
for possible inclusion   
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 6.4.2 Assessing the risk of bias 
 
  Five of the papers selected scored as a high or medium risk of bias 
in at least one domain.  These were excluded from the systematic 
review.  10 of the studies were finally included.  Table 6.4 
summarizes the 15 papers and the risk of bias scoring for each 
domain.  Two of the papers which scored a high or medium risk of 
bias were due to the limits of only accessing abstract.  One study 
was a conference presentation and published in abstract only and 
the other was published in Chinese and abstract only available in 
English.  Whilst this paper may have offered a valuable contribution 
to the review, there were limitations to accessing translation.  The 
other three studies excluded due to a high or medium risk of bias did 
not present all required information, such as not defining the sample 
size or control group.   
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Study Risk of bias 
Risk of bias within internal 
validity domain 
Risk of bias in overall 
assessment 
Risk of bias in study 
description 
(Anton et al., 2005) Low Low Low 
(Gerber et al., 2009) Low Low Low 
(Hoshino et al., 2002) Low Low Low 
(Kuperman et al., 2005) Low Low Low 
(Liu et al., 2004) High High Low 
(Moore et al., 2008) Low High Medium 
(Nakano et al., 2006) Medium Low Medium 
(Range et al., 2007) Low Low Low 
(Ryhner et al., 2008) Low Low Low 
(Toda et al., 2002) Low Low Low 
(Wang et al., 2007a) Low Low Low 
(Wang et al., 2007b) Low Low Low 
(Woodruff et al., 2007) Low Low Low 
(Yim et al., 2011) Low Medium Low 
(Zhou et al., 2001) Low Medium Medium 
Table 6.4:  Summary of identified papers and resultant risk of bias assessment:  Table outlines the risk of bias assessment 
in all three domains for each paper identified.  Those highlighted in grey were excluded from the final systematic review as they 
attracted a medium or high risk of bias in at least one of the three domains assessed. 
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 6.4.3  Characteristics of included studies 
 
  The key characteristics of the final selected studies are presented in 
Table 6.5.  Seven of the 10 selected studies were published within 
the last five years and all were within 10 years.  60% had a sample 
of humans whereas the remaining 40% were equine.  All tissues 
were extracted from the bronchus of each species.  Of the studies, 
the majority focused upon asthma (90%) with three of these also 
considering COPD.  Only one study focused upon COPD alone 
however it was noted that the first author of this was also first 
author on a similar paper that considered asthma.  The title, 
methodologies and conclusions for these two papers were similar, 
and the title only differed by interchanging “COPD” and “asthma”.  
These were considered two papers arising from the same study as 
discussed in later text.  All studies used the expression of RNA as an 
outcome measure through experimental techniques such as 
quantitative RT-PCR or immunohistochemistry.  
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 Study Sample size Sample 
species 
Tissue 
type 
Disease 
focus 
Chloride 
ion 
channel 
focus 
Experimental 
techniques 
Outcome 
measures Experimental Control 
(Anton et 
al., 2005) 
 
3 3 Equine Lung Asthma eCLCA1 Northern blot, 
immunoblotting, 
electrophysiology and 
quantitative RT-PCR 
RNA and 
protein 
(Gerber et 
al., 2009) 
5 5 Equine Small 
cartilagino
us 
conducting 
airway 
Asthma 
and 
COPD 
eCLCA1 Quantitative RT-PCR RNA and 
neutrophil 
count 
(Hoshino et 
al., 2002) 
21 13 Human Bronchial Asthma Calcium-
activated 
chloride 
channel 1 
Quantitative RT-PCR, 
histochemical analysis 
RNA  
(Kuperman 
et al., 2005) 
30 28 Human 
and 
murine 
Bronchial Asthma hCLCA1 
and 
mCLCA3 
Microarray analysis 
and quantitative RT-
PCR 
Gene 
expression 
by fold 
change 
 
(Range et 
al., 2007) 
9 9 Equine Trachea 
and 
bronchus 
Asthma 
and 
COPD 
 
eCLCA1 Immunohistochemistry 
and quantitative RT-
PCR 
RNA and 
protein 
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(Ryhner et 
al., 2008) 
19 11 Equine Bronchial Asthma 
and 
COPD 
eCLCA1 Cytology and 
quantitative RT-PCR 
RNA 
(Toda et al., 
2002) 
9 10 Human Bronchial Asthma hCLCA1 Hybridization, 
histochemistry and 
immunocytochemistry 
 
RNA 
(Wang et 
al., 2007a) 
25 20 Human Bronchial COPD Calcium-
activated 
chloride 
channel 1 
RT-PCR, 
immunohistochemistry 
RNA and 
protein 
(Wang et 
al., 2007b) 
6 10 Human Bronchial Asthma Calcium-
activated 
chloride 
channel 1 
RT-PCR, 
immunohistochemistry 
RNA and 
protein 
(Woodruff 
et al., 2007) 
42 28 Human Bronchial Asthma hCLCA1 Quantitative RT-PCR, 
immunohistochemistry 
RNA and 
protein 
Table 6.5:  Table summarizing the key characteristics of the selected studies:  The studies were assessed for the risk of 
bias and key characteristics identified to allow comparability within discussion.  The final ten selected papers are presented in this 
table 
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 6.4.4  Data extraction 
 
  Data from the ten selected studies could not be pooled for meta-
analysis due to the variety of outcome measures that were used.  
Some studies used fold difference gene expression whereas others 
used copy number per nanogram of total RNA.  Data extraction 
therefore is from individual papers and the outcome measures 
discussed in principle. 
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 6.4.5  Summary of results 
 
  Of the ten finally selected studies, nine focused upon asthma, five 
of which used human bronchial epithelial tissue to explore the 
expression of particular chloride ion channels (Hoshino et al., 2002; 
Toda et al., 2002; Kuperman et al., 2005; Wang et al., 2007b; 
Woodruff et al., 2007).  The remaining four used equine bronchial 
tissues as a model of asthma in humans (Anton et al., 2005; Range 
et al., 2007; Ryhner et al., 2008; Gerber et al., 2009).  Equine 
studies have been included for systematic review as it has been 
suggested that horses with recurrent airway obstruction (RAO) are a 
model for human asthma due to similar clinical features (Anton et al., 
2005; Gerber et al., 2009).  It must be reiterated however that 
equine models are weak due to the potential environmental effects 
of stabling (Range et al., 2007).  There have been previous studies 
that use murine models for chloride ion channels and it has been 
shown that that mCLCA3 is homologous with hCLCA1 (Section 
1.1.3.3).  It has been previously suggested that mCLCA3 and 
hCLCA1 have a similar isoform to eCLCA1 however there are slight 
structural differences.  To what extent this may impact upon function 
is not clearly addressed in the selected studies.  The findings of the 
systematic review however must be considered with the limitations.  
That there were only 10 papers finally selected, and that there was a 
mix of human, murine and equine studies, suggests that findings 
cannot be used to support or reject the hypothesis.   
 
  Of the nine studies, CLCA was the only chloride channel that was 
examined.  However, as discussed in section 1.1.3.3, CLCA is not 
considered a chloride ion channel in itself (Greenwood & Leblanc, 
2007).  Hamann (2009) has suggested that CLCA modulates the 
function of other Ca2+ activated Cl- channels.  CLCAs are therefore 
implicated in the conductance of chloride and have been included in 
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 the systematic review.  Two of the selected studies measured 
expression of Ca2+-activated Cl- channel 1 (CaCC1) (Hoshino et al., 
2002; Wang et al., 2007b) which is considered an alternative name 
for hCLCA1 (homologous to mCLCA3 and eCLCA1) (Wang et al., 
2007b).  Hoshino et al (2002) suggest that it is similar in distribution 
and structure to murine gob-5 which is considered as an alias for 
mCLCA3 (Anton et al., 2005).  Both Wang et al (2007b) and Hoshino 
et al (2002) state that CaCC1 has similar homology to gob-5.  All 
studies reported an increase in the expression of CLCA in response to 
inflammation.  That only CLCA has been identified, and is not 
considered a chloride ion channel in itself is another limitation of the 
current systematic review. 
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 6.5  Discussion 
 
  The symptoms of chronic inflammatory lung disease include mucus 
over-production, airway inflammation and hyper-reactivity (Toda et 
al., 2002; Kuperman et al., 2005; Wang et al., 2007b).  It has been 
suggested that chloride ion channels are responsible for these 
symptoms as discussed in Chapter 1 (Anton et al., 2005; Wang et 
al., 2007b).  The expression of the bestrophin family has been 
screened in numerous cell types, and preliminary functional 
properties explored (Chapter 4 and Chapter 5).  To establish whether 
chloride ion channels are implicated in chronic inflammatory lung 
disease, a systematic review question was formulated; Is the gene 
and protein expression of chloride ion channels upregulated in the 
respiratory epithelia, or granulocytes, of subjects with chronic 
inflammatory lung disease, as assessed by Bestrophins (1-4), CLCAs, 
ANOs, ClCs, Tweety protein and gene expression, using all available 
cohort, case control and laboratory studies? 
 
  This question remains unanswered through this systematic review.  
It appears there is an increase in hCLCA1 expression in those with 
chronic inflammatory lung disease however this cannot be 
necessarily applied to chloride ion channels until the relationship 
between hCLCA1 and other potential molecular candidates is 
clarified.  In addition, there is a high risk of bias due to the limited 
number of studies that could be compared as four used an equine 
population.  The consistency between studies was also problematic 
due to variables in controls, sample size and sample preparation.  
Outcomes (gene and protein expression) were also not comparable 
due to different measures used across the studies.  It is also 
important to acknowledge that there is a high risk of publication bias, 
as discussed, which further limits the ability to draw conclusions from 
the systematic review.  
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 6.5.1  Limitations of the systematic review 
 
  Whilst the methodology has followed the principles of systematic 
reviewing it must be acknowledged that the results are extremely 
limited.  Primarily, a weakness of the systematic review is that 
methods have been adapted from processes designed to collate RCT 
evidence and answer questions related directly to healthcare (as 
discussed in Section 6.1).  The intention was to identify whether 
chloride ion channels are upregulated in chronic inflammatory lung 
diseases.  Whilst the the validity of each paper was reliably assessed, 
due to the limits of adapting a process designed for alternative 
evidence, any discussion must be considered cautiously. 
 
  A limitation of the current systematic review may also be the search 
terms used.  To ensure that every available paper was accessed, the 
search terms were broad and a systematic process to exclude 
evidence was used.  This resulted in a large number of papers being 
identified (524 as in Figure 6.1) which were initially screened for 
abstract and title leaving 86 which were examined in further depth 
for possible inclusion.  Alternative search terms were initially 
identified however there were no papers identified using the 
databases described.  By broadening search terms, papers that met 
criteria were included (Section 6.4.1 for further discussion regarding 
inclusion and exclusion of papers).  It could be argued however that 
by broadening the search terms it encouraged a thorough and 
systematic search for all potential studies.  The final number of 
papers selected was very limited as only 10 met criteria, and whilst 
they were considered to have a low risk of bias, the population of 
each differed, making comparability difficult.  This must also be 
considered when assessing the validity and reliability of the 
systematic review. 
 
290 
   A further limitation is that of the 10 studies that were finally 
included, 40% used equine samples.  Anton et al (2005) suggest that 
human COPD and human asthma can be modelled effectively using 
RAO affected horses.  They state that there are similarities between 
RAO and human COPD/asthma pathologies, clinical symptoms and 
allergic responses.  Whilst this is supported by Gerber et al (2009) 
who acknowledge the similarities in clinical features, they also 
acknowledge that stabling horses in itself can cause many of the 
allergic symptoms that are considered similar to COPD and asthma in 
humans.  This includes the effect of both allergic and non-allergic 
irritants such as dust or mould spore irritation.  RAO in horses is 
therefore considered a relatively weak model for human asthma and 
COPD (Range et al., 2007).  As a result, the findings of equine 
studies can only be considered in the current systematic review with 
caution.  Further research to examine the similarities between 
human and equine studies is required in order to draw conclusions 
with any confidence.    
 
  A substantial limitation of the systematic review is that there is a 
high risk of publication bias.  Whilst key laboratories were written to 
requesting potential data, both positive and null, there were no 
responses.  This may indicate that there were no prospective studies 
that should be included, regardless of whether they have been 
published or not.  However, if a researcher perceives results to be 
null, it is unlikely that data would be in an appropriate format and 
available for dissemination.  Therefore, that none of the laboratories 
responded is not a reliable measure of reduced publication bias.  
Furthermore, that the populations were not comparable, and sample 
sizes were small, prohibited use of a funnel plot to assess bias.  As a 
result, it is likely that findings from the current systematic review 
over-estimate any potential correlation between chloride ion 
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channels and chronic inflammatory lung disease due to publication 
bias (Song et al., 2010). 
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 6.5.2  Expression of chloride ion channels in asthma 
6.5.2.1   Equine studies 
 
  Equine studies are considered to be an appropriate animal model 
for asthma in humans due to the similarities in clinical symptoms and 
pathophysiology between RAO and asthma (Anton et al., 2005; 
Ryhner et al., 2008).  It has been argued however that due to the 
environmental effects of stabling, and non-allergic irritants, equine 
models for asthma and COPD are weak. However, Anton et al (2005) 
suggested from their data that eCLCA1 is the equine orthologue of 
hCLCA1, mCLCA3 and pCLCA1.  The distribution of eCLCA1 and 
mCLCA3 is similar in each species with some differences noted in 
sweat glands of both animals (Leverkoehne & Gruber, 2002; Anton 
et al., 2005).  It has been established, however, that there is similar 
expression of mCLCA3 and eCLCA1 in the mucin producing cells of 
animal airways (Anton et al., 2005; Range et al., 2007).  Anton et al 
(2005) has shown in their study of horses that eCLCA1 mRNA is 
strongly up-regulated in the RAO lung compared to healthy horses.  
They used Northern blot hybridization on horses (n=3) 
spontaneously affected with RAO compared to healthy controls 
(n=3).  They also demonstrated that eCLCA1 protein was up-
regulated in RAO horse lung, compared to a weak signal in healthy 
lung on Western blotting.  They suggested therefore that this would 
be indicative of an increase in the human asthmatic lung.  As stated 
however, this is not conclusive due to the variables that would 
impact upon the expression of symptoms in RAO that are associated 
with asthma or COPD and that equine models are not considered a 
strong animal model for humans.  In addition, Anton et al (2005) did 
not quantify the number of goblet cells in the RAO affected horses, 
compared to controls.  It has been shown in a later study on horses 
with RAO, that the observed increased expression of eCLCA1 is not 
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 at transcription (Range et al., 2007).  In this study, there was a 
larger sample of 9 horses in the RAO group, and 9 healthy controls.  
Range et al (2007) quantified goblet cells by using the housekeeping 
gene EF-la as a marker of goblet cells.  They found that there was a 
direct correlation between eCLCA1 mRNA and protein expression 
with goblet cell metaplasia and hyperplasia.  This is an essential 
component in understanding the role that eCLCA1 may have in RAO 
affected horses.   
 
  Range et al (2007)  demonstrated that by using whole lungs from 
RAO affected horses could lead to misinterpretation and that in their 
study, the up-regulation of eCLCA1 was due to increased numbers of 
mucin-producing goblet cells.  If there was transcriptional up-
regulation of hCLCA1, and increase in protein, it would seem 
reasonable to assume that this has a role to play in the symptoms of 
the disease.  However, if there is observed up-regulation of goblet 
cells, and as a result, a correlated increase in expression of eCLCA1 
then it may be that it is the goblet cells that have a pivotal role.  In 
the study by Range et al (2007) they also demonstrated that the 
eCLCA1 protein was completed secreted, with no association with the 
plasma membrane of a cell. This was established using Western blot 
techniques to establish glycosylation patterns in both cell lysate and 
supernatant of HEK293 transfected cells.  As discussed, this further 
suggests that horses are not an appropriate model for human 
disease.  In human studies, there is some evidence to suggest that 
hCLCA1 retains a membrane bound portion, however in the Range et 
al (2007) study, the protein was completed secreted.  This difference 
in CLCA structure between species further limits findings of equine 
studies when applying to human asthma and COPD.  In opposition to 
the study by Anton et al (2005) it was suggested by Range et al 
(2007) that there is no clear role for eCLCA1 in the symptoms and 
pathophysiology of RAO in horses.  It was suggested, however, that 
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 the symptoms observed in RAO were as a direct result of increased 
goblet cell hyperplasia and metaplasia which may be regulated by 
eCLCA1 in horses.   
 
  The relationship between mucous production in RAO is examined in 
another equine study by Gerber et al (2009).  In this study RAO 
affected horses (n=5) and control horses (n=5) were euthanized by 
barbiturate overdose following five days of stabling.  Each subject 
was dissected and airway samples collected from a number of sites.  
Additionally, neutrophil count was established by cytology brushing 
of intraluminal secretions.  It was concluded that in RAO affected 
horses, neutrophil count in airways was significantly increased, 
compared to control horses, and correlated with intensity of 
symptoms.  Conversely, there was not a significant change in 
eosinophil count. However, in the study by Gerber et al (2009) there 
was no significant difference between control groups or the RAO 
affected horses in intraepithelial mucous production, or up-regulation 
of eqMUC5AC.  They found similar values in both groups of horses 
however have acknowledged that by stabling the horses prior to 
euthanasia, they may experience dust irritation.  This would result in 
similar irritation to airways in both RAO horses and control horses.  
Dust irritation may account for any of the observed symptoms.  
Gerber et al (2009) in contrast to Range et al (2007) found no 
significant difference between experimental groups in goblet cell 
metaplasia or hyperplasia however did suggest that there was an 
increase in both groups due to stabling, compared to healthy horses 
that had been kept in pasture. 
 
  Despite the similarities in control and RAO affected horses, Gerber 
et al (2009) has shown that there is a positive correlation between 
eqMUC5AC and eCLCA1 expression.  In each group, the relationship 
differed however.  In the experimental group, there was a 
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 comparatively larger expression of eCLCA1 in relation to MUC5AC.  
Conversely, there was a greater expression of MUC5AC in relation to 
eCLCA1 in the control group of horses.  It was suggested that 
eCLCA1 acts as a regulator of MUC5AC in response to IL-13 (Gerber 
et al., 2009).  This was also supported by an earlier study on mice 
which showed a larger increase in mCLCA3 in mice compared to 
MUC5AC when IL-13 was administered intra-tracheally (Thai et al., 
2005).  In the human asthmatic airway, symptoms are often 
exacerbated by allergen or dust exposure, which would increase IL-
13 and therefore may have similar responses as the RAO horses in 
this study.  However, as highlighted, equine studies may not prove 
to be a useful model, particularly due to differences in the structure 
of CLCAs between species.  Gerber et al (2009) suggest that the 
relationship between IL-13, eqMUC5AC and eCLCA1 that is observed 
is likely to be as a consequence of neutrophilic inflammation and that 
eCLCA1 is an important molecule in the regulation of mucous 
production in RAO affected horses. 
 
  In contrast to the three previous equine studies, Ryhner et al 
(2008) has shown that despite an increase in mucous production in 
the RAO affected horses (n=12) compared to healthy controls 
(n=11), there is no significant difference in MUC5AC or eCLCA1 
genes.  They also found that IL-13 was down-regulated in RAO 
horses.  This contradicts the hypothesis that in RAO IL-13 is 
increased in response to, and causing a response in, eosinophil 
accumulation (Lee et al., 2001; Nakano et al., 2006).  It has also 
previously been found that increased IL-13 will up-regulate CLCA1, 
and goblet cell metaplasia (Nakanishi et al., 2001).  The findings of 
the study by Ryhner et al (2008) demonstrated that increased 
mucous secretion is not correlated to IL-13 or eCLCA1 and suggested 
this to be as a result of neutrophilic airway inflammation.  The horses 
used in this study, however, were chronically affected with RAO and 
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 as acknowledged, IL-13 and increases in MUC5AC and eCLCA1 may 
only occur in the acute phase of disease.  
 
  Equine studies which consider the expression of chloride channels 
in RAO are contradictory to date.  There are 3 studies which 
demonstrate an up-regulation of eCLCA1 in horses with RAO, as an 
animal model for asthma.  One of which presents this as a 
transcriptional up-regulation (Anton et al., 2005).  As second study 
states that whilst the is an overall increase in eCLCA1, this is because 
eCLCA1 is expressed in goblet cells and during RAO, there is an 
increase in goblet cell metaplasia and hyperplasia (Range et al., 
2007).  A third study found no difference between RAO and control 
horses in the expression of MUC5AC or eCLCA1 but did find an 
increase in mucous production and eCLCA1 in both groups.  This was 
attributed to both groups being stabled for five days prior to 
euthanasia and both being exposed to allergen and dust irritants.  
They also presented a positive correlation between MUC5AC and 
eCLCA1 which was postulated to be IL-13 driven (Gerber et al., 
2009).  Controversially, the final equine study found no significant 
difference in gene expression between RAO horses and control 
horses and that IL-13 was controversially decreased in RAO horses 
compared to the control group (Ryhner et al., 2008).  In this 
instance, the horses were chronically affected with RAO and it was 
considered that the differences in study results may be because 
eCLCA1 and MUC5AC may only be up-regulated in the acute phase of 
disease. 
 
  In summary, it appears that equine studies may not be directly 
applicable to human asthmatic responses and results should only be 
considered with caution.  First and foremost, RAO shares similar 
symptoms to asthma however it cannot be used as a model for 
asthma due to differing pathologies, and variables such as dust 
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 irritation in equine studies.  It has also become evident that there 
may be structural differences in CLCA between humans and horses.     
As previously discussed (Chapter 1) CLCA1 is not considered a 
channel in itself however there is a correlation between CLCA1 and 
chloride flux.  This may be attributable to the postulated regulatory 
role of CLCA1 on other Ca2+ activated Cl- ion channels.  However, 
that it is not a channel in itself is another limitation.  Using the 
equine studies, the hypothesis cannot be supported in light of the 
acknowledged limitations.  
 
6.5.2.2  Human studies 
 
  Human studies seem to support the hypothesis that hCLCA1 
expression is greater in the airway epithelial tissues of people with 
asthma.  Woodruff et al (2007) found that asthmatic subjects had a 
6.2 fold greater expression of hCLCA1 compared to healthy control 
subjects.  This was compared against smokers as a disease control 
group which found that the expression of hCLCA1 was not increased 
in this group.  The likely mechanism by which hCLCA1 is up-
regulated is a response to inflammation.  Within this study, primary 
airway cells were grown as a monolayer and stimulated with IL-13.  
The result was a marked increase in hCLCA1 expression (Woodruff et 
al., 2007).  IL-13 is released during inflammation, such as that in 
asthma, which may correlate the observed response in vitro with 
primary airway cells, to that found in vivo from the bronchial 
brushings of asthmatic subjects.  In addition, the expression of 
hCLCA1 was decreased in response to inhaled cortico-steroids.  
However, the study by Woodruff et al (2007) did not quantify goblet 
cell hyperplasia or metaplasia.  Given the suggestion from the equine 
studies that CLCA1 is up-regulated due to its distribution in goblet 
cells, this may have been useful to establish in the Woodruff et al 
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 (2007) study.  This would indicate whether, in humans, hCLCA1 is 
up-regulated in relation to goblet cell numbers.  
  
  Toda et al (2002) have supported this in humans by examining the 
expression of hCLCA1, IL-9 and the quantity of mucous producing 
cells.  They found that in asthmatic subjects, there is greater 
expression of hCLCA1 but equally, the number of mucous producing 
cells is increased in asthmatic subjects, compared to healthy 
controls.  Toda et al (2002) have considered hCLCA1 as a chloride 
ion channel however, as previously discussed, since the publication 
of this study it has been found that CLCA1 is not in itself a channel 
but may, however, regulate other channels.  The correlation between 
mucous producing epithelial cells and hCLCA1 is further supported 
however, as the increased expression of hCLCA1 is correlated with 
increased IL-9 which is thought to stimulate goblet cells (Toda et al., 
2002).  If hCLCA1 is found to interact with other chloride ion 
channels, it seems reasonable to suggest that chloride ion channels 
are implicated in the disease process and symptoms of asthma.   
 
  The increased expression of CLCA1 has been confirmed in a study 
that used both human samples, and mouse models of asthma 
(Kuperman et al., 2005).  In the murine model, there were three 
experimental groups; control mice that were allergen challenged, IL-
13-over-expressing transgenic mice with signal transducer and 
activator of transcription factor 6 (STAT6) limited to airway epithelial 
cells, and IL-13 over-expressing mice with normal STAT6.  Those 
with normal STAT6 produce symptoms of asthma however those 
with STAT6 limited to airway epithelial cells produced symptoms of 
asthma but without inflammation, fibrosis or emphysema.  By using 
the three murine models of asthma, Kuperman et al (2005) were 
able to establish which genes were over-expressed as a result of 
allergen stimulation only, and which were attributable to certain 
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 symptoms of asthma, such as mucous hyper-secretion and 
inflammation.  By using the two models +/- STAT6 the effects of IL-
13 as a single mediator were established.  Kuperman et al (2005) 
found that in all three murine asthmatic models, there was increased 
expression of mCLCA3 (human orthologue hCLCA1).  This suggests 
that in allergen stimulated asthma, there is increased expression of 
mCLCA3.  This pattern was similar in human subjects with asthma, 
compared to controls however the over-expression of hCLCA1 in 
airway epithelial cells was greater in humans, than observed in 
murine models as measured by fold change.   
 
  The two other studies which used human subjects used the term 
CaCC1 (calcium activated chloride channel 1) (Hoshino et al., 2002; 
Wang et al., 2007b).  This is an alternative term for hCLCA1 as 
identified by Wang et al (2007b).   
 
  Hoshino et al (2002) found that there was a marked increase in 
hCaCC1 in asthmatic subjects compared to control subjects.  They 
found that the distribution of this chloride channel was similar to that 
of eCLCA1 (Range et al., 2007) and hCLCA1 (Woodruff et al., 2007).  
Also, similarly, Hoshino et al (2002) demonstrated that hCaCC1 was 
expressed in the epithelium of the bronchus, and particularly in the 
goblet cells.  However, as with the Woodruff et al (2007) study, 
there was no quantification of goblet cells and so the up-regulation 
was not clearly transcriptional, or whether it was due to metaplasia 
of goblet cells.  The images provided within the study by Hoshino et 
al (2002) do clearly demonstrate a correlation between location of 
hCaCC1 and goblet cells by immunohistochemical staining. 
 
  The observations from Hoshino et al (2002) were supported by 
Wang et al (2007b) in their study however they also examined the 
correlation with goblet cells.  hCaCC1 had a greater expression in the 
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 asthmatic subjects, throughout the bronchial tissues, compared to 
controls.  This was statistically significant and was positively 
correlated with the expression of MUC5AC protein and quantities of 
goblet cells.   
 
  The studies of hCLCA1 support that there is significant up-
regulation of this gene in asthmatic subjects.  It is not clear whether 
this is because there is more expression within goblet cells, and 
these are up-regulated, or whether it is transcriptional up-regulation 
is not clear.  However, there appears more evidence to suggest that 
the increased expression of hCLCA1 is due to hyperplasia and 
metaplasia of goblet cells.  That the relationship between hCLCA1 
and goblet cells is unclear, and that was a limited number of studies 
identified, further limits application of findings to the current project.  
As with equine studies, only hCLCA1 has been identified and 
therefore not a chloride ion channel in itself.  In light of these 
limitations, the findings of the human studies do not support the 
hypothesis and further evidence is required.  
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 6.5.3  Expression of chloride ion channels in chronic 
obstructive pulmonary disease (COPD)   
 
  Four of the included studies discussed chloride ion channels in 
COPD.  Of these, only one considered COPD alone and the remaining 
three were both asthma and COPD.  It should be noted, however, 
that the study by Wang et al (2007b) was published by the same 
laboratory group that published a similar paper which focused upon 
asthma only with the same chloride ion channels examined (Wang et 
al., 2007a).  The abstracts and methodology for each of the papers 
by the Wang laboratory are similar with “asthma” substituted with 
“COPD”.  It seems reasonable, therefore, to assume that these 
differing papers are a result of a single study (Wang et al., 2007a; 
Wang et al., 2007b).  The discussion therefore for COPD can be 
directly extracted from section 6.5.2.2 for equine studies (Range et 
al., 2007; Ryhner et al., 2008; Gerber et al., 2009) and 6.5.2.3 for 
human studies (Wang et al., 2007a; Wang et al., 2007b). 
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 6.5.4  Systematic review concluding remarks 
 
  The studies examining chloride ion channels all focus upon hCLCA1 
or the animal homologue, eCLCA1.  As discussed in section 1.1.3.3, 
hCLCA1 is no longer considered a chloride ion channel in itself but 
may modulate other Ca2+ activated Cl- channels.  Therefore, the 
increased expression of hCLCA1 can be correlated with an increased 
flux of chloride.  The exact relationship between hCLCA1 and 
alternative channels, such as hBest1 or hANO1, is not yet clear.  In 
light of this, the findings cannot be applied with confidence to the 
current project and do not support the hypothesis that chloride ion 
channels are upregulated in chronic inflammatory lung diseases.   
 
  The papers used in the systematic review have suggested a positive 
correlation between increased hCLCA1 expression and goblet cell 
hyperplasia and metaplasia.  There is also a relationship between 
increased hCLCA1 and increased IL-13 and IL-9.  From these results 
it appears that hCLCA1 expression is increased in inflammatory 
aiways as a result of cytokine release and goblet cell metaplasia and 
hyperplasia.  The interaction between hCLCA1 and other chloride ion 
channels requires further experimentation to be established.  The 
relationship between goblet cell metaplasia and hyperplasia also 
requires further clarity before the findings of the current systematic 
review can be applied with confidence to the hypothesis.   
 
  There are several limitations to the systematic review highlighted 
(Section 6.5.1).  These include; adaptation of systematic reviewing 
methods intended for RCTs in healthcare, mixed species evidence, a 
small number of papers finally selected, that CLCA1 is not considered 
a chloride ion channel in itself, structural differences in CLCA1 across 
species and that findings across papers are contradictory.  In light of 
these limitations, the systematic review has not answered the 
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 question posed, nor proved supportive of the current project and the 
hypothesis is not supported.    
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CHAPTER 7:  CONCLUSIONS 
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 7.1  Limitations  
 
 
  There are limitations to the current project which need defining in 
order to assess any risk of bias or application of results.   
 
  Initial experimental data was using commercial cell lines and 
primary cells from “healthy” donors.  It could be argued that in order 
to further elucidate potential candidates for chloride ion channels 
then there should be a comparison to granulocytes in either donors 
with allergic responses, or chronic inflammatory lung diseases.  This 
may further be examined by using alternative experimental groups 
and defining specific lung diseases within each.  For example, 
healthy donors as control, COPD and asthma as experimental 
groups.  This would clarify any changes or up-regulation during the 
disease process.  It may also be useful to expand the tissue types to 
include nasal or bronchial brushings, again from three experimental 
groups.  Ethics approval, scope of the project timeline and financial 
constraints prohibited this in the current project. 
 
  Some methodological concerns regarding calcium and chloride flux 
assays which would need extensive optimization in order to achieve 
significant results.  This could also be used on primary cells with 
different experimental groups.  HL60s however could be used to 
establish method as the financial commitment is less, and the cells 
are more readily available than primary cells.   
 
  Systematic reviewing is an established technique in research which 
is considered rigorous in the hierarchy of evidence.  There are, 
however, limitations for this project.  There are many systematic 
reviews that have been published however they are more commonly 
employed when examining randomized controlled trials.  Therefore, 
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 much of the guidance, and tools available are structured towards this 
particular field of research.  The tool used for assessing the risk of 
bias was designed using several different tools and applying them to 
primary, laboratory experiments.  In addition, there were many 
limitations (Section 6.5.1) which suggest that the systematic review 
was not productive in the current project.  Any discussion cannot 
support the hypothesis.  Further research should be directed towards 
laboratory experimentation, using human subjects, to identify which 
chloride ion channels may be upregulated in chronic inflammatory 
lung diseases.  
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 7.2  Addressing the hypothesis 
 
  The aim of this project (section 1.2) was initially to elucidate the 
potential candidates for chloride ion channels in granulocytes, and 
the commercial cell line, HL60s.  There has also been considerable 
screening of epithelial cells used as controls.  It was shown that 
HL60s are an appropriate model for human granulocytes as they 
have a similar phenotype for the bestrophin family of chloride ion 
channels (section 3.2). 
 
  RT-PCR has been employed to screen a number of positive 
controls, and airway epithelial tissues to examine the potential 
candidates.  Many of the airway cells were used as positive controls 
and all bands for hCLCA1-4, hBest1-4 and hANO1-10 were confirmed 
by sequence analysis with the exception of hCLCA4 and hANO9.  
These were non-specific (Table 3.5).  As a result, phenotyping for all 
cells was considered to be an accurate reflection of the physiological 
expression of mRNA.  For the purpose of this project, the putative 
channels were narrowed to focus upon hCLCA1, hBest1 and hANO1 
for further analysis using flow cytometry and western blotting for 
protein expression.  The aim was to clarify whether these were 
surface or membrane bound proteins.  Secondly, there has been 
some suggestion that hCLCA1 may interact with hBest1 to modulate 
activity (Greenwood & Leblanc, 2007; Hamann et al., 2009).  
Previous studies have demonstrated that hBest1 is localized to the 
endoplasmic reticulum and have suggested that in turn, hANO1 is 
activated (Loewen & Forsyth, 2005; Barro-Soria et al., 2010).  This 
was not supported with the RT-PCR data however, this may be due 
to cessation of mRNA signal when optimal activity is reached.  Flow 
cytometry does however, support this hypothesis.  Section 4.2 shows 
that there is a statistically significant difference in hCLCA1 and 
hBest1 expression.  There is a negative correlation between the two 
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 proteins in that as hCLCA1 decreases, hBest1 increases and vice 
versa.  The overall expression of hBest1 is less than hCLCA1 as 
supported by the work of Loewen and Forsyth (2005).  In addition, 
as highlighted in section 4.2, there is a greater fluorescence when 
hBest1 is labelled intracellulary which supports other studies stating 
that hBest1 is predominantly localised to the endoplasmic reticulum 
(Barro-Soria et al., 2010).  There was also an increased expression of 
hANO1 which also correlated with decreased expression of hBest1 
(figure 4.2 and 4.3).  This was statistically significant.  Also of note, 
and potentially important in discussion of the hypothesis is that there 
is a statistically significant greater expression of both hCLCA1 and 
hBest1 in granulocytes, compared to eosinophils.  It has been 
postulated that hCLCA1 may have a role in maturation and 
differentiation of granulocytes (Loewen & Forsyth, 2005) which may 
be supported by the difference between granulocytes and 
eosinophils.  It is hypothesised that hCLCA1 is involved in the 
terminal differentiation of eosinophils, secondary to an increase in 
hBest1 expression.  This, in turn, increases the recruitment and 
activation of granulocytes at the site of inflammation (Matsumoto et 
al., 2008; Spencer & Weller, 2010). 
 
  That granulocytes are implicated in COPD and asthma is clear 
(Barnes, 2008) however the role of hBest1 in granulocyte function in 
these disease processes needs clarity.  This may be of importance 
when considering the differing granulocyte sub groups associated 
with pathology of differing inflammatory lung diseases (Part 1.1).  In 
this instance, it may be that eosinophils have a different expression 
of chloride ion channels than neutrophils which may be attributable 
to the differing clinical manifestations of the diseases.  This may 
support a role for chloride ion channels in chronic inflammatory lung 
diseases. 
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   To address the secondary aim exploring potential role of hBest1 in 
granulocyte during inflammation, cells were stimulated with 
cytokines and examined with RT-PCR and flow cytometry.  Results 
indicate that hBest1 peaks after 24 hours stimulation with pro-
inflammatory cytokine, IL-13.  This was demonstrated using flow 
cytometry with changes measured in median fluorescence and RT-
PCR (Section 5.1).  This supports a potential role for hBest1 in 
inflammation, and possibly inflammatory lung disease.  In particular 
asthma which is known to have a peak in eosinophil accumulation, 
and symptoms, at 24 hours after exposure to allergens (O'Byrne et 
al., 2004; Holgate & Polosa, 2008).   The role of hBest1 is not clear 
at this point, whether involved in maturation of granulocytes and 
differentiation, or whether up-regulation may be linked to 
accumulation of granulocytes to sites of inflammation.  The evidence 
presented in this project and current literature indicates hBest1 has a 
role in the migration and attraction of granulocytes in inflammatory 
responses (Raap & Wardlaw, 2008; Walsh & August, 2010).  Flow 
cytometry has demonstrated that hBest1 is up-regulated in response 
to IL-4, IL-5 and IL-13 which is likely to occur in vivo.  The 
mechanism by which hBest1 may be responsible in migration of 
granulocytes may be through Cl- flux and resultant changes in cell 
volume and shape. 
 
  Migration of granulocytes in COPD and asthma, secondary to up-
regulation of hBest1 as observed in the project, may have a direct 
impact upon severity of symptoms.  It has been suggested that 
granulocyte accumulation results in up-regulation of MUC5A, 
therefore hyper secretion and hyperplasia of goblet cells (Rogers, 
2003; Caramori et al., 2004; Barnes, 2008).  This would result in 
mucous hyper secretion.  Martinez-Anton et al (2006) however relate 
granulocyte accumulation to mucous secretion through MUC4 and 
MUC8.   
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  The accumulation of granulocytes in inflammatory lung disease has 
been implicated in symptoms such as airway hyper-responsiveness 
and fibrosis (Kariyawasam & Robinson, 2007; Cheng et al., 2008; 
Venge, 2010).  Whilst these processes are linked to detrimental 
responses leading to tissue damage, hBest1 may also be implicated 
in therapeutic inflammatory responses.  Up-regulation of hBest1 
would increase flux of Cl-, and in turn fluid shift.  This has an 
important role in cell volume and shape regulation in granulocytes.  
This is implicated in the process of phagocytosis, an important 
process in defence mechanisms. 
 
  Transmigration assay was performed and it was found that when 
HL60s were transfected with hBest1, there was a statistically 
significant greater migration of cells, compared to controls towards 
both fMLP and IL-13.  This supports then hypothesis that hBest1 in 
granulocytes may be involved in migration, and therefore cellular 
accumulation.  There may also be a role in increasing cellular 
permeability at the site of inflammation.  It has been demonstrated 
that fMLP stimulated neutrophils are attracted to the site of 
inflammation, and stimulates an increase in intracellular Ca2+ (Zhu et 
al., 2005). This may cause a greater stimulation of hBest1 as a 
calcium activated chloride channel.  It has also been postulated that 
hBest1 may be responsible for respiratory burst and release of 
oxygen free radical species (Tintinger et al., 2005).  This is 
supported by (Menegazzi et al., 1999) who state that granulocytes 
must migrate to the area of inflammation, and be immobilised by 
fibronectin.  Further stimulation by TNF alpha results in respiratory 
burst which is associated with symptom exacerbation and tissue 
damage in COPD and asthma.  This further suggests a role for 
hBest1 as it has been shown that airway epithelium directly 
stimulated with fMLP do not respond.  However, when neutrophils 
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 are stimulated with fMLP there is accumulation at the site of 
inflammation, and a greater respiratory burst with release of oxygen 
free radicals causing cellular permeability (Virchow et al., 1998; Zhu 
et al., 2005).   
 
  To establish a link between chloride ion channels and inflammatory 
lung disease, a systematic review was performed to identify whether 
the expression of chloride ion channels is different in the cells of 
people with inflammatory lung diseases.  The papers identified for 
inclusion into the systematic review focussed upon predominantly 
hCLCA1 (or animal orthologues) in either asthma or COPD (Chapter 
6).  As identified in previous studies, hCLCA1 is no longer considered 
an ion channel in itself but may modulate the activity of hBest1.  
There were only 10 papers identified for inclusion of which 40% 
were equine studies.  The limitations were acknowledged within 
Chapter 6 and as a result, the systematic review did not support the 
hypothesis. 
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 7.3  Concluding remarks and recommendations 
  
  This project has demonstrated that there is expression of a number 
of chloride ion channels in granulocytes in both health and disease.  
The focus was on hBest1 primarily which has been up-regulated in 
response to pro-inflammatory cytokine stimulation with IL-13 and 
fMLP stimulation.  hBest1 may have a complex relationship with both 
hCLCA1 and hANO1 which requires further clarity.  There may be a 
direct role for these chloride ion channels in symptoms when 
localised to respiratory epithelium however the role within 
granulocytes in subjects with inflammatory lung diseases may be 
multi-facetted.  Firstly, the relationship between hCLCA1, hBest1 and 
hANO1 may cause a flux of chloride that is directly responsible for 
cell volume, particularly for those channels that are volume 
regulated.  In this instance, cells may migrate with ease through 
permeable membranes, such as those in inflammatory responses.  
Secondly, the up-regulation of hCLCA1, and hBest1 may be 
responsible for granulocyte differentiation, maturation and eventual 
apoptosis and necrosis.  This is stimulated by pro-inflammatory 
cytokines further increasing accumulation at the site of inflammation, 
and release of cytokines from granulocytes themselves.  Another 
positive feedback relationship is evident and may be self-terminating 
as cells become terminally differentiated, and apoptotic.  This may 
relate to the termination of clinical manifestations and symptoms.  
hBest1 may also have a role in respiratory burst and superoxide 
release which will directly increase inflammation and cell permeability 
of respiratory epithelia when there is accumulation of granulocytes.   
 
  There is a complex picture emerging which indicates several areas 
for further research.  Primarily, the relationship between hCLCA1, 
hBest1 and hANO1 requires clarity.  This may also be examined over 
several time courses and in relation to cellular development, maturity 
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 and differentiation.  Further examination of function of hBest1 
relating to chloride or calcium flux, particularly in granulocytes as a 
currently under-researched area.  Other research would be indicated 
looking at primary granulocytes from both allergic, and control 
subjects.  Also, differentiation between diseases such as asthma and 
COPD may further enlighten expression and function of alternative 
chloride ion channels.  These areas would further illuminate the 
complex physiological processes in chronic inflammatory lung 
diseases and particular focus should be on the potential relationship 
between the key candidates for chloride ion channels. 
 
  Evidence from the literature, and the presented experimental data, 
shows that hBest1 is up-regulated in granulocytes in response to 
inflammatory mediators.  It has been postulated from this project 
that hBest1 is implicated in the attraction of granulocytes to the site 
of inflammation and the maturation and activation of such.  This may 
occur predominantly through cell volume regulation, possibly in a 
complex relationship between hCLCA1, hBest1 and hANO1.  hBest1 
may also have a role in symptom exacerbation in COPD and asthma 
through stimulation of goblet cell hyperplasia and metaplasia with 
resultant mucous hyper-secretion.  There is also suggestion that 
through stimulation of respiratory burst in granulocytes, hBest1 is 
implicated in fibrosis and airway hyper-responsiveness.  It has been 
acknowledged, however, that through modulation of cell shape, 
hBest1 has a role in phagocytosis, a therapeutic inflammatory 
response. 
 
  In early responses to inflammation, therefore, hBest1 may have a 
therapeutic effect.  Prolonged inflammation, however can cause 
tissue damage through processes such as fibrosis and airway hyper-
responsiveness.  hBest1, and potentially hCLCA1 and hANO1, may be 
involved in these processes.   
314 
  
 
 
 
 
 
 
REFERENCES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
315 
 Abdel-Ghany M, Cheng HC, Elble RC & Pauli BU. (2001). The breast cancer beta 4 
integrin and endothelial human CLCA2 mediate lung metastasis. Journal of Biological 
Chemistry 276, 25438-25446. 
 
Ackerman SJ, Liu L, Kwatia MA, Savage MP, Leonidas DD, Swaminathan GJ & Acharya 
KR. (2002). Charcot-Leyden crystal protein (Galectin-10) is not a dual function galectin 
with lysophospholipase activity but binds a lysophospholipase inhibitor in a novel 
structural fashion. The Journal of Biological Chemistry 277, 14859-14868. 
 
Agnel M, Vermat T & Culouscou J. (1999). Identification of three novel members of the 
calcium-dependent chloride channel (CaCC) family predominantly expressed in the 
digestive tract and trachea. FEBS lett 455, 295. 
 
Agrawal DK, Cheng G, Kim M-J & Kiniwa M. (2008). Interaction of suplatast tosilate 
(IPD) with chloride channels in human blood eosinophils: a potential mechanism 
underlying its anti-allergic and anti-asthmatic effects. Clinical and Experimental Allergy 
38, 305-312. 
 
Ahluwalia J. (2008). Tamoxifen does not inhibit the swell activated chloride channel in 
human neutrophils during the respiratory burst. Biochemical and Biophysical Research 
Communications 375, 596-601. 
 
Ahmen N, Ramjeesingh M, Wong S, Varga A, Garami E & Bear CE. (2000). Chloride 
channel activity of ClC-2 is modified by the actin cytoskeleton. Biochemical Journal 
352, 789-794. 
 
316 
 Al-Jumaily M, Kozlenkov A, Mechaly I, Fichard A, Matha V, Scamps F, Valmier J & 
Carroll P. (2007). Expression of three distinct families of calcium-activated chloride 
channel genes in the mouse dorsal root ganglion. Neuroscience Bulletin 23, 293-299. 
 
Aldehni F, Spitzner M, Martins JR, Barro-Soria R, Schreiber R & Kunzelmann K. (2009). 
Bestrophin 1 promotes epithelial-to-mesenchymal transition of renal collecting duct 
cells. Journal of the American Society of Nephrology 20, 1556-1564. 
 
Allakhverdi Z, Comeau MR, Smith DE, Toy D, Endam L, Desrosiers M, Liu Y-J, Howie 
KJ, Denburg JA, Gauvreau GM & Delespesse G. (2009). CD34+ hemopoietic progenitor 
cells are potent effectors of alergic inflammation. Journal of Allergy and Clinical 
Immunology 123, 472-478. 
 
Almaça J, Tian Y, Aldehni F, Ousingsawat J, Kongsuphol P, Rock JR, Harfe BD, 
Schreiber R & Kunzelmann K. (2009). TMEM16 proteins produce volume-regulated 
chloride currents that are reduced in mice lacking TMEM16A. The Journal of  Biological 
Chemistry 284, 28571-28578. 
 
Altenberg GA. (2005). Guest Editorial: The multidrug resistance protein P-glycoprotein 
and the regulation of chloride channels. Leukemia Research 29, 983-984. 
 
Anton F, Leverkoehne I, Mundhenk L, Thoreson WB & Gruber AD. (2005). 
Overexpression of eCLCA1 in Small Airways of Horses with Recurrent Airway 
Obstruction. Journal of Histochemistry and Cytochemistry 53, 1011-1021. 
 
317 
 Bakall B, Marmorstein LY, Hoppe G, Peachey NS, Wadelius C & Marmorstein AD. 
(2003). Expression and localization of bestrophin during normal mouse development. 
Investigative Opthalmology and Visual Science 44, 3622-3628. 
 
Bakall B, McLaughlin PJ, Stanton JB, Zhang Y, Hartzell C, Marmorstein LY & 
Marmorstein AD. (2008). Bestrophin-2 is involved in the generation of intraocular 
pressure. Investigative Opthalmology and Visual Science 49, 1563-1570. 
 
Bangel N, Dahlhoff C, Sobczak K, Weber W-M & Kusche-Vihrog K. (2008). Upregulated 
expression of ENaC in human CF nasal epithelium. Journal of Cystic Fibrosis 7, 197-
205. 
 
Barnes PJ. (2008). Immunology of asthma  and chronic obstructive pulmonary disease. 
Nature Review 8, 183-191. 
 
Barro-Soria R, Aldehni F, Almaça J, Witzgall R, Schreiber R & Kunzelmann K. (2010). 
ER-Localized Bestrophin 1 Activates Ca²+- Dependent Ion Channels TMEM16A and SK4 
Possibly by Acting as a Counterion Channel. Pflugers Archiv-European Journal of 
Physiology 459, 485-497. 
 
Barro-Soria R, Schreiber R & Kunzelmann K. (2008). Bestrophin 1 and 2 are 
components of the Ca2+ activated Cl- conductance in mouse airways. Biochemica et 
Biophysica Acta 1783, 1993-2000. 
 
318 
 Barro-Soria R, Spitzner M, Schreiber R & Kunzelmann K. (2009). Bestrophin-1 enables 
Ca2+-activated Cl- conductance in epithelia. The Journal of  Biological Chemistry 284, 
29405-29412. 
 
Bauman RW. (2006). Microbiology. Pearson Benjamin Cummings. 
 
Berlin AA, Lincoln P, Tomkinson A & Lukacs NW. (2004). Inhibition of stem cell factor 
reduces pulmonary cytokine levels during allergic airway responses. Clinical and 
Experimental Immunology 136, 15-20. 
 
Berryman M & Bretscher A. (2000). Identification of a novel member of the chloride 
intracellular channel gene family (CLIC5) that associates with the actin cytoskeleton of 
placental microvilli. Molecular Biology of the Cell 11, 1509-1521. 
 
Board PG, Coggan M, Watson S, Gage PW & Dulhunty AF. (2004). CLIC-2 modulates 
cardiac ryanodine receptor Ca2+ release channels. International Journal of 
Biochemistry and Cell Biology 36, 1599-1612. 
 
Bonfield TL, Konstan MW & Berger M. (1999). Altered respiratory epithelial cell 
cytokine production in cystic fibrosis. Journal of Allergy and Clinical Immunology 104, 
72-78. 
 
Boon CJF, Klevering BJ, Leroy BP, Hoyng CB, Keunen JEE & Hollander AI. (2009). The 
spectrum of ocular phenotypes caused by mutations in the BEST1 gene. Progress in 
Retinal and Eye Research 28, 187-205. 
 
319 
 Bothe MK, Braun J, Mundhenk L & Gruber AD. (2008). Murine mCLCA6 is an integral 
apical membrane protein of non-goblet cell enterocytes and co-localizes with the cystic 
fibrosis transmembrane conductance regulator. Journal of Histochemistry and 
Cytochemistry 56, 495-509. 
 
Bothe MK, Mundhenk L, Beck CL, Kaup M & Gruber AD. (2012). Impaired 
autoproteolytic cleavage of mCLCA6, a murine integral membrane protein expressed in 
enterocytes, leads to cleavage at the plasma membrane instead of the endoplasmic 
reticulum. Molecules & Cells 33, 251-257. 
 
Boucher RC. (2007). Evidence for airway surface dehydration as the initiating 
event in CF airway disease. Journal of Internal Medicine 261, 5-16. 
 
Boudes M, Sar C, Menigoz A, Hilaire C, Péquignot MO, Kozlenkov A, Marmorstein AD, 
Carroll P, Valmier J & Scamps F. (2009). Best1 is a gene regulated by nerve injury and 
required for Ca2+-activated Cl- current expression in axotomized sensory neurons. The 
Journal of Neuroscience 29, 10063-10071. 
 
Braun J, Bothe MK, Mundhenk L, Beck CL & Gruber AD. (2010). Murine mCLCA5 is 
expressed in granular layer keratinocytes of stratified epithelia. Histochemistry and Cell 
Biology 133, 285-299. 
 
Britton FC, Ohya S, Horowitz B & Greenwood IA. (2002). Comparison of the properties 
of CLCA1 generated currents and ICl(Ca) in murine portal vein smooth muscle cells. The 
journal of Physiology 539, 107-117. 
 
320 
 Brouillard F, Bensalem N, Hinzpeter A, Tondelier D, Trudel S, Gruber AD, Ollero M & 
Edelman A. (2005). Blue native/SDS-PAGE analysis reveals reduced expression of the 
mCLCA3 protein in cystic fibrosis knock-out mice. Molecular and Cellular Proteomics 4, 
1762-1775. 
 
Bubien JK. (2001). CFTR may play a role in regulated secretion by lymphocytes: a new 
hypothesis for the pathophsiology of cystic fibrosis. Pflugers Archiv-European Journal 
of Physiology 443, S36-S39. 
 
Bubien JK, Kirk KL, Rado TA & Frizzell RA. (1990). Cell cycle dependence of chloride 
permeability in normal and cystic fibrosis lymphocytes. Science 248, 1416-1419. 
 
Burgess R, Millar ID, Leroy BP, Urquhart JE, Fearon IM, Baere E, Brown PD, Robson 
AG, Wright GA, Kestelyn P, Holder GE, Webster AR, Manson FDC & Black GCM. (2008). 
Biallelic mutation of BEST1 causes a distinct retinopathy in humans. The American 
Journal of Human Genetics 82, 19-31. 
 
Bykova EA, Zhang XD, Chen TY & Zheng J. (2006). Large movement of C terminus of 
ClC-0 chloride channel during slow gating. Nature Structural and Molecular Biology 13, 
1115-1119. 
 
Caputo A, Caci E, Ferrera L, Pedemonte N, Barsanti C, Sondo E, Pfeffer U, Ravazzolo R, 
Zegarra-Moran O & Galietta LJ. (2008). TMEM16A, a membrane protein associated 
with calcium-dependent chloride channel activity. Science 322, 590-594. 
 
321 
 Caramori G, Gregorio C, Carlstedt I, Casolari P, Guzzinati I, Adcock IM, Barnes PJ, 
Ciaccia A, Cavallesco G, Chung KF & Papi A. (2004). Mucin expression in peripheral 
airways of patients with chronic obstructive pulmonary disease. Histopathology 45, 
477-484. 
 
Chen JH, Schulman H & Gardner P. (1989). A cAMP-regulated chloride channel in 
lymphocytes that is affected in cystic fibrosis. Science 243, 657-660. 
 
Chen TY. (2005). Structure and function of CLC channels. Annual Review of Physiology 
67, 809-839. 
 
Cheng G, Ramanathan A, Shao Z & Agrawal DK. (2008). Chloride channel expression 
and functional diversity in the immune cells of allergic diseases. Current Molecular 
Medicine 8, 401-407. 
 
Chien L-T & Hartzell HC. (2007). Drosophila bestrophin-1 chloride current is dually 
regulated by calcium and cell volume. The Journal of General Physiology 130, 513-
524. 
 
Chien L-T, Zhang Z-R & Hartzell C. (2006). Single Cl- channels activated by Ca2+ in 
Drosophila S2 cells are mediated by bestrophins. The Journal of General Physiology 
128, 247-259. 
 
Chmiel JF, Berger M & Konstan MW. (2002). The role of inflammation in the 
pathophysiology of CF lung disease. Clinical Reviews in Allergy and Immunology 23, 5-
27. 
322 
  
Choi JS, Jang AS, Park JS, Park SW, Paik SH, Uh ST & Kim YH. (2012). Role of 
neutrophils in persistent airway obstruction due to refractory asthma. Respirology 17, 
322-329. 
 
Chuang J-Z, Milner TA, Zhu M & Sung C-H. (1999). A 29kDa intracellular chloride 
channel p64H1 is associated with large dense-core vesicles in rat hippocampal 
neurons. The Journal of Neuroscience 19, 2919-2928. 
 
Coelho RR, Souza EP, Soares PMG, Meireles AVP, Santos GCM, Scarparo HC, Assreuy 
AMS & Criddle DN. (2004). Effects of chloride channel blockers on hypotonicity-induced 
contractions of the rat trachea. British Journal of Pharmacology 141, 367-373. 
 
Connon CJ, Kawasaki S, Yamasaki K, Quantock AJ & Kinoshita S. (2005). The 
quantification of hCLCA2 and colocalisation with integrin beta4 in stratified human 
epithelia. Acta Histochemistry 106, 421-425. 
 
Connon CJ, Yamasaki K, Kawasaki S, Quantock AJ, Koizumi N & Kinoshita S. (2004). 
Calcium-activated chloride channel-2 in human epithelia. Journal of Histochemistry and 
Cytochemistry 52, 415-418. 
 
Cromer BA, Gorman MA, Hansen G, Adams JJ, Coggan M, Littler DR, Brown LJ, 
Mazzanti M, Breit SN, Curmi PMG, Dulhunty AF, Board PG & Parker MW. (2007). 
Structure of the Janus protein human CLIC2. Journal of Molecular Biology 374, 719-
731. 
 
323 
 Cunningham SA, Awayda MS, Bubien JK, Ismailov II, Arrate MP, Berdiev BK, Benos DJ 
& Fuller CM. (1995). Cloning of an epithelial chloride channel from bovine trachea. 
Journal of Biological Chemistry 270, 31016-31026. 
 
Davidson AE, Millar ID, Urquhart JE, Burgess-Mullan R, Shweikh Y, Parry N, O'Sullivan 
AJ, Maher GJ, McKibbin M, Downes SM, Lotery AJ, Jacobson SG, Brown PD, Black GCM 
& Manson FDC. (2009). Missense mutations in a retinal pigment epithelium protein, 
Bestrophin-1, causes retinitis pigmentosa. The American Journal of Human Genetics 
85, 581-592. 
 
Davis-Volk AP, Heise CK, Hougen JL, Artman CM, Volk KA, Wessels D, Soll DR, Nauseef 
WM, Lamb FS & Moreland JG. (2008). ClC-3 and ICIswell are required for normal 
neutrophil chemotaxis and shape change. Journal of Biological Chemistry 283, 34315-
34326. 
 
Döring G & Gulbins E. (2009). Cystic fibrosis and innate immunity: how chloride 
channel mutations provoke lung disease. Cellular Microbiology 11, 208-216. 
 
Duan D, Winter C, Cowley S, Hume JR & Horowitz B. (1997). Molecular identification of 
a volume-regulated chloride channel. Nature 390, 417-421. 
 
Ducharme G, Newell EW, Pinto C & Schlichter LC. (2007). Small conductance Cl- 
channels contribute to volume regulation and phagocytosis in microglia. European 
Journal of Neuroscience 26, 2119-2130. 
 
324 
 Duta V, Duta F, Puttagunta L, Befus2 D & Duszyk M. (2006). Regulation of Basolateral 
Cl- Channels in Airway Epithelial Cells: The Role of Nitric Oxide. The Journal of  
Membrane Biology 213, 165-174. 
 
Duta V, Szkotak AJ, Nahirney D & Duszyk M. (2004). The role of bestrophin in airway 
epithelial ion transport. Federation of European Biochemical Societies 577, 551-554. 
 
Dutzler R. (2006). The ClC family of chloride channels and transporters. Current 
Opinion in Structural Biology 16, 439-446. 
 
Dutzler R, Campbell EB, Cadene M, Chait BT & MacKinnon R. (2002). X-ray structure of 
a ClC chloride channel at 3.0A reveals the molecular basis of anion selectivity. Nature 
415, 287-294. 
 
Dyer KD & Rosenberg HF. (1996). Eosinophil Charcot-Leyden Crystal protein binds to 
beta-galactoside sugars. Life Sciences 58, 2073-2082. 
 
Edwards JC. (1999). A novel p64-related Cl- channel: subcellular distribution and 
nephron segment-specific expression. American Journal of Physiology Renal Physiology 
276, F398-F408. 
 
Edwards JC & Kahl CR. (2010). Chloride channels of intracellular membranes. FEBS 
Journal 584, 2102-2111. 
 
325 
 Eggermont J. (2004). Calcium-activated chloride channels: (Un)known, (un)loved? 
Proceedings of the American Thoracic Society 1, 22-27. 
 
Eggermont J, Buyse G, Voets T, Tytgat J, De Smedt H, Droogmans G & Nilius B. 
(1997). Alternative splicing of ClC-6 (a member of the ClC chloride-channel family) 
transcrips generates three truncated isoforms one of which, ClC-6c, is kidney-specific. 
Biochemical Journal 325, 269-276. 
 
Eksandh L, Adamus G, Mosgrove L & Andréasson S. (2008). Autoantibodies against 
bestrophin in a patient with vitelliform paraneoplastic retinopathy and a metastatic 
choroidal malignant melanoma. Archives of Opthalmology 126, 432-435. 
 
Elble RC, Ji G, Nehrke K, DeBiasio J, Kingsley PD, Kotlikoff MI & Pauli BU. (2002). 
Molecular and functional characterization of a murine calcium-activated chloride 
channel expressed in smooth muscle. The Journal of  Biological Chemistry 277, 18586-
18591. 
 
Elble RC, Walia V, Chen H-c, Connon CJ, Mundhenk L, Gruber AD & Pauli BU. (2006). 
The putative chloride channel hCLCA2 has a single transmembrane segment. The 
Journal of  Biological Chemistry 281, 29448-29454. 
 
Elble RC, Widom J, Gruber AD, Abdel-Ghany M, Levine R, Goodwin A, Cheng HC & 
Pauli BU. (1997). Cloning and characterization of lung-endothelial cell adhesion 
molecule 1 suggest it is an endothelial chloride channel. Journal of Biological Chemistry 
272, 27853-27861. 
 
326 
 Engh AM, Faraldo-Gomez JD & Maduke M. (2007). The mechanism of fast-gate 
opening in ClC-0. Journal of General Physiology 130, 335-349. 
 
Evans SR, Thoreson WB & Beck CL. (2004). Molecular and functional analyses of two 
new calcium-activated chloride channel family members from mouse eye and intestine. 
The Journal of  Biological Chemistry 279, 41792-41800. 
 
Fahlke C, Beck CL & George ALJ. (1997a). A mutation in autosomal dominant myotonia 
congenita affects pore properties of the muscle chloride channel. Proceedings of the 
National Academy of Sciences USA 94, 2729-2734. 
 
Fahlke C, Dürr C & George ALJ. (1997b). Mechanism of ion permeation in skeletal 
muscle chloride channels. Journal of General Physiology 110, 551-564. 
 
Fahlke C, Rhodes TH, Desai RR & George ALJ. (1998). Pore stoichiometry of a voltage-
gated chloride channel. Nature 394, 687-690. 
 
Fahlke C, Rosenbohn A, Mitrovic N, George AL & Rüdel R. (1996). Mechanism of 
voltage-dependent gating in skeletal muscle chloride channels. Biophysical Journal 71, 
695-706. 
 
Femling JK, Cherny VV, Morgan D, Rada B, Davis AP, Czirják G, Enyedi P, England SK, 
Moreland JG, Ligeti E, Nauseef WM & DeCoursey TE. (2006). The antibacterial activity 
of human neutrophils and eosinophils requires proton channels but not BK channels. 
Journal of General Physiology 127, 659-672. 
327 
  
Fischkoff SA, Pollak A, Gleich GJ, Testa JR, Misawa S & Reber TJ. (1984). Eosinophilic 
differentiation of the human promyelocytic leukemia cell line, HL60. Journal of 
Experimental Medicine 160, 179-196. 
 
Fischmeister R & Hartzell C. (2005). Volume sensitivity of the bestrophin family of 
chloride channels. Journal of Physiology 562, 477-491. 
 
Freedman SD, Weinstein D, Blanco PG, Martinez-Clark P, Urman S, Zaman M, Morrow 
JD & Alvarez JG. (2002). Characterization of LPS-induced lung inflammation in cftr -/- 
mice and the effect of docosahexaenoic acid. Journal of Applied Physiology 92, 2169-
2176. 
 
Friedli M, Guipponi M, Bertrand S, Bertrand D, Neerman-Arbez M, Scott HS, 
Antonarakis SE & Reymond A. (2003). Identification of a novel member of the CLIC 
family, CLIC6, mapping to 21q22.12. Gene 320, 31-40. 
 
Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CMM & Tsai M. 
(2005). Mast cells as "tunable" effector and immunoregulatory cells: Recent advances. 
Annual Review of Immunology 23, 749-786. 
 
Gaspar KJ, Racette KJ, Gordon JR, Loewen ME & Forsyth GW. (2000). Cloning a 
chloride conductance mediator from the apical membrane of porcine ileal enterocytes. 
Physiological Genomics 3, 101-111. 
 
328 
 Gauvreau GM, Plitt JR, Baatjes A & MacGlashan DW. (2005). Expression of functional 
cysteinyl leukotriene receptors by human basophils. The Journal of Allergy and Clinical 
Immunology 116, 80-87. 
 
Gerber V, De Feijter-Rupp H, Wagner J, Harkema JR & Robinson NE. (2009). 
Differential association of MUC5AC and CLCA1 expression in small cartilaginous airways 
of RAO-affected and control horses. Equine Veterinary Journal 41, 817-823. 
 
Gibbs BF. (2005). Human basophils as effectors and immunomodulators of allergic 
inflammation and innate immunity. Clinical and Experimental Medicine 5, 43-49. 
 
Gibson A, Lewis AP, Affleck K, Aitken AJ, Meldrum E & Thompson N. (2005). hCLCA1 
and mCLCA3 Are Secreted Non-integral Membrane Proteins and Therefore Are Not Ion 
Channels. The Journal of Biological Chemistry 280, 27205-27212. 
 
Gleich GJ, Loegering DA, Mann KG & Maldonado JE. (1976). Comparative properties of 
the Charcot-Leyden Crystal protein and the major basic protein from human 
eosinophis. The Journal of Clinical Investigation 57, 633-640. 
 
Gonem S, Raj V, Wardlaw AJ, Pavord ID, Green R & Siddiqui S. (2012). Phenotyping 
airways disease: an A to E approach. Clinical & Experimental Allergy 42, 1664-1683. 
 
Graeber SY, Zhou-Suckow Z, Schatterny J, Hirtz S, Boucher RC & Mall MA. (2013). 
Hypertonic saline is effective in the prevention and treatment of mucus obstruction but 
not airway inflammation in mice with chronic obstructive lung disease. American 
Journal of Respiratory Cell & Molecular Biology. 
329 
  
Greenwood IA & Leblanc N. (2007). Overlapping pharmacology of 
Ca2+-activated Cl- and K+ channels. TRENDS in Pharmacological Sciences 28, 1-5. 
 
Griffon N, Jeanneteau F, Prieur F, Diaz J & Sokoloff P. (2003). CLIC6, a member of the 
intracellular chloride channel family, interacts with dopamine D2-like receptors. 
Molecular Brain Research 117, 47-57. 
 
Gritli-Linde A, Sani FV, Rock JR, Hallberg K, Iribarne D, Harfe BD & Linde A. (2009). 
Expression patterns of the Tmem16 gene family during cephalic development in the 
mouse. Gene Expression Patterns 9, 178-191. 
 
Gruber AD, Elble RC, Ji HL, Schreur KD, Fuller CM & Pauli BU. (1998). Genomic cloning, 
molecular characterization, and functional analysis of human CLCA1, the first human 
member of the family of Ca2+-activated Cl- channel proteins. Genomics 54, 200-214. 
 
Gruber AD & Pauli BU. (1999a). Clustering of the human CLCA gene family on the short 
arm of chromosome 1 (1p22-31). Genome 42, 1030-1032. 
 
Gruber AD & Pauli BU. (1999b). Molecular cloning and biochemical characterization of a 
truncated, secreted member of the human family of Ca2+-activated Cl- channels. 
Biochimica et Biophysica Acta 1444, 418-423. 
 
Gruber AD & Pauli BU. (1999c). Tumorigenicity of human breast cancer is associated 
with loss of Ca2+-activated Cl- channel CLCA2. Cancer Research 59, 5488-5491. 
330 
  
Gruber AD, Schreur KD, Ji HL, Fuller CM & Pauli BU. (1999). Molecular cloning and 
transmembrane structure of hCLCA2 from human lung, trachea, and mammary gland. 
American Journal of Physiology and Cellular Physiology 276, 1261-1270. 
 
Guziewicz KE, Zangert B, Lindauer SJ, Mullins RF, Sandmeyer LS, Grahn BH, Stone EM, 
Acland GM & Aguirre GD. (2007). Bestrophin gene mutations cause canine multifocal 
retinopathy: A novel animal model for best disease. Investigative Opthalmology and 
Visual Science 48, 1959-1967. 
 
Hagen AR, Barabote RD & Saier MH. (2005). The bestrophin family of anion channels: 
identification of prokaryotic homologues. Molecular Membrane Biology 22, 291-302. 
 
Hagiwara G, Krouse M, Müller U & Wine J. (1989). Is regulation of a chloride channel 
in lymphocytes affected in cystic fibrosis? Science 246, 1049-1050. 
 
Hamann M, Gibson A, Davies N, Jowett A, Walhin JP, Partington L, Affleck K, Trezise D 
& Main M. (2009). Human ClCa1 Modulates Anionic Conduction of Calcium-Dependent 
Chloride Currents. The Journal of Physiology 587, 2255-2274. 
 
Harada Y, Tanaka K, Yamashita K, Ishibashi M, Miyazaki H & Katori M. (1983). The 
anti-inflammatory mechanism of MK-447 in rat carrageenin-induced pleurisy. 
Prostaglandins 26, 79-90. 
 
331 
 Hauber H-P, Goldmann T, Vollmer E, Wollenberg B, Hung H-L, Levitt RC & Zabel P. 
(2007). LPS-induced mucin expression in human sinus mucosa can be attenuated by 
hCLCA1 inhibitors. Journal of Endotoxin Research 13, 109-116. 
 
Hauber H-P, Steffen A, Goldmann T, Vollmer E, Hung H-L, Wollenberg B & Zabel P. 
(2008). Effect of steroids, acetyl-cysteine and calcium-activated chloride channel 
inhibitors on allergic mucin expression in sinus mucosa. Laryngoscope 118, 1528-
1533. 
 
Hegab AE, Sakamoto T, Nomura A, Ishii Y, Morishima Y, Iizuka T, Kiwamoto T, 
Matsuno Y, Homma S & Sekizawa K. (2007). Niflumic acid and AG-1478 reduce 
cigarette smoke-induced mucin synthesis: the role of hCLCA1. Chest 131, 1149-1156. 
 
Hegab AE, Sakamoto T, Saitoh W, Massoud HH, Massoud HM, Hassanein KM & 
Sekizawa K. (2004). Polymorphisms of IL4, IL13, and ADRB2 
Genes in COPD*. Chest 126, 1832-1839. 
 
Heinemann A, Sturm GJ, Ofner M, Sturm EM, Weller C, Peskar BA & Hartnell A. (2005). 
Stem cell factor stimulates the chemotaxis, integrin upregulation, and survival of 
human basophils. The Journal of Allergy and Clinical Immunology 116, 820-826. 
 
Heiss NS & Poustka A. (1997). Short Communication: Genomic structure of a novel 
chloride channel gene, CLIC2, in Xq28. Genomics 45, 224-228. 
 
Higgins JPT & Green S, ed. (2008). Cochrane Handbook for Systematic Reviews of 
Interventions. John Wiley and Sons Ltd, Chichester. 
332 
  
Holgate ST & Polosa R. (2008). Treatment strategies for allergy and asthma. Nature 
Reviews 8, 218-230. 
 
Horowitz B, Tsung SS, Hart P, Levesque PC & Hume JR. (1993). Alternative splicing of 
CFTR Cl- channels in heart. American Journal of Physiology 264, H2214-H2220. 
 
Hoshino M, Morita S, Iwashita H, Sagiya Y, Nagi T, Nakanishi A, Ashida Y, Nishimura O, 
Fujisawa Y & Fujino M. (2002). Increased expression of the human Ca2+-activated Cl- 
channel 1 (CaCC1) gene in the asthmatic airway. American Journal of Respiratory and 
Critical Care Medicine 165, 1132-1136. 
 
Huan C, Greene KS, Shui B, Spizz G, Sun H, Doran RM, Fisher PJ, Roberson MS, Elble 
RC & Kotlikoff MI. (2008). mCLCA4 ER processing and secretion requires luminal 
sorting motifs. American Journal of Cell Physiology 295, C279-C287. 
 
Huang F, Rock JR, Harfe BD, Cheng T, Huang X, Jan YN & Jan LY. (2009). Studies on 
expression and function of the TMEM16A calcium-activated chloride channel. 
Proceedings of the National Academy of Sciences 106, 21413-21418. 
 
Illek B, Fu Z, Schwarzer C, Banzon T, Jalickee S, Miller SS & Machen TE. (2008). 
Flagellin-stimulated Cl- secretion and innate immune responses in airway epithelia: role 
for p38. American Journal of Physiology- Lung Cell and Molecular Physiology 295, 
L531-L542. 
 
333 
 Ishibashi K, Yamasaki J, Okamura K, Teng Y, Kitamura K & Abe K. (2006). Roles of 
CLCA and CFTR in electrolyte re-absorption from rat saliva. Journal of Dental Research 
85, 1101-1105. 
 
Ito Y, Satoh T, Takayama K, Miyagishi C, Walls AF & Yokozeki H. (2011). Basophil 
recruitment and activation in inflammatory skin diseases. Allergy 66, 1107-1113. 
 
Itoh R, Kawamoto S, Miyamoto Y, Kinoshita S & Okubo K. (2000). Isolation and 
characterization of a Ca2+-activated chloride channel from human corneal epithelium. 
Current Eye Research 21, 918-925. 
 
Iyer R, Iverson TM, Accardi A & Miller C. (2002). A biological role for prokaryotic ClC 
chloride channels. Nature 419, 715-718. 
 
Izuhara K, Ohta S, Shiraishi H, Suzuki S, Taniguchi K, Toda S, Tanabe T, Yasuo M, 
Kubo K, Hoshino T & Aizawa H. (2009). The mechanism of mucus production in 
bronchial asthma. Current Medicinal Chemistry 16, 2867-2875. 
 
Jacobsen EA, Taranova AG, Lee NA & Lee JJ. (2007). Eosinophils: Singularly 
destructive effector cells or purveyors of immunoregulation? The Journal of Allergy and 
Clinical Immunology 119, 1313-1320. 
 
Jacquot J, Tabary O, Le Rouzic P & Clement A. (2008). Airway epithelial cell 
inflammatory signalling in cystic fibrosis. The International Journal of Biochemistry and 
Cell Biology 40, 1703-1715. 
 
334 
 Jame AJ, Lackie PM, Cazaly AM, Sayers I, Penrose JF, Holgate ST & Sampson AP. 
(2007). Human bronchial epithelial cells express an active and inducible biosynthetic 
pathway for leukotrienes B4 and C4. Clinical and Experimental Allergy 37, 880-892. 
 
Jeck N, Konrad M, Peters M, Weber S, Bonzel KE & Seyberth HW. (2000). Mutations in 
the chloride channel gene, CLCNKB, leading to a mixed Bartter-Gitelman phenotype. 
Pediatric Research 48, 754-758. 
 
Jentsch TJ. (2008). CLC chloride channels and transporters: from genes to protein 
structure, pathology and physiology. Critical Reviews in Biochemistry and Molecular 
Biology 43, 3-36. 
 
Jentsch TJ, Günther W, Pusch M & Schwappach B. (1995). Properties of voltage-gated 
chloride channels of the ClC gene family. Journal of Physiology 482, 19S-25S. 
 
Jentsch TJ, Maritzen T & Zdebik AA. (2005). Chloride channel diseases resulting from 
impared transepithelial transport or vesicular function. The Journal of Clinical 
Investigation 115, 2039-2046. 
 
Jentsch TJ, Stein V, Weinreich F & Zdebik AA. (2002). Molecular Structure and 
Physiological Function 
of Chloride Channels. Physiological Reviews 82, 503-568. 
 
335 
 Jiang B, Hattori N, Liu B, Kitagawa K & Inagaki C. (2002). Expression of swelling- 
and/or pH-regulated chloride channels (ClC-2, 3, 4 and 5) in human leukemic and 
normal immune cells. Life Sciences 70, 1383-1394. 
 
Jiang B, Hattori N, Liu B, Nakayama Y, Kitagawa K, Sumita K & Inagaki C. (2004). 
Expression and roles of Cl- channel ClC-5 in cell cycles of myeloid cells. Biochemical and 
Biophysical Research Communications 317, 192-197. 
 
KanehisaLaboratories. (2009). http://www.genome.jp/dbget-
bin/show_pathway?ecb04740+100052615. 
 
KanKaanranta H, Janka-Junttila M, Ilmarinen-Salo P, Ito K, Jalonen U, Ito M, Adcock 
IM, Moilanen E & Zhang X. (2010). Histone deacetylase inhibitors induce apoptosis in 
human eosinophils and neutrophils. Journal of Inflammation 7, 9-24. 
 
Kariyawasam HH & Robinson DS. (2007). The role of eosinophils in airway tissue 
remodelling in asthma. Current Opinion in Immunology 19, 681-686. 
 
Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ & Riches DW. (1995). Early 
pulmonary inflammation in infants with cystic fibrosis. American Journal of Respiratory 
and Critical Care Medicine 151, 1075-1082. 
 
Khodoun MV, Orekhova T, Potter C, Morris S & Finkelman FD. (2004). Basophils initiate 
IL-4 production during memory T-dependent response. The Journal of Experimental 
Medicine 200, 857-870. 
 
336 
 Kim K, Suzuki N, Ohneda K, Minegishi N & Yamamoto M. (2010). Fractionation of 
mature eosinophils in GATA-reporter transgenic mice. Tohoku Journal of Experimental 
Medicine 220, 127-138. 
 
Klimmeck D, Daiber PC, Bruhl A, Baumann A, Frings S & Möhrlen F. (2009). Bestrophin 
2: An anion channel associated with neurogenesis in chemosensory systems. The 
Journal of Comparative Neurology 515, 585-599. 
 
Knight DA, Yang IA, Ko FWS & Lim TK. (2012). Year in review 2011: Asthma, chronic 
obstructive pulmonary disease and airway biology. Respirology 17, 563-572. 
 
Komiya T, Tanigawa Y & Hirohashi S. (1999). Cloning and identification of the gene 
gob-5, which is expressed in intestinal goblet cells in mice. Biochemical and Biophysical 
Research Communications 255, 347-351. 
 
Koncz C & Daugirdas J. (1994). Use of MQAE for measurement of intracellular [Cl-] in 
cultured aortic smooth muscle cells. American Journal of Physiology (Heart and 
Circulatory Physiology 36), H2114-H2123. 
 
Korchak HM, Eisenstat BA, Hoffstein ST, Dunham PB & Weissmann G. (1980). Anion 
channel blockers inhibit lysosomal enzyme secretion from human neutrophils without 
affecting generation of superoxide anion. Proceedings of the National Academy of 
Sciences 77, 2721-2725. 
 
337 
 Kornak U, Kasper D, Bosl MR, Kaiser E, Schweizer M, Schulz A, Friedrich W, Delling G & 
Jentsch TJ. (2001). Loss of the ClC-7 chloride channel leads to osteopetrosis in mice 
and man. Cell 104, 205-215. 
 
Krause K-H & Welsh MJ. (1990). Voltage-dependent and Ca2+-activated ion channels in 
human neutrophils. The Journal of Clinical Investigation 85, 491-498. 
 
Krauss RD, Bubien JK, Drumm ML, Zheng T, Peiper SC, Collins FS, Kirk KL, Frizzell RA 
& Rado TA. (1992). Transfection of wild-type CFTR into cystic fibrosis lymphocytes 
restores chloride conductance at G1 of the cell cycle. The EMBO Journal 11, 875-883. 
 
Kunzelmann K, Kongsuphol P, Aldehni F, Tian Y, Ousingsawat J, Warth R & Schreiber 
R. (2009). Bestrophin and TMEM16-Ca2+ activated Cl- channels with different functions. 
Cell Calcium 46, 233-241. 
 
Kunzelmann K, Milenkovic VM, Spitzner M, Soria RB & Schreiber R. (2007). Calcium-
dependent chloride conductance in epithelia: is there a contribution by bestrophin? 
Pflugers Archiv-European Journal of Physiology 454, 879-889. 
 
Kuperman DA, Lewis CC, Woodruff PG, Rodriguez MW, Yee HY, Dolganov GM, Fahy JV 
& Erle DJ. (2005). Dissecting asthma using focused transgenic modeling and functional 
genomics. Journal of Allergy and Clinical Immunology 116, 305-311. 
 
Kyoh S, Kanazawa H, Tochino Y, Kodama T, Asai K & Hirata K. (2008). Comparison of 
N-(carboxymethyl) lysine levels and percentage of eosinophils in induced sputum for 
338 
 assessment of small airway involvements in asthma. Medical Science Monitor 14, 
CR375-380. 
 
Laan M, Lotvall J, Chung KF & Linden A. (2001). IL-17 induced cytokine release in 
human bronchial epithelial cells in vitro: role of mitogen-activated protein (MAP) 
kinases. British Journal of Pharmacology 133, 200-206. 
 
Landry DW, Sullivan S, Nicolaides M, Redhead CR, Edelman AE, Field M, Al-Awqati Q & 
Edwards J. (1993). Molecular cloning and characterization of p64, a chloride channel 
protein from kidney microsomes. The Journal of  Biological Chemistry 268, 14948-
14955. 
 
Leblanc N, Ledoux J, Saleh S, Sanguinetti A, Angermann J, O’Driscoll K, Britton F, 
Perrino BA & Greenwood IA. (2005). Regulation of calcium-activated chloride channels 
in smooth muscle cells: a complex picture is emerging. Canadian Journal of Physiology 
and Pharmacology 83, 541-556. 
 
Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, Mathur AK, Cowley 
HC, Chung KF, Djukanovic R, Hansel TT, Holgate ST, Sterk PJ & Barnes PJ. (2000). 
Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-
responsiveness and the late asthmatic response. Lancet 356, 2144-2148. 
 
Lee JH, Kaminski N, Dolganov G, Grunig G, Koth L, Solomon C, Erle DJ & Sheppard DN. 
(2001). Interleukin-13 induces dramatically different transcriptional programs in three 
human airway cell types. American Journal of Respiratory Cell and Molecular Biology 
25, 474-485. 
339 
  
Lee SH, Goswami S, Grudo A, Song LZ, Bandi V, Goodnight-White S, Green L, Hacken-
Bitar J, Huh J, Bakaeen F, Coxson HO, Cogswell S, Storness-Bliss C, Corry DB & 
Kheradmand F. (2007). Antielastin autoimmunity in tobacco smoking-induced 
emphysema. Nature Medicine 13, 567-569. 
 
Leonidas DD, Elbert BL, Zhou Z, Leffler H, Ackerman SJ & Acharya KR. (1995). Crystal 
structure of human Charcot-Leyden crystal protein, an eosinophil lysophospholipase, 
identifies it as a new member of the cardohydrate-binding family of galectins. Structure 
3, 1379-1393. 
 
Lepple-Wienhues A, Szabò I, Laun T, Kaba NK, Gulbins E & Lang F. (1998). The 
tyrosine kinase p56lck mediates activation of swelling-induced chloride channels in 
lymphocytes. The Journal of Cell Biology 141, 281-286. 
 
Lepple-Wienhues A, Wieland U, Laun T, Heil L, Stern M & Lang F. (2001). A src-like 
kinase activates outwardly rectifying chloride channels in CFTR-defective lymphocytes. 
The FASEB Journal 15, 927-931. 
 
Leverkoehne I & Gruber AD. (2002). The murine mCLCA3 (Alias gob-5) protein is 
located in the mucin granule membranes of intestinal, respiratory, and uterine goblet 
cells. The journal of Histochemistry and Cytochemistry 50, 829-838. 
 
340 
 Leverkoehne I, Holle H, Anton F & Gruber AD. (2006). Differential expression of 
calcium-activated chloride channels (CLCA) gene family members in the small intestine 
of cystic fibrosis mouse models. Histochemistry and Cell Biology 126, 239-250. 
 
Leverkoehne I, Horstmeier BA, Samson-Himmelstjerna G, Scholte BJ & Gruber AD. 
(2002). Real-time RT-PCR quantitation of mCLCA1 and mCLCA2 reveals differntially 
regulated expression in pre- and postnatal murine tissues. Histochemistry and Cell 
Biology 118, 11-17. 
 
Linley JE, Boese SH, Simmons NL & Gray MA. (2009). A voltage-dependent Ca2+ influx 
pathway regulates the Ca2+-dependent Cl- conductance of renal IMCD-3 cells. Journal 
of Membrane Biology 230, 57-68. 
 
Littler DR, Harrop SJ, Goodchild SC, Phang JM, Mynott AV, Jiang L, Valenzuela SM, 
Mazzanti M, Brown LJ, Breit SN & Curmi PMG. (2010). The enigma of the CLIC 
proteins: Ion channels, redox proteins, enzymes, scaffolding proteins? FEBS Letters 
584, 2093-2101. 
 
Liu JB, Zhang ZX, Xu YJ, Xing LH & Zhang HL. (2004). Effects of interleukin-13 on the 
gob-5 and MUC5AC expression in lungs of a murine asthmatic model. Zhonghua jie he 
he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and 
respiratory diseases 27, 837-340. 
 
Liu YJ. (2006). Thymic stromal lymphoprotein: master switch for allergic inflammation. 
Journal of Experimental Medicine 203, 269-273. 
 
341 
 Lloyd CM & Saglani S. (2010). Between Bedside and Bench: The Emerging Epithelium. 
Nature Medicine 16, 273-274. 
 
Loewen ME, Bekar LK, Gabriel SE, Walz W & Forsyth GW. (2002a). pCLCA1 becomes a 
cAMP-dependent chloride conductance mediator in Caco-2 cells. Biochemical and 
Biophysical Research Communications 298, 531-536. 
 
Loewen ME, Bekar LK, Walz W, Forsyth GW & Gabriel SE. (2004). pCLCA1 lacks 
inherent chloride channel activity in an epithelial colon carcinoma cell line. American 
Journal of Physiology- Gastrointestinal and Liver Physiology 287, G33-G41. 
 
Loewen ME & Forsyth GW. (2005). Structure and function of CLCA proteins. 
Physiological Reviews 85, 1061-1092. 
 
Loewen ME, Gabriel SE & Forsyth GW. (2002b). The calcium-dependent chloride 
conductance mediator pCLCA1. American Journal of Cell Physiology 283, C412-C421. 
 
Loewen ME, Smith NK, Hamilton DL, Grahn BH & Forsyth GW. (2003). CLCA protein nd 
chloride transport in canine retinal pigment epithelium. American Journal of Cell 
Physiology 285, C1314-C1321. 
 
Lollike K, Lindau M, Calafat J & Borregaard N. (2002). Compound exocytosis of 
granules in human neutrophils. Journal of Leukocyte Biology 71, 973-980. 
 
342 
 Ludewig U, Jentsch TJ & Pusch M. (1997). Analysis of a protein region involved in 
permeation and gating of the voltage-gated Torpedo chloride channel ClC-0. Journal of 
Physiology 498, 691-702. 
 
Mall M, Gonska T, Thomas J, Schreiber R, Seydewitz HH, Kuehr J, Brandis M & 
Kunzelmann K. (2003). Modulation of Ca2+-activated Cl- secretion by basolateral K+ 
channels in human normal and cystic fibrosis airway epithelia. Pediatric Research 53, 
608-618. 
 
Marandi N, Konnerth A & Garaschuk O. (2002). Two-photon chloride imgaing in 
neurons of brain slices. Pflugers Archiv- European Journal of Physiology, 357-365. 
 
Markovic S & Dutzler R. (2007). The structure of the cytoplasmic domain of the 
chloride channel ClC-Ka reveals a conserved interaction interface. Structure 15, 715-
725. 
 
Marmorstein AD, Marmorstein LY, Rayborn M, Wang X, Hollyfield JG & Petrukhin K. 
(2000). Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), 
localizes to the basolateral plasma membrane of the retinal pigment epithelium. 
Proceedings of the National Academy of Sciences 97, 12758-12763. 
 
Marmorstein LY, McLaughlin PJ, Stanton JB, Yan L, Crabb JW & Marmorstein AD. 
(2002). Bestrophin interacts physically and functionally with protein phosphatase 2A. 
The Journal of  Biological Chemistry 277, 30591-30597. 
 
343 
 Marmorstein LY, Wu J, McLaughlin PJ, Yocom J, Karl MO, Neussert R, Wimmers S, 
Stanton JB, Gregg RG, Strauss O, Peachey NS & Marmorstein AD. (2006). The light 
peak of the electroretinogram is dependent on voltage-gated clacium channels and 
antagonized by bestrophin (best-1). Journal of General Physiology 127, 577-589. 
 
Marone G, Triggiani M & de Paulis A. (2005). Mast cells and basophils: friends as well 
as foes in bronchial asthma. TRENDS in Immunology 26, 25-31. 
 
Marsey LL & Winpenny JP. (2009). Bestrophin expression and function in the human 
pancreatic duct cell line, CFPAC-1. The journal of Physiology 587, 2211-2224. 
 
Martínez-Antón A, de Bolós C, Garrido M, Roca-Ferrer J, Barranco C, Alobid I, Xaubet 
A, Picado C & Mullol J. (2006). Mucin genes have different expression patterns in 
healthy and diseased upper airway mucosa. Clinical and Experimental Allergy 36, 448-
457. 
 
Matchkov VV, Larsen P, Bouzinova EV, Rojek A, Boedtkjer DM, Golubinskaya V, 
Pedersen FS, Aalkjaer C & Nilsson H. (2008). Bestrophin-3 (vitelliform macular 
dystrophy 2-like 3 protein) is essential for the cGMP-dependent calcium-activated 
chloride conductance in vascular smooth muscle cells. Circulation Research 103, 864-
872. 
 
Matsumoto K, Tamari M & Saito H. (2008). Involvement of eosinophils in the onset of 
asthma. The Journal of Allergy and Clinical Immunology 121, 26-27. 
 
344 
 Matulef K & Maduke M. (2007). The ClC 'chloride channel' family: revelations from 
prokaryotes. Molecular Membrane Biology 24, 342-350. 
 
McCann FV, McCarthy DC & Noelle RJ. (1990). Patch-clamp profile of ion channels in 
resting murine B lymphocytes. Journal of Membrane Biology 114, 175-188. 
 
Mellor L, Knudson CB, Hida D, Askew EB & Knudson W. (2013). Intracellular Domain 
Fragment of CD44 Alters CD44 Function in Chondrocytes. Journal of Biological 
Chemistry 288, 25838-25850. 
 
Menegazzi R, Busetto S, Decleva E, Cramer R, Dri P & Patriarca P. (1999). Triggering of 
chloride ion efflux from human neutrophils as a novel function of leukocyte β2 
integrins: relationship with spreading and activation of the respiratory burst. The 
Journal of Immunology 162, 423-434. 
 
Middleton RE, Pheasant DJ & Miller C. (1996). Homodimeric architecture of a ClC-type 
chloride channel. Nature 383, 337-340. 
 
Milenkovic VM, Barro-Soria R, Aldehni F, Schreiber R & Kunzelmann K. (2009). 
Functional assembly and purinergic activation of bestrophins. Pflugers Archiv-European 
Journal of Physiology 458, 431-441. 
 
Milenkovic VM, Langmann T, Schreiber R, Kunzelmann K & Weber BHF. (2008). 
Molecular evolution and functional divergence of the bestrophin protein family. BMC 
Evolutionary Biology 8, 72-82. 
345 
  
Milenkovic VM, Rivera A, Horling F & Weber BHF. (2007). Insertion and topology of 
normal and mutant bestrophin-1 in the endoplasmic reticulum membrane. The Journal 
of  Biological Chemistry 282, 1313-1321. 
 
Moore B, Cheng G, Shao Z, Bewtra AK & Agrawal DK. (2008). Abstract 175: ClC-3 
channels and migration of eosinophils in asthma: Effect of TGF-Β1. Journal of Allergy & 
Clinical Immunology 121, S45. 
 
Moran O & Zegarra-Moran O. (2008). On the measurement of the functional properties 
of the CFTR. Journal of Cystic Fibrosis, 1-12. 
 
Moreland JG, Davis AP, Bailey G, Nauseef WM & Lamb FS. (2006). Anion channels, 
including ClC-3, are required for normal neutrophil oxidative function, phagocytosis and 
transendothelial migration. Journal of Biological Chemistry 281, 12277-12288. 
 
Moreland JG, Davis AP, Matsuda JJ, Hook JS, Bailey G, Nauseef WM & Lamb FS. 
(2007). Endotoxin priming of neutrophils requires NADPH oxidase-generated oxidants 
and is regulated by the anion transporter ClC-3. Journal of Biological Chemistry 282, 
33958-33967. 
 
Mullins RF, Kuehn MH, Faidley EA, Syed NA & Stone EM. (2007). Differential macular 
and peripheral expression of bestrophin in human eyes and its implication for Best 
disease. Investigative Opthalmology and Visual Science 48, 3372-3380. 
 
346 
 Mummery JL, Killey J & Linsdell P. (2005). Expression of the chloride channel CLC-K in 
human airway epithelial cells. Canadian Journal of Physiology and Pharmacology 83, 
1123-1128. 
 
Mundhenk L, Alfalah M, Elble RC, Pauli BU, Naim HY & Gruber AD. (2006). Both 
cleavage products of the mCLCA3 protein are secreted soluble proteins. The Journal of  
Biological Chemistry 281, 30072-30080. 
 
Murzin AG. (2008). Biochemistry.  Metamorphic proteins. Science 320, 1725-1726. 
 
Nakanishi A, Morita S, Iwashita H, Sagiya Y, Ashida Y, Shirafuji H, Fujisawa Y, 
Nishimura O & Fujino M. (2001). Role of gob-5 in mucus overproduction and airway 
hyperresponsiveness in asthma. Proceedings of the National Academy of Sciences of 
the United States of America 98, 5175-5180. 
 
Nakano T, Inoue H, Fukuyama S, Matsumoto K, Matsumura M, Tsuda M, Matsumoto T, 
Aizawa H & Nakanishi Y. (2006). Niflumic acid suppresses interleukin-13-induced 
asthma phenotypes. American Journal of Respiratory and Critical Care Medicine 173, 
1216-1221. 
 
Neagoe I, Stauber T, Fidzinski P, Bergsdorf EY & Jentsch TJ. (2010). The late 
endosomal ClC-6 mediates proton/chloride countertransport in heterologous plasma 
membrane expression. Journal of Biological Chemistry 285, 21689-21697. 
 
347 
 Neussert R, Mϋller C, Milenkovic VM & Straub O. (2010). The presence of bestrophin-1 
modulates the Ca2+ recruitment from Ca2+ stores in the ER. Pflugers Archiv-European 
Journal of Physiology 460, 163-175. 
 
NICE. (2007). The Guidelines Manual; Appendix C Methodology Checklist: Randomised 
Controlled Trials. In wwwniceorguk/niceMedia/pdf/GDM_AppendixC_0305pdf. 
 
Nishizawa T, Nagao T, Iwatsubo T, Forte JG & Urushidani T. (2000). Molecular Cloning 
and Characterization of a Novel Chloride Intracellular Channel-related Protein, 
Parchorin, Expressed in Water-secreting Cells. Journal of Biological Chemistry 275, 
11164-11173. 
 
Nouri-Aria KT & Durham SR. (2004). Basophils in human allergen-induced late-phase 
responses. Revue Francaise D'Allergologie et D'Immunologie Clinique 44, 138-143. 
 
Ntimbane T, Comte B, Mailhot G, Berthiaume Y, Poitout V, Prentki M, Rabasa-Lhoret R 
& Levy E. (2009). Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative 
stress. Clinical Biochemical Reviews 30, 153-177. 
 
O'Byrne PM, Inman MD & Adelroth E. (2004). Reassessing the Th2 cytokine basis of 
asthma. TRENDS in Pharmacological Sciences 25, 244-248. 
 
O'Driscoll KE, Hatton WJ, Burkin HR, Leblanc N & Britton F. (2008). Expression, 
localization, and functional properties of bestrophin 3 channel isolated from mouse 
heart. American Journal of Cell Physiology 295, C1610-C1624. 
 
348 
 O'Driscoll KE, Leblanc N, Hatton WJ & Britton F. (2009). Functional properties of 
murine bestrophin 1 channel. Biochemical and Biophysical Research Communications 
384, 476-481. 
 
Onuma Y, Haramoto Y, Nejigane S, Takahashi S & Asashima M. (2009). Bestrophin 
genes are expressed in Xenopus development. Biochemical and Biophysical Research 
Communications 384, 290-295. 
 
Page C & Pitchford S. (2013). Neutrophil and platelet complexes and their relevance to 
neutrophil recruitment and activation. International Immunopharmacology. 
 
Painter RG, Marrero L, Lombard GA, Valentine VG, Nauseef WM & Wang G. (2010). 
CFTR-mediated halide transport in phagosomes of human neutrophils. Journal of 
Leukocyte Biology 87, 933-942. 
 
Painter RG, Valentine VG, Lanson NA, Leidal K, Zhang Q, Lombard G, Thompson C, 
Viswanathan A, Nauseef WM, Wang G & Wang G. (2006). CFTR expression in human 
neutrophils and the phagolysosomal chlorination defect in cystic fibrosis. Biochemistry 
45, 10260-10269. 
 
Park H, Oh S-J, Han K-S, Woo DH, Park H, Mannaioni G, Traynelis SF & Lee CJ. (2009). 
Bestrophin-1 encodes for the Ca2+ activated anion channel in hippocampal astrocytes. 
Journal of Neuroscience 29, 13063-13073. 
 
349 
 Parnham MJ, Adolfs MJP & Bonta IL. (1979). Effects of 2-aminomethyl-4-t-butyl-6-
iodophenol (MK-447) on granulomatous inflammation: Lack of correlation with changes 
in levels of prostaglandin-like material. Inflammation Research 9, 275-279. 
 
Patel AC, Brett TJ & Holtzman MJ. (2009). The role of CLCA proteins in inflammatory 
airway disease. Annual Review of Physiology 71, 425-449. 
 
Paul CC, Ackerman SJ, Mahrer S, Tolbert M, Dvorak AM & Baumann MA. (1994). 
Cytokine induction of granule protein synthesis in an eosinophil-inducible human 
myeloid cell line, AML14. Journal of Leukocyte Biology 56, 74-79. 
 
Pauli BU, Abdel-Ghany M, Cheng H-C, Grunig G, Archibald HA & Elble RC. (2000). 
Molecular characteristics and functional diversity of CLCA family members. Clinical and 
Experimental Pharmacology and Physiology 27, 901-905. 
 
Pawlowski K, Lepisto M, Meinander N, Sivars U, Varga M & Wieslander E. (2006). Novel 
conserved hydrolase domain in the CLCA family of alleged calcium-activated chloride 
channels. PROTEINS:  Structure, Function, and Bioinformatics 63, 424-439. 
 
Phipps DJ, Branch DR & Schlichter LC. (1996). Chloride-channel block inhibits T 
lymphocyte activation and signalling. Cellular Signalling 8, 141-149. 
 
Picollo A, Liantonio A, Babini E, Camerino DC & Pusch M. (2007). Mechanism of 
interaction of niflumic acid with heterologously expressed kidney CLC-K chloride 
channels. Journal of Membrane Biology 216, 73-82. 
 
350 
 Picollo A & Pusch M. (2005). Chloride/proton antiporter activity of mammalian CLC 
proteins ClC-4 and ClC-5. Nature 436, 420-423. 
 
Pifferi S, Dibattista M & Menini A. (2009a). TMEM16B induces chloride currents 
activated by calcium in mammalian cells. Pflugers Archiv 458, 1023-1038. 
 
Pifferi S, Dibattista M, Sagheddu C, Boccaccio A, Qteishat AA, Ghirardi F, Tirindelli R & 
Menini A. (2009b). Calcium-activated chloride currents in olfactory sensory neurons 
from mice lacking bestrophin-2. Journal of Physiology 587, 4265-4279. 
 
Pifferi S, Pascarella G, Boccaccio A, Mazzatenta A, Gustincich S, Menini A & Zucchelli S. 
(2006). Bestrophin-2 is a candidate calcium-activated chloride channel involved in 
olfactory transduction. Proceedings of the National Academy of Sciences 103, 12929-
12934. 
 
Piirsoo M, Meijer D & Timmusk T. (2009). Expression analysis of the CLCA gene family 
in mouse and human with emphasis on the nervous system. BMC Developmental 
Biology 9, 10-21. 
 
Planells-Cases R & Jentsch TJ. (2009). Chloride channelopathies. Biochemica et 
Biophysica Acta 1792, 173-189. 
 
Plath KES, Grabbe PJ, Strenzke N, Wolff HH & Gibbs BF. (2001). Effect of chloride 
channel blockers on anti-IgE-stimulated histamine and IL-4/IL-13 release from human 
basophils. Inflammation Research 50, S51-S52. 
 
351 
 Plog S, Grotzsch T, Klymiuk N, Kobalz U, Gruber AD & Mundhenk L. (2012). The 
porcine chloride channel calcium-activated family member pCLCA4a mirrors lung 
expression of the human hCLCA4. Journal of Histochemistry and Cytochemistry 60, 45-
56. 
 
Plog S, Mundhenk L, Klymiuk N & Gruber AD. (2009). Genomic, tissue expression, and 
protein characterization of pCLCA1, a putative modulator of cystic fibrosis in the pig. 
Journal of Histochemistry and Cytochemistry 57, 1169-1181. 
 
Pollock NS, Kargacin ME & Kargacin GJ. (1998). Chloride channel blockers inhibit Ca2+ 
uptake by the smooth muscle sarcoplasmic reticulum. Biophysical Journal 75, 1759-
1766. 
 
Polosa R & Blackburn MR. (2009). Adenosine receptors as targets for therapeutic 
intervention in asthma and chronic obstructive pulmonary disease. TRENDS in 
Pharmacological Sciences 30, 528-535. 
 
Pulford K, Jones M, Banham AH, Haralambieva E & Mason DY. (1999). Lymphocyte-
specific protein 1: a specific marker of human leucocytes. Immunology 96, 262-271. 
 
Pusch M, Ludewig U, Rehfeldt A & Jentsch TJ. (1995). Gating of the voltage-dependent 
chloride channel ClC-0 by the permeant anion. Nature 373, 527-531. 
 
Qian Z, Okuhara D, Abe MK & Rosner MR. (1999). Molecular cloning and 
characterization of a mitogen-activated protein kinase-associated intracellular chloride 
channel. The Journal of  Biological Chemistry 274, 1621-1627. 
352 
  
Qiang Z, Yu K, Cui YY, Ying C & Hartzell C. (2007). Activation of bestrophin Cl- 
channels is regulated by C-terminal domains. Journal of Biological Chemistry 282, 
17460-17467. 
 
Qu Z, Cheng W, Cui Y, Cui Y & Zheng J. (2009). Human disease-causing mutations 
disrupt an N-C-terminal interaction and channel function of bestrophin 1. The Journal 
of  Biological Chemistry 284, 16473-16481. 
 
Qu Z, Cui Y & Hartzell C. (2006). A short motif in the C-terminus of mouse bestrophin 
4 inhibits its activation as a Cl channel. Federation of European Biochemical Societies 
580, 2141-2146. 
 
Qu Z, Fischmeister R & Hartzell C. (2004). Mouse Bestrophin-2 Is a Bona fide Cl-
Channel: Identification of a Residue Important in Anion Binding and Conduction. The 
Journal of General Physiology 123, 327-340. 
 
Qu Z, Han X, Cui Y & Li C. (2010). A PI3 kinase inhibitor found to activate bestrophin 
3. Journal of Cardiovascular Pharmacology 55, 110-115. 
 
Qu Z & Hartzell C. (2008). Bestrophin Cl- channels are highly permeable to HCO3-. 
American Journal of Cell Physiology 294, C1371. 
 
353 
 Qu Z, Wei RW, Mann W & Hartzell C. (2003). Two bestrophins cloned from xenopus 
laevis oocytes express Ca2+-activated Cl- currents. The Journal of  Biological Chemistry 
278, 49563-49572. 
 
Raap U & Wardlaw AJ. (2008). A new paradigm of eosinophil granulocytes: 
neuroimmune interactions. Experimental Dermatology 17, 731-738. 
 
Range F, Mundhenk L & Gruber AD. (2007). A soluble secreted glycoprotein (eCLCA1) 
is overexpressed due to goblet cell hyperplasia and metaplasia in horses with recurrent 
airway obstruction. Veterinary Pathology 44, 901-911. 
 
Redhead CR, Edelman AE, Brown D, Landry DW & Al-Awqati Q. (1992). A ubiquitous 
64-kDa protein is a component of a chloride channel of plasma and intracellular 
membranes. Proceedings of the National Academy of Sciences USA 89, 3716-3720. 
 
Robinson NC, Huang P, Kaetzel MA, Lamb FS & Nelson DJ. (2004). Identification of an 
N-terminal amino acid of the ClC-3 chloride channel critical in phosphorylation-
dependent activation of a CaMKII-activated chloride current. The journal of Physiology 
556, 353-368. 
 
Rock JR, Futtner CR & Harfe BD. (2008). The transmembrane protein TMEM16A is 
required for normal development of the murine trachea. Developmental Biology 321, 
141-149. 
 
Rock JR, Lopez MC, Baker HV & Harfe BD. (2007). Identification of genes expressed in 
the mouse limb using 
354 
 a novel ZPA microarray approach. Gene Expression Patterns 8, 19-26. 
 
Rogers DF. (2003). The airway goblet cell. The International Journal of Biochemistry 
and Cell Biology 35, 1-6. 
 
Rosenberg HF, Phipps S & Foster PS. (2007). Eosinophil trafficking in allergy and 
asthma. The Journal of Allergy and Clinical Immunology 119, 1303-1310. 
 
Rosenthal R, Bakall B, Kinnick T, Peachey NS, Wimmers S, Wadelius C, Marmorstein AD 
& Strauss O. (2005). Expression of bestrophin-1, the product of the VMD2 gene, 
modulates voltage-dependent Ca2+ channels in retinal pigment epithelial cells. The 
FASEB Journal 20, 178-180. 
 
Ross PE, Garber SS & Cahalan MD. (1994). Membrane chloride conductance and 
capacitance in jurkat T lymphocytes during osmotic swelling. Biophysical Journal 66, 
169-178. 
 
Roussa E, Wittschen P, Wolff NA, Torchalski B, Gruber AD & Thévenod F. (2010). 
Cellular distribution and subcellular localization of mCLCA1/2 in murine gastrointestinal 
epithelia. Journal of Histochemistry and Cytochemistry 58, 653-668. 
 
Rychkov GY, Pusch M, Roberts ML, Jentsch TJ & Bretag AH. (1998). Permeation and 
block of the skeletal muscle chloride channel, ClC-1, by foreign anions. Journal of 
General Physiology 111, 653-665. 
 
355 
 Ryhner T, Muller N, Balmer V & Gerber V. (2008). Increased mucus accumulation in 
horses chronically affected with recurrent airway obstruction is not associated with up-
regulation of CLCA1, EGFR, MUC5AC, Bcl-2, IL-13 and INF- expression. Veterinary 
Immunology and Immunopathology 125, 8-17. 
 
Salmon MD & Ahluwalia J. (2009). Swell activated chloride channel function in human 
neutrophils. Biochemical and Biophysical Research Communications 381, 462-465. 
 
Sanz J, von Kanel T, Schneider M, Steiner B, Schaller A & Gallati S. (2010). The CFTR 
frameshift mutation 3905insT and its effect at transcript and protein level. European 
Journal of Human Genetics 18, 212-217. 
 
Schreiber R, Uliyakina I, Kongsuphol P, Warth R, Mirza M, Martins JR & Kunzelmann K. 
(2010). Expression and Function of Epithelial Anoctamins. The Journal of Biological 
Chemistry 285, 7838-7845. 
 
Schrenzel J, Demaurex N, Foti M, Van Delden C, Jacquet J, Mayr G, Lew DP & Krause 
K-H. (1995). Highly co-operative Ca2+ elevations in response to Ins (1,4,5) P3 
microperfusion through a patch-clamp pipette. Biophysical Journal 69, 2378-2391. 
 
Schroeder BC, Cheng T, Jan YN & Jan LY. (2008). Expression Cloning of TMEM16A as a 
Calcium-Activated Chloride Channel Subunit. Cell 134, 1019-1029. 
 
Schwiebert EM, Benos DJ, Egan ME, Stutts MJ & Guggino WB. (1999). CFTR is a 
conductance regulator as well as a chloride channel. Physiological Reviews 79, S145-
S166. 
356 
  
Schwingshackl A, Moqbel R & Duszyk M. (2000). Involvement of ion channels in human 
eosinophil respiratory burst. The Journal of Allergy and Clinical Immunology 106, 272-
279. 
 
Sheppard DN & Welsh MJ. (1999). Structure and function of the CFTR chloride 
channel. Physiological Reviews 79, S23-S45. 
 
Siddiqui S, Cruse G, Mckenna S, Monteiro W, Mistry V, Wardlaw A & Brightling C. 
(2009). IL-13 expression by blood T cells and not eosinophils is increased in asthma 
compared to non-asthmatic eosinophilic bronchitis. BMC Pulmonary Medicine 9, 34-41. 
 
Simchowitz L, Textor JA & Cragoe EJ. (1993). Cell volume regulation in human 
neutrophils: 2-(aminomethyl) phenols as Cl- channel inhibitors. American Journal of 
Physiology 265, C143-C155. 
 
Simon D & Simon H-U. (2007). Eosinophilic disorders. The Journal of Allergy and 
Clinical Immunology 119, 1291-1300. 
 
Singh H & Ashley RH. (2007). CLIC4 (p64H1) and its putative transmembrane domain 
form poorly selective, redox-regulated ion channels. Molecular Membrane Biology 24, 
41-52. 
 
357 
 Singh H, Cousin MA & Ashley RH. (2007). Functional reconstitution of mammalian 
‘chloride intracellular channels’ CLIC1, CLIC4 and CLIC5 reveals differential regulation 
by cytoskeletal actin. FEBS Journal 274, 6306-6316. 
 
Sokol CL, Chu N-Q, Yu S, Nish SA, Laufer TM & Medzhitov R. (2009). Basophils 
function as antigen presenting cells for an allergen-induced Th2 response. Nat 
Immunol 10, 713-720. 
 
Song F, Parekh S, Hooper L, Loke YK & Ryder J. (2010). Dissemination and publication 
of research findings : an updated review of related biases. Health Technology 
Assessment 14, 234. 
 
Song J, Zhang XD, Qi Z, Sun G, Chi S, Zhu Z, Ren J, Qiu Z, Liu K, Myatt L & Ma RZ. 
(2009). Cloning and characterization of a calcium-activated chloride channel in rat 
uterus. Biology of Reproduction 80, 788-794. 
 
Spencer LA & Weller PF. (2010). Eosinophils and Th2 immunity: contemporary insights. 
Immunology and Cell Biology 88, 250-256. 
 
Spitzner M, Martins JR, Soria RB, Ousingsawat J, Scheidt K, Schreiber R & Kunzelmann 
K. (2008). Eag1 and bestrophin 1 are up-regulated in fast growing colonic cancer cells. 
The Journal of  Biological Chemistry 283, 7421-7428. 
 
358 
 Srivastava A, Romanenko VG, Gonzalez-Begne M, Catalán MA & Melvin JE. (2008). A 
variant of the Ca2+-activated Cl channel Best3 is expressed in mouse exocrine glands. 
Journal of Membrane Biology 222, 43-54. 
 
Stanton JB, Goldberg AFX, Hoppe G, Marmorstein LY & Marmorstein AD. (2006). 
Hydrodynamic properties of porcine bestrophin-1 in Triton X-100. Biochemica et 
Biophysica Acta 1758, 241-247. 
 
Steinmeyer K, Lorenz C, Pusch M, Koch MC & Jentsch TJ. (1994). Multimeric structure 
of ClC-1 chloride channel revealed by mutations in dominant myotonia congenita 
(Thomsen). EMBO Journal 13, 737-743. 
 
Steinmeyer K, Ortland C & Jentsch TJ. (1991). Primary structure and functional 
expression of a developmentally regulated skeletal muscle chloride channel. Nature 
354, 301-304. 
 
Stöhr H, Marquardt A, Nanda I, Schmid M & Weber BHF. (2002). Three novel human 
VMD2-like genes are members of the evolutionary highly conserved RFP-TM family. 
European Journal of Human Genetics 10, 281-284. 
 
Sturton G, Persson C & Barnes PJ. (2008). Small airways: An important but neglected 
target in the treatment of obstructive airway diseases. TRENDS in Pharmacological 
Sciences 29, 340-345. 
 
359 
 Sun H, Tsunenari T, Yau KW & Nathans J. (2002). The vitelliform macular dystrophy 
protein defines a new family of chloride channels. Proceedings of the National 
Academy of Sciences USA 99, 4008-4013. 
 
Suzuki M. (2006). The Drosophila tweety family: molecular candidates for large-
conductance Ca2+-activated Cl– channels. Experimental Physiology 91, 141-147. 
 
Suzuki M, Morita T & Iwamoto T. (2006). Review:  Diversity of Cl– Channels. Cellular 
and Molecular Life Sciences 63, 12-24. 
 
Taraseviciene-Stewart L, Douglas IS, Nana-Sinkam PS, Lee JD, Tuder RM, Nicolls MR & 
Voelkel NF. (2006). Is alveolar destruction and emphysema in chronic obstructive 
pulmonary disease an immune disease? Proceedings of the American Thoracic Society 
3, 687-690. 
 
Terheggen-Lagro SW, Rijkers GT & van der Ent CK. (2005). The role of airway 
epithelium and blood neutrophils in the inflammatory response in cystic fibrosis. 
Journal of Cystic Fibrosis 4, 15-23. 
 
Thai P, Chen Y, Dolganov G, Wu R, Thai P, Chen Y, Dolganov G & Wu R. (2005). 
Differential regulation of MUC5AC/Muc5ac and hCLCA-1/mGob-5 expression in airway 
epithelium. American Journal of Respiratory Cell & Molecular Biology 33, 523-530. 
 
Tintinger G, Steel HC & Anderson R. (2005). Taming the neutrophil: calcium clearance 
and influx mechanisms as novel targets for pharmacological control. Clinical and 
Experimental Immunology 141, 191-200. 
360 
  
Tintinger GR & Anderson R. (2004). Counteracting effects of NADPH oxidase and the 
Na+/Ca2+ exchanger on membrane repolarisation and store-operated uptake of Ca2+ 
by chemoattractant-activated neutrophils. Biochemical Pharmacology 67, 2263-2271. 
 
Toda M, Tulic MK, Levitt RC, Hamid Q, Toda M, Tulic MK, Levitt RC & Hamid Q. (2002). 
A calcium-activated chloride channel (HCLCA1) is strongly related to IL-9 expression 
and mucus production in bronchial epithelium of patients with asthma. Journal of 
Allergy & Clinical Immunology 109, 246-250. 
 
Tonini R, Ferroni A, Valenzuela SM, Warton K, Campbell TJ, Breit SN & Mazzanti M. 
(2000). Functional characterization of the NCC27 nuclear protein in stable transfected 
CHO-K1 cells. FASEB Journal 14, 1171-1178. 
 
Tsunenari T, Nathans J & Yau KW. (2006). Ca2+-activated Cl- current from human 
bestrophin-4 in excised membrane patches. Journal of General Physiology 127, 749-
754. 
 
Tsunenari T, Sun H, Williams J, Cahill H, Smallwood P, Yau KW & Nathans J. (2003). 
Structure-function analysis of the bestrophin family of anion channels. The Journal of  
Biological Chemistry 278, 41114-41125. 
 
Tulk BM, Kapadia S & Edwards JC. (2002). CLIC1 inserts from the aqueous phase into 
phospholipid membranes where it functions as an anion channel. American Journal of 
Cell Physiology 282, C1103-C1112. 
 
361 
 Tyner JW, Kim EY, Ide K, Pelletier MR, Roswit WT, Morton JD, Battaile JT, Patel AC, 
Patterson A, Castro M, Spoor MS, You Y, Brody SL & Holtzman MJ. (2006). Blocking 
airway  mucous cell metaplasia by inhibiting EGFR antiapoptosis and IL-3 
transdifferentiation signals. The Journal of Clinical Investigation 116, 309-321. 
 
Ulrich M, Worlitzsch D, Viglio S, Siegmann N, Iadarola P, Shute JK, Geiser M, Pier GB, 
Friedel G, Barr ML, Schuster A, Meyer KC, Ratjen F, Bjarnsholt T, Gulbins E & Döring 
G. (2010). Alveolar inflammation in cystic fibrosis. Journal of Cystic Fibrosis 9, 217-
227. 
 
Valenzuela SM, Martin DK, Por SB, Robbins JM, Warton K, Bootcov MR, Schofield PR, 
Campbell TJ & Breit SN. (1997). Molecular Cloning and Expression of a Chloride Ion 
Channel of Cell Nuclei. Journal of Biological Chemistry 272, 12575-12582. 
 
Varnai P, Demaurex N, Jaconi M, Schlegel W, Lew DP & Krause K-H. (1993). Highly co-
operative Ca2+ activation of intermediate-conductance K+ channels in granulocytes 
from a human cell line. Journal of Physiology 472, 373-390. 
 
Venge P. (2010). The eosinophil and airway remodelling in asthma. The Clinical 
Respiratory Journal 4, 15-19. 
 
Vercelli D. (2008). Discovering susceptibility genes for asthma and allergy. Nature 
Reviews 8, 169-182. 
 
362 
 Virchow S, Ansorge N, RÃ¼bben H, Siffert G & Siffert W. (1998). Enhanced fMLP-
stimulated chemotaxis in human neutrophils from individuals carrying the G protein Î²3 
subunit 825 T-allele. FEBS Letters 436, 155-158. 
 
Walsh E, Sahu N & August A. (2007). Abstract 600: Eosinophils are Required for T Cell 
Infiltration of Lungs During Allergic Asthma Responses. The Journal of Allergy and 
Clinical Immunology; Supplement 119, S153. 
 
Walsh ER & August A. (2010). Eosinophils and allergic airway disease: there is more to 
the story. TRENDS in Immunology 31, 39-44. 
 
Wang G, Qian Y, Qiu Q, Lan X, He H & Guan Y. (2006). Interaction between Cl- 
channels and CRAC-related Ca2+ signalling during T lymphocyte activation and 
proliferation. Acta Pharmacologica Sinica 27, 437-446. 
 
Wang K, Feng YL, Wen FQ, Chen XR, Ou XM, Xu D, Yang J, Deng ZP, Wang K, Feng Y-
L, Wen F-Q, Chen X-R, Ou X-M, Xu D, Yang J & Deng Z-P. (2007a). Increased 
expression of human calcium-activated chloride channel 1 is correlated with mucus 
overproduction in the airways of Chinese patients with chronic obstructive pulmonary 
disease. Chinese Medical Journal 120, 1051-1057. 
 
Wang K, Wen FQ, Feng YL, Ou XM, Xu D, Yang J, Deng ZP, Wang K, Wen F-Q, Feng Y-
L, Ou X-M, Xu D, Yang J & Deng Z-P. (2007b). Increased expression of human 
calcium-activated chloride channel 1 gene is correlated with mucus overproduction in 
Chinese asthmatic airway. Cell Biology International 31, 1388-1395. 
 
363 
 Wartosch L, Fuhrmann JC, Schweizer M, Stauber T & Jentsch TJ. (2009). Lysosomal 
degradation of endocytosed proteins depends on the chloride transport protein ClC-7. 
FASEB Journal 23, 4056-4068. 
 
Willis-Karp M. (2004). Interleukin-13 in asthma pathogenesis. Immunological Reviews 
202, 175-190. 
 
Winpenny JP, Marsey LL & Sexton DW. (2009). The CLCA gene family: Putative 
therapeutic target for respiratory diseases. Inflammation and Allergy 8, 146-160. 
 
Woodruff PG, Boushey HA, Dolganov GM, Barker CS, Yee HY, Donnelly S, Ellwanger A, 
Sidhu SS, Dao-Pick TP, Pantoja C, Erle DJ, Yamamoto KR & Fahy JV. (2007). Genome-
wide profiling identifies epithelial cell genes associated with asthma and with treatment 
response to corticosteroids. Proceedings of the National Academy of Sciences of the 
United States of America 104, 15858-15863. 
 
Xanthou G, Duchesnes CE, Williams TJ & Pease JE. (2003). CCR3 functional responses 
are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11. European 
Journal of Immunology 33, 2241-2250. 
 
Xiao Q, Prussia A, Yu K, Cui Y-Y & Hartzell C. (2008). Regulation of bestrophin Cl 
channels by calcium: role of the C terminus. Journal of General Physiology 132, 681-
692. 
 
Xiao Q, Yu K, Cui Y-Y & Hartzell C. (2009). Dysregulation of human bestrophin-1 by 
ceramide-induced dephosphorylation. Journal of Physiology 587, 4379-4391. 
364 
  
Yamazaki J, Okamura K, Ishibashi K & Kitamura K. (2005). Characterization of CLCA 
protein expressed in ductal cells of rat salivary glands. Biochemica et Biophysica Acta 
1715, 132-144. 
 
Yang YD, Cho H, Koo JY, Tak MH, Cho Y, Shim WS, Park SP, Lee JD, Lee B, Kim BM, 
Raouf R, Shin YK & Oh U. (2008). TMEM16A confers receptor-activated calcium-
dependent chloride conductance. Nature 455, 1210-1215. 
 
Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S & Madden TL. (2012). Primer-
BLAST: A tool to design target-specific primers for polymerase chain reaction. BMC 
Bioinformatics 13, 134. 
 
Yim PD, Gallos G, Xu D, Zhang Y, Emala CW, Yim PD, Gallos G, Xu D, Zhang Y & Emala 
CW. (2011). Novel expression of a functional glycine receptor chloride channel that 
attenuates contraction in airway smooth muscle. FASEB Journal 25, 1706-1717. 
 
Yoon I-S, Jeong SM, Lee SN, Lee J-H, Kim J-H, Pyo MK, Lee J-H, Lee B-H, Choi S-H, 
Rhim H, Choe H & Nah S-Y. (2006). Cloning and heterologous expresion of a Ca2+-
activated chloride channel isoform from rat brain. Biological and Pharmaceutical 
Bulletin 29, 2168-2173. 
 
Yoshimura K, Nakamura H, Trapnell BC, Chu C-S, Dalemans W, Pavirani A, Lecocq J-P 
& Crystal RG. (1991). Expression of the cystic fibrosis transmembrane conductance 
regulator gene in cells of non-epithelial origin. Nucleic Acids Research 19, 5417-5423. 
 
365 
 Yu K, Cui YY & Hartzell C. (2006). The bestrophin mutation A243V, linked to adult-
onset vitelliform macular dystrophy, impairs its chloride channel function. Investigative 
Opthalmology and Visual Science 47, 4956-4961. 
 
Yu K, Lujan R, Marmorstein AD, Gabriel SE & Hartzell C. (2010). Bestrophin-2 mediates 
bicarbonate transport by goblet cells in mouse colon. The Journal of Clinical 
Investigation 120, 1722-1735. 
 
Yu K, Qu Z, Cui YY & Hartzell C. (2007). Chloride channel activity of bestrophin 
mutants associated with mild or late-onset macular degeneration. Investigative 
Opthalmology and Visual Science 48, 4694-4705. 
 
Yu K, Xiao Q, Cui G, Lee A & Hartzell C. (2008). The best disease-linked Cl- channel 
hBest1 regulates Cav1 (L type) Ca2+ channels via src-homology-binding domains. The 
Journal of Neuroscience 28, 5660-5670. 
 
Zhang SJ, Steijaert MN, Lau D, Schutz G, Delucinge-Vivier C, Descombes P & Bading H. 
(2007). Decoding NMDA receptor signaling: identification of genomic programs 
specifying neuronal survival and death. Neuron 53, 549-562. 
 
Zhang Y, Davidson BR, Stamer WD, Barton JK, Marmorstein LY & Marmorstein AD. 
(2009). Enhanced inflow and outflow rates despite lower IOP in bestrophin-2-deficient 
mice. Investigative Opthalmology and Visual Science 50, 765-770. 
 
366 
 Zhang Y, Patil RV & Marmorstein AD. (2010). Bestrophin 2 is expressed in human non-
pigmented ciliary epithelium but not retinal pigment epithelium. Molecular Vision 16, 
200-206. 
 
Zholos A, Beck B, Sydorenko V, Lemonnier L, Bordat P, Prevarskaya N & Skryma R. 
(2005). Ca2+ - and Volume-sensitive Chloride Currents Are Differentially Regulated by 
Agonists and Store-operated Ca2+ Entry. The Journal of General Physiology 125, 197-
211. 
 
Zhou Y, Dong Q, Louahed J, Dragwa C, Savio D, Huang M, Weiss C, Tomer Y, McLane 
MP, Nicolaides NC & Levitt RC. (2001). Characterization of a calcium-activated chloride 
channel as a shared target of Th2 cytokine pathways and its potential involvement in 
asthma. American Journal of Respiratory Cell and Molecular Biology 25, 486-491. 
 
Zhu L, Castranova V & He P. (2005). fMLP-stimulated neutrophils increase endothelial 
[Ca2+]i and microvessel permeability in the absence of adhesion: role of reactive 
oxygen species. American Journal of Physiology - Heart and Circulatory Physiology 
288, H1331-H1338. 
 
Zifarelli G, Liantonio A, Gradogna A, Picollo A, Gramegna G, De Bellis M, Murgia AR, 
Babini E, Camerino DC & Pusch M. (2010). Identification of sites responsible for the 
potentiating effect of niflumic acid on ClC-Ka kidney chloride channels. British Journal 
of Pharmacology 160, 1652-1661. 
 
 
 
 
367 
  
 
 
 
 
 
 
 
 
APPENDICES 
 
 
 
 
 
 
 
 
 
 
368 
Appendix 1: Letter of ethics approval for blood harvest 
Mr Darren Sexton 
Biomedical Research Centre 
School of Medicine, Health Policy and Practice 
UEA 
NR4 7TJ 
Faculty of Health 
Research Office 
University of East Anglia 
Norwich NR4 7TJ 
United Kingdom 
Email: Jane.Carter@uea.ac.uk 
Tel:  +44 (0) 1603 591023 
Fax: +44 (0) 1603 591132 
Web:www.uea.ac.uk 
20.04.2009 
Dear Darren, 
Mechanisms of airway diseases - 2008042 
The resubmission of your above proposal has now been considered by the Chair of the FOH 
Ethics Committee and we can now confirm that your proposal has now been approved.  
Please could you ensure that any amendments to either the protocol or documents submitted 
are notified to us in advance and also that any adverse events which occur during your project 
are reported to the committee. Please could you also arrange to send us a report once your 
project is completed. 
The committee would like to wish you good luck with your project.  
Yours sincerely, 
Dr. Jane Carter 
+44 (0) 1603 591023 
Jane.Carter@uea.ac.uk 
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Appendix 2: Letter to laboratories for systematic review 
 
Biomedical Research Centre address 
 
Lab address 
 
Dear  
 
I am currently undertaking a PhD examining the role of calcium 
activated chloride ion channels, in granulocytes, during chronic 
inflammatory lung disease.  As part of my study I am undertaking a 
systematic review of all the studies that examine the expression of 
chloride ion channels in people with, and without, chronic 
inflammatory lung diseases.  I am including granulocytes, 
agranulocytes and airway epithelial cells from all mammals and 
mammalian cell lines.   
 
As you may be aware, in order to enable a rigorous systematic 
review, it is important that I can access any potential sources, 
including unpublished works.  In order to complete this, I am writing 
to ask if you, your colleagues, or any member of your laboratory, 
have undertaken research that may be published or unpublished at 
this point, for consideration for inclusion in the systematic review.  
 
Research to be included in the review will: 
• Study  any chloride channels 
• Assess factors relating to  chronic inflammatory lung disease  
• Methodology could include expression and/or functional 
studies. 
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 • Inclusion criteria; mammals or mammalian cell lines and all 
chloride ion channels 
• Whether the results were positive, negative or unclear is not 
important to inclusion in the review 
 
Please could you send me contact details of any researchers 
(including yourself) who have conducted potentially relevant 
research?  I would like to negotiate access to the raw data from any 
relevant studies, in return for co-authorship on the published 
systematic review.  It is anticipated that this would be published 
within 18 months.  Therefore any help, or contribution, from you that 
you would be able to give would be invaluable.  If you are able to 
contribute information for this systematic review, I would ask that 
you forward this to the above address, for the attention of my 
supervisor, Dr John Winpenny. 
 
With many thanks for your time. 
 
Yours Sincerely 
 
 
Kirsty Kirk    
RN (Dip) HE, BA(Hons), PGC(M)E, MSc, FHEA 
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 Appendix 3: Inclusion/exclusion form for systematic review 
 
In/Out form for inclusion of studies in systematic review: Is 
the expression of chloride ion channels different in cells 
from people with and without chronic inflammatory lung 
disease? 
 
Study Ref:      Reviewer: 
 
Criteria 
no. 
Inclusion/Exclusion criteria Meets 
inclusion? 
1 Is the study laboratory based/cohort study? 
(Include all primary laboratory research.  
Exclude all opinion papers, reviews, meta-
analyses, editorials, letters and studies 
published only in abstract form) 
Y 
N 
Unsure 
2 Are the samples/subjects mammalian? 
(Include all studies using either human 
subjects, mammals or mammalian 
commercial cell lines.  Exclude all samples 
taken from non-mammals such as 
amphibians, reptiles and fish)  
Y 
N 
Unsure 
3 Is the focus upon blood cells or airway 
tissue? (Include all blood cell types such as 
granulocytes and agranulocytes, and all 
airway cells such as nasal, bronchial etc.  
Exclude cells/samples from other organs 
such as pancreas) 
Y 
N 
Unsure 
4 Focussed upon chronic inflammatory lung 
diseases? (Include all inflammatory lung 
diseases.  Exclude non-inflammatory 
Y 
N 
Unsure 
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 disease of the lungs such as cancers, 
inflammatory disease or symptoms not of 
the airways such as bowel, exclude cystic 
fibrosis) 
5 Chloride ion channels? (To include all types 
such as voltage gated, volume regulated, 
calcium activated and ligand gated.  Include 
those assumed to be either regulators of 
chloride flux or a channel; CLCA, 
bestrophins, ClC, tweety etc.  Exclude all 
other ion channels such as potassium and 
sodium) 
Y 
N 
Unsure 
 
If all answers to the above are “Y” circle “include”.  If any 
answers are “N” then circle “exclude”.  If any are unsure 
then circle “pending” and detail action to resolve: 
 
Include   Exclude   Pending 
(Action?): 
 
Summary:  (Brief summary of reasons for exclusion if applicable) 
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 Appendix 4:  Risk of bias tool for systematic review 
 
Risk of Bias Assessment 
Tool adapted from Cochrane Risk of Bias checklist for RCT and the 
National Institute for Health and Clinical Excellence 
(www.nice.org.uk/niceMedia/pdf/GDM_AppendixC_0305.pdf) from 
Scottish Intercollegiate Guidelines Network 
Study ID: Reference 
Completed by: Date: 
INTERNAL VALIDITY 
1.1 The question is clear 
and focussed which is 
addressed by the study 
Well covered 
Adequately covered 
Poorly addressed 
Not addressed 
Not reported 
Not applicable 
1.2 Methodology is 
appropriate to the 
defined question 
Well covered 
Adequately covered 
Poorly addressed 
Not addressed 
Not reported 
Not applicable 
1.3 The treatment and 
control groups are 
similar at the start of 
the study 
Well covered 
Adequately covered 
Poorly addressed 
Not addressed 
Not reported 
Not applicable 
1.4 The only difference 
between groups is the 
treatment under 
investigation 
Well covered 
Adequately covered 
Poorly addressed 
Not addressed 
Not reported 
Not applicable 
1.5 All relevant outcomes 
are measured in a 
standard, valid and 
reliable way 
Well covered 
Adequately covered 
Poorly addressed 
Not addressed 
Not reported 
Not applicable 
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 1.6 Was the attrition of the 
sample from the study 
considered/defined 
Well covered 
Adequately covered 
Poorly addressed 
Not addressed 
Not reported 
Not applicable 
JUDGEM
ENT 
Overall risk of bias: 
(50% or more “not 
addressed/not 
reported”=high risk of 
bias, 30% or 
more=medium risk of 
bias, 15% or less =low 
risk of bias) 
High 
Medium 
 
Low 
Unknown 
What is the likely 
effect of bias? 
(High=conclusions are 
likely to alter, 
medium=unlikely to 
alter conclusions and 
low = very unlikely to 
alter) 
 
 
 
 
 
OVERALL ASSESSMENT 
2.1 How well was the risk 
of bias identified and 
considered 
Well covered 
Adequately covered 
Poorly addressed 
Not addressed 
Not reported 
Not applicable 
2.2 Evaluation of the 
methodology to the 
overall outcome of the 
study and the power of 
statistical analysis 
Well covered 
Adequately covered 
Poorly addressed 
Not addressed 
Not reported 
Not applicable 
2.3 Is it likely that the Well covered Not addressed 
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 overall effect is due to 
the study intervention 
Adequately covered 
Poorly addressed 
Not reported 
Not applicable 
2.4  Are the results likely to 
be generalizable due to 
study design? 
Well covered 
Adequately covered 
Poorly addressed 
Not addressed 
Not reported 
Not applicable 
JUDGEM
ENT 
Overall risk of bias: 
 
High 
Medium 
 
Low 
Unknown 
What is the likely 
effect of bias? 
 
 
 
 
 
STUDY DESCRIPTION 
3.1 What was the sample size? 
Was it 
appropriate/adequate? 
Yes No 
3.2 Was the sample mammalian 
or mammalian cell line? 
Yes No 
3.3 Is the sample applicable to 
blood cells or airway tissue? 
Yes No 
3.4 Is the study generalizable to 
chronic inflammatory lung 
diseases? 
Yes No 
3.5 Is the study focussed upon 
chloride ion channels? 
Yes No 
3.6 Is there an intervention that 
is appropriate to systematic 
Yes No 
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 review? 
3.7 Is there an adequate 
measure of controls? 
Yes No 
 
3.8 Are the outcome measures 
appropriate? 
Yes No 
3.9 Was the study externally 
funded? 
Yes No 
3.10 Is any external funding 
considered to reduce the 
risk of bias? 
Yes No 
3.11 Does the study help to 
answer systematic review 
question? 
Yes No 
JUDGEM
ENT 
Overall risk of bias: High 
Medium 
 
Low 
Unknown 
What is the likely effect of 
bias? 
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 DESCRIPTORS (for tabulating key characteristics of the study) 
 
What was the sample size? 
 
 
 
What was the sample species? 
 
 
 
 
What was the tissue type? 
 
 
 
 
What disease was focussed on? 
 
 
 
 
 
What type of study was it? 
(experimental/cohort study etc) 
 
 
What chloride ion channels were 
examined? 
 
 
 
 
What were the experimental 
techniques used? 
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 What were the controls? 
 
 
 
 
What were the outcome measures? 
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       PRISMA 2009 Checklist  APPENDIX 5: Completed PRISMA checklist for systematic review 
Section/topic  # Checklist item  Reported on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  262 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
NA 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  263 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
265 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
266 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
268 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
270 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
271 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
268 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
275 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
275 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
273 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  275 
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Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I2) for each meta-analysis.  
275 
Risk of bias across studies 15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
273 
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
NA 
RESULTS 
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
276 
Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
280 
Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). 278 
Results of individual studies 20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
284 
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency. NA 
Risk of bias across studies 22 Present results of any assessment of risk of bias across studies (see Item 15). 288 
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). NA 
DISCUSSION 
Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
289 
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
286 
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research. 299 
FUNDING 
Funding 27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
NA 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. 
doi:10.1371/journal.pmed1000097  
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